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Abstract 
 
Prostate cancer is an important disease in the modern era, based on its prevalence, the 
controversies surrounding diagnosis and treatment selection, the long lead time prior to the 
development of aggressive disease and metastatic disease, and the paucity of effective 
treatment options for advanced and metastatic disease. YBX1 is a multi-functional 
transcription factor with diverse roles in DNA and RNA regulation, DNA repair, control of 
transcription and translation, and the cellular response to stress and xenobiotics. It has been 
shown to be an important prognostic indicator in numerous cancers, and its diverse roles 
suggest that it may play a role as a central regulator in tumour progression. Very little was 
known about YBX1 in prostate cancer, but recent work has outlined its association with 
clusterin, the progression to androgen independent disease and regulation of the androgen 
receptor. The work presented in this thesis has demonstrated the following important points 
regarding YBX1 in prostate cancer: 
1) YBX1 pseudogenes do not appear to be expressed at appreciable levels in 6 
different prostate cancer cell lines, and therefore assays and experiments using these 
cell lines are unlikely to be compromised by expression of pseudogene mRNA and 
protein. We have created a YBX1 RefSeq-specific primer pair that should reliably 
exclude pseudogene amplification in PCR assays and this can be verified in other 
cell lines. 
2) YBX1 does not appear to induce an EMT in prostate cancer cell lines without the 
presence of other factors, for example an activated H-Ras pathway.  Although 
results found in transformed breast cancer cell lines have not been reproduced here, 
we have demonstrated strong evidence for effects on migration and invasion in 
prostate cancer cell lines. 
3) Microarray cDNA expression analysis has revealed a diverse set of genes regulated 
by YBX1. Many of these are genes implicated in multiple cancers, including 
prostate cancer. Significant results included AR, BRCA1, BRCA2,  bcl2 and a 
number of genes already implicated in prostate cancer including MXI1, CD82 and 
CHEK2. 
4) Validation of  YBX1 regulation of  several genes implicated in prostate cancer has 
been completed and confirms that CD82, CHEK2, MXI1, ITGB1, IGFBP5, RAC1 
and TFF1 all show evidence of YBX1 regulation in different assays and cell lines 
but with some conflicting results. However, the overall results support further 
investigation of these proteins and their relationship with YBX1. 
In summary, the results here add significantly to the body of knowledge on YBX1 and 
in particular with respect to prostate cancer. The findings confirm the previously known roles 
for YBX1 in RNA and DNA regulation, DNA repair and stress response, but also unveil a 
number of new associations, in particular for regulation of cancer genes. YBX1 may indeed 
have a master regulatory role in the progression of prostate cancer and further work to clarify 
this might identify this protein as a plausible future therapeutic target in men with prostate 
cancer, allowing researchers and clinicians to add a true molecularly-targeted therapy to their 
armamentarium for this challenging cancer.  
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Chapter 1: Introduction and Literature Review 
1.1 INTRODUCTION 
Prostate cancer is the second most common cancer in men worldwide, and a growing 
healthcare burden owing to an ageing population and increased disease detection owing to 
greater awareness and the use of PSA screening. Although cure is possible in localized 
disease, up to 30% of men develop metastatic disease which is incurable. In Australia annual 
prostate cancer deaths now outnumber deaths from breast cancer, and the annual direct and 
indirect treatment costs exceed $1 billion. Although there are scattered insights into the 
causation and progression of this disease, the heterogeneity of this cancer, like many others, 
makes it difficult to create successful treatments for metastatic disease, the cancer showing 
resilience and disheartening relapse in many men despite recent advances in chemotherapy, 
bone-targeted therapy and cancer vaccine therapies. 
Y-box binding protein 1 (YBX1) is a multifunctional, conserved member of a large 
family of proteins with a conserved cold-shock domain and acts as a transcription factor with 
multiple secondary functions in humans, which include regulation of transcription, 
translation, DNA and RNA chaperoning, DNA repair, a role in embryogenesis, response to 
external stressors and xenobiotics including chemotherapeutics. It has been implicated as an 
adverse prognostic factor in multiple human cancers including breast, ovarian, colorectal, 
bone, brain, lung and prostate cancer. However, despite numerous publications on YBX1 and 
its functions, there is little true understanding as to how it confers an aggressive phenotype or 
survival advantage to cancers.   
This thesis aims to explore the role of YBX1 in prostate cancer more fully and elucidate 
novel mechanisms and pathways that may be regulated by YBX1 in order to gain a broader 
understanding of how it contributes to cancer aggressiveness, persistence or relapse. 
This introductory chapter will provide a detailed overview of prostate cancer, its 
pathogenesis and current treatment options, as well as a summary of the current knowledge of 
YBX1 and its known roles in various cancers. This should provide a clear foundation to the 
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work covered in this thesis and identify current deficiencies in the scientific literature for this 
important protein. 
1.2 THE BURDEN OF PROSTATE CANCER IN AUSTRALIA AND GLOBALLY 
The burden of prostate cancer internationally is truly significant, and has become more 
so over the last two decades with an ever increasing and ageing world population. The most 
recent Australian and global figures for prostate cancer incidence, prevalence and mortality 
are from 2008. Globally, prostate cancer is the second most commonly diagnosed cancer of 
men (899 000 new cases in 2008, 13.6% of all new cancer cases) (Ferlay J, 2008) and the 
fifth most common cancer overall. Incidence rates vary across the world by a factor of 25. 
The highest incidence is seen in Australia and New Zealand with an incidence of 104.2 per 
100 000 (Ferlay J, 2008). The lowest age-standardised incidence is found in South-Central 
Asia, 4.1 per 100 000. Worldwide there were 258 000 deaths from prostate cancer, making 
this cancer the sixth leading cause of cancer death in men (6.1% of all cancer deaths). It is 
interesting to note that the mortality rate across the world does not differ as widely as does 
the incidence rate, by a factor of 10 instead of 25-fold. The reason for this is partly related to 
the effect of PSA screening in developed nations leading to lead-time bias and early diagnosis 
or diagnosis of clinically insignificant cancers (defined as cancers that would not pose a risk 
to an individual man’s overall health or life expectancy). Mortality rates are highest in poorer 
areas of African populations (Caribbean, 26.3 per 100 000) and very low in Asia ( 2.5 per 100 
000 in Eastern Asia). Figure 1.1 shows the age- standardised incidence and mortality rates for 
prostate cancer from various countries and economic regions around the world. There is a 
clear demarcation between the high incidence rates in developed and western nations 
compared to the very low incidence in the Asian subcontinent and North Africa. What is also 
clear is the large difference between prostate cancer incidence and mortality. Although very 
many men each year are diagnosed with prostate cancer, a relatively small number of men die 
from prostate cancer each year. There are multiple reasons for this, which will be discussed in 
more detail in section 1.5. 
Figure 1.2 shows the sharp rise in the incidence of prostate cancer since the mid-1980s 
to early 1990s largely brought on by the introduction of the prostate specific antigen (PSA) 
serum blood test and large scale opportunistic screening practices that followed. 
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Figure 1.1 Estimated age-standardise rates (World) per 100 000 for prostate cancer incidence and 
mortality, 2008. Reproduced from GLOBOCAN 2008, 
(http://globocan.iarc.fr/factsheets/cancers/prostate.asp) 
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Figure 1.2 Trends in the incidence of prostate cancer in selected countries: age standardised rate per 
100 000. Reproduced from GLOBOCAN 2008, 
(http://globocan.iarc.fr/factsheets/cancers/prostate.asp) 
 
 
Figure 1.3 Trends in mortality from prostate cancer in selected countries: age-standardised rate per 
100 000. Reproduced from GLOBOCAN 2008, 
(http://globocan.iarc.fr/factsheets/cancers/prostate.asp) 
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Figure 1.3 depicts the trends in prostate cancer mortality across selected nations since 
1975. As can be appreciated there was a peak in mortality in the mid-1990s followed by a 
significant decline since then. The reasons for the decline are several fold, including better 
treatment with surgery and radiotherapy, but the most significant factor accepted by 
epidemiologists and urologists is the effect of stage migration brought on by PSA screening 
leading to a large lead time bias and therefore an effectively lower annual mortality rate 
(Dickman & Adami, 2006). Most cancers diagnosed before 1990 were locally advanced or 
metastatic, with concomitantly higher mortality rates. However, since the advent of the PSA-
era, prostate cancer has been diagnosed at earlier clinical stages and today the majority of 
diagnoses in men from developed cancers are of localized prostate cancer (that is to say, 
prostate cancer that is confined to the prostate and has not spread beyond the prostate 
capsule). 
In Australia in 2007, prostate cancer was the most common cancer diagnosed, 
accounting for almost one third of all Australian cancers that year (AIHW, 2012). In total 
there were 19403 new cases diagnosed that year and 2938 men died from prostate cancer 
(AIHW, 2010). The age-standardised incidence rate was 182.9 per 100 000 and by the age of 
75 one in seven men will be diagnosed with prostate cancer, at an average age at diagnosis of 
68 (AIHW, 2010). Figure 1.4 shows the incidence rate and mortality rate by age in Australia. 
It is clear that prostate cancer is a disease of the ageing male, with a sharp increase in 
incidence becoming apparent from the late 50s. However, the 5-year survival for prostate 
cancer is fairly favourable, as outlined in Table 1.1. It can be seen that the expected 5-year 
survival for a man diagnosed in Australia between 2006-2010 was 92%. What this means is 
that once diagnosed, most men will live for many years, often succumbing to other causes of 
death including cardiovascular disease and stroke. As of the end of 2007, there were 129 978 
men alive in Australia with a diagnosis of prostate cancer (AIHW, 2012). Many of these men 
will however eventually develop metastatic disease, which results in significant adverse 
health and quality of life effects, and a large health economic burden in managing the 
complications of advanced metastatic prostate cancer. It is difficult to quantify the number of 
men living with metastatic disease at any one time, but evidence from the United States 
CAPSURE database estimates that between 1990 and 2003, 2.6% of men were found to have 
metastatic  
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Figure 1.4 Prostate cancer incidence and mortality rates by age at diagnosis, Australia 2007. 
Reproduced from Cancer in Australia 20:an overview. AIHW, Canberra 2010 
 
 
Table 1.1  One, 5 and 10 year relative survival for prostate cancer, Australia, 1982-87 through 2006-
2010. In the contemporary era, 5-year relative survival is 92%, far higher than most other common 
cancers. 
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disease at diagnosis (Ryan et al, 2006). In 2007, 2938 men died from prostate cancer in 
Australia. The median overall survival for a man with newly diagnosed hormone-sensitive 
metastatic prostate cancer is between five and seven years (Choueiri et al, 2009; Nayyar et al, 
2010; Tangen et al, 2003), so it can be roughly calculated, assuming an average median 
survival of five years, that at any time in Australia there may be approximately 15000 men 
living with metastatic prostate cancer. This cohort represents a significant clinical burden of 
disease and accounts for the highest healthcare costs of prostate cancer treatment (Wilson et 
al, 2007), and poses a significant challenge to researchers and clinicians as there is no cure 
for metastatic prostate cancer. The total medical costs of treating prostate cancer in Australia 
in 2006 were $267 million, while the overall costs, including loss of productivity and welfare 
costs and the costs of informal care, totalled over $1.4 billion. Between 2006 and 2011 the 
total cost of prostate cancer care in Australia is estimated at $7.6 billion.  
In summary, it is evident that prostate cancer as a disease places a significant burden on 
the health system and society through its high prevalence and prolonged survival, but with a 
large cohort of men with metastatic disease and high treatment costs and indirect costs. As 
the population ages into the future, the impact of prostate cancer and the requirements for 
care of prostate cancer patients will form a large part of the health and research budget here 
in Australia and internationally. 
 
1.3 ANATOMY AND DEVELOPMENT OF THE PROSTATE 
1.3.1 Embryology of the prostate 
The prostate arises from the primitive urogenital sinus, which is formed by division of 
the cloaca by the urorectal septum. This tissue consists of primitive endoderm. The urogenital 
sinus divides into a urinary bladder at the cranial end and the urethra caudally. The prostate 
arises from a region just caudal to the bladder neck as a proliferation of epithelial buds 
branching out from the epithelial lining of the urogenital sinus. This process is androgen 
dependent and occurs during the 10
th
 week of foetal life. The process requires intricate 
epithelial mesenchymal interactions involving growth factors, androgens and oestrogens, 
IGF-1 and IGF-2. Buds initially grow as solid cords of cells before later branching and 
forming hollow canals, and more complex arborizing systems (Sugimura et al, 1986). 
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During embryological development, distinct cell types develop from the urogenital 
sinus epithelium. The epithelium develops basal and luminal layers with distinct cytokeratin 
markers in both embryonic life and adulthood (Wang et al, 2001), and it is recognized that 
neuro-endocrine cells are present in large numbers during budding but these numbers regress 
during further development. 
An important part of the epithelial budding process is the process of mesenchymal 
condensation, in which mesenchymal cells surrounding the growing buds become tightly 
packed. Studies in mice show that mice defective for Noggin (a bone morphogenic protein 
(BMP) antagonist) fail to achieve proper ventral mesenchymal condensation (Cook et al, 
2007), as well as showing other urogenital anomalies. Also important in this process is the 
role of fibroblast growth factors, in particular FGF10 (Donjacour et al, 2003). Furthermore, 
mutations in TP63 and the androgen axis can also severely impair normal prostatic 
development (Cunha et al, 1987; Signoretti et al, 2000). 
 
1.3.2 Anatomy of the prostate 
The prostate gland is a small yet complex gland encircling the urethra below the 
bladder neck. As mentioned above, it originates from primitive endoderm and induces 
surrounding mesenchyme to create a supporting stroma for the arborizing ductal system. This 
stroma is fibromuscular in nature, consisting of connective tissue, smooth muscle, fibroblasts 
and mesenchymal cells. There is a pseudo-capsule enveloping the gland but no true 
anatomical capsule is present. The prostate can typically vary in size from 15ml to 100ml in 
adult men, averaging between 30-50ml in most men. However, benign prostatic hypertrophy 
(BPH) can cause massive enlargement of the prostate, with glands reaching 100-200ml not 
uncommonly, and some record specimens of over 1kg have been reported in the literature. 
Descriptions of prostate anatomy date back to the work of Sir Everard Home in 1806 
who was the first to describe a “third lobe” of the prostate (presumably BPH by modern 
understanding). Several other seminal papers added to the body of knowledge about prostate 
anatomy between 1857 and 1954 (Franks, 1953; Griffiths, 1889; Lowsley, 1918; Thompson, 
1857; Walker, 1906). These studies all provided an incomplete understanding of prostate 
anatomy, for various reasons. Lowsley, for example, only studied foetal prostates, and his 
description of lobar anatomy was later repudiated by Franks who examined adult specimens. 
23 
 
Franks was credited with first describing the small peri-urethral glands which did not belong 
to any prostate lobe and were the site of origin of BPH. In 1968 McNeal was the first to use 
serial blocks through the entire prostate in multiple planes to gain a better understanding of 
ductal and zonal anatomy (McNeal, 1968). His work over the next thirteen years led to a 
seminal paper which forms the basis for the modern understanding of prostate zonal anatomy 
(McNeal, 1981). This paper defined four zones of the prostate gland, consisting of:  
i) Peripheral zone – constituting 70% of the glandular prostate. This has 
traditionally been understood to be the zone in which the majority of prostate 
cancers arise 
ii) Central zone  - constitutes 25% of the glandular prostate . Its ducts arise close to 
the ejaculatory duct orifices and follow these proximally 
iii) Transition zone – a zone surrounding the urethra proximal to the verumontanum 
and containing only small ducts which later give rise to BPH 
iv) Anterior fibromuscular stroma - forms the entire anterior surface of the prostate 
as “a thick , non-glandular apron” (McNeal).  
 
Figure 1.5 depicts the zones of the prostate as described by McNeal and as commonly 
applied by urologists today. 
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Figure 1.5 Anatomical zones of the prostate  Prostate cancers commonly arise in the peripheral 
zone, although 30% of cancers arise in the transition zone and anterior horns of the peripheral zone 
 
1.4 PATHOGENESIS OF PROSTATE CANCER 
The precise cause of prostate cancer has not yet been determined, though evidence 
suggests that interplay of genetics and environment is necessary for the pathogenesis of 
prostate cancer.  
1.4.1 Genetic factors 
There is clear evidence that prostate cancer has a familial and genetic component. It 
was demonstrated in a familial clustering study that the risk of prostate cancer was higher in 
first degree relatives of patients with prostate cancer (Woolf, 1960). This finding was 
confirmed in subsequent studies including twin studies (Ahlbom et al, 1997; Gronberg et al, 
1994). A meta-analysis published in 2003 showed that the relative risk for a male with an 
affected father was 2.17; this rose to 3.37 if a brother was affected and 5.08 if more than two 
first degree relatives were affected (Zeegers et al, 2003). Most prostate cancers, about 85%, 
appear to be sporadic, with no history of an affected family member. The remaining 15% are 
termed familial or hereditary. 
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Interestingly, studies of familial breast and prostate cancers have identified the BRCA1 
and BRCA2 mutations as conferring increased risk of prostate cancer, with a 30% increased 
risk for carriers of BRCA1 founder mutations (Struewing et al, 1997). BRCA2 mutations, 
although rare, have been found to be associated with a 5-7 fold increased risk of prostate 
cancer (Edwards et al, 2003). 
A number of susceptibility genes for prostate cancer have been identified through 
linkage studies. One of these is HPC1, or hereditary prostate cancer 1 (Cooney et al, 1997). 
This was mapped to the gene which encodes the antiviral and pro-apoptotic enzyme RNaseL, 
which helps block viral infections by mediating the actions of interferons (Carpten et al, 
2002; Rokman et al, 2002). A number of inactivating and missense mutations of RNaseL 
have been found in families of men with hereditary prostate cancer, with the R462Q SNP 
being associated with an increased risk of prostate cancer (Casey et al, 2002). The authors 
found that one copy of the mutated allele was carried by at least 60% of the men in their 
study. This finding adds weight to the role of viral infection in prostate cancer aetiology (see 
below). 
1.4.2 Infection and Inflammation 
Evidence from other cancers including colonic, oesophageal , stomach, bladder and 
liver has shown that chronic inflammation can lead to cellular hyper-proliferation during the 
healing process which leads to the development of infection-related cancers (Coussens & 
Werb, 2002). There is evidence that a history of prior infections or chronic 
infection/inflammation is associated with an increased risk of prostate cancer. Two meta-
analyses have shown a relative risk of 1.4 for a history of prior sexually transmitted infections 
and an odds ratio of 1.57 for prior prostatitis (Dennis & Dawson, 2002; Dennis et al, 2002). 
Further evidence comes from studies showing positive associations between the presence of 
antibodies to human papilloma virus (HPV), syphilis and human herpes virus 8 (HHV-8) and 
prostate cancer (De Marzo et al, 2007). Evidence of viral pathogens have been found in 
human prostate tissue, including HPV, human herpes simplex virus type 2 (HSV2), 
cytomegalovirus (CMV) and HHV-8 (Samanta et al, 2003; Strickler & Goedert, 2001). 
However, conflicting evidence comes from a large negative study examining a longitudinal 
cohort of over 50 000 American men which showed no relationship between a history of 
prior syphilis or gonorrhoea and prostate cancer, nor with prior Chlamydia trachomatis, 
HPV-16, HPV-18 or HPV-33 infections (Sutcliffe et al, 2006; Sutcliffe et al, 2007).  
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A model of prostate carcinogenesis in the setting of chronic inflammation was recently 
proposed. This model (Figure 1.6) summarises the effects of chronic infection leading to 
epithelial proliferation, chronic inflammation, and defects in multiple  key genes including 
toll-like receptors, inflammatory response genes (MSR1, MIC1), antioxidant enzymes 
(PON1, GSTP1) and DNA repair genes (OGG1, CHEK2, BRCA2) all predisposing to cell 
damage and pre-neoplastic change.  
Recent work has also revisited the role of RNaseL in prostate cancer and detected a 
previously undescribed γ-retrovirus, xenotropic murine leukaemia-related virus (XMRV) in 
prostate cancer tissue of 8 out of 20 men with the R462Q allelic variant of the HPC1/RNaseL 
gene (Urisman et al, 2006). This finding was corroborated by other groups (Fischer et al, 
2008).  
 
1.4.3 Hormonal factors associated with prostate cancer  
Androgens 
Androgens are important for the development, maturation and maintenance of the 
prostate and it is now well established that androgens play a key role in prostate cancer 
initiation and progression. Androgens maintain prostate cancer growth, as is evident 
historically from the fact that most prostate cancers respond to androgen deprivation initially. 
Charles Huggins pioneered the use of androgen deprivation in prostate cancer, initially 
through surgical castration. He presented his initial results in 1942 (Huggins, 1942) and five 
year results in 1946 (Huggins, 1946) and was awarded the Nobel Prize for his work in 1966. 
Primary prevention of prostate cancer through the inhibition of conversion of testosterone to 
dihydrotestosterone was demonstrated in the PCPT Trial, with patients randomised to 
finasteride showing a 25% lower incidence of cancer (Thompson et al, 2003). However, it 
appears that the risk conferred by androgens is not necessarily dose related, as a recent review 
of 18 studies did not find an increased prostate cancer risk in men with higher serum levels of 
testosterone, free testosterone or dihydrotestosterone (Roddam et al, 2008). The exact role 
that the androgen receptor (AR) plays in the development and maintenance of prostate cancer 
are not clear. However, androgens and the AR do regulate the expression of genes involved 
in cell cycle regulation, survival and growth (Wang et al, 2007a; Wang et al, 2009; Xu et al, 
2006). AR is also known to stimulate expression of the TMPRSS2:ERG fusion gene (Cai et 
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al, 2009), higher levels of which may contribute to prostate cancer development (Tomlins et 
al, 2008). 
 
 
 
 
Figure 1.6 The role of infection and inflammation in prostate carcinogenesis. 
Chronic infection leads to epithelial proliferation and inflammation, and together with defects in 
genes regulating the inflammatory response, DNA damage and antioxidant function, cell damage 
leads to pre-neoplastic changes such as proliferative inflammatory atrophy (PIA) (TLR – toll-like 
receptors; PAMP – pathogen associated molecular pattern; MSR1) (Reproduced from 
Wein:Campbell-Walsh Urology, 10
th
 ed. © Saunders 2011) 
 
 
 
Oestrogens 
The role of oestrogens in prostate cancer has been debated, as traditionally they have 
been considered protective against prostate cancer and used in treatment for advanced 
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disease. However, some animal studies provide evidence that oestrogens may be pro-
carcinogenic (Leav et al, 1988). Oestrogens may act through stromal ERα receptors to 
promote cancer in animal prostates (Prins & Korach, 2008). This paper showed that ERβ 
receptors may play a critical role in initiating prostate cancer. Oestrogen can also be 
synthesised in the prostate through prostatic aromatase (Risbridger et al, 2003). It has been 
found that circulating levels of oestrogens are higher in African American men than in 
Caucasian Amercians (Rohrmann et al, 2007). African Americans are known to develop more 
aggressive prostate cancer and have the highest incidence of prostate cancer in North 
Amercia. Other circumstantial evidence for a role for oestrogen comes from the fact that 
prostate cancer incidence rises with increasing age, and this is paralleled by a significant rise 
in the ratio of circulating oestrogen to androgen, which may increase by up to 40% (Ellem & 
Risbridger, 2010; Feldman et al, 2002). In particular, the role of stromal tumoral oestrogen 
may be important in altering the intratumoral oestrogen/testosterone ratio in prostate 
carcinogenesis (Ellem et al, 2004). 
Insulin-like growth factor axis 
IGF-1 has been implicated in prostate cancer, and promotes proliferation and inhibits 
apoptosis in normal prostate and tumour cells (Cohen et al, 1991). Elevated serum levels have 
been linked to an increased risk for prostate cancer (Mantzoros et al, 1997; Roddam et al, 
2008; Wolk et al, 1998). IGF-1 circulates in the serum bound to insulin-like growth factor 
binding protein, the most important being IGFBP-3. IGFBP-3 can promote apoptosis and 
mediate growth inhibition in the prostate  and is induced by 1,25-(OH)-2-vitamin D3 (Boyle 
et al, 2001). 
 
1.4.4 Somatic mutations associated with prostate cancer 
Androgen receptor 
Changes in the androgen receptor can lead to cancer initiation or progression in a 
number of ways. For example, increased AR expression is commonplace in castrate resistant 
disease, making these cancers more sensitive to lower available androgen levels in the 
androgen-depleted treatment state (Bubendorf et al, 1999). The AR has also been shown to be 
mutated in up to 50% of prostate cancers, leading to increased ligand affinity or 
indiscriminate activation by various ligands (Bostwick et al, 2004). Cross talk between the 
AR and other pathways can lead to AR activation and permit ongoing AR mediated 
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transcription (Culig et al, 1994). Knockdown of AR in an in-vivo mouse model of implanted 
tumours showed that significant inhibition of tumour growth, PSA decline and tumour 
regression is possible using shRNA to the AR (Snoek et al, 2009) 
 
TMPRSS2 
One of the most well-known gene fusions in prostate cancer is the fusion of the 5’ 
untranslated end of the TMPRSS2 gene (21q22.2) to members of the ETS family of 
oncogenic transcription factors (Tomlins et al, 2005). In the original work the investigators 
discovered the gene fusion in 23 of 29 prostate cancer samples. It was found that the 
androgen responsive elements of TMPRSS2 facilitate the overexpression of ETS proteins.  
The most common variant of this fusion appears to be between TMPRSS2 and ERG 
(21q22.3), in roughly 50% of patients (Kumar-Sinha et al, 2008). The TMPRSS2 gene is 
specific to the prostate and expressed in both benign and malignant tissue, and is induced by 
androgens. The presence of this gene fusion has been found to be associated with a much 
higher risk of death in men treated with watchful waiting (Demichelis et al, 2007). Currently 
the diagnosis of TMPRSS2:ETS gene fusions has not translated into any meaningful change 
in clinical practice, despite its potential as a diagnostic and therapeutic target.  
 
PTEN 
The phosphatase and tensin homolog, PTEN, has been widely implicated in cancer 
pathogenesis.  It is mutated in a large number of cancer types at high frequency. The protein 
product dephosphorylates phospho-inositide substrates and negatively regulates intracellular 
levels of phosphatidylinositol-3,4,5-trisphosphate in cells and acts as a tumour suppressor by 
also negatively regulating the AKT/PKB pathway. In prostate cancer it has been shown to 
induce cancer in mice when deleted (Wang et al, 2003), and loss of PTEN function is 
associated with a higher Gleason score and androgen  independent tumours (Rubin et al, 
2000). 
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Glutathione-S-Transferase (GST) 
GST is responsible for inactivating reactive oxygen species, and the expression of 
GSTP1 is absent in approximately 70% of PIN lesions and in virtually all cases of prostate 
cancer (Nelson et al, 2003). 
 
CDKN1B/p27 
CDKN1B is part of the CIP/KIP family of cyclin-dependent kinase inhibitors and 
regulates progression of the cell cycle from G1 to S phase. It has been shown that loss of 
CDKN1B may accelerate tumourigenesis by allowing cells to progress unchecked through 
the cell cycle. Mice lacking CDKN1B develop prostate hyperplasia, and mice lacking both 
CDKN1B and PTEN develop prostate cancer in a significant proportion of animals, with 
lower levels of CDKN1B  protein being associated with more aggressive carcinoma (Cordon-
Cardo et al, 1998). Human studies have demonstrated loss of heterozygosity in 50% of 
patients with metastatic disease (Kibel et al, 2000). Loss of CDKN1B in radical 
prostatectomy specimens has also been linked to a higher risk of disease recurrence (Guo et 
al, 1997). 
E-cadherin 
E-cadherin is located on 16q22.1 and encodes a transmembrane glycoprotein important 
in mediating calcium-dependent intercellular adhesion and cell signalling (Takeichi, 1991). 
E-cadherin expression is reduced or lost in a large proportion of prostate cancers, especially 
in poorly differentiated tumours and expression of the protein correlates inversely with 
tumour grade, stage, metastasis, recurrence and survival (Bussemakers et al, 1992; Umbas et 
al, 1994; Umbas et al, 1992). E-cadherin is typically lost during the epithelial to 
mesenchymal transition (EMT), discussed later in this chapter. It is therefore functional as a 
tumour suppressor in this respect, as cells gain an invasive phenotype during the process of 
EMT. E-Cadherin levels appear to be regulated by both oestrogen and androgens in LNCaP 
cells, with both steroids causing increased E-cadherin expression (Carruba et al, 1995). 
However, when compared to other markers such as TP53, bcl-2 and CD44, E-cadherin 
performed less well than TP53 and Gleason score in predicting relapse of disease after radical 
prostatectomy(Brewster et al, 1999). Interestingly , E-cadherin has been detected in bone 
metastases of prostate cancer (Bryden et al, 1999), which may reflect re-expression of this 
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protein in the metastatic lesion, or the fact that loss of the protein is not necessary for 
metastasis.  
1.4.5 Prostate cancer susceptibility loci identified through Genome-wide association 
studies (GWAS) 
Data from a number of international GWAS in prostate cancer, in particular the 
PRACTICAL Consortium, have yielded some important new candidate alleles conferring 
familial risk for prostate cancer (Kote-Jarai et al, 2011; Schumacher et al, 2011).  The top 
candidates include rs10187424 on 2p11, rs7584330 on 2q37, rs6763931 on 3q23, rs2242652 
on 5p15, rs10936632 on 3q26 and rs10875943 on 12q13. One of these , rs2242652 showed 
an association with PSA level in the direction consistent with its association for prostate 
cancer risk. Only one SNP, rs5919432, has shown an association for a higher per-allele OR 
for Gleason score ≥ 8 disease. Many of these loci have been shown to lie within plausible 
causative genes, including TERT, ZBTB38 (encoding a zinc finger transcriptional repressor 
which binds methylated DNA), FGF10 (often overexpressed in breast cancers), CCHCR1 
(upregulated in skin cancer and associated with EGFR expression and also promoting 
steroidogenesis by interacting with the steroidogenic acute regulator protein (StAR)). Overall, 
more than 40 susceptibility loci for prostate cancer have been identified, accounting for 23% 
of familial risk for prostate cancer (Kote-Jarai et al, 2011), with the top 10% of the population 
at highest risk holding a 2.4-fold greater risk than the average population for developing 
prostate cancer. 
 
 
1.5 THE CLINICAL COURSE AND CONTEMPORARY TREATMENT OPTIONS 
FOR PROSTATE CANCER 
1.5.1 Diagnosis, Grading and Staging of Prostate cancer  
Prostate cancer today is commonly diagnosed after suspicion is triggered by the 
presence of an elevated serum prostate specific antigen (PSA) level and/or an abnormal rectal 
exam performed by a physician. The diagnosis is made in most men by transrectal 
ultrasound-guided needle biopsy of the prostate, in which from 6 to 26 cores (usually 12) are 
taken from all zones of the prostate and examined by a pathologist after histological staining. 
PSA has a low sensitivity and specificity as a diagnostic test, but is currently the best 
available marker of the possibility of prostate cancer being present in a particular patient. 
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Further discussion about prostate cancer screening and other diagnostic biomarkers is beyond 
the scope of this thesis. 
Decisions about treatment options for prostate cancer are generally made using a 
combination of the clinical stage of disease at diagnosis, the Gleason score of the tumour at 
biopsy, and the serum PSA level. 
The National Cancer Institute defines stages of prostate cancer at diagnosis as follows: 
i) Localized – an invasive neoplasm confined entirely to the prostate 
ii) Regional – a neoplasm that has directly extended beyond the limits of the 
prostate capsule into surrounding organs or tissue; into regional lymph nodes, or 
both 
iii) Distant – a neoplasm that has spread to parts of the body remote from the 
primary prostate tumour, i.e., metastatic 
In clinical practice, cancer staging is formalised through the use of the TNM system 
(T=primary tumour, N=lymph nodes, M=metastases), drafted and updated by the UICC 
(http://www.uicc.org/resources/tnm). The TNM staging for prostate cancer is shown in figure 
1.7. The TNM system is used by urologists and oncologists in decision making and 
recommending treatment options for a particular patient, in conjunction with the Staging 
Classification shown in figure 1.8.  As a general rule, patients with cancer up to and including 
Stage III disease will be offered curative treatment, based on age and co-morbidities. For 
patients with nodal or metastatic disease, cure is usually impossible, and non-curative therapy 
is initiated, which is discussed below.  
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Figure 1.7 UICC/TNM classification for prostate cancer, 7
th
 Edition 2009 
T-assessment of primary tumour; N-assessment of loco-regional lymph nodes; M- assessment of 
presence of metastatic disease. N0 - no lymph nodes involved; N1 - local pelvic or para-aortic lymph 
nodes involved; M0 – no evidence of distant metastases; M1 – distant bony or soft tissue/organ 
metastases present   
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Figure 1.8 Staging risk-classification system for prostate cancer   
(Reproduced from Guidelines on Prostate Cancer, © European Association of Urology 2012) 
 
The Gleason scoring system is the second component integral to decision- making in 
the treatment of prostate cancer. The ISUP 2005 Gleason score is the current standard for 
grading adenocarcinoma of the prostate on core biopsy and operative specimens (Epstein et 
al, 2005). The Gleason grade or pattern represents a low power pathological assessment of 
the architecture of prostate cancer glands, and is given a number from 1 to 5, as depicted in 
figure 1.9 (1 being histological features closest to normal epithelium, 5 representing 
completely disordered architecture usually consisting of sheets of tumour cells with no 
glandular components).  The Gleason score ranges between 2 and 10, with 2 being the least 
aggressive and 10 the most aggressive. It is an arithmetic sum of the two most common 
Gleason grades seen in low power assessment. A tertiary score is also referenced where it 
may modify the overall prognosis. For example, a tumour may be scored as Gleason 3+4, 
with tertiary pattern 5. This means that the most common pattern/grade was 3, with areas of 
pattern 4 present in smaller amounts. However, areas of pattern 5 were also seen and would 
be quantified if possible by the pathologist.   
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Figure 1.9 Schematic diagram of modified Gleason grading system  Reproduced from Epstein et. 
al, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason 
Grading of Prostatic Carcinoma (Epstein et al, 2005) 
Since the advent of widespread PSA testing in the early 1990s there has been a 
significant change in the stage at which prostate cancer is diagnosed. Prior to PSA testing, 
prostate cancer was often diagnosed at a locally advanced or metastatic stage, with no hope 
for cure for the patient, and palliative treatment often being the only option. SEER data reveal 
that during the PSA screening years, the rate of distant disease at diagnosis fell by 56% (from 
14.9 per 100,000 in 1985 to 6.6 per 100,000 in 1995) with a sharp rise in the diagnosis of 
localized disease (Stanford et al, 1998). This trend is shown in figure 1.10, which shows the 
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SEER data for the period 1983-1995. The sharp rise in diagnosis of localized disease (blue 
line) with the advent of widespread PSA testing, is contrasted against a steady fall in the rate 
of distant or metastatic disease over time (red line). 
 
 
Figure 1.10 Prostate cancer SEER incidences by Stage, 1983-1995 
Reproduced from Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute 
(Stanford et al, 1998) 
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1.5.2 Treatment options for localised prostate cancer 
Localised prostate cancer consists of prostate cancer that has not spread beyond the 
confines of the prostate gland, or may have only spread microscopically beyond the confines 
of the prostate capsule. In broad terms men with localised prostate cancer can be offered the 
following options based on their age, general health status and the grade and clinical stage of 
prostate cancer and PSA level: 
i) No treatment – reserved for men where treatment would not make a difference 
to the patient’s expected life span or quality of life 
ii) “Active Surveillance” – reserved for low volume, low grade cancers (usually 
Gleason score <=6) in otherwise healthy men who are eligible for curative 
treatment 
iii) Radical prostatectomy – by open surgery, laparoscopic-assisted or robotically-
assisted surgery 
iv) Radiotherapy – a number of modalities are available, including external beam 
radiotherapy (3D-conformal (3D-CRT) or intensity modulated external beam 
radiotherapy (IMRT)) and transperineal seed brachytherapy 
v) Experimental therapies – Cryotherapy; HIFU (high intensity focussed 
ultrasound) 
Active Surveillance 
The rationale behind active surveillance is that the disease, in this case prostate cancer, 
is not expected to advance rapidly and become a threat to the patient in the foreseeable future. 
This premise is built on various evidence bases, including autopsy studies showing high 
prevalence of prostate cancer in older men, many of whom were not diagnosed with prostate 
cancer and died from other causes (Haas et al, 2008). Prostate cancer is diagnosed in only 15-
20% of men during their lifetime, and the lifetime risk of death is 3% (Jemal et al, 2006). 
Nowadays the term ‘active surveillance’ is the preferred term for denoting expectant 
management and involves close follow-up of the patient with an early re-biopsy usually at 6 
or 12 months to exclude missed significant cancer. Triggers to initiate treatment include more 
aggressive Gleason grade found on follow-up biopsy, Gleason grade 6 cancer in multiple 
cores (usually more than 3), or rising PSA in the absence of demonstrable increased cancer 
grade or volume (in other words, it is assumed a significant cancer is present in the prostate 
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but it has been missed on biopsy). One of the benefits of active surveillance is the desire to 
avoid over-treatment of cancers that would not pose a material threat to a patient’s life span 
or health. The most advanced cohort of active surveillance to date was reported in 2010 and 
showed a 10 year disease specific survival of 97.2%, and 30% of patients had undergone 
curative treatment (Klotz et al, 2010). 
 
Radical Prostatectomy 
Radical prostatectomy is a surgical procedure whose aim is complete removal of the 
prostate gland and seminal vesicles, as well as a pelvic lymph node dissection where 
indicated, culminating in the creation of a new anastomosis between the bladder neck and 
remnant membranous urethra at the level of the perineal membrane of the pelvis. The 
“trifecta” of complete cancer removal, maintenance of continence and erectile function is the 
goal that every surgeon strives to achieve in this challenging procedure.  There are no 
absolute criteria for patient eligibility for this procedure, but in general the assessment should 
establish that cure is possible based on the presence of localised disease only, and the 
patient’s general condition should be adequate to tolerate major surgery, with an expected life 
span of 10 years or more. The surgery is usually not performed in the setting of Stage IV 
disease (invasion of prostate cancer into adjacent organs or pelvic sidewalls). For the first 
half of the 20
th
 century the procedure was performed perineally, until Memmelaar and Millin 
described a retropubic approach (Memmelaar, 1949). In 1982 Walsh and Donker published a 
seminal work describing the anatomy of the dorsal vein complex of the prostate and the 
neurovascular bundles, which revolutionized the procedure and helped to greatly alleviate 
blood loss and improve potency rates (Walsh & Donker, 1982). The procedure was refined 
over the following two decades with resultant lowering of complication rates and improved 
cure, potency and continence rates (Augustin et al, 2003; Lepor et al, 2001; Potosky & 
Warren, 1999). Laparoscopic radical prostatectomy emerged in the early 1990s, followed by 
the advent of robotically assisted laparoscopic prostatectomy since 2000. Radical 
prostatectomy is the only curative treatment modality that has been shown in large trials to 
reduce the risk of death from prostate cancer (Bill-Axelson et al, 2011). 
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Radiotherapy 
There are no randomised studies comparing radical prostatectomy with either external 
beam radiation therapy (EBRT) or brachytherapy for localised prostate cancer. However, it is 
generally accepted that EBRT affords patients the same long term survival outcomes as 
surgery, with equivalent quality of life measures (Fowler et al, 1996). Intensity modulated 
radiotherapy (IMRT) is the current gold standard of treatment and is being adopted 
progressively. Recent studies have underlined the importance of dose escalation , and 
currently a minimum dose of 74Gy is recommended for EBRT and hormonal therapy (Viani 
et al, 2009). 
Transperineal brachytherapy is also safe and effective for carefully selected patients 
with low risk disease (Salembier et al, 2007) 
There are many combinations of radiotherapy and androgen deprivation treatment that 
have been assessed and reported in the literature. Discussion of these regimens is beyond the 
scope of this thesis.  
Experimental therapies 
Cryotherapy and HIFU of the prostate are emerging therapies that have not yet been 
accepted into mainstream practice by urologists or oncologists, although the American 
Urological Association (AUA) lists cryosurgical ablation of the prostate (CSAP) as a valid 
therapeutic alternative. These modalities may gain broader acceptance as better imaging 
modalities for prostate cancer (e.g. multi-parametric MRI) allowing lesion surveillance 
become mainstream in the coming years.  
 
1.5.3 Treatment of relapse after curative intent and metastatic disease 
Despite thorough assessment and planning in the delivery of curative treatment for 
prostate cancer, a significant proportion of patients undergoing curative treatment will 
develop disease recurrence, usually with distant metastases in lymph nodes and bones, 
resulting in incurable disease. Between 27% and 53% of all patients undergoing radical 
prostatectomy (RP) or radiation therapy develop local or distant disease recurrence in 10 
years, and 16-35% will receive second line treatment within five years of initial therapy 
(Fowler et al, 1993; Grossfeld et al, 1998; Lu-Yao et al, 1996; Partin et al, 1994). Relapse is 
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usually first evident by a rising PSA (following RP, a value >0.2ng/mL on 2 consecutive 
measures, and following radiotherapy, a PSA value of 2ng/mL above the nadir following 
treatment). Roughly half of men having relapse after radical prostatectomy will have local 
recurrence in the pelvis, and these men are usually offered salvage radiotherapy. For men 
developing distant recurrence or metastases, the mainstay of treatment is attempted 
stabilisation of the disease and prolongation of life using androgen deprivation therapy. The 
effectiveness of androgen deprivation therapy has been well established beginning with the 
work of Huggins noted above (Huggins, 1946). The testes are the source of most circulating 
androgens, with adrenal synthesis accounting for only 5-10% of androgen production. 
Testosterone secretion is regulated by the hypothalamic-pituitary gonadal axis. Hypothalamic 
luteinising hormone releasing hormone (LHRH) stimulates the anterior pituitary gland to 
release luteinising hormone (LH) and follicle stimulating hormone (FSH). LH stimulates the 
Leydig cells of the testes to secrete testosterone. Within the prostate, testosterone is converted 
to 5-α-dihydrotestosterone (DHT) by the enzyme 5-α reductase. DHT is an androgenic 
stimulant approximately ten times more potent than testosterone. Prostate cells deprived of 
androgens undergo apoptosis, making androgen deprivation therapy (ADT) a successful 
treatment for disease stabilisation and temporisation. Unfortunately, experience has shown 
that ADT seldom results in death of all prostate cancer cells, leading to the development of 
castrate-resistant disease, discussed below. The standard castrate level is defined as a 
circulating testosterone <50ng/dL, though some authors suggest <20ng/dL should be defined 
as the appropriate castrate level.  
Contemporary options for androgen ablation / ADT  in prostate cancer include: 
i) Bilateral surgical orchidectomy 
ii) LHRH agonists – long acting LHRH agonists such as leuproreline, gosereline 
and busereline have been used for over 15 years and constitute the mainstay of 
current ADT treatment. These are synthetic analogues of LHRH delivered as 
subcutaneous depot injections every one, three or six months. Their mechanism 
of action is to initially stimulate an LH and FSH surge, which leads to a 
temporary elevation of testosterone. However, within a matter of a few weeks, 
LHRH receptors in the pituitary are downgraded, resulting in down-regulation 
of the pituitary-gonadal axis and greatly diminished testicular production of 
testosterone (Limonta et al, 2001) 
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iii) LHRH antagonists – these compounds bind immediately and competitively to 
the LHRH receptors in the pituitary gland and cause a rapid decrease in LH, 
FSH and testosterone levels. The two compounds available include Degarelix 
and Abarelix. 
iv) Oestrogens – oestrogens have several mechanisms of action , including down-
regulation of LHRH secretion, androgen inactivation, direct suppression of 
Leydig cell function and direct cytotoxicity to prostate epithelium.(Oh, 2002). 
Diethylstilboestrol was commonly used but complicated by significant 
cardiovascular side effects including thrombogenic complications. Development 
of novel oestrogen compounds with minimal cardiovascular side effects is still 
ongoing. 
v) Anti-androgens – These compounds compete with testosterone and DHT at the 
receptor level in prostate cell nuclei and inhibit the androgen axis, thus 
promoting apoptosis and inhibiting cancer growth (Anderson, 2003). There are 
two classes of anti-androgens currently in use  
a. Steroidal anti-androgens – synthetic derivatives of hydroxyprogesterone e.g. 
Cyproterone acetate, medroxyprogesterone acetate. These compounds also 
suppress testosterone secretion through their progesterone-like effects, 
leading to adverse effects for patients 
b. Non-steroidal anti-androgens – bicalutamide, flutamide and nilutamide. 
These compounds do not suppress testosterone secretion, but have other side 
effects such as hepatotoxicity 
There are multiple protocols for the use of these agents, including monotherapy, 
combination therapy, and various schemas of continuous or intermittent therapy. Further 
discussion is beyond the scope of this thesis. 
 
1.5.4 Castration-Resistant  Prostate Cancer (CRPC) 
Despite the effectiveness of ADT in the early treatment of locally advanced or 
metastatic disease, most patients will eventually develop castrate resistant prostate cancer. 
This signifies progressive tumour growth in the presence of very low or castrate serum 
testosterone levels, and represents a fundamental change and evolution in the cancer biology 
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of that patient. It is usually heralded by a progressive rise in PSA despite ongoing ADT. 
There are a number of theories aiming to explain how CRPC arises. An alteration in normal 
androgen signalling is thought to be pivotal to the pathogenesis of castrate resistant prostate 
cancer (Schroder, 2008) 
i) Androgen receptor-independent mechanisms – AR-independent mechanisms 
may be associated with deregulation of apoptosis through deregulation of 
oncogenes. For example, high levels of bcl-2 are commonly seen as prostate 
cancer progresses. Bcl-2 may protect cancer cells from chemotherapy through 
its regulation of microtubule integrity (Haldar et al, 1997). Most 
chemotherapeutics in prostate cancer function by inhibiting microtubule 
formation. Furthermore, the tumour suppressor gene TP53 is more frequently 
mutated in castrate-resistant prostate cancer, and overexpression of bcl-2 and 
TP53 predict an aggressive course with poorer outcomes (Bauer et al, 1996; 
Theodorescu et al, 1997) 
ii) AR dependent mechanisms – These mechanisms account for the major 
biological changes leading to castrate-resistant disease. These include ligand 
independent AR activation, including through cross-talk with the tyrosine 
kinase activated pathways IGF-1, KGF and EGF. EGF is a potent mitogen of 
prostate stromal and epithelial cells and is produced in high levels within 
tumours and acts as a paracrine stimulator (Leotoing et al, 2007; Orio et al, 
2002; Recchia et al, 2009; Reinikainen et al, 1996; Wang et al, 2007c). Another 
mechanism is that of AR amplification and overexpression, which is observed 
in one-third of CRPC tissues (Hu et al, 2009; Koivisto & Helin, 1999; Koivisto 
& Rantala, 1999; Linja et al, 2001). Androgen receptor mutations are also well 
described and may lead to promiscuous binding with other steroids including 
oestrogen or progesterone, or constitutive activation (Ruijter et al, 1999; Taplin 
et al, 1995). Finally, it has been shown that prostate cancer cells are capable of 
synthesizing steroids autologously, allowing them to bypass serum-depleted 
levels of androgen (Locke et al, 2008; Montgomery et al, 2008; Stanbrough et 
al, 2006). Metastatic prostate cancer samples have shown high levels of 
androgens, suggesting local synthesis (Stanbrough et al, 2006). 
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Patients who develop castrate-resistant prostate cancer have incurable disease and 
limited survival. In the presence of a rising PSA and no evidence of metastases, mean 
survival is 36 months at most. In the setting of extensive metastases and symptoms, mean 
survival is only 9 to 12 months (Mottet et al, 2011). 
There are a number of therapeutic options for patients with castrate-resistant disease, as 
outlined in figure 1.11.  However, as mentioned above, all of these options are only palliative, 
gaining the patient a few extra months of life in each case, and with many of the options only 
showing an effect in under half of patients treated.  
Two recent therapies have provided added hope for these patients, both at significant 
cost however. The first is abiraterone acetate, an inhibitor of 17 α-hydroxylase/C17,20 lyase, 
a steroidal synthesis enzyme expressed in testicular, adrenal and tumour tissues. A recent 
phase III clinical trial showed that abiraterone prolonged survival from a median 10.9 months 
to 14.8 months in men with castration resistant metastatic prostate cancer following failure on 
docetaxel treatment.(de Bono et al, 2011) The second agent is Sipuleucel-T, a synthetic 
therapeutic cancer vaccine manufactured using patients’ own dendritic cells. The results of 
the IMPACT trial showed a 22% relative reduction in the risk of death with a 4.1 month 
added median survival advantage (25.8  in the Sipuleucel-T group vs 21.7 months in the 
placebo group)(Kantoff et al, 2010). 
The treatment of metastatic prostate cancer is a field that is in need of a breakthrough in 
translational research. The constellation of bony pain, anorexia, weakness, malaise and 
treatment side effects, including pathologic bone fractures, make this a particularly difficult 
group of patients to treat and palliate. Although prostate cancer can be cured in its early 
stages, the inevitable mortality that proceeds from metastatic disease should make research 
and innovation in this area a high priority.  
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Figure 1.11 Therapeutic options after initial androgen deprivation therapy in prostate cancer. 
(Reproduced from EAU Guidelines on Prostate Cancer 2012, (Mottet et al, 2011)) 
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1.6 Y-BOX BINDING PROTEIN 1 (YBX1) 
Y-box binding protein 1 (YBX1) is a multifunctional and conserved member of a large 
family of proteins with a conserved cold shock domain. It has numerous roles in cellular 
biology, including proliferation, regulation of transcription and translation, DNA repair, RNA 
chaperoning, a role in embryogenesis and importantly, a central role in the cellular response 
to stress, including radiation and foreign chemicals and pharmaceutical treatment. More 
importantly for cancer research, YBX1 overexpression has been implicated as an adverse 
prognostic factor in multiple cancer types. It appears to be a central molecule in cellular 
biology with diverse roles. A recent excellent and exhaustive review has been published on 
YBX1 to which the reader is referred for a complete synopsis of this protein (Eliseeva et al, 
2011). In the following section, a broad overview of YBX1 and its functions relevant to 
understanding its role in cancer, and prostate cancer in particular, will be presented. 
1.6.1 YBX1 gene structure and function 
Y-box binding proteins were described and characterised in a number of animals in the 
1970’s including duck, rabbit and amphibians (Morel et al, 1973; Morel et al, 1971) (van 
Venrooij et al, 1977). At that time the proteins were found to migrate on SDS polyacrylamide 
gels at a molecular weight of approximately 50kDa, and so were named p50, p54 or p56. In 
1988, one of these proteins was sequenced and found to interact with the Y-box motif in the 
promoter of the major histocompatibility complex class II genes (Didier et al, 1988). The 
gene was named Y-box binding protein 1 and was found to bind to an inverted CCAAT box 
(5′-CTGATTG-GC/TC/TAA-3′) in the Y box of the promoter and was calculated as having 
35,414 residues with a putative nuclear localization signal.   
There are three families of Y-box binding proteins, with slightly differing gene 
structure as outlined in figure 1.12. The first family (YB-1) includes human YB-1 and rabbit 
p50 and mouse MSY-1. These proteins are found in somatic cells and have multiple 
functions. The second family (YB-2) includes proteins specific for germ cells, such as mouse 
MSY-2, FRGY2 from X. laevis and human YB-2 and dpbC. The third family (YB-3) 
includes human dpbA, mouse MSY-3 and YB-3 from X. laevis. These are mainly embryonic 
proteins. 
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As can be seen in figure 1.12, all three gene families possess a cold-shock domain 
(CSD) nearer the N-terminus  and an elongated C-terminal domain (CTD) with 
alternating clusters of positively and negatively charged amino acid residues. The N-
terminal domain is rich in alanine and proline (also called A/P domain therefore). The 
cold-shock domains show over 90% homology 
 
Figure 1.12 Gene structure of the Y-box families 
(Reproduced from Y-box binding 1 (YB-1) and its functions, Eliseeva et. al. (Eliseeva et al, 2011)) 
 
The CSD is a conserved amino-acid sequence found to be homologous across many species 
of euakaryotes and prokaryotes. Eukaryotic CSDs are very similar to bacterial cold shock 
proteins (Csps), many of which are induced by environmental cold stress and are involved in 
adaptation to low temperatures. Bacterial Csps are known to bind to single stranded nucleic 
acids and function as RNA chaperones and can affect any step of gene expression involving 
RNA (Mihailovich et al, 2010). YBX1 is one of the most well-known eukaryotic cold-shock 
domain containing proteins.  
YBX1 and its homologs can form oligomers with a mass of up to 800kDa and has been found 
to affect RNA secondary structure (Evdokimova et al, 1995). In addition it has also been 
shown that YBX1 is capable of forming elongated fibrils 15-20nm in diameter and several 
micrometres long and with a helical configuration.  
The human YBX1 gene is found at chromosome 1p34 and encodes a protein of 324 amino 
acids. There are a number of YBX1 pseudogenes which have been annotated and these are 
discussed in Chapter 3. The calculated molecular mass is 35.9kDa, but it has been repeatedly 
shown to migrate at 50kDa on SDS polyacrylamide gels, possibly due to glycosylation. 
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1.6.2 YBX1 and embryogenesis 
In embryonic tissues there is high level YBX1 expression in heart, muscle, lung, adrenal 
gland and brain, and low amounts in thymus, kidney, bone marrow and spleen (Spitkovsky et 
al, 1992). YBX1 has been demonstrated to be vital for normal embryonic development, 
particularly late embryonic development in mice (Lu et al, 2005). Mice that were YBX1(-/-) 
were shown to develop growth retardation after 13.5 days, exencephaly, craniofacial defects 
and progressive mortality. Neural tube closure is also deficient in YBX1(-/-) mice (Uchiumi 
et al, 2006). 
1.6.3 Cellular location and translocation 
It is well known that YBX1 is mainly localised in the cellular cytosol and moves to the 
nucleus or peri-nuclear region after varying, usually noxious, stimuli such as UV irradiation, 
hyperthermia (Stein et al, 2001) and drugs such as cisplatin (Izumi et al, 2001; Ohga et al, 
1996). An early paper in 1997 showed that UV irradiation induces YBX1 translocation into 
the nucleus, and experimental evidence suggested that a protein kinase mediated this process, 
as a protein kinase C inhibitor repressed YBX1 translocation (Koike et al, 1997). The authors 
also established that the C-terminal domain was the likely region of a cytoplasmic retention 
signal. Further work a few years later by another team identified the splicing factor SRp30c 
as an important co-localizing protein in YBX1 nuclear translocation and identified the YBX1 
N-terminal domain as the interacting terminus for SRp30c (Raffetseder et al, 2003). In the 
same year, wild-type TP53 was identified as a necessary co-factor for YBX1 nuclear 
localisation, and that mutant TP53 was associated with much lower levels of YBX1 nuclear 
localisation (Zhang et al, 2003). The authors also showed that YBX1 inhibits TP53 induced 
gene transactivation and inhibits apoptosis. Another factor necessary for YBX1 nuclear 
localization was found to be Akt mediated phosphorylation of YBX1, demonstrated in 
ovarian cancer cell lines (Basaki et al, 2007). The effect was specific to Akt, as inhibitors of 
MEK, p38MAPK and JNK had no effect on YBX1 translocation. Aside from its location in 
the cytoplasm and nucleus, YBX1 has also been shown to localize in P-bodies (involved in 
mRNA degradation) and stress granules (involved in storage and triggered release of mRNA 
(Goodier et al, 2007; Kedersha & Anderson, 2007; Kozak et al, 2006; Onishi et al, 2008) 
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1.6.4 DNA Binding and repair 
YBX1 binds both double and single stranded DNA, though it has a higher affinity for 
single-stranded DNA (Izumi et al, 2001). The CSD is necessary for double-stranded DNA 
binding, while the CTD interacts with both single-stranded DNA and RNA independently of 
the CSD. In addition, the same authors described an intrinsic 3’-5’ exonuclease activity of the 
protein. Other authors have demonstrated that YBX1 binds with higher affinity to damaged 
DNA than undamaged DNA (Hasegawa et al, 1991) and also to cisplatin-modified DNA (Ise 
et al, 1999). It has also been shown that YBX1 has a clear role to play in DNA damage repair, 
with the ability to mediate strand separation of cisplatin-modified DNA or regions containing 
mismatches (Gaudreault et al, 2004) as well as binding the DNA repair proteins Ku80, MSH2 
and DNA polymerase delta. YBX1 is not only essential for nuclear DNA repair, but it has 
also been shown to play an important role in mitochondrial DNA repair, especially in the 
mismatch repair pathway (de Souza-Pinto et al, 2009). 
1.6.5 RNA regulation 
YBX1 has several important roles to play in RNA regulation.  It is a major component 
of cytoplasmic messenger ribonucleoprotein particles (mRNPs) with roles in pre-mRNA 
splicing, mRNA stability and translation. In general YBX1 has high nonspecific affinity for a 
large variety of inhomologous mRNA species. However, it has been shown to display 
particular affinity for mRNA with certain characteristics. It has the highest affinity for 
poly(G) sequences, followed by poly(U), poly(A) and poly(C) (Minich et al, 1993). Secondly 
YBX1 preferentially binds to mRNA sequences high in A and C residues (in particular, C in 
the third position, A in the fourth and C in the sixth position) (Bouvet et al, 1995; Giorgini et 
al, 2001). Finally it has been shown that YBX1 has higher affinity for RNA containing an 
oxidized base 8-oxoguanine, which can be formed under conditions of oxidative stress and 
result in errors in protein synthesis (Hayakawa et al, 2002). 
YBX1 has a role in suppressing mRNA translation, and competes with poly(A)-binding 
protein (PABP) for regulatory sites in mRNA (Lyabin et al, 2011). It also inhibits the 
initiation of protein synthesis by preventing the interaction of eIF4F with mRNA (Nekrasov 
et al, 2003). An interesting study uncovered the fact that the ratio of YBX1 molecules to 
mRNA is important for determining the fate of the mRNA. When the YBX1 level is 
relatively low, YBX1 is able to bind to mRNA through both its CTD and CSD. As the level 
of YBX1 is increased, binding through the CTD lessens, leaving only the CSD bound to 
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mRNA. At high YBX1 to mRNA ratios, YBX1 is able to prevent the interaction of mRNA 
with translation initiation factors (Evdokimova et al, 2001). Under physiological conditions 
YBX1 accelerates annealing of RNA strands and catalyses the exchange of complementary 
strands, acting as an RNA chaperone (Skabkin et al, 2001). In addition YBX1 facilitates the 
binding of mRNA to microtubules along with PABP (Chernov et al, 2008a). It also plays a 
role in alternative splicing of mRNA transcripts, and this has been demonstrated for a number 
of proteins (Allemand et al, 2007; Rapp et al, 2002; Stickeler et al, 2001). 
 
1.6.6 YBX1 self-regulation 
There is strong evidence showing that YBX1 regulates its own expression. It has been shown 
that YBX1 binds its own mRNA in the cytoplasm via its C-terminal domain and that the 
5’UTR stimulates YBX1 gene expression (Fukuda et al, 2004). The same paper showed that 
recombinant YBX1 protein is able to inhibit YBX1 mRNA translation. (This effect was 
confirmed in experiments reported in Chapter 5). Another group has shown that 3’UTR 
fragments of YBX1 mRNA are also able to strongly inhibit YBX1 mRNA translation, and 
also found that Poly(A)-Binding protein (PABP) positively regulates YBX1 mRNA 
translation (Skabkina et al, 2003). This group went on to show that YBX1 and PABP 
compete for binding to YBX1 mRNA and that YBX1 inhibits translation whilst PABP 
stimulates translation by displacing YBX1 from a 3’UTR regulatory element (Skabkina et al, 
2005). 
 
1.6.7 Regulation of YBX1 
A number of factors controlling the expression of YBX1 have been elucidated. An 
early paper investigating YBX1 regulation showed that YBX1 levels increase 6-fold with 
cisplatin exposure in the KB human cancer cell line, and that this up-regulation is  mediated 
through p73 which functions to recruit the c-Myc-Max complex to the E-box in the YBX1 
promoter (Uramoto et al, 2002). A key insight into YBX1 regulation and nuclear 
translocation came in a paper which showed that YBX1 is a substrate of the P-Akt 
serine/threonine kinase, which phosphorylates YBX1 at Ser102 (within the CSD) in the 
breast MDA-MB-231 cell line (Sutherland et al, 2005). The authors also showed that 
mutation of YBX1 at Ser102 disrupts anchorage independent growth of breast cancer cells 
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and suppressed YBX1 nuclear translocation. Within the foetal brain, it has been shown that 
Math2 protein binds to an E-box in the 5’UTR of YBX1 and drives protein expression in the 
period between 5 days and 3 weeks of foetal growth (Ohashi et al, 2009). Mechanisms of 
YBX1 degradation and ubiquitination have also been identified. The F-box protein FBX33 
has been found to bind YBX1 and target it for ubiquitination and proteasome degradation 
through recruitment of Skp-1/Cull (Lutz et al, 2006). Retinoblastoma binding protein 6 
(RBBP6) has also been shown to bind and target YBX1 for proteasomal degradation through 
its RING finger domain interacting directly with residues 262-324 of the YBX1 protein, a 
region that overlaps with the YBX1 binding site for TP53 (Chibi et al, 2008). 
 
1.6.8 YBX1 and cell cycle control 
There is strong evidence linking YBX1 to cell cycle control and cell proliferation. An 
early paper in 2003 clarified the role of YBX1 in cell proliferation, after general effects of 
YBX1 on proliferation had been noted in cancer cell lines. The authors found that YBX1 
relocates from the cytoplasm to the nucleus at the G1/S phase transition in HeLa cells and 
showed that the charged zipper domain and CSD are involved in this process (Jurchott et al, 
2003). The authors also showed that nuclear accumulation of YBX1 was associated with 
increased mRNA and protein expression of cyclin A and cyclin B1, both of which contain Y-
boxes in their promoter regions. This co-expression of YBX1 and cyclin A and cyclin B1 was 
confirmed by immunohistochemistry in breast cancer tissue samples. Work by other groups 
confirmed this, with YBX1 overexpression in mesangial cells leading to increased DNA 
synthesis and increased numbers of cells in S and G2 phases of the cell cycle (Feng et al, 
2009). Furthermore, it was shown that the expression of cyclins A2, D1, E and p27 were 
increased, with a concomitant decrease in p21 levels, and that these changes were mediated 
through the ERK1/2 signalling pathway. A YBX1 shRNA knockdown and cDNA microarray 
study in the leukaemia cell line K562/A02 confirmed these findings broadly, showing down-
regulation of genes involved in cell cycle progression, gene replication, metabolism, 
apoptosis and cell signal transduction, as well as increased numbers of cells in G1 with a 
lower ratio of cells in G2 and  S phases (Xu et al, 2009). Another study using YBX1 
knockdown found that YBX1 suppression led to down-regulation of  cell division cycle 
homolog 6 (CDC6) and marked suppression of cell proliferation and S phase entry (Basaki et 
al, 2010), and associated down-regulation of cyclin D1, CDK1 and CDK2 along with 
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elevated levels of p21 and p16/INK4A.  It is evident therefore from these studies that a 
central role of YBX1 is modulating the cell cycle and cell proliferation. These findings are 
recapitulated for prostate cancer in the work reported in Chapter 5 (see Figure 5.13). 
1.6.9 YBX1 facilitates drug and chemotherapy resistance 
One of the earliest discoveries of YBX1 function related to its induction of P-
glycoprotein or ABCB1/MDR1 (ATP-binding cassette, sub-family B (MDR/TAP), member 
1) on 7q21.12. This is a member of the ATP binding cassette family of proteins involved in 
multi-drug resistance. ABCB1/MDR1 is an ATP-dependent drug efflux pump for xenobiotic 
compounds with broad substrate specificity. It is responsible for removing a wide range of 
drugs and chemotherapeutics from cells and has been shown to mediate the resistance of 
cancer cells to anticancer drugs. YBX1 was shown to induce MDR1 (this older term is used 
by most of the literature prior to 2007) in a variety of cell lines. The first paper reporting 
YBX1 induction came in 1994, showing that in KB cells (a subline of HeLa cells containing 
human papilloma virus 18) treated with actinomycin , YBX1 binds to the CCAAT box of 
MDR1 and mediates its response to actinomycin (Asakuno et al, 1994). This relationship was 
confirmed by multiple studies that followed (Fujita et al, 2005; Gu et al, 2001; Oda et al, 
2003; Ohga et al, 1998; Saji et al, 2003; Stein et al, 2001). Various groups have shown that 
YBX1 overexpression in cancers is associated with a poorer prognosis and relapse after 
chemotherapy, including breast cancer (Janz et al, 2002; Saji et al, 2003), and synovial 
sarcoma (Oda et al, 2003) an B-cell lymphoma (Shen et al, 2011). Another group showed that 
human AP-endonuclease (APE1/Ref-1), an enzyme involved  in repair of oxidative base 
damage and DNA strand breaks, appears to play an important role in facilitating YBX1 
binding to the MDR1 Y-box element and gene activation (Chattopadhyay et al, 2008) 
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1.6.10 YBX1 overexpression and nuclear localisation is an adverse prognostic factor in 
human cancers 
 
YBX1 has been implicated as an adverse prognostic factor in multiple human cancers, 
with YBX1 overexpression and nuclear localisation showing strong and consistent 
associations with early disease recurrence, chemotherapy resistance, relapse after 
chemotherapy and early death compared to patients whose tumours did not exhibit YBX1 
overexpression or nuclear localisation. The following section summarizes major findings for 
common human cancers and is not an exhaustive list.  
Breast cancer 
From 1997 reports began emerging of the link between YBX1 expression levels and 
adverse outcomes in breast cancer. It was shown that in tissue from untreated breast cancer 
patients, YBX1 nuclear localization was associated with MDR1 expression and multidrug 
resistance, and this was confirmed in-vitro using MCF-7 breast cancer cells (Bargou et al, 
1997). This finding was strengthened by a paper in 2002 showing patients expressing high 
levels of YBX1 in their breast cancers had a 66% 5-year relapse rate, despite chemotherapy, 
compared to patients with low expression.  In addition, YBX1 characterisation allowed better 
prognostic discrimination than HER2 expression (Janz et al, 2002). These findings were 
confirmed in another paper which also interestingly showed that YBX1 expression was 
higher in breast tumours which were oestrogen-receptor (ER) negative and lymph-node 
positive (Huang et al, 2005). A large study in 2008 lent strong support to the usefulness of 
YBX1 in breast cancer outcome prediction. Across a tumour tissue microarray of 4049 cases, 
YBX1 was highly predictive of relapse and poor survival across all breast cancer subtypes 
and outperformed ER and HER-2 as a prognostic marker (Habibi et al, 2008). YBX1 
expression was then used to validate selection of a dose-intensified chemotherapy regime, 
rather than a conventional dose-dense chemotherapy regime. Adjustment of the 
chemotherapy regime based on YBX1 expression led to better outcomes in terms of overall 
survival (OS) and disease-free survival (DFS) (Gluz et al, 2009). These findings seem to hold 
across ethnic groups, with Chinese patients with YBX1 nuclear localization in breast cancers 
also showing poorer OS and DFS (Xie et al, 2012). In-vitro treatment of breast cancer cell 
lines with a YBX1 decoy peptide was shown to inhibit YBX1 phosphorylation at S102 and 
led to a 90%  inhibition of growth of breast cancer cell lines SUM149, MDA-MB-453 and 
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AU565, as well as prostate cancer cell lines PC3 and LNCaP. This provided proof of 
principle that targeting YBX1 may hold promise in clinical treatment (Law et al, 2010) 
Prostate cancer 
The first paper to show a role for YBX1 in prostate cancer was published in 2004. 
Androgen independent (AI) LNCaP cells were generated after subcutaneous inoculation in 
nude mice followed by castration, and YBX1 expression was shown to increase with 
progression to androgen independence (Gimenez-Bonafe et al, 2004) in both cDNA arrays 
and by tumour sample immunohistochemistry. This increase in YBX1 expression was 
associated with up-regulation of P-glycoprotein, which interestingly also caused an efflux of 
DHT from cells with consequent decreased androgen-dependent gene transcription. YBX1 
expression levels in tumour tissue were found to be higher in higher Gleason grade prostate 
cancer, and correlated with P-glycoprotein expression. Lastly, YBX1 nuclear staining was 
enhanced after a period of neo-adjuvant hormone treatment in men undergoing radical 
prostatectomy. This paper clearly established a role for YBX1 in the progression of prostate 
cancer to androgen independent disease, and the effect on DHT efflux from cells through P-
glycoprotein provides an interesting possible mechanism for driving cells into an androgen-
independent phenotype. 
Further insights into the role of YBX1 and androgen regulation in prostate cancer came 
in 2011 from a Japanese group, who showed that YBX1 expression correlates positively with 
Gleason grade and also that YBX1 regulates AR expression at the transcriptional level, with 
YBX1 and AR levels showing immunohistochemical correlation in clinical cancers from men 
undergoing radical prostatectomy (Shiota et al, 2011a). This group was the first to show that 
YBX1 regulates expression of the AR and that it does so by binding to the Y-box in the AR 
promoter region. This group also demonstrated important findings that YBX1 knockdown 
caused more profound growth retardation in prostate cancer cell lines than AR knockdown, 
and that YBX1 overexpressing cells were resistant to castration-induced growth suppression. 
Finally, these researchers also showed that YBX1 induction after chemotherapy in prostate 
cancers leads to activation and expression of clusterin, a cytoprotective chaperone known for 
its role in treatment resistance in prostate cancer (Shiota et al, 2011c). Knockdown of YBX1 
or clusterin sensitized prostate cancer cells to paclitaxel treatment, and this effect was 
abrogated by clusterin rescue. 
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These two papers provide important insights into the multiple roles for YBX1 in 
prostate cancer. It appears that YBX1 expression increases with increasing tumour aggression 
and is induced by androgen withdrawal. YBX1 also serves to induce DHT efflux from cells 
through P-glycoprotein expression, but at the same time regulates AR and appears to increase 
AR levels when YBX1 expression is higher.  
Ovarian Cancer 
A number of papers have outlined a role for YBX1 in ovarian cancer. A team from 
Japan showed that YBX1 nuclear staining in Stage III ovarian serous carcinomas (present in 
30%) was associated with significantly worse disease-free survival (Kamura et al, 1999). 
Another Japanese paper five years later found that YBX1 was expressed in 50% of primary 
epithelial ovarian tumours, and that co-expression with P-glycoprotein conferred an adverse 
prognostic outcome (Huang et al, 2004). YBX1 nuclear expression has also been shown to 
correlate with disease recurrence and acquired cisplatin resistance (Yahata et al, 2002).  
Brain cancer 
YBX1 expression has been implicated in the pathogenesis and aggressiveness of a 
number of histological subtypes of brain cancer.  At a developmental level, YBX1  
expression has been shown to correlate with neural stem cell markers and to have a role in 
growth promotion and inhibition of differentiation, and is expressed in-vitro in brain tumour-
initiating cells (Fotovati et al, 2011). YBX1 has been found to be expressed in 94.6% of 
neuroblastoma samples in a tumour tissue microarray, however no correlation could be 
established with survival or other oncologic outcomes, given the high expression rates across 
the array (Wachowiak et al, 2010). YBX1 has also been found to be expressed in paediatric 
glioblastoma, a rare and aggressive brain tumour with very poor outcomes; YBX1 was 
expressed in subtypes showing Ras/Akt activation and those without activation of this 
pathway (Faury et al, 2007). YBX1 is also expressed in adult glioblastoma and inhibition of 
YBX1 resulted in reduced tumour cell invasion and growth in-vitro and delayed tumour onset 
in mice (Gao et al, 2009). Furthermore, blocking YBX1 enhanced sensitivity to 
temozolomide, a methylating agent and pivotal drug in treating adult glioblastoma. A very 
interesting manipulation of YBX1 nuclear expression and its known role in the adenoviral 
life cycle has been used to achieve adenoviral oncolysis of glioblastoma. By increasing 
nuclear YBX1 with chemotherapy exposure, researchers were able to boost the replication of 
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engineered adenoviruses and achieve very high levels of tumour cell oncolysis (Bieler et al, 
2006; Holzmuller et al, 2011).  
Colorectal cancer 
YBX1 has also been studied in colorectal cancer. In contrast to other cancers, an early 
study showed that YBX1 was expressed in the majority of clinical specimens examined by 
IHC and associated with DNA topoisomerase II expression, but had no relation to MDR-1 
expression (Shibao et al, 1999). Another paper showed that cultured HCT116 colon cancer 
cells transfected with YBX1/GFP developed resistance to vinblastine and this was paralleled 
by increased expression of MDR-1/P-glycoprotein (Vaiman et al, 2007). 
Other human cancers 
YBX1 has been implicated in many other human cancers, with overexpression and nuclear 
localization conferring an adverse prognostic outlook and an association with chemotherapy 
resistance. Multiple publications have examined its role in gastric cancer (Wu et al, 2012), 
bladder cancer (Shiota et al, 2011b), oesophageal cancer (Li et al, 2011), osteosarcoma (Oda 
et al, 2003; Oda et al, 1998b), lung cancer (Gessner et al, 2004; Shibahara et al, 2001), 
melanoma (Schittek et al, 2007) and liver cancer (Yasen et al, 2005).  
 
1.6.11 YBX1 interacts with multiple biological pathways 
In addition to the above mentioned functions, YBX1 also interacts with a diverse range 
of biologic pathways and molecules, many of which are key factors implicated in cancer 
pathogenesis. Interactions relevant to a role in cancer are discussed below. 
TP53 
Tumour protein 53, or TP53, is one of the best described human tumour suppressor 
genes and is implicated in a wide variety of human cancers. Its known functions include cell 
cycle regulation, induction of growth arrest or apoptosis and it is induced in response to 
various cellular stresses. Mutation of this gene at the germ-line or somatic level is known to 
be a key factor in the pathogenesis of multiple cancer types. YBX1 was shown early on to 
interact directly with TP53 through three independent domains of YBX1 and also to facilitate 
binding of TP53 to its consensus DNA sequence (Okamoto et al, 2000). Interestingly 
however, YBX1 has also been shown to be negative regulator of TP53 and to repress 
transcription of the TP53 promoter, with YBX1 inhibition resulting in induction of TP53 in a 
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variety of cell lines and resultant apoptosis via a TP53-dependent pathway (Lasham et al, 
2003; Shiota et al, 2008a) 
Epidermal Growth Factor Receptor (EGFR) 
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a 
member of the receptor tyrosine kinase ErbB family. EGFR (also known as ERbB1 or HER1) 
is a cell surface receptor and its ligand is epidermal growth factor. Binding of the ligand leads 
to receptor dimerization, tyrosine autophosphorylation and cellular proliferation. The 
activated receptor complex activates at least four downstream signalling cascades, including 
RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs modules. Other 
members of this group of receptors include HER2, HER3 and HER4.  
YBX1 has been shown to regulate EGFR in several papers. The first reports of the 
relationship of YBX1 and EGFR were reported by the team led by Sandra Dunn from 
Vancouver. YBX1 overexpression in HMEC breast cancer cells leads to overexpression and 
constitutive phosphorylation of EGFR and growth factor independence (Berquin et al, 2005). 
This work was complemented by a paper the following year showing that overexpression of 
YBX1 in a breast cancer cell line was associated with overexpression of EGFR and HER-2, 
while knockdown suppressed expression of these proteins (Wu et al, 2006). This paper also 
showed that YBX1 mutated at Ser(102) was unable to bind the promoters for EGFR and 
HER-2. This work outlined the key role of YBX1 and EGFR in driving the growth of breast 
tumour cells. Work by the same team identified two YBX1 responsive elements in the EGFR 
promoter at -940 and -968 using ChiP and gel shift assays, and also showed that inhibition of 
EGFR and YBX1 suppression inhibited anchorage-independent growth of human basal-like 
breast cancer cells (Stratford et al, 2007). In lung cancer cell lines, YBX1 nuclear 
overexpression has been shown to be positively correlated with HER-2 expression in non-
small cell lung cancer cell lines (Hyogotani et al, 2012; Kashihara et al, 2009). In PC-3 cells, 
use of an integrin-linked kinase inhibitor was shown to facilitate the dephosphorylation of 
Akt and inhibit the expression of YBX1 and EGFR, leading to decreased proliferation (Lee et 
al, 2011b). 
 
Fas (CD95/Apo-1), Collagen alpha 1 
Fas is a member of the TNF-receptor superfamily and contains a death domain. It has 
been shown to play a central role in the physiological regulation of programmed cell death 
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and has been implicated in the causation of various malignancies and immune diseases. 
YBX1 has been shown to be a transcriptional repressor of Fas, and overexpression of YBX1 
in Jurkat cells (immortalized T lymphocytes) is associated with decreased Fas surface 
staining (Lasham et al, 2000). YBX1 may therefore assist tumour cells in escaping immune-
mediated cell death triggers by repressing a key protein in the apoptotic cascade. 
Collagen is a key component of the extracellular matrix and presents part of the barrier 
to cell invasion and migration. Collagen alpha 1 is a key component of bone and cartilage.  
YBX1 has been reported to transcriptionally repress human collagen alpha 1 expression 
(Norman et al, 2001). Theoretically this may allow YBX1 overexpressing cells to facilitate 
the establishment of bone metastases by disrupting the local bone environment and 
preventing normal bone collagenisation and structural integrity. 
1.6.12 Summary and discussion of YBX1 functions and interactions 
As can be appreciated from the above literature review, YBX1 has many disparate roles 
in eukaryotic cells. It has major functions in DNA and RNA chaperoning, including the 
modulation of mRNA transcription and translation, DNA repair, and resistance to DNA-
damaging agents, particularly chemotherapeutics. It has also been found to interact with 
numerous cellular pathways and control systems, including the cell-cycle control proteins, 
TP53, EGFR and Fas. It has also been shown in multiple publications that YBX1 
overexpression correlates with an adverse prognosis and early recurrence in multiple human 
cancers, particularly breast, ovarian, brain and colorectal cancers. For breast cancer in 
particular, the evidence is fairly robust that YBX1 overexpression is a reliable indicator of 
early relapse and adverse outcomes, even outperforming HER2, which is a standard 
component of prognostic panels currently. The reasons why YBX1 has not been adopted into 
routine clinical use for some of these cancer types is not clear. From the perspective of a 
clinician and surgeon, the candidate would comment that YBX1 appears to possess many 
favourable features of a prognostic biomarker, including expression in a significant 
proportion of patients. One can only speculate that it has not been developed into a 
commercial assay either due to breast surgeons and physicians being unaware of the data, or 
difficulties experienced with older commercial antibodies in delivering reliable and 
repeatable staining of YBX1 in tissue samples. Given the above however, our insights into 
how YBX1 confers an advantage to particular cancers is limited. Aside from inferring effects 
based on its known biological functions, we have no direct evidence for how it promotes 
58 
 
aggression or survival of certain cancers. In prostate cancer for example, as discussed in 
section 1.6.10, we know from in-vitro and mice studies that YBX1 expression increased with 
a progression to an androgen-independent cancer phenotype, and that YBX1 levels are higher 
in some high Gleason grade tumours. However, the evidence for YBX1 having a causative 
effect in progression to androgen-independent disease was lacking until recently. Important 
evidence in this regard emerged recently showing that YBX1 regulates AR expression 
(Shiota et al, 2011a) and that YBX1 overexpressing cells were resistant to castration-induced 
growth suppression. The same group also showed that YBX1 induction after chemotherapy 
led to induction of clusterin, which protects cells from chemotherapy and is implicated in 
treatment resistance (Shiota et al, 2011c). Aside from these two recent papers, evidence is 
scant on how YBX1 mechanistically confers an advantage to prostate cancers.  
Another important problem the candidate was alerted to early on during this thesis was 
the presence and expression of YBX1 pseudogenes. The issue has confounded design of 
exclusive primers owing to the high sequence homology of YBX1 genomic DNA and the 
pseudogene (PG) DNA. It became clear that it would be important to address this problem 
thoroughly in order to avoid the confounding effects of PG interference in various assays and 
also to prevent these interfering with identification of new target genes with which YBX1 
may interact. This problem is expanded upon in the next section, and current knowledge 
about pseudogenes and YBX1 pseudogenes is presented. 
 
1.7 YBX1 PSEUDOGENES 
The presence of pseudogenes in the human genome is a well-established fact dating 
back three decades. Numerous pseudogenes for multiple genes have been identified and 
characterised, and YBX1 has been no exception. To this candidate’s knowledge while 
undertaking this research, no prior research had investigated whether the known YBX1 
pseudogenes are expressed in commonly used cell lines, in particular prostate cancer cell 
lines. This is an important question, as it will be shown below that the pseudogene sequences 
are highly conserved when compared to the YBX1 mRNA, and any transcriptional 
expression of pseudogene mRNA or protein may play a potential confounding role in the 
experiments and quantifications undertaken during this research. It was therefore deemed 
important from the outset to gain some understanding of the known YBX1 pseudogenes and 
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to ascertain whether these are expressed in prostate cancer cell lines and further to ensure that 
any such expression does not interfere with standard assays used in the laboratory such as 
quantitative real time PCR or western blot assays. To understand the framework of the 
potential confounding role of the YBX1 pseudogenes, it is necessary firstly to examine the 
current views of pseudogenes and their role in the genome and cell biology, and then examine 
what is known regarding the YBX1 pseudogenes and their origin. 
 
1.7.1 Origin and characteristics of pseudogenes 
There are a number of definitions of what constitutes a pseudogene. One commonly 
accepted definition is :  
Pseudogenes are gene copies that have coding-sequence deficiencies like frameshifts and 
premature stop codons but resemble functional genes (Tutar, 2012) 
 
Another definition is as follows: 
Pseudogenes are “genomic loci that resemble real genes, yet are considered to be 
biologically inconsequential because they harbor premature stop codons, deletions/insertions 
and frameshift mutations that abrogate their translation into functional proteins” (Poliseno 
et al, 2010) 
 
It is estimated that there are approximately 27 000 pseudogenes in the human genome 
(Han et al, 2011). It is generally accepted that there are two types of pseudogene: 
 
 Processed – this is a pseudogene formed through retrotransposition by reintegration 
of a length of cDNA, or a reverse transcribed mRNA transcript into a new location 
in the genome. The double stranded sequences of processed pseudogenes are 
generated from single stranded RNA by RNA polymerase II and this explains why 
pseudogenes lack introns, a 5’ promoter sequence, and also commonly possess 
flanking direct repeats and a 3’ poly-A tag. 
 Unprocessed – pseudogenes of this type maintain their exon-intron structure and 
can be either “unitary”, meaning that a single-copy parent gene becomes non-
functional, or “duplicated” 
 
There are approximately five times more human processed than non-processed 
pseudogenes (Karro et al, 2007). It is thought that pseudogenes arose from decay of genes 
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that originated through duplication. This degradation includes point mutations, insertions, 
deletions, misplaced stop codons or frameshifts within the gene (Tutar, 2012).  The first 
pseudogene was reported in 1977, consisting of a genomic region coding for oocyte-type 5S 
RNA of Xenopus laevis (Jacq et al, 1977). The authors reported that the pseudogene had a 
truncated 5’ end and 14 base pair mismatches in comparison with its parental gene. Over the 
next three years, several pseudogenes from the globin family were identified in rabbit, 
humans, mice, goat and sheep (Blattner et al, 1978; Fritsch et al, 1980; Hardison et al, 1979; 
Lacy et al, 1979; Lauer et al, 1980; Smithies et al, 1978; Vanin et al, 1980). 
 
1.7.2 Pseudogene function 
The key question that arises from study of pseudogenes is whether they are able to 
express mRNA or a protein product. Initially it was thought that pseudogenes could not 
express a functional product, as evinced by several authors in Nature in the early 1980s (Li et 
al, 1981; Proudfoot, 1980).  However, from the late 1990s, evidence began to emerge that 
some pseudogenes do in fact code for expressed mRNA and even truncated proteins. In 1999, 
it was reported that a pseudogene for nitric oxide synthase (NOS) encoded an antisense 
transcript able to regulate the parental gene at a post-transcriptional level (Korneev et al, 
1999). It was found that the pseudogene shared 80% complementarity with the sequence of 
the parent gene and was a natural antisense transcript measuring 145bp in length, associating 
with the mRNA of NOS and inhibiting its transcription. A similar finding was later reported 
in 2003 for the gene Makorin1 (Hirotsune et al, 2003). The transcript of the pseudogene, 
named Makorin1-p1, appeared to regulate expression of the parental gene in the mouse. 
However these results were brought into question several years later when another group 
showed evidence that in fact both Makorin1-p1 alleles were methylated and therefore it is a 
silent pseudogene (Gray et al, 2006). However, many pseudogenes have since been shown to 
be transcribed, including PTEN (Fujii et al, 1999), the adrenal steroid hydroxylase P450c21A 
(Bristow et al, 1993), GAPDH (Tso et al, 1985), glucocerebrosidase (Sorge et al, 1990) and 
Oct4 (Redshaw & Strain, 2010). 
In 2008 two papers showed that siRNAs from pseudogenes can regulate gene 
expression in mouse oocytes (Tam et al, 2008; Watanabe et al, 2008). In addition to 
pseudogenes regulating parental genes via antisense transcripts, various groups have found 
that pseudogene transcripts can act as decoys for micro-RNAs (mi-RNAs), thereby allowing 
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the true parental gene mRNA to escape degradation and increase expression of the parental 
protein. This concept was elucidated recently by Poliseno and colleagues (Poliseno et al, 
2010). A number of recent studies using microarray techniques suggest that the number of 
transcribed human pseudogenes is probably in the range of 2% to 20% (Harrison et al, 2005; 
Yano et al, 2004; Zheng et al, 2007). 
 
1.7.3  Pseudogenes and Cancer 
Various groups have demonstrated that expression of some important tumour related 
genes may also be influenced by related pseudogenes. For example,  increased transcription 
of the human pseudogene PTENP1 has been shown to act as a decoy for miRNAs that 
normally target PTEN, through its close homology to the 3’ UTR of the PTEN mRNA. This 
allows PTEN to escape miRNA control mechanisms and alter gene expression levels 
(Alimonti et al, 2010). This group showed that in DU-145 prostate cancer cells, miR-19b and 
miR-20a are able to repress both the PTEN and PTENP1 levels of mRNA. A similar scenario 
has been described for octamer-binding transcription factor 4 (OCT4), in which multiple 
OCT4-pseudogenes have been show to regulate expression of the parent gene. In fact, two of 
the OCT4 pseudogenes, OCT4-pg1 and OCT4-pg5, have been shown to be expressed only in 
cancer tissues and not in normal tissues (Suo et al, 2005). 
 
1.7.4 Detection of Pseudogenes 
Detection of transcripts from pseudogenes can be very challenging. This is partly due to 
the fact that most technologies formulated for transcript level measurement were not designed 
with pseudogene expression in mind. This is complicated by the fact that pseudogene 
sequences are usually very similar to parent gene sequences, with just occasional base pair 
mutations. For example, micro-array probe design relies on uniqueness of probe design, in 
order to avoid cross-hybridization, thereby complicating pseudogene detection. Furthermore, 
the process of RNA-Seq analysis often eliminates reads that align to multiple genomic 
locations, some of which by definition are likely to be pseudogenes. Another complicating 
issue is that pseudogene transcript levels are often much lower than that of the corresponding 
parental genes (Harrison et al, 2005). However, sometimes the expression level can be 
comparable or even higher , for example the glucocerebrosidase gene in Gaucher disease 
(Sorge et al, 1990).  Estimates as to the proportion of pseudogenes that are actually 
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transcribed varies, and this has historically been estimated at a figure between 2% and 10%. 
However, a recent analysis of transcription from annotated pseudogenes from the ENCODE 
project demonstrates that at least 20% of the pseudogenes are transcribed (Zheng & Gerstein, 
2007). 
 
1.7.5 Known YBX1 Pseudogenes 
One of the early clues that YBX1 is associated with multiple pseudogenes came in 
1996 when a Japanese group attempted to map the location of YBX1 to a specific 
chromosome location using FISH (Fluorescent in-situ hybridization). During this process the 
researchers mapped YBX1 to 1p34. However, they also identified more than 50 other 
positive clones, 24 of which were characterized by Southern hybridization using two probes 
derived from cDNA (Makino et al, 1996). 
As of May 2012, ten official YBX1 pseudogenes are listed in PubMed/NCBI (Table 
1.2). However, performing a BLAT search on the UCSC genome browser 
(http://genome.ucsc.edu/cgi-bin/hgBlat) using the official YBX1 mRNA yields 31 sequences 
similar to the YBX1 mRNA. There are some key points to note regarding the ten official 
YBX1 pseudogenes. Firstly, they do not contain introns and are therefore classified as 
processed pseudogenes. Secondly, the pseudogene sequences differ from YBX1 mainly as a 
pattern of random point mutations. Specifically, there is only one nucleotide difference 
between YBX1 and the 4 major pseudogenes, nt1251 (A in YBX1 and T in YBX1-
pseudogenes).  The pseudogenes also contain the 3’ and 5’ UTR as does the parental YBX1 
mRNA. The 3’ UTR is highly conserved showing again only point mutation differences to 
YBX1, while the 5’UTR is slightly longer for YBX1 mRNA compared to the pseudogenes. 
The aforementioned points illustrate the fact that this researcher and colleagues in our 
laboratory have found it very difficult to design PCR primers specific to the YBX1 cDNA 
and exclusive of the major pseudogenes. Some of the NCBI pseudogenes match or partially 
match with AceView transcript predictions in the UCSC genome browser, suggesting that 
they are expressed at the RNA level; the relative expression level, however, remains 
unknown. At least two of the pseudogenes (YBX1P1 and YBX1P10) possess an ORF and 
could therefore potentially be translated into a protein product. YBX1P1 has documented 
expression in multiple tissues, including one sample from a prostate tumour 
(http://www.ncbi.nlm.nih.gov/nucest/BF858412?report=genbank) and YBX1P10 has 
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documented expression from normal prostate 
(http://www.ncbi.nlm.nih.gov/nucest/AA659918?report=genbank). 
1.7.6 Summary of potential issues from YBX1 pseudogenes 
It is evident from the preceding section that YBX1 pseudogenes exist, are numerous 
and have high sequence homology to the native YBX1 DNA and mRNA sequences. More 
importantly as shown in table 1.2, several of these have appreciable expression levels and 
have been shown to be expressed in human tissue samples. However, this candidate is not 
aware of any evidence investigating the expression levels of YBX1 pseudogenes in human 
prostate cancer cell lines, such as LNCaP, PC-3, DU-145, etc. This is an important question 
to answer as in-vitro work using these cell lines was planned as the bulk of the experimental 
work for this thesis. This candidate is currently also not aware of any other human cell lines 
known to express YBX1 at a significant level which could be used as a control and 
comparotor for experimental work. For this reason, the work in chapter 3 seeks to definitively 
answer the question of whether any significant YBX1 pseudogene expression is present in 
prostate cancer cell lines.  
The next section deals with the question of epithelial to mesenchymal transition (EMT). 
During the research and literature review in preparing experimental planning, an interesting 
paper was found strongly supporting a role for YBX1 inducing an EMT in a breast cancer 
cell line (Evdokimova et al, 2009). The process of EMT is discussed in detail in the next 
section, and is a burgeoning field in cancer research for many reasons, particularly as it is 
believed to be important in the process of cancer dissemination from its original site and also 
in cancer survival. The fact that YBX1 could potentially induce and maintain this process 
was extremely interesting, and therefore mandated investigation of this process in prostate 
cancer. For this reason also it was very important to exclude the presence of YBX1 
pseudogenes as a potential confounding effect in investigating this question. The reader will 
note that the question of YBX1 pseudogenes is investigated in Chapter 3, and following on 
from this the major question of a possible role for YBX1 in inducing EMT in prostate cancer 
is addressed in Chapter 4. 
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Table 1.2 NCBI indexed pseudogenes for YBX1. AceView Gene expression levels shown as percentage relative to YBX1. 
Gene/Pseudogene:   NCBI entry  UCSC 
BLAT 
 UCSC Ace View 
transcript 
AceView Gene Summary 
YBX1 Chr.1 (+) NM_004559.3 1561 nt #1 100% gi|109134359    very highly expressed  
YBX1P1/ LOC50631 Chr.14 (-) NG_001276.3 1496 nt #2 98% YBX1P1.aApr07-unspliced
  
well expressed (90%) 
YBX1P2/ LOC646531 Chr.7  (-) NG_006863.2 1553 nt #4 97% LOC646531.aApr07-
unspliced 
low level (8.3%) 
YBX1P3 Chr.3 (+) NG_032054.1 909 nt #7 87% none (in ZBTB20 intron)  
YBX1P4/ LOC100131012 Chr.7 (+) NG_011685.1 820 nt #11 81% kohara.aApr07-unspliced low level (1.8%) 
YBX1P5 Chr.5 (+) NG_032056.1 775 nt #9 90% none (ZNF366&MRPS27)  
YBX1P6/ LOC402375 Chr.9 (-) NG_030460.1 1799 nt #5 94% LOC402375.aApr07-
unspliced 
low level (3.7%) 
YBX1P7 Chr.2 (-) NG_032001.1 841 nt #13 88% none (in GPR39 intron)  
YBX1P8/ FLJ20344 Chr.X  (-) NG_032031.1 711 nt #12 85% none (in SLC9A7 intron)  
YBX1P9 Chr.1 (-) NG_032027.1 690 nt #10 90% none  
YBX1P10/ bA327L3.4 Chr.9 (-) NG_003008.3 1514 nt #3 98% bA327L3.4.aApr07-unspliced well expressed (60%) 
LOC729701/ 
LOC100287243 
Chr.15 (+) AC_000147.1  #6 94% LOC729701.aApr07-
unspliced 
low level (5.5%) 
 Chr.2 (+)   #8 88% none (in OLA1 intron)  
 Chr.20 (-)   #17  NCOA5.gApr07  (very partial overlap only) 
 Chr.16 (-)   #19  LOC440359.aApr07/CSDAP1  (very partial overlap only) 
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1.8 EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) 
 
Introduction 
A key feature of cancers is the ability for cancer cells to escape their location 
of origin and spread throughout the body and form metastatic deposits. This involves 
a tumour cell of epithelial origin breaking through the barriers that normally confine 
a cell population within a functional structure within an organ, which includes the 
basement membrane and extracellular matrix. This is followed by the cell invading 
through the wall of a blood vessel or lymphatic duct and being carried to a distant 
site in the body, and then re-attaching itself to the wall of the blood vessel or lymph 
conduit and  a reverse process whereby the tumour cell is able to invade through the 
wall of the blood vessel or lymph duct and leave that compartment to enter the tissue 
environment at its new location. In this new locus, the cell is able to influence its 
local environment to set up an independent colony of tumour cells termed a 
‘metastatic deposit’, by influencing the local environment. It is now accepted that for 
the most part, tumour cells achieve this remarkable translocation by a well-described 
process termed the “epithelial to mesenchymal transition” (EMT). The EMT is a 
normal embryonic process that has been extensively studied, and is crucial for 
normal development of embryonal tissues. In particular, it allows embryonal cells 
which develop far from their final destination organ to reach that destination by 
moving through the intervening embryonic structures and modulating the local 
environment as they do so in order to facilitate their passage.  The majority of adult 
tissues form through a process of one or more rounds of EMT and the converse 
process of mesenchymal to epithelial transition (MET). One of the key features of 
EMT is a phenotypic change in cell morphology from an epithelial type to a 
mesenchymal type, with a concomitant capacity for migration and invasion in the 
mesenchymal state. 
It is understood that cancer cells co-opt the EMT pathways and processes to 
enable the metastatic cascade. The means by which cancer cells integrate this process 
into their biology at the right time (cancer being inherently an entropic and 
disorganized state) is still a question under intensive investigation.   
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The importance of EMT in relation to YBX1 and prostate cancer will be 
explored in chapter 4, in which a possible role for YBX1 in inducing EMT in 
prostate cancer will be explored. This avenue of thought follows on from a recent 
paper seemingly showing a key role for YBX1 promoting EMT in breast cancer cell 
lines and promoting invasion and metastasis in a murine model of breast cancer 
(Evdokimova et al, 2009). Demonstrating a similar role for YBX1 in prostate cancer 
would be an important discovery and add to the knowledge base for the role of 
YBX1 in aggressive disease.  
History 
The first description of the characteristics of EMT was unwittingly described in 
1890 by Ramón y Cajal, who described some ductal epithelial cells with a different 
morphology and ability to invade the stroma in breast tumours (Cajal, 1890). It was 
not until 1968 that the term ‘epithelial to mesenchymal transformation’ was coined 
by Elizabeth Hay who described the process as pivotal for cell movement in embryos 
(Hay, 1968). The word ‘transition’ later replaced ‘transformation’. Following this 
important paper little was added to knowledge in this area until the relevance of 
EMT in cancers was established (Polyak & Weinberg, 2009; Tarin et al, 2005). 
There has been an explosion of published papers in EMT since 2010, with much of 
the research focussing on the role of EMT in cancer. However, EMT has been 
established to play a role in a number of diverse processes, including organogenesis 
and embryonic morphogenesis, tissue regeneration, inflammation and wound 
healing, fibrosis and finally tumour initiation, migration and invasion and resistance 
to cancer treatment.  
Several fundamental concepts underpin the modern understanding of EMT. 
These include the discovery of signalling molecules acting as inducers of the process, 
including members of the TGF-β superfamily, Wnts, Notch, EGF, hepatocyte growth 
factor (HGF), fibroblast growth factor (FGF), hypoxia-inducible factor (HIF) and 
Sonic hedgehog (Shh) (Potts & Runyan, 1989; Thiery & Sleeman, 2006; Valles et al, 
1990). An important advance was the identification of transcription factors that were 
capable of activating EMT (Nieto et al, 1994), in this case the transcription factor 
Slug being the first identified factor. This was followed by elucidation of the cellular 
programmes involved (Inukai et al, 1999; Vega et al, 2004). 
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Characteristics of EMT 
A key feature of EMT is the ability of cells to acquire individual motility. Cell 
migration can be typed as collective or individual. Collective migration involves 
groups of cells moving en masse while maintaining close contacts through E-
cadherin expression during the entire process. This can be seen in the migration of 
the lateral line in zebrafish or,  for example, in the leading group of mesendodermal 
precursors in Xenopus and zebrafish embryos (Arboleda-Estudillo et al, 2010; Lopez-
Schier, 2010). Individual cell migration, as the name implies, involves one or more 
single cells separating from the cell mass of origin and migrating independently to a 
new destination. This is seen in avian and mammal embryos during the migration of 
individual cells from the primitive streak and neural crest cells from the neural tube 
(Thiery et al, 2009) and is the mechanism of migration characteristic of EMT. The 
process involves the transcription factors Snail, Twist and Zeb repressing E-cadherin 
expression and allowing cells to break-down cell-cell junctional complexes and 
imbuing those cells with the ability to migrate and invade (Olmeda et al, 2007; 
Peinado et al, 2007). Embryos deficient in Snail1 show abnormal development as 
mesodermal cells are unable to down-regulate E-cadherin and cannot undergo EMT 
to migrate to their correct destination (Carver et al, 2001).  In mouse models of breast 
cancers, tumour cells have been seen to detach from the tumour mass and invade the 
adjacent tissue (Wang et al, 2002) , with a similar process occurring in colorectal 
cancer with loss of E-cadherin expression (Brabletz et al, 2001). A key recognisable 
feature of cells undergoing individual migration is the loss of apico-basal polarity 
that is normally evident in epithelial cell layers. EMT inducers such as Snail and Zeb 
directly repress the transcription of certain polarity genes, including Crumbs 
(Spaderna et al, 2008). In contrast cells undergoing collective migration retain their 
apico-basal polarity at all times. Loss of E-cadherin in cells undergoing EMT and 
individual migration is paired with the expression of mesenchymal-type cadherins, 
including N-cadherin or cadherin-11, which are involved in the weaker cell-cell 
contacts through filopodia typical of individually migrating cells (Oda et al, 1998a; 
Peinado et al, 2004b). 
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EMT inducers 
The repression of E-cadherin discussed above is a key and pivotal feature of 
EMT. Over the last few years, a picture has been constructed of the mechanisms 
which control and activate this repression. Known repressors have been divided into 
two groups: 
a) Snail, Zeb, E47 and KLF8 factors bind to and repress the 
activity of the E-cadherin promoter (Peinado et al, 2007; 
Wang et al, 2007b). 
b) Twist, Goosecoid, E2.2, and  FOXC2 repress E-cadherin 
transcription indirectly (Sobrado et al, 2009; Yang et al, 
2008) 
The interactions of these various inducers is summarised in figure 1.13. 
 
 
Figure 1.13 E-cadherin transcription in normal and cancer cells 
Snail, Zeb, E47 and KLF8 factors directly repress E-cadherin transcription while Twist, Goosecoid, 
E2.2 and FOXC2 indirectly suppress E-cadherin. The miR-200 family repress the Zeb family of genes 
and thereby prevent EMT. Snail1 may repress the expression of miR-200 family members. ( 
Reproduced from Thiery et al, Epithelial-Mesenchymal transitions in Development and Disease, Cell, 
139, Nov 25, 2009, p877) 
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Snail1 appears to be expressed at the onset of EMT in both developmental 
processes and cancer, while Snail2/Slug, Zeb, E47 and Twist are induced later to 
maintain the migratory mesenchymal state (Peinado et al, 2007). In this regard, 
Snail1 and Snail2 work together in primary tumour growth and in site-directed 
metastasis growth (Olmeda et al, 2008) 
Finally, an important inducer of EMT in cancer is TGF-β. This has been 
demonstrated in multiple cancer cell lines, where short or long-term exposure to 
TGF-β results in a demonstrable EMT and loss of E-cadherin (Cufi et al, 2010; Gal 
et al, 2008). 
 
EMT and cancer 
In recent years a number of key publications have underlined the role of EMT 
in the metastatic cascade of tumour biology.  
Multiphoton microscopy in the study of live tumours has demonstrated proof 
of the EMT and individual cell delamination from primary tumour masses and 
migration through extracellular matrix fibres and individual cell intravasation which 
is aided by macrophages in a breast cancer model (Wang et al, 2002). Furthermore, 
while  breast cancer cells migrating collectively are able to invade lymphatic 
channels, it has been shown that only individually migrating cells are able to invade 
both the lymphatic  and blood vessels, and that the switch from collective to 
individual migration is triggered by TGF-β signalling (Giampieri et al, 2009). 
Although TGF-β suppresses early stages of tumour development by arresting 
proliferation and inducing cell death, when coupled with Snail1 activation cells are 
able to escape the cell-death response to TGF-β signalling and instead an EMT is 
induced (Franco et al, 2010) Individual cells isolated migrating from primary 
tumours show a decreased proliferation rate and are resistant to cell death while 
expressing EMT markers (Roussos et al, 2010). Similarly in colon cancer, at the 
invading front EMT is seen to occur and produces single migratory cells which have 
lost E-cadherin expression, and this is accompanied by deregulation of the Wnt 
pathway and selective loss of the basement membrane (Brabletz et al, 2001). 
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While tumour cells can become dependent on oncogenes or certain signalling 
pathways for survival (for example, FGFR or EGFR mediated pathways) which 
allows treatment with Ras or tyrosine kinase inhibitors, it has been shown that cells 
undergoing EMT lose their dependence on these pathways (Acevedo et al, 2007; 
Singh et al, 2009). 
It is also interesting to note that resistance to chemotherapy in a number of 
cancer cell lines is also associated with an acquisition of EMT traits in these cell 
lines. This includes colon cancer cells conditioned to be oxaliplatin resistant (Yang et 
al, 2006), epithelial ovarian cancer cell lines resistant to paclitaxel (Kajiyama et al, 
2007) and breast cancer cell lines resistant to paclitaxel (Cheng et al, 2007). It has 
also been shown that Snail1 expression is associated with breast tumour recurrence 
(Moody et al, 2005) and that Snail1 expression is associated with activation of 
immunosuppressive cytokines, regulatory T cells and cytotoxic T cell resistance , 
thereby allowing melanoma cells to escape immune surveillance and metastasize 
(Kudo-Saito et al, 2009). 
E-cadherin loss has been associated as a poor prognostic factor in prostate 
cancer and expression has been shown to be inversely related to tumour grade 
(Umbas et al, 1994; Umbas et al, 1992). The authors postulated allelic loss as one 
likely mechanism, though it is probable that multiple mechanisms are responsible. 
For example, transfection of PC-3 cells with human kallikrein 4 was shown to lead to 
repression of E-cadherin expression, an increase in vimentin and increased migration 
(Veveris-Lowe et al, 2005) 
 
Summary 
Epithelial to mesenchymal transition is an important process identified to play 
key roles in embryogenesis, tissue regeneration and healing, fibrosis and cancer. The 
key features include the acquisition of individual cell motility and delamination of 
cells from their site of origin, coupled with E-cadherin repression and gain of 
mesenchymal markers including N-cadherin and vimentin. The EMT is induced by 
key transcription factors including Snail1, Zeb, E47, KLF8 and Twist, and multiple 
signalling networks converge on this induction cluster. EMT appears to be a vital 
step in cancer cell invasion and metastasis and resistance to both immune 
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surveillance and treatments such as chemotherapy. A number of processes have been 
shown to be associated with EMT induction in prostate cancer cell lines. An 
important question which will be investigated in Chapter 4 is whether there is a role 
for YBX1 in inducing EMT in prostate cancer cell lines. 
 
1.9 CONCLUSION 
The burden of prostate cancer is a significant healthcare issue, and one that will 
continue to grow with an ageing population through the coming century. Australia 
currently shares the lead for the highest prostate cancer incidence worldwide, with 
significant health dollars spent on treating a disease with prolonged survival in most 
men but also a significant burden from incurable metastatic disease.  
The causes of prostate cancer are not clearly understood, with only a small 
fraction of men developing the disease due to inherited genetic factors. There is 
evidence for a causative role for infection and inflammation, but no single cause has 
prominence. The role of gene fusions and hormonal factors in pathogenesis is well 
established, as is the role of the androgen receptor in disease development and 
progression. While cure is possible for localized disease, approximately 30% of men 
will develop disease recurrence with painful bony metastases, the treatment of which 
is compounded by significant side effects and poor quality of life, with no known 
cure. Our understanding of the biology of metastatic disease and its triggers is 
rudimentary, and like other cancers, prostate cancer exhibits a great heterogeneity in 
its biology, with significant variability in the molecular pathways and survival 
mechanisms evident between patients even from the same population. We still do not 
understand what makes some prostate cancers more aggressive than others, nor can 
we clearly assert whether there is a temporal progression from lower to higher cancer 
grades within a single prostate gland, or whether disparate cancers of different grades 
arise simultaneously.  
The role of YBX1 in multiple cancers has been established as an adverse 
prognostic indicator and marker for resistance to drug therapy and chemotherapy. 
Although we know a great deal about the roles of YBX1 in DNA and RNA 
chaperoning, DNA repair, transcriptional and translational control and the response 
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to external stressors, we have only a few limited insights into why YBX1 
overexpression and nuclear localization may predispose to adverse outcomes in 
cancer. In the main, these relate to its regulation of MDR1 and chemoresistance, and 
the role of YBX1 in DNA damage repair. Few other mechanistic insights have come 
to light despite over 550 publications in peer reviewed journals.  
In prostate cancer we know that YBX1 expression increases with progression 
to androgen independence and that expression levels are also higher in tumours of 
higher Gleason grade (Gimenez-Bonafe et al, 2004). In the last two years, it has 
emerged that YBX1 regulates androgen receptor expression in prostate cancer and 
that YBX1 induction after chemotherapy leads to the expression of clusterin (Shiota 
et al, 2011a; Shiota et al, 2011d). However, aside from these scattered highlights, a 
deeper understanding of the role of YBX1 in prostate cancer pathogenesis and 
progression is lacking. The fact that YBX1 is implicated in so many cancers suggests 
that it may have important roles in cancer survival, treatment resistance and 
metastatic disease. Uncovering the mechanics of YBX1 function in prostate cancer 
may yield important clues in other cancers and position YBX1 as a promising cancer 
therapeutic target in coming years. 
1.10 RATIONALE AND HYPOTHESIS 
From the preceding discussion it can be surmised that our knowledge about the 
mechanisms in which YBX1 assists cancer survival and aggression is limited. We 
know from a handful of papers that in prostate cancer, YBX1 expression is related to 
the progression to androgen independence, that it regulates the AR and that it reduces 
the effects of castration-induced growth inhibition and also induces clusterin 
expression. However, owing to its implication in many other cancers, it is possible 
that YBX1 may also act in other ways in prostate cancers that do not involve the 
above mechanisms and this may include interactions with proteins not previously 
described with YBX1, but known to be important in prostate cancer.  
For these reasons this thesis will aim to examine the role of YBX1 in more 
detail in prostate cancer, specifically by addressing three key hypotheses: 
i) YBX1 pseudogene expression in prostate cancer cell lines is not high 
enough to cause interference with standard molecular assays and 
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techniques (Chapter 3). Exclusion of a significant level of pseudogene 
expression will be important to provide confidence in all assays and 
experimental results throughout this thesis. 
ii) YBX1 has a role in inducing or regulating EMT in prostate cancer cell 
lines (Chapter 4). YBX1 has been shown to induce an EMT in a breast 
cancer cell line. EMT is an important contemporary research area and 
showing a role for YBX1 in EMT in prostate cancer may have 
important implications for future therapeutic developments.  
iii) YBX1 is a regulator of  known cancer and prostate cancer genes 
(Chapter 5). Review of the broader literature and the role of YBX1 in 
other cancers suggests that YBX1 potentially interacts with numerous 
other genes, many of which may be important in prostate cancer 
survival and aggression. Data on this is currently lacking and may 
provide important insights for future work. 
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Chapter 2: Materials and Methods 
The materials and methods detailed in this chapter refer to general methods 
used throughout the thesis and include commonly used techniques relevant to all 
experiments. For experiments relevant only to a single results chapter, details of 
materials and methods relevant to those experimental methods are presented in the 
relevant chapter as outlined below: 
 Chapter 3 – Unique YBX1 primer design; restriction enzyme digests of 
PCR products 
 Chapter 4 – Incucyte™ Proliferation assay; Transwell migration and 
invasion assays 
 Chapter 5 – Agilent microarray RNA labelling, hybridization and 
scanning; analysis of microarray raw data  
 Chapter 6 – Preparation of tumour tissue microarray and immunostaining 
2.1 CELL CULTURE 
Prostate cancer cell lines were obtained from laboratory stocks originally 
purchased from the American Type Culture Collection (ATCC – www.atcc.org).  
Principal cell lines utilised were LNCaP clone FGC (ATCC Number CRL-1740),   
PC-3 (ATCC Number CRL-1435) and 22Rv1 (ATCC Number CRL-2505). All cells 
were cultured in phenol-red free Roswell Park Memorial Institute (RPMI) 1640 
medium,  L-glutamine + (Gibco, Invitrogen , SKU# 11835-030) supplemented with 
5% foetal bovine serum (Gibco, Invitrogen, SKU# 10099-149) without the addition 
of antibiotics. Cells were passaged when 80-90% confluent and maintained in T75 
flasks for growth and passage and cell treatments were routinely carried out in 6 well 
plates. Cells were passaged by aspirating media, performing a wash with 3mL PBS 
for a T75 flask followed by trypsinization with 1ml of 0.05% Trypsin EDTA 
(Invitrogen, SKU#15400-054) until cells had lifted into suspension. 5mL of complete 
growth medium was then added to the flask and cells gently resuspended throughout 
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the medium by pipetting. Cells were seeded at each passage at densities ranging from 
1:6 (LNCaP) to 1:10 (PC-3). Medium was changed every 3-4 days as required.  
Cells were incubated at 37°C in a 5% CO2 atmosphere in a Sanyo CO2 incubator 
(Model MCO-18AIC) 
 
2.1.1 LNCaP clone FGC 
This clone was isolated in 1977 from a needle aspiration biopsy of a 
supraclavicular lymph node of a 50 year old Caucasian male (blood type B+) with a 
confirmed diagnosis of metastatic prostate cancer. The cells express a mutated 
androgen receptor responsive to 5-alpha-dihydrotestosterone and are tumourigenic. 
The cells are of epithelial origin and express prostate specific antigen and prostatic 
acid phosphatase.  The cells are typically hypotetraploid with a modal chromosome 
number of 84 in 22% of cells. 
2.1.2 PC-3 
This cell line was initiated from a bone metastasis of a grade IV prostatic 
adenocarcinoma from a 62 year old male Caucasian. The cells display low acid 
phosphatase and testosterone-5-alpha reductase activity.  This is a tumourigenic cell 
line with a near triploid chromosome number and a modal chromosome number of 
62. It does not express the androgen receptor. 
2.1.3 22Rv1 
This is an epithelial prostate cancer cell line derived from a xenograft that was 
serially propagated in mice after castration-induced regression and relapse of the 
parental, androgen-dependent CWR22 xenograft.  The cell line expresses the 
androgen receptor and prostate specific antigen and is weakly stimulated by 
dihydrotestosterone. Recently it has been shown that these cells produce high titre of 
the human retrovirus XMRV (xenotropic murine leukaemia virus-related virus). 
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2.2 RNA EXTRACTION 
RNA-extraction from cultured cells was performed by two methods depending on 
down-stream requirements. For PCR and QRT-PCR, RNA was extracted using the 
TRI-Reagent protocol (Ambion 15596018). For RNA isolation for use in micro-array 
analysis, RNA was collected using the RNeasy Mini Kit (Qiagen, Cat. No. 74106) as 
outlined below. Pipettes and bench equipment were treated for RNase contamination 
by spraying with RNase Zap (Ambion Cat. No. AM9780) prior to any RNA 
preparation.  
 
2.2.1 TRI-Reagent protocol 
Cell treatments were routinely carried out in 6-well plates. RNA collection was 
commenced by aspirating media and lysing cells directly in the wells by the addition 
of 1mL per well of Trizol Reagent (Ambion cat. No. 15596018) in a fume hood. Cell 
lysis was assisted by pipetting the well contents and allowing the homogenate to 
incubate for 5 minutes at room temperature. The homogenate was then collected in a 
1.75mL RNase- and DNase–free Eppendorf tube. 100µL of 1-bromo-3-
chloropropane (Sigma, cat. No. 1001084377) was then added to each Eppendorf tube 
(also undertaken in a fume hood) and each tube was shaken vigorously for 15 
seconds before being allowed to incubate at room temperature for ten minutes. Tubes 
were then centrifuged on a bench-top centrifuge (Eppendorf 5415R, Hamburg, 
Germany) at 12000g for 15 minutes at 4°C. The aqueous phase containing RNA was 
then carefully transferred to a new Eppendorf tube without disturbing the lower 
interphase and organic phases sedimented in the lower part of the solution. 500µL of 
isopropanol (Sigma-Aldrich, product code 101041912) was then added to each tube 
and the tube vortexed for 15 seconds followed by room temperature incubation for 
ten minutes. Samples were then centrifuged again at 12000g for 8 minutes at 4°C. 
This step precipitates the RNA as a small pellet at the apex of the tube and the 
supernatant is removed without disturbing the pellet. 1mL of 75% RNase-free 
ethanol (Sigma-Aldrich, Cat. No. E7023, product code 1001084377) was then added 
to each sample to wash the pellet. The sample tubes were centrifuged at 7500g for 5 
minutes to wash the pellet. The ethanol wash was then removed with a fine pipette 
tip, again taking care not to disturb the RNA pellet.  Residual ethanol was removed 
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after another brief centrifuge and pipetting the residual volume. The samples were 
allowed to air dry for 3 to 5 minutes before the RNA pellet was resuspended in a 
volume of 30-50µL of RNase- and DNase-free water, depending on pellet size.  
Samples were then DNase treated prior to use in first strand synthesis using DNase I  
Amplification Grade 1U/µL  (Life Technologies (formerly Invitrogen) Cat. No. 
18068-015) according to the protocol as follows; 1µg of RNA in solution was treated 
by the addition of 1µL 10x DNase I Reaction Buffer (Life Technologies Cat. No. 
Y02340) and 1µL DNase I, Amp Grade to a total volume of 10µL in DEPC-treated 
water. The samples were gently vortexed and incubated at room temperature for 15 
minutes. DNase I activity was inactivated by the addition of 1µL of 25mM EDTA 
solution (Life Technologies Cat. No. Y02353) to the reaction mixture and heating for 
10 minutes at 65°C.  
 
2.2.2 RNeasy Kit 
RNA was extracted according to the protocol for human cells grown in a monolayer 
as outlined in the RNeasy Mini Handbook 09/2010 pp27-30. Briefly, the steps 
involved are as follows. Cells were lysed directly in 6 well plates by adding 350µL 
of buffer RLT to each well and homogenizing the lysate by pipetting. The lysate was 
transferred to an RNase-free Eppendorf tube and further mixed by pipetting to 
eliminate any cell clumps. 350µL of RNase-free 70% ethanol was added to each 
sample tube and mixed by pipetting. 700µL of the sample mix was then transferred 
to an RNeasy spin column placed in a 2ml collection tube and centrifuged on a bench 
top centrifuge for 15 seconds at 12000rpm to wash the spin column membrane. The 
flow-through was discarded and the same spin tube re-used in the following step.  
On-column DNase treatment was then performed as follows : 350µL of Buffer RW1 
was added to each RNeasy spin column and the column centrifuged for 15 seconds at 
12000rpm to wash the spin column membrane. The flow-through was discarded and 
80µL of DNase I incubation mix (10µL of DNase I stock solution mixed with 70µL 
of Buffer RDD) was added directly to the RNeasy spin column membrane. The 
samples were then incubated at room temperature for 15 minutes. This was followed 
by another wash step with 350µL of buffer RW1 added to each spin column and the 
flow-through discarded. This completed the on-column DNase treatment. The sample 
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spin columns were then further processed according to the protocol by addition of 
500µL of Buffer RPE to the spin column and centrifugation for 15 seconds at 
12000rpm. This wash step was repeated once more for two minutes and centrifuged 
at 12000rpm. The RNA was then eluted by placing the spin column in a new 2mL 
collection tube and adding 40µL of RNase-free water directly onto the spin column 
membrane and centrifuging for one minute at 12000rpm. 
2.2.3 Assessment of RNA yield and quality 
RNA yield and quality was assessed using the NanoDrop
TM
 1000 Spectrophotometer 
(Thermo Fisher Scientific, Wilmington, DE, USA). After blank calibration using a 
volume of RNase–free water, resuspended RNA samples were checked using the 
RNA-40 selection using sample volumes of 1.5µL. Target 260/280 ratios were 2.0 or 
greater  and a 260/230 ratio of 1.8 or greater.  
 
2.3 FIRST STRAND CDNA SYNTHESIS 
First strand cDNA synthesis in preparation for PCR or quantitative real-time PCR 
(QRT-PCR) was carried out using a standardized protocol for all experiments. 
DNase treated sample RNA was used for all experiments as outlined above. 1µg of 
sample RNA was used for each sample. RNA was pre-treated by combining 1µg of 
RNA in RNase–free water with 1µL 50ng/µL random hexamers (Life Technologies 
Cat. No. N808127), 1µL 10mM dNTP mix (Life Technologies Cat. No. 18427013), 
and the solution made up to a final volume of 18µL with RNase free water. This 
solution was incubated for 5 minutes at 65°C in a bench top thermal cycler. 
Following incubation, 7µL of first strand reaction mix comprising the following 
elements was added to each 18µL RNA sample mix: 4µL 5x First Strand Buffer  
(Life Technologies Cat. No.  Y02321), 1µL 0.1mM DTT (Invitrogen Cat. No. 
Y00147), 1µL RNase Out (40U/µL) (Invitrogen Cat. No. 10777-019) and 1µL 
Superscript III Reverse Transcriptase (200U/µL) (Life Technologies Cat. No. 
18080044). The final 25µL was vortexed briefly and spun down and then incubated 
in a thermal cycler using the following protocol: 10 minutes at 25°C, 50 minutes at 
50°C and 5 minutes at 85°C. The samples were then held at 4°C. 
 
 
79 
 
2.4 POLYMERASE CHAIN REACTION 
Standard bench-top polymerase chain reaction was carried out for all experiments 
according to the following protocol: 2µL of cDNA prepared in the first strand cDNA 
synthesis step described in section 2.3 was used in a 50µL reaction including the 
following reagents for each reaction mix: 5µL 10x PCR Reaction Buffer (Invitrogen 
Cat. No. Y02340), 1.5µL 50mM MgCl2 (Invitrogen Cat. No. Y02016), 1µL 10mM 
dNTP (Life Technologies Cat. No. 18427013), 1µL forward primer (10µM solution), 
1µL reverse primer (10µM solution) (Primers used are listed in Appendix A), 
Platinum Taq DNA polymerase 5U/µL (Invitrogen Cat. No. 10966034), 38µL 
RNase- and DNase-free water. The reaction mixtures were briefly vortexed and spun 
down and then cycled in a Bio-Rad C1000 Thermal Cycler (Bio-Rad Laboratories, 
Hercules, CA, USA) using the following cycling parameters :  
i) 95°C for 30 seconds 
ii) 60°C for 1 minute 
iii) 72°C for 1 minute 
iv) Repeat steps ii and iii for 35 cycles 
 
2.5 QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION 
(QRT-PCR) 
QRT-PCR was carried out using a 384-well plate format on an Applied Biosystems 
7900HT Fast Real-Time PCR System (Applied Biosystems, Warrington, UK, Part 
no. 4329001). 10µL reaction mixtures were prepared in triplicate for each sample 
and 9µL of the reaction mix loaded into each well. The reaction mix was prepared 
according to the following protocol: 5µL SYBR Green PCR Master Mix (Applied 
Biosystems , Part no. 4309155), 0.64µL forward primer (5µM stock), 0.64µL reverse 
primer (5µM stock)(See appendix A for primers used), 0.5µL cDNA from First 
Strand synthesis in Section 2.3, 3.2µL DNase-free water for a total volume of 10µL. 
Cycling parameters were standard for all reactions as follows : Stage 1 : 50°C, 2 
minutes; Stage 2:  95°C , 10 minutes; Stage 3:  95°C 15 seconds followed by 60°C 
for 1 minute for 40 cycles.  Fold-change for genes of interest was calculated using 
the CT method using a reference house-keeping gene, RPL32, for each treated 
sample and control. RPL32 ranked 26/1037 unique genes assessed for adequacy as 
housekeeping genes across a variety of publicly available microarray expression data 
(de Jonge et al, 2007). It is the most commonly used housekeeping gene for prostate 
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cell lines used in our laboratory and for these two reasons was selected as the 
housekeeping gene of choice for all real time PCR work. Each experimental 
treatment was carried out in 6 well plates with three biological replicates and QRT-
PCR was carried out with 3 technical replicates of each biological replicate. 
Therefore 9 data points were accrued for each treatment condition. Mean fold-
change, standard deviation and standard error of the mean were calculated for each 
gene of interest using Microsoft® Excel 2007 statistical functions (Microsoft Office 
Excel 2007 (12.0.6654.5003), © 2006 Microsoft Corporation). All results for fold 
change for each gene of interest were reported as normalised data against control 
samples run in triplicate for each experimental condition. 
 
2.6 siRNA TRANSIENT TRANSFECTION 
Initially during the first part of this thesis research period several months were spent 
identifying a suitable YBX1 siRNA to achieve reliable and repeatable YBX-1 protein 
knockdown. The first commercial siRNA successfully validated was the 
SureSilencing™ siRNA set for Human YBX1 (SABiosciences, Cat. No. 
SIH209908D and SIH209908B). Unfortunately, soon after these two siRNAs were 
validated and selected for all further work, SABiosciences was acquired by Qiagen 
and these siRNAs were discontinued commercially. At that stage the only validated 
YBX1 siRNA available from Qiangen was FlexiTube Human YBX1 siRNA 
(Qiagen, Cat. No. SI03019191). This siRNA was purchased and again validated and 
found to be effective. To avoid further delays to commencing the experimental work, 
it was decided to proceed with only this siRNA. For all experiments knockdown was 
carried out according to the manufacturer’s protocol, modified for  volume in a 6-
well plate format.  Control samples were treated using AllStars Negative Control 
siRNA (Qiagen, Cat. No. 1027281) using the same treatment protocol. Knockdown 
experiments were carried out as follows: cells were seeded in 6-well plates on day 0 
at 90 000 cells/well in 2mL (final siRNA concentration of 150nM) of RPMI/5% FCS 
medium and allowed to settle undisturbed for 48 hours. siRNA treatment was carried 
out at 48 hours using the following treatment mix:  In a 1.75mL Eppendorf tube, 
1.5µL of YBX1 or negative control siRNA (20µM stock) was pipetted followed by 
250µL of Opti-MEM® Reduced Serum Medium (Life Technologies Cat. No. 31985-
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070). This was briefly vortexed and centrifuged on a bench-top centrifuge. In a 
second 1.75mL Eppendorf tube, 250µL of Opti-MEM® Reduced Serum Medium 
was added followed by 2µL of Lipofectamine™ 2000 Transfection Reagent (Life 
Technologies Cat. No. 11668019). This tube was briefly vortexed and spun down, 
allowed to incubate for 5 minutes at room temperature and then added drop-wise to 
the first tube. The first tube mix was then incubated at room temperature for 15 
minutes. Individual reaction tubes were prepared in this way for each well in the 6 
well plate. At 15 minutes the reaction mix in tube 1 was added to the relevant 
treatment well in a drop-wise fashion and the medium mixed by gentle swirling of 
the cell culture plate. The volume of 1.5µL (20µM stock) for YBX1 siRNA was 
determined by experimental titration to provide optimal knockdown while 
minimizing siRNA volume and cell toxicity. At first medium was changed after 16 
hours to remove Opti-MEM® and siRNA, however this resulted in inevitable lifting 
of LNCaP cells and cell loss. It was found that not changing the medium for the 
duration of the treatment (usually 48 hours) did not affect cells adversely and did not 
affect knockdown efficiency. For this reason medium change was abandoned for 
most experiments after this.  
 
 
 
Figure 2.1 Chromosome map showing position of Qiagen YBX1 siRNA cat. No. 
SI03019191 with that of the YBX1 gene  
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In order to ensure that scramble siRNA and mock no-siRNA treatments did not 
adversely affect cells through off-target effects, and thereby confound the 
interpretation of QRT-PCR results, the knockdown efficiency of siRNA for YBX1 
was compared against both scramble siRNA and a mock, no siRNA treatment. These 
treatment efficacies were then compared using QRT-PCR as described above. As can 
be seen in Figure 2.2, there is no appreciable change in knockdown efficiency when 
comparing YBX1 siRNA knockdown against scramble siRNA or mock treatment.  
This reassured the candidate that the scramble siRNA and transfection medium 
(Lipofectamine ™ 2000 and Opti-MEM® were not having unexpected deleterious 
effects on cells. 
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Figure 2.2 Data showing comparison of YBX1 siRNA knockdown calculated against 
scramble siRNA or no-siRNA/mock-treatment 
Cells were plated in 6-well plates at 90 000 cells per well in 1.5ml 5% FBS without 
antibiotic. Cells were allowed to incubate overnight and treated the following morning with 
YBX1 siRNA to final concentration of 150nM, or scramble siRNA or no-siRNA mock 
treatment and then incubated without media change for 48 hours. At 48 hours cells were 
harvested in Trizol reagent for RNA collection, followed by cDNA synthesis and QRT-PCR. 
Fold change knockdown shown normalized to scramble siRNA (blue) or mock treatment 
(red). It can be seen that for both LNCaP cells and PC-3, there is no appreciable difference in 
knockdown efficiency when comparing scramble siRNA and mock control treatments. Error 
bars represent SEM for three biological replicates in each experiment.  
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
1 2 3
R
e
la
ti
v
e
 K
n
o
c
k
d
o
w
n
 f
o
r 
Y
B
X
1
 
s
iR
N
A
 
LNCaP Experiment no. 
vs scramble siRNA
vs Mock treatment
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
1 2 3
PC-3 Experiment no.
R
e
la
ti
v
e
 K
n
o
c
k
d
o
w
n
 f
o
r 
Y
B
X
1
 
s
iR
N
A
 
vs scramble siRNA
vs Mock treatment
84 
 
2.7 YBX-1 HUMAN CDNA ORF CLONE TRANSIENT TRANSFECTION 
YBX-1 protein overexpression was achieved using a commercial expression-
validated cDNA clone, YBX1 (NM_004559) Human cDNA ORF Clone (Origene, 
Cat. No. RC209835). This is a Myc-DDK-tagged ORF clone in a pCMV6 entry 
vector, prepared as transfection ready DNA.  
 
Figure 2.3 Vector map for the YBX1 Human cDNA ORF clone – Origene cat. No. RC 
209835 with incorporated DDK tag and CMV promoter 
 
For the purposes of multiple experiments, the plasmid was amplified in E. Coli 
bacteria using a standardized procedure as follows:  Competent E. Coli DH5α 
(Invitrogen Cat. No.  18263012) were obtained from Dr. Patrick Ling (APCRC-Q). 
One vial was thawed on ice and then 25µL transferred to a 0.6mL Eppendorf tube. 
100ng of YBX1 plasmid DNA (1µL of a 10µg/100µL solution) was added and the 
solution mixed by gentle tapping. The solution was then left on ice for 30 minutes. 
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The E. Coli were then permeabilized by immersion of the tube in a water bath at  
42°C for 45 seconds exactly. The tube was then returned to ice for 2 minutes. At this 
point 250µL of SOC medium (Invitrogen Cat. No. 15544-034) was added to the 
mixture and the solution transferred to a 15mL Falcon tube and placed in a horizontal 
rocker at 37°C for 1 hour at 225rpm. Following incubation, 150µL of the solution 
was spread on a Kanamycin LB agar plate using aseptic precautions and Bunsen 
burner. The agar plate was placed inverted in a 37°C incubator for 16 hours. The 
following day 3 bacterial colonies were seeded from the agar plate into each of three 
50mL Falcon tubes containing 6mL of LB broth (Invitrogen Cat. No. 12780-052) 
containing 25µg/mL Kanamycin for selection of transformed bacteria. Falcon tubes 
were incubated on a horizontal rocker overnight for 16 hours at 37°C to allow for 
bacterial multiplication. After 16 hours plasmid was extracted from the bacterial 
suspensions using a QIAprep Spin Miniprep Kit (Qiagen, Cat. No. 27106) according 
to the manufacturer’s protocol as follows: bacterial suspensions from the 6mL 
overnight incubations in each Falcon tube were aliquoted into 1mL volumes in 
1.75mL Eppendorf tubes and pelleted down by centrifugation and the supernatant 
removed. Pelleted bacterial cells were resuspended in 250µL Buffer P1 and 
transferred to a clean microcentrifuge tube. 250µL of buffer P2 was added and the 
solution mixed by inverting 4-6 times. 350µL Buffer N3 was added and the solution 
again mixed immediately by inverting 4-6 times. Tubes were centrifuged for 10 
minutes at 13 000rpm in a bench top centrifuge. The supernatant from each tube was 
removed by pipette and transferred to a QIAprep spin column. The spin column was 
then centrifuged for 30-60 seconds and the flow-through discarded. The spin column 
was then washed by addition of 0.5mL Buffer PB and centrifuging for 30-60 
seconds. A further wash step was carried out by addition of 750µL Buffer PE and 
centrifuging for 30-60 seconds. The flow through was discarded and the spin column 
centrifuged for an additional one minute to remove residual wash buffer. Plasmid 
DNA was eluted by placing the QIAprep spin column in a clean 1.5mL 
microcentrifuge tube and adding 50µL of DNase-free water to the centre of each spin 
column and allowing to stand for 1 minute prior to a final 1 minute centrifugation 
step. Plasmid concentration and purity was then checked using the NanoDrop™ 1000 
Spectrophotometer  using the “DNA-50” Selection. 
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Transient plasmid transfections were carried out according to the manufacturer’s 
protocol, with volumes modified for a 6 well plate. Dose titration experiments were 
carried out to ascertain the optimal plasmid concentration per well. It was found that 
1µg of plasmid per well of a 6-well plate gave equivalent YBX1 over-expression as 2 
µg, 3µg or 4µg in LNCaP cells. Therefore 1µg/well was used for all experiments in 6 
well plates. The transfection mixture was prepared as follows: in a 1.5mL Eppendorf 
tube 100µL of Opti-MEM® Reduced Serum Medium (Life Technologies Cat. No. 
31985-070) was added followed by 1µg of Origene YBX1 Human cDNA ORF 
plasmid in DNase-free water (volume typically 2-4µL after Miniprep collection). 
The mixture was then briefly vortexed. 3µL of Lipofectamine™ 2000 Transfection 
Reagent (Life Technologies Cat. No. 11668019) was then added followed by a 
dedicated 10 second vortex of each sample and brief spin-down. Reaction mixtures 
were then allowed to incubate at room temperature for 10 minutes before being 
added drop-wise to respective wells of the 6-well culture plates in a tissue-culture 
hood. Cells had been seeded 48 hours prior at a density of 90 000/well in 2mL 
RPMI/5% FCS medium.  Similar to siRNA transient transfections, it was found that 
medium exchange after transfection was not necessary. Control samples were treated 
with vehicle only (Opti-MEM® and Lipofectamine™ 2000) except for micro-array 
experiments where an empty pCMV6-Entry vector was used for all control well 
treatments (Origene, Cat. No. PS100001). 
 
 
 
2.8 WESTERN BLOT 
2.8.1 Cell culture and harvest 
Cells for western blot were grown and treated in 6 well plates as described 
above. Cells were collected at designated experimental time points as follows: 
medium was aspirated from wells and the plates placed on ice. 100-150µL of ice-
cold RIPA lysis buffer (50mM Tris HCl pH7.4, 150mM NaCl, 2mM EDTA, 1% NP-40, 
0.1% SDS) containing pre-mixed EDTA-free protease-inhibitor cocktail (Roche cat. No. 
04693159001). Cells were bathed in lysis buffer for 60 seconds then removed with a cell 
scraper and collected in chilled micro-centrifuge tubes and then held on ice for 30 
minutes. The cells were then centrifuged at 13200rpm for twenty minutes at 4°C in a 
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bench top centrifuge (Eppendorf 5415R, Hamburg, Germany). The supernatant was 
collected in a separate tube and the pellet discarded.  
2.8.2 BCA Protein assay 
Sample protein concentrations were determined using the BCA Protein Assay 
(Thermo-Scientific cat. # 23225) according to the manufacturer’s protocol.  Reagent 
A and B were mixed in a 50:1 ratio. Samples were loaded for assay in a 96 well plate 
as follows: 4µL RIPA lysis buffer, 1µL sample, 100µL reagent A:B mix. Bovine 
serum albumin (BSA) standards were added to the control wells.  Each sample was 
assayed twice in two wells of a 96 well plate and the result averaged. The plate was 
incubated for 1 hour at 37°C and then read in a spectrophotometric microplate reader 
at 562nm (FLUOstar Omega, BMG LABTECH, Ortneberg, Germany). The 
microplate reader software was used to generate a standard curve according to the 
formula  
Y= Bottom + (Top-Bottom)/(1+(EC50/x)^Slope) 
and interpolate sample concentration in ng/µL. 
 
2.8.3 SDS Gel preparation 
All western blots were performed using a 4% stacking gel and a 7% resolving 
gel. Gels were prepared as per the recipe in Table 2.1. 
Table 2.1 Recipe for Western blot SDS-PAGE resolving and stacking gels 
Reagent Volume for 1x 7% 
resolving gel (µL) 
Reagent Volume for 1x 4% 
stacking gel 
Milli-Q water 2812.5 Milli-Q water 1625 
40% acrylamide 937.5 40% acrylamide 250 
4x resolving buffer 1250 Stacking buffer 620 
10% APS 60 10% APS 30 
TEMED 10 TEMED 5 
 
88 
 
SDS-PAGE gels were prepared using Bio-Rad Mini-PROTEAN 10 or 15 well 
1mm combs. As experimental throughput increased, BIO-RAD 7.5% Mini-Protean® 
TGX™ Precast gels (10 well, 30µL, cat. No. 456-1023) were used for later 
experiments, as well as BIO-RAD Any KD Mini-Protean TGX Precast gels (10 well, 
30µL,  cat. no.456-9033) for smaller sized proteins. 6µL of Amersham Full Range 
Rainbow Molecular Weight Markers (GE Healthcare, cat. no. RPN800E) was used 
as a protein ladder and 15µg of sample was loaded into each well. Prior to loading, 
samples were brought to volume with RIPA buffer and then 2µL of sample buffer 
(0.625M TRIS, 10% SDS, 50% glycerol, 500mM DTT and bromophenol blue 
0.0025%).  Gels were loaded into a Bio-Rad Mini-Protean® Tetra-Cell Transfer 
Tank (Bio-Rad Laboratories, Hercules, CA, USA) and filled appropriately with 1x 
SDS Running Buffer (25mM TRIS, 192mM Glycine and 3.5mM SDS) and run at 
0.05mA for 90 minutes, or until sufficient protein band separation had been achieved 
based on inspection of the protein ladder.  
2.8.4 Wet transfer 
All membrane transfers were performed using a wet transfer system as follows. 
Gels were transferred to Immobilon-P membrane, PVDF, (Millipore, cat.# 
IPVH00010), using a Bio-Rad Mini-Trans Blot® Electrophoretic Transfer Cell (Bio-
Rad Laboratories, Hercules, CA, USA) as follows : the SDS gel was first immersed 
in transfer buffer (25mM Tris, 192mM glycine, pH 9.3) for 15 minutes to allow 
equilibration. The Immobilon-P membrane was cut to size and then immersed in 
100% methanol for 15 seconds, then transferred to Milli-Q water for 2 minutes. The 
membrane was then transferred to transfer buffer for 5 minutes. Laboratory filter 
paper was then cut to size and also soaked in transfer buffer for 30 seconds. The 
transfer stack was assembled as a sandwich in the following layers, from top to 
bottom: foam pad, filter paper, gel, Immmobilon-P membrane, filter paper, foam pad. 
The sandwich was loaded into the Transfer Cell cassette with the gel closest to the 
cathode and the cassette mounted in the tank. The transfer tank was filled with 
enough transfer buffer to cover the cassette holder and ice pack, and the 
electrophoretic transfer was commenced at 6-8V/cm inter-electrode distance for 90 
minutes with a magnetic mixing rod. Prior to primary antibody incubation, the PVDF 
membrane was blocked in 10% skim milk for 1 hour, followed by two washes of 
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fifteen minutes in TBS-T (150mM NaCl, 10mM Tris, 0.1% Tween 20, pH 8.0). All 
primary antibodies were incubated overnight in 5% skim milk in a rocker at 4°C.  A 
list of all antibodies and dilutions used can be found in Appendix F. The following 
morning the membrane was again washed in TBS-T twice for fifteen minutes each, 
followed by incubation of the secondary antibodies at room temperature for 1 hour.  
This was followed by another two washes in TBS-T for fifteen minutes each. After 
the washing step membranes were incubated in Millipore Immobilon Western 
Chemiluminescent HRP substrate (cat. No. WBKLS0500) prepared as per 
manufacturer instructions. After incubation in the horse-radish peroxidase substrate 
for 5 minutes, membranes were imaged using a BIO-RAD ChemiDoc™ XRS+ 
Molecular Imager® using the supplied Image Lab™ Software.  
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Chapter 3: Exclusion of YBX1 pseudogene 
expression in prostate cancer cell 
lines 
3.1 INTRODUCTION 
As has been discussed in section 1.7, there are at least ten annotated YBX1 
pseudogenes with variable expression levels documented in various tissues and cell 
lines. To the candidate’s knowledge, no prior research has investigated whether the 
known YBX1 pseudogenes are expressed in commonly used prostate cancer cell 
lines. This is an important question, as expression of pseudogene mRNA or protein 
may play a confounding role in the experiments and quantifications undertaken 
during this PhD.  Consequently, the possibility of YBX1 pseudogene expression in 
prostate cancer cell lines is explored in this Chapter. 
 It was deemed necessary to attempt to design primer pairs for YBX1 that 
would solely identify mRNA transcripts from the true YBX1 gene and exclude those 
possibly originating from pseudogene expression. To achieve this, a number of 
techniques were employed, which are outlined in the Methods section. These 
included cataloguing of possible pseudogene candidates using the UCSC genome 
browser (http://genome.ucsc.edu), the NCBI pseudogene annotation for YBX1 
(http://www.ncbi.nlm.nih.gov/gene/?Term=related_functional_gene_4904[group), 
selecting a short-list of candidates most likely to interfere with quantitative 
methodologies, and then lastly using several techniques to check primer specificity 
and exclude pseudogene expression in commonly used prostate cancer cell lines.  
 
3.2 METHODS 
3.2.1 Selection of pseudogene candidates for expression analysis 
A list of potential important pseudogenes was developed by combining the 
analysis of the NCBI pseudogene annotation for YBX1 (Table 1.1) and by 
performing a UCSC Genome Browser BLAT search using the reference YBX1 
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mRNA sequence (http://www.ncbi.nlm.nih.gov/nuccore/NM_004559.3) (Figure 3.1). 
The  full YBX1 mRNA sequence, as well as the sequences for select pseudogenes 
are detailed in Appendix B. The YBX1 RefSeq mRNA is 1561 bp long, and based on 
the top hits for both these lists, candidate pseudogenes were chosen based on 
pseudogene homology and length compared to the YBX1 RefSeq mRNA sequence 
(Table 3.1). Specifically, candidate pseudogenes with over 90% homology to the 
YBX1 mRNA, or that are over 1000bp (compared to the YBX1 mRNA transcript 
length of 1561bp) were selected.  Transcripts with a difference of over 10% to the 
YBX1 mRNA, or a transcript length less than 1000bp (compared to the YBX1 
mRNA 1561bp) were less likely to form functional YBX1 protein.  By the same 
token, a number of pseudogenes were excluded for further analysis due to the 
presence of truncated or fragmented exons that would therefore be unlikely to 
contribute to a functional protein that could confound the role and activity of the 
ReSeq YBX1. Based on this systematic process of exclusion, a final shortlist of six 
pseudogenes were selected (Table 3.1) for consideration as possible confounders as 
expressed genes in prostate cancer cell lines.
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Figure 3.1 BLAT search results for YBX1 NC_000001.10 Reference GRCh37.p9 Primary Assembly. 
The top ranking results with a score over  90% and span over 1000bp were considered for exclusion 
as possible confounding expressed pseudogenes. 
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Table 3.1  Final list of pseudogenes selected for exclusion  
 
Chromosome / Strand Locus BLAT Identity 
14 - 65548876-65550399 96.2% 
9 - 35960925-35962454 95.2% 
7 - 105009538-105011090 94.6% 
15 + 61032287-61033781 92.9% 
9 - 111334515-111336572 91.9% 
2 174744995-174746586 84.9% 
 
3.2.2 Design of RefSeq YBX1 specific, pseudogene-excluding primers 
A key issue that needed to be resolved was to design PCR primers that target the YBX1 
gene and mRNA, but none of the YBX1 pseudogenes.  
The mRNA sequences for YBX1 and the pseudogenes listed in table 3.1 were aligned 
using Clustal X2 (Larkin et al, 2007) in order to search out potential PCR primer sites that are 
specific for YBX1. However, it was readily apparent from inspection of the Clustal alignment 
that YBX1 and the six pseudogene sequences are highly homologous, as per the selection 
criteria for candidate pseudogenes (PGs), thus precluding specific primer design at any locus 
in the YBX1 mRNA transcript without the risk of pseudogene amplification. The entire 
Clustal alignment was searched for sites of unique YBX1 base identity compared to the 
pseudogene (PG) sequences; however there was no region in which YBX1 differed 
sufficiently from the PG sequences to allow a unique primer design. YBX1 differed from PG 
sequences at single base pair sites, but more often than not the PG sequences would differ at 
single base pair sites from each other but not from the reference YBX1 sequence. 
After this initial assessment it seemed that it would not be possible to design a YBX1 
specific primer set. A literature search was undertaken to identify techniques for primer 
design in situations requiring discrimination of highly homologous sequences. An interesting 
paper describing the use of ARMS – Amplification Refractory Mutations System (Newton et 
al, 1989) was found, which describes a PCR system used to identify point mutations in DNA 
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that differ to the target sequence at the final 3’ base of the PCR primer. Essentially, 
oligonucleotides with a mismatched 3’ residue will not function properly as primers in a PCR 
reaction, allowing the identification of heterozygotes at a locus without the need for 
restriction enzyme digests or product sequencing. The key requirement is that the target 
sequence can be differentiated from the comparison sequence at a nucleotide base which can 
be located at the 3’ end of one of the primer pairs. The principle in this paper was applied to 
the Clustal alignment of YBX1 and the 6 top-ranking pseudogenes of concern, and the YBX1 
mRNA in particular was inspected for single base mismatches with the pseudogenes. As a 
result, two sites were identified in the alignment where YBX1 could potentially be 
distinguished from the pseudogenes. The first site is seen at base pair 1927 on the Clustal 
alignment for YBX1 (see Figure 3.2). This region lies within the 3’ UTR. At this point the 
YBX1 nucleotide is an adenine (A), whereas all the pseudogenes possess a thymine (T), 
except for the pseudogene on chromosome 15, which is also an A. At position 1974, the 
chromosome 15 pseudogene can be separated from all the other pseudogenes and also YBX1, 
as at this position it has a mismatch with a cytosine (C), while the other transcripts possess an 
adenine. These two sites allowed the design of a unique primer pair which would allow 
specific amplification of the YBX1 mRNA only, by the ARMS principle, as depicted in 
Figure 3.3. This primer pair results in the amplification of a 98bp product in various prostate 
cancer cell lines (Figures 3.4 and 3.5). 
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Figure 3.2  Clustal X2 alignment for YBX1 and six potential pseudogene candidates showing 98bp segment flanked by YBX1 specific primer pair 
(underlined in white). Primer pairs are based on ARMS principle discussed in text and each primer’s 3’ end takes advantage of a base mismatch for the YBX1 
reference gene and the pseudogene on chromosome 15 in order to amplify only the true YBX1 transcript.
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Figure 3.3 Comparison of PCR reaction illustrating the effect of one primer not amplifying the 
template, as in the case of an ARMS primer design with a mismatched 3’ end base. The left panel 
shows a normal situation, where both primers are designed to amplify the respective template strands 
in a PCR reaction. After 35 cycles, assuming near perfect efficiency, approximately 35 billion strands 
of dsDNA would have been amplified.  
The right hand panel shows the situation in which one template has an ARMS designed mismatch at 
the 3’ end base, causing it not to anneal and amplify one strand of the template pair. At the end of 35 
cycles, only 35 strands of ssDNA are amplified, and one strand of dsDNA. In this way it is possible to 
use the ARMS method and the base pair mismatch illustrated in Figure 3.2 to selectively amplify only 
the true YBX1 transcript. 
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3.2.3 Determination of YBX1 pseudogene expression from prostate cancer cell lines by 
PCR restriction fragment length polymorphism (RFLP) analysis  
RFLP analysis was used on ARMS amplified products to further validate the expression of 
YBX1 and PGs.  The aligned YBX1 and pseudogene sequences for the 98bp ARMS PCR 
product were entered into an online restriction fragment calculator 
(http://bis.zju.edu.cn/virs/index.html, accessed between 24/10/11 to 12/1/13) and the results 
were sorted by restriction enzyme and pseudogene transcript to ascertain if any enzyme 
would uniquely cleave a single transcript. This process allowed the identification of several 
restriction enzymes which would cleave either one or only two or three pseudogene PCR 
products but not the true YBX1 ARMS amplification product. As it seemed that there were 
unique restriction enzyme and pseudogene pairs it was concluded that this method might 
feasibly allow validation of the YBX1 specific primers (hereafter also referred to as the 
“YBX1 ARMS-primers” to distinguish them from other YBX1 primers used during this 
research). An Excel spread sheet was compiled containing all the cleavage sites and 
restriction enzymes generating fragments for each pseudogene transcript and YBX1 transcript 
(Appendix C). Through a manual process unique enzymes cleaving each transcript were 
identified and shortlisted. For some of the pseudogenes, no unique enzyme could be found to 
distinguish them from other pseudogenes but it was possible to use restriction enzymes to 
distinguish them from the true YBX1 amplification product. Table 3.2 outlines the final 
restriction enzyme selected to cleave each expected pseudogene product from the YBX1-
ARMS primer pair, as well as the expected cleavage site and expected cleaved fragment 
lengths. The restriction endonuclease HpyCH4V was chosen as a positive control for the true 
YBX1 ARMS PCR product. The true YBX1 product has no restriction sites unique to it 
alone, and several of the pseudogenes possess a HpyCH4V site – however, these 
pseudogenes can be excluded based on absence of restriction with the endonuclease chosen 
for each pseudogene. 
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Table 3.2 Sequence of expected YBX1 and pseudogene PCR products from YBX1-specific ARMS 
primer pair, and expected restriction site for selected restriction enzyme. As can be seen, MseI, which 
cleaves at bases TTAA, had a cleavage site in all the pseudogenes expect that from chromosome 15. 
However it does not have a cleavage site on the true YBX1 expected PCR product. None of the 
selected restriction enzymes recognise a cleavage site in the expected true YBX1 PCR product. 
Restriction enzyme recognition sequences are shown in red text. 
 
 
 
Gene, locus and expected PCR sequence from YBX1-ARMS PCR primers and 
restriction cleavage site 
Restriction 
enzyme and 
expected 
fragment 
lengths 
YBX1 gene  HpyCH4V 
ACAAAAGATTGGAGCTGAAGACCTAAAGTGCTTGCTTTTTGCCCGTTGAC 
CAGATAAATAGAACTATCTGCATTATCTATGCAGCATGGGGTTTTTAT 
70,11,17 
Chr 14 : 65548876-65550399 BfuCI 
 
ACAAAAGATTGGAGCTGAAGACCTTAAATGCTTGCATTTTGCCCGTTGAC 
CAGATAAATAGATCTGCATTATCTATGCAGCATGGGGTTTTTAT 
60,34 
Chr 15 : 61032287-61033781 MnlI 
ACAAAAGATTGGAGTGGAAGACCTAAAGTGCTTGCTTTTTGCCCGTTGAC 
CAGAGAAGCAGAACTATCTGCCTTATCTATGCAGCATGAGGTTATTAT 
81,17 
Chr 2 : 174744995-174746586 CViQI 
ACAAAATATTGGAGCTGAAGACCTTAAGTACTTGCTTTCGTCGAATGGTC 
AGATAACTAGAACTATTTTCATTACCTATACGGCGTGAGGTTTTTAT 
28,69 
Chr 7 : 105009538-105011090 MseI 
ACAAAAGATTGGAGCTGAAGACCTTAAGTGCTTGCTTTTTGCCCGTTGAC 
CAGATAAATAGAACTATCTGCATTATCTATGCAGCATGGGGTTTTTAT 
24,74 
Chr 9 :111334515-111336572 DdeI 
ACAAAAGATTGGAGCTGAAGACCTTAAGTGCTTGCTTTTTGCCCaTTGAC 
CAGATAAATAGAACTATCTGtATTATCTAaGCAGCATGGGGTTTTTAT 
 
77,21 
Chr 9: 35960925-35962454 MseI 
ACAAAAGATTGGAGCTGAAGACCTTAAGTGCTTGCTTTTTGCCCGTTGAC 
CAGATAAATAGAACTATCTGCATTATCTATGCAGCATGGGATTTTTAT 
24,74 
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The experimental process involved the following steps: 
1. Extraction of RNA from five commonly used,  low-passage prostate cancer cell 
lines (LNCaP, PC-3, 22RV1, LAPC4 and DU-145) and also from the non-
malignant cell line, RWPE1. 
2. cDNA synthesis and PCR using the YBX1-ARMS primer pair. A non-ARMS 
primer pair, that lacks the last nucleotide at the 3’ end  was also used to detect 
YBX1 and any pseudogenes (3’ ARMS bases highlighted in red. These bases 
are missing in the non-ARMS primers) :  
a. ARMS forward primer : 5’- ACAAAAGATTGGAGCTGAAGACCTA-3’ 
b. Non-ARMS forward primer: 5’- AACAAAAGATTGGAGCTGAAGACCT -3’ 
c. ARMS reverse primer : 5’-AAAACCCCATGCTGCATAGATAAT-3’ 
d. Non-ARMS reverse primer : 5’-TAAAAACCCCATGCTGCATAGATAA-3’ 
3. Agarose gel electrophoresis of ARMS and non-ARMS PCR products to validate 
amplification  
4. Restriction digestion of ARMS and non-ARMS PCR products. Custom 
designed 100bp  oligonucleotides were also used as positive controls for each 
digestion (Table 3.3) 
5. Agarose gel electrophoresis of PCR products following restriction digestions 
 
RNA extraction, cDNA synthesis and PCR  
Cells were grown in culture in appropriate media as outline in Chapter 2 : Materials and 
Methods. Untreated cells were harvested using Trizol RNA extraction as per section 2.2.1 
followed by assessment of RNA quality using the Nanodrop 1000 spectrophotometer. cDNA 
synthesis was carried out as per the protocol set out in section 2.3. All PCR reactions were 
carried out as set out in section 2.4.  
Agarose gel electrophoresis 
Initial PCR products (98bp amplicons) were run on a 2% agarose gel to assess for PCR 
specificity. Restriction fragment digestion products were run on a 5% LE agarose gel 
(Ambion cat.no. AM9042)  at 100V for 75 minutes  using a protocol for hot plate agarose 
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preparation  (Cambrex Bio Science Rocklands, Inc., Rockland, Maine, USA ). Briefly, this 
protocol involves using a beaker 2-4 times the volume of the final solution and adding chilled 
electrophoresis buffer (1xTAE buffer). The agarose powder is slowly added to the solution 
while the solution is stirred on a cold magnetized hot plate. Once all the agarose is added, the 
beaker is covered with plastic wrap and a hole pierced for ventilation, and the hot plate is 
turned on, while stirring continues, and heating applied until the solution is brought to boil. 
Gentle boiling is maintained until all the agarose is dissolved. The solution is cooled to 50-60 
° C and then cast, cooled at room temperature and then placed at 4°C for 20 minutes to ensure 
optimal gel quality.  
 
Restriction enzyme digestions of ARMS and non-ARMS PCR products 
The following restriction endonucleases were purchased from New England Biolabs® 
Inc. (Ipswich, MA, USA) and used as per  the manufacturer’s protocol : HpyCH4V 
(cat.#R0620L); BfuCI (cat.#R0636L); CViQI (cat.#R0639L); DdeI (cat.#R0175L); MseI 
(cat.#R0525L) and MnlI (cat.#R0163L). 
Table 3.3 shows the reaction setup for each enzyme using 200ng of PCR product. For 
each cell line, both ARMS and non-ARMS PCR products were subjected to digestion, as well 
as custom made positive control oligonucleotides for each restriction enzyme. Table 3.4 
shows the sequences for each control oligonucleotide and its reverse complement partner. 
Oligonucleotides were mixed with their reverse complement partner in a 1:1 ratio to give a 
final concentration of 1000ng/µL and placed in a Bio-Rad C1000 thermal cycler for 
denaturation and annealing as follows: 98°C for 2 min, 72°C for 1 min, 60°C for 1 min, then 
cooled to 4°C. The annealed control oligonucleotides were also run on a 2% agarose 
electrophoresis gel for size validation (100bp). 
 
RNA-seq analysis for YBX1 pseudogenes using  the LNCaP cell line 
Cell treatments were repeated in LNCaP cells using the YBX1 siRNA and plasmid 
over-expression treatments described in section 2.6 and 2.7. In addition, these treatments 
were performed in media containing 10nM DHT and also androgen-starved conditions using 
charcoal-stripped media (CSS) containing 70% EtOH instead of DHT. In brief, cells were 
incubated and treated as described in section 2.6 and 2.7 and incubated for 48 hours in 10% 
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CSS containing either 10nM DHT or EtOH control. At 48 hours cells were harvested and 
RNA was collected and prepared for RNA-seq by Dr. John Lai, PhD, APCRC-Q. RNA-seq 
was performed by the Beijing Genome Institute using the Illumina HiSeq platform and using 
a strand specific protocol with 100 bp paired end resolution. Reads were mapped by TopHat, 
and wiggle plots were generated to visualise gene expression using the UCSC genome 
browser and the NCBI36/hg18 Assembly. 
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Table 3.3 Reaction conditions for restriction endonucleases for 200ng input DNA 
 
Enzyme DdeI MseI CviQI BfuCI MnlI 
Enzyme 
volume 
2µL 1 µL 1 µL 1 µL 1 µL 
Buffer NE3 10x 
2µL 
NE4 10x 
2µL 
NE3 10x 
2µL 
NE4 10x 
2µL 
NE4 10x 
2µL 
BSA 1x - 4 µL 4 µL 4 µL 4 µL 
DNA 200ng As per conc. As per conc. As per conc. As per conc. As per conc. 
DEPC H2O To volume To volume To volume To volume To volume 
Total 
volume 
20µL 20µL 20µL 20µL 20µL 
Incubation 
temperature 
37°C 37°C 25°C 37°C 37°C 
 
Reaction mixtures were incubated at the stated temperature for 1 hour in a Bio-Rad 
C1000 thermal cycler and then cooled to 4°C prior to loading on an agarose gel. 15µL of 
each reaction mixture was mixed with 3µL of 6x DNA loading dye and loaded into each well 
of the 5% agarose gel. 4µL of ready-to-use GeneRuler Ultra Low Range DNA Ladder 
(Thermo Scientific cat.#SM1213) were used as ladders in each gel. 
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Table 3.4 Control oligonucleotides and reverse complementary sequences custom designed 
for each restriction endonuclease. Restriction site shown in red. 
 
BfuCI AAGGGAAAGGGAAAGGGAAAGGGAAGGAAGGAAGGAAAGGGAAAGGGAAAG
GGAAAGGGAAGGAAGAAGATCGGGAAAGGGAAAGGAAGGAAGGAAGGGAA 
 
TTCCCTTCCTTCCTTCCTTTCCCTTTCCCGATCTTCTTCCTTCCCTTTCCCTTTCCCT
TTCCCTTTCCTTCCTTCCTTCCCTTTCCCTTTCCCTTTCCCTT 
CviQI AAGGGAAAGGGAAAGGGAAAGGGAAGGAAGGAAGGAAAGGGAAAGGGAAAG
GGAAAGGGAAGGAAGAAGTACGGGAAAGGGAAAGGAAGGAAGGAAGGGAA 
 
TTCCCTTCCTTCCTTCCTTTCCCTTTCCCGTACTTCTTCCTTCCCTTTCCCTTTCCCT
TTCCCTTTCCTTCCTTCCTTCCCTTTCCCTTTCCCTTTCCCTT 
DdeI AAGGGAAAGGGAAAGGGAAAGGGAAGGAAGGAAGGAAAGGGAAAGGGAAAG
GGAAAGGGAAGGAAGAACTAAGAAGAAAGGGAAAGGAAGGAAGGAAGGGAA 
 
TTCCCTTCCTTCCTTCCTTTCCCTTTCTTCTTAGTTCTTCCTTCCCTTTCCCTTTCCC
TTTCCCTTTCCTTCCTTCCTTCCCTTTCCCTTTCCCTTTCCCTT 
MseI AAGGGAAAGGGAAAGGGAAAGGGAAGGAAGGAAGGAAAGGGAAAGGGAAAG
GGAAAGGGAAGGAAGAATTAAGGGAAAGGGAAAGGAAGGAAGGAAGGGAA 
 
TTCCCTTCCTTCCTTCCTTTCCCTTTCCCTTAATTCTTCCTTCCCTTTCCCTTTCCCT
TTCCCTTTCCTTCCTTCCTTCCCTTTCCCTTTCCCTTTCCCTT 
MnlI AAGGGAAAGGGAAAGGGAAAGGGAAGGAAGGAAGGAAAGGGAAAGGGAAAG
GGAAAGGGACCTCAGGAAGAGGAAAGGGAAAGGAAGGAAGGAAGGGAA 
 
TTCCCTTCCTTCCTTCCTTTCCCTTTCCCTTCTTCCTGAGGTCCCTTTCCCTTTCCC
TTTCCCTTTCCTTCTCCTTCCCTTTCCCTTTCCCTTTCCCTT 
HpyCH4V AAGGGAAAGGGAAAGGGAAAGGGAAGGAAGGAAGGAAAGGGAAAGGGAAAG
GGAAAGGGAAGGAAGAATGCAGGGAAAGGGAAAGGAAGGAAGGAAGGGAA 
 
TTCCCTTCCTTCCTTCCTTTCCCTTTCCCTGCATTCTTCCTTCCCTTTCCCTTTCCCT
TTCCCTTTCCTTCCTTCCTTCCCTTTCCCTTTCCCTTTCCCTT 
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3.3 RESULTS  
3.3.1 Validation of PCR products, control oligonucleotides and control oligonucleotides 
digests. 
Figure 3.4 shows the results of PCR and restriction endonuclease reactions using 
LNCaP cDNA. Control oligonucleotides are loaded in lanes marked “C”. Each control 
oligonucleotide shows successful digestion with its respective enzyme with fragment sizes 
approximately 75bp and 25bp as expected. PCR products from the ARMS PCR are shown in 
lanes marked “A”  and products from non-ARMS PCR reactions in lanes “N”.  All 3 lanes for 
the HpyCH4V enzyme show digestion as expected, as this enzyme cleaved both the YBX1 
product and all pseudogene products at 2 sites. The absence of pseudgene PCR product is 
inferred from the lack of cleavage in the remaining enzyme lanes marked “N”. 
The experimental process was repeated multiple times for the other prostate cancer cell 
lines investigated – PC-3, 22RV1, DU-145, LAPC4 and RWPE1.  In each case, cDNA from 
each cell line was used in an ARMS and non-ARMS PCR reaction and the reaction products 
combined in a restriction endonuclease reaction. For these experiments, HpyCH4V, having 
served as a positive control for the true YBX1 amplicon, was replaced by MnlI in order to 
allow exclusion of the chromosome 15 pseudogene. Figure 3.5 is a composite image collating 
all the results from these experiments into one image. For some of the cell lines, certain 
restriction reactions were repeated owing to non-digestion of control oligonucleotides or poor 
gel quality. In this case, the repeated reactions were run on a new gel and the relevant lanes 
overlaid on the first gel image for that cell line. These lanes are marked in all cases with an 
asterisk to show they represent repeat digests run on a separate gel. As can be seen from 
inspection of the image, for every cell line there is no appreciable digestion of the ARMS or 
non-ARMS PCR product. In all cases the larger digestion fragment of 75bp can be clearly 
seen, and in many cases the smaller ~25bp fragment is also visible. Allowing for very low 
pseudogene expression levels, these images allow the candidate to draw the conclusion that 
no significant levels of YBX1 pseudogene is occurring in the cell lines concerned.  
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Figure 3.4  - 5% agarose gel showing RFLP digestion results for LNCaP cells. Lanes are labelled 
according to enzyme used in digestion and expected PG(s) to be cleaved. (C= control oligonucleotide, 
A = ARMS PCR product, N=non-ARMS PCR product). It can be seen that all the control 
oligonucleotides digested as expected with a band at 75bp (smaller 25bp fragments not seen) and all 3 
digestions succeeded with HpyCH4V as expected. If a pseudogene were expressed, it would be 
expected that the product in the “N” (non-ARMS) lane would be digested. This has not occurred for 
any of the 5 pseudogenes selected. The digestion for the Chromosome 15 pseudogene is shown in 
Figure 3.5 
 
 
Figure 3.5 (Overleaf) – Composite results for all six prostate cancer cell lines investigated for the 
presence of the six selected pseudogenes listed in Table 3.2 Asterisk-marked lanes represent repeat 
digests run on a second gel and overlaid on the parent image for the respective reactions. Other 
features are labelled as in Figure 3.4. It can be seen that no pseudogene PCR product was present, 
based on the lack of digestion in the lanes labelled “N” (non-ARMS)
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3.3.2 RNA-seq validation of pseduogene restriction digest results 
The results from Figure 3.4 show that no significant pseudogene expression could be 
detected for the selected pseduogene in the commonly used prostate cancer cell lines 
investigated in this experiment. The intention was to try to validate these results in any way 
possible, but performing standard PCR or QRT-PCR would be prone to difficulties with 
primer design already outlined above, including primer mis-alignment generating false 
positive results. It was possible to participate in a concurrent RNA-seq experiment being 
conducted by other researchers in the candidate’s laboratory. Cell treatments were repeated 
for YBX1 knockdown and overexpression in both androgen-replete media and charcoal 
stripped media. The intention of this experiment was purely investigational, as the candidate 
was aware of the fact that despite the high fidelity and resolution of RNA-seq platforms, there 
was still a possibility that RNA reads from YBX1 might be mapped to pseudogenes by the 
alogrithms, and vice-versa. This could potentially make meaningful interpretation impossible. 
One caveat was relying on the fact that presumably pseudogene expression levels should not 
change markedly across the different treatment conditions unless YBX1 or DHT directly 
regulate pseudogene expression. This was unknown at the time of performing the analysis. If 
pseudogene levels were shown to expressed based on RNA-read mapping but moving in 
concert with the changes with YBX1 for each treatment condition, then it might be fair to 
assume that what the algorithm was actually mapping to the pseudogene loci was in fact just 
varying levels of true YBX1 mRNA which was being assigned by the software to 
homologous sites in the genome. The wiggle file results for the repeated cell treatments were 
loaded into the UCSC genome browser as custom tracks and used to assess the RNA reads at 
the YBX1 RefSeq locus and also at the locus for each pseudogene.  
Figure 3.6 shows the RNA-seq read plots for the YBX1 RefSeq gene in the UCSC 
genome browser. There are high read counts mapped to exons 5,7 and 8 and these vary 
substantially depending on the YBX1 treatment, from 7420 reads for YBX1 overexpression 
in the presence of DHT down to low read counts of 234 and 254 for YBX1 knockdown in 
DHT and ethanol respectively. This nicely confirms the success of the YBX1 cell treatments 
at the RNA level. 
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Figure 3.6 RNA-seq plots for YBX1 RefSeq gene shown on UCSC genome browser (NCBI36/hg18).  
Cell treatments were repeated in LNCaP cells using the YBX1 siRNA and plasmid over-expression treatments described in section 2.6 and 2.7. In addition, these treatments were performed in 
media containing 10nM DHT and also androgen-starved conditions using charcoal-stripped media (CSS) containing 70% EtOH instead of DHT. In brief, cells were incubated and treated as 
described in section 2.6 and 2.7 and incubated for 48 hours in 10% CSS containing either 10nM DHT or EtOH control. At 48 hours cells were harvested and RNA was collected and prepared 
for RNA-seq. RNA-seq was performed by the Beijing Genome Institute using the Illumina HiSeq platform and using a strand specific protocol with 100 bp paired end resolution. Reads were 
mapped by TopHat, and wiggle plots were generated to visualise gene expression using the UCSC genome browser and the NCBI36/hg18 Assembly. It is evident that multiple reads map to 
exons 5, 7 and 8 and that the read count varies substantially between different YBX1 treatments – from 7420 reads for YBX1 overexpression in the presence of DHT down to 
a level of 234 and 254 reads for YBX1 knockdown in the presence of DHt and ethanol respectively. This confirms the success of the YBX1 treatments. PL_YB1 = YBX1 
overexpression; SI_YB1 = YBX1 siRNA 
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Using the genome browser the loci for the YBX1 pseudogenes  listed in Table 3.1 were 
inspected sequentially. There was no evidence of any RNA reads for the pseudogenes on 
chromosome 15, chromosome 9:111,334,515, or chromosome 2. Figures 3.7, 3.9 and 3.10 
show the UCSC genome browser views for the pseudogene loci on chromosome 14, 
chromosome 9:35,960,925 and chromosome 7 respectively. It can be seen that each of these 
shows significant RNA read counts for each of the loci in question, suggesting perhaps that 
the pseuodogenes at these locations are actually expressed. However, the algorithms used in 
RNA-seq analysis cannot distinguish whether an RNA fragment comes from 1 or more 
homologous sites to the true gene, and this is constrained with a 2bp tolerance. Therefore 
highly similar sequences, as in the case of YBX1 and the pseudogenes studied here, cannot 
be distinguished by RNA-seq methodology alone. A clue available in the browser views 
suggests in fact that these reads are actually YBX1 reads incorrectly assigned to these loci. 
This is drawn from the fact that the read counts vary for each treatment in very similar ways 
to the read counts for the YBX1 cell treatments in Figure 3.6, with high reads for YBX1 
overexpression (annotated as PL_YB1_DHT/ETOH) and low reads for YBX1 siRNA treated 
cells (SI_YB1_DHT/ETOH). One would assume that the pseudogenes would not be 
regulated by YBX1 directly, however there is no evidence in the literature for or against this 
assumption. The aligment of the read count for the chromosome 14 PG was compared to the 
YBX1 RefSeq sequence for the same region by retrieving the DNA sequence for 
Chr14:65549310-65550015 on the genome browser which corresponds to the shaded wiggle 
read profiles in Figure  3.7. The alignment for this region against YBX1 is shown below in 
Figure 3.8. As described in the figure legend, there are only 8 base mismatches between this 
700bp Chr 14 PG segment and the corresponding YBX1 mRNA. This is within the 2bp 
tolerance allowed by the RNA-seq alignment algorithm and means that the reads on this locus 
may actually be from YBX1 mRNA or PG mRNA from this locus – it is impossible to be 
sure how the software has assigned the reads. The second point to note for this particular PG 
is that the ARMS primers designed to detect any possible product lie outside of the wiggle 
reads displayed on the genome browser for this PG – they lie in the 3’ downstream region at 
chr14:65,549,122-65,549,215, which is outside of the annotated single exon for CR594591. 
This is annotated in Figure 3.7 with the arrowhead. Therefore it is possible that no digestion 
product was seen for this pseudogene in the results in the previous section as the primer came 
from an untranslated region. Again, this is difficult to resolve as there is no other region on 
the Chr 14 PG sufficiently different to the RefSeq YBX1 sequence to design unique primers.  
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The same was found to be true of the Chr 9:35,960,452 PG in which the ARMS PCR product 
lies well outside and downstream of the wiggle reads, thereby again making interpretation of 
the restriction digests uncertain. However, for both this PG and the Chr 14 PG, what can be 
said is that the ARMS PCR primer for YBX1 is unlikely to be confounded by expressed 
pseudogene products from these loci. However, in the case of the PG on chromosome 7, the 
ARMS PCR product was found to lie within the region showing wiggle RNA read counts 
(image not shown). In this case, lack of digestion in the restriction digest experiments in the 
previous section may instead support the premise that the wiggle reads here are actually from 
YBX1 RefSeq mRNA and have been incorrectly aligned to the locus on the chromosome 7 
PG. This is a limiting factor of RNA-seq technology, and a particular difficulty thrown up by 
the close homology of the YBX1 pseudogenes to the parental YBX1 RefSeq sequence. 
However, a factor against these loci being mis-assigned YBX1 RefSeq gene reads is the fact 
that the read counts are not equally distributed across the three pseudogene (PG) loci. For 
example, the chromosome 14 PG has approximately 16000 reads for YBX1 overexpression 
in DHT, whereas for the same treatment in the chromosome 9:35,960,925 PG the read count 
is only 3871, and only 503 for that on chromosome 7. One would expect a fairly even 
distribution of reads across the three loci if the algorithm was simply distributing the true 
YBX1 RNA reads across all matching loci in the genome, but this does not appear to be the 
case. It may be that there is genuine pseudogene expression in these three loci and that their 
expression level is in fact regulated by the native YBX1 protein. This is not possible to rule 
out using the RNA-seq technique alone, and will probably remain unanswered until other 
very time-consuming and painstaking methods are employed to settle this question. What can 
be stated with confidence is that the RNA-seq analysis here has ruled out pseudogene 
expression on chromsomes 15, 9:111,334,515 and chromosome 2. The remaining 
pseudogenes may possibly be truly expressed in LNCaP cells, but this was not evident in the 
restriction digest analyses in the previous section.  
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Figure 3.7 RNA-seq plots for YBX1 pseudogene on Chr 14:65,548,876-65,550,339 
Cell treatments were repeated in LNCaP cells using the YBX1 siRNA and plasmid over-expression treatments described in section 2.6 and 2.7. In addition, these treatments were performed in media containing 10nM 
DHT and also androgen-starved conditions using charcoal-stripped media (CSS) containing 70% EtOH instead of DHT. In brief, cells were incubated and treated as described in section 2.6 and 2.7 and incubated for 48 
hours in 10% CSS containing either 10nM DHT or EtOH control. At 48 hours cells were harvested and RNA was collected and prepared for RNA-seq. RNA-seq was performed by the Beijing Genome Institute using 
the Illumina HiSeq platform and using a strand specific protocol with 100 bp paired end resolution. Reads were mapped by TopHat, and wiggle plots were generated to visualise gene expression using the UCSC 
genome browser and the NCBI36/hg18 Assembly. The pseudogene on the (-) strand of chromosome 14 shows significant read numbers across all cell treatments suggesting expression of this 
pseudogene which is annotated by the Genome Browser in blue as CR594591. However the read levels vary significantly, with very high read counts of 16350 for YBX1 overexpression in DHT 
(Pl_YB1_DHT_LNCaP) compared to counts of 603 for YBX1 siRNA knockdown in DHT (SI_YB1_DHT_LNCaP). This suggests that the reads here may be YBX1 mRNA that is incorrectly 
assigned by the sequencing alogorithms to this locus. The position of the ARMS PCR primer product is shown, lying outside the annotated exon and wiggle reads. PL_YB1 = YBX1 
overexpression; SI_YB1 = YBX1 siRNA 
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Figure 3.8 Alignment of Chr 14:65549310-65550015 against YBX1 RefSeq sequence  
Base pair mismatches shown in lower case. As can be seen from the alignment, there are only 8 base mismatches between the YBX1 RefSeq sequence and 
this part of the Chr 14 PG (700bp) segment, which is within the tolerance of 2bp mismatches per 100bp allowed by the RNA-seq alignment algorithm. This 
means that it is possible that the reads detected at this locus on Chr 14 may in fact be YBX1 mRNA that was incorrectly assigned to this PG on chromosome 
14. 
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Figure 3.9 RNA-seq plots for YBX1 pseudogene on Chromosome 9:35,960,925-35,962,454 
Cell treatments were repeated in LNCaP cells using the YBX1 siRNA and plasmid over-expression treatments described in section 2.6 and 2.7. In addition, these treatments were performed in 
media containing 10nM DHT and also androgen-starved conditions using charcoal-stripped media (CSS) containing 70% EtOH instead of DHT. In brief, cells were incubated and treated as 
described in section 2.6 and 2.7 and incubated for 48 hours in 10% CSS containing either 10nM DHT or EtOH control. At 48 hours cells were harvested and RNA was collected and prepared 
for RNA-seq. RNA-seq was performed by the Beijing Genome Institute using the Illumina HiSeq platform and using a strand specific protocol with 100 bp paired end resolution. Reads were 
mapped by TopHat, and wiggle plots were generated to visualise gene expression using the UCSC genome browser and the NCBI36/hg18 Assembly. This locus shows significant read counts 
for each cell treatment. At this locus there is no annotated pseudogene for this assembly. The read counts again vary in concert with what is seen in Figure 3.6 for the YBX1 treatments, 
suggesting that at this locus too the reads may have been incorrectly assigned by the RNA-seq algorithm. PL_YB1 = YBX1 overexpression; SI_YB1 = YBX1 siRNA 
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Figure 3.10 RNA-seq plots for YBX1 pseudogene on Chromosome 7:105,009,538-105,011,090 
Cell treatments were repeated in LNCaP cells using the YBX1 siRNA and plasmid over-expression treatments described in section 2.6 and 2.7. In addition, these treatments were performed in 
media containing 10nM DHT and also androgen-starved conditions using charcoal-stripped media (CSS) containing 70% EtOH instead of DHT. In brief, cells were incubated and treated as 
described in section 2.6 and 2.7 and incubated for 48 hours in 10% CSS containing either 10nM DHT or EtOH control. At 48 hours cells were harvested and RNA was collected and prepared 
for RNA-seq. RNA-seq was performed by the Beijing Genome Institute using the Illumina HiSeq platform and using a strand specific protocol with 100 bp paired end resolution. Reads were 
mapped by TopHat, and wiggle plots were generated to visualise gene expression using the UCSC genome browser and the NCBI36/hg18 Assembly. At this locus no pseudogene is annotated in 
this assembly. As for the previous two figures, there are significant read counts across treatments but again these vary according to the YBX1 treatment – high for plasmid YBX1 overexpression 
and very low for YBX1 knockdown. Here too this may suggest that the reads are mapping true YBX1 mRNA to this locus incorrectly.PL_YB1 = YBX1 overexpression; SI_YB1 = YBX1 
siRNA 
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3.4 DISCUSSION 
The existence of YBX1 pseudogenes is well documented and annotated gene databases 
such as NCBI list at least 10 official YBX1 pseudogenes, with varying levels of expression 
documented in catalogues such as AceView (Thierry-Mieg, 2006). AceView reports 
appreciable expression for two of the YBX1 pseudogenes.  Pseudogene YBX1P1 is reported 
to be expressed at 0.9 times the level of YBX1, including one documented source from a 
prostate tumour, while YBX1P10 has been shown to be expressed at up to 0.6 times the level 
of YBX1, and also in normal prostate. Consequently, it was imperative to design YBX1 
specific primers to differentiate YBX1 expression from possible significant YBX1 
pseudogene expression in the various prostate cancer cell lines that are used throughout this 
PhD. Failure to achieve these two aims would leave many of the experimental results open to 
question in terms of their accuracy in reflecting true YBX1 gene activity, transcript levels, 
and the quantification thereof. 
Analysis of the YBX1 transcript alignment with that of the six most homologous 
pseudogenes confirmed the known issue of high sequence homology between YBX1 and the 
pseudogenes. This has made it difficult in the past to design YBX1 specific primers with 
previous YBX1 studies ignoring the possible confounding results that might stem from 
measuring YBX1 pseudogene expression rather than YBX1. Consequently, the ARMS 
principle has been applied in this study to differentiate YBX1 and YBX1 pseudogene 
expression, thereby determining whether YBX1 pseudogenes are expressed in prostate cancer 
cell lines. The ARMS PCR demonstrated that YBX1 but none of the six candidate 
pseudogenes are expressed in the LNCaP cells.  
The second step in determining whether pseudogenes are expressed in the prostate 
cancer cell lines utilised was the use of RFLP. The extensive experiments performed in six 
cell lines with multiple digests for the six candidate pseudogenes further validated that no 
significant levels of YBX1 pseudogene transcripts appear to be present in these cell lines. 
This is an important and reassuring finding for setting the stage for the remaining 
experimental work, and to the candidate’s knowledge is a novel finding using a technique 
(restriction digests) to eliminate pseudogenes that has not been described in the literature in 
relation to YBX1. This same experimental design can be easily duplicated to assess other 
tumour cell lines of interest for the presence of YBX1 pseudogenes, in particular breast 
116 
 
cancer and ovarian cancer cell lines, cancers for which a large body of published literature 
exists for the role of YBX1.  
In an attempt to confirm the findings with RNA-seq it was possible to determine that 
there is no expression of the pseudogenes on chromosomes 15, 2 and 9:111,334,515. No 
RNA reads were shown in the wiggle files for these PG’s in the UCSC genome browser. 
However, for the other three PG’s on chromosomes 14, 7 and 9:35,960,925, substantial read 
counts were seen and these appeared to vary with YBX1 treatment suggesting that possibly 
these were actually true YBX1 mRNA reads being incorrectly assigned. However, the count 
distribution across the loci was not even, thereby throwing this assumption into some doubt. 
On analysing the sequence of chromosome 14 showing read counts, it was seen that this 
approximately 700bp region differed from the YBX1 mRNA in only 8bp, thereby making it 
possible that this was indeed a misassignment.  For this pseudogene, the ARMS PCR primer 
product was seen to lie outside of the annotated wiggle reads in an untranslated region, 
thereby making it difficult to completely rule out expression of this PG based on the 
restriction digest experiments alone. However, what this does allow one to conclude is that 
for this PG, even if it is expressed, the location of the ARMS PCR primer in an unexpressed 
region means that this PG on Chr 14 is unlikely to confound any experimental work in 
assaying the true YBX1 gene. The same is true for the pseudogene on Chr 9: 35,960,925, but 
in the case of the chromosome 7 PG the ARMS PCR primer product lies within the same 
region as the wiggle reads. This fact, together with the absence of any restriction digestion for 
this pseudogene in the RFLP experiments above signify that this pseudogene is most likely 
not expressed at all and that the reads here have been incorrectly assigned by the RNA-seq 
algorithm. 
In summary then, it can be concluded from the restriction digest experiments and the 
RNA-seq data that the pseudogenes on chromosomes 7, 15, 2 and 9:111,334,515 are not 
expressed. However for the pseudogenes on chromosome 14 and 9:35,960,925 it is less 
certain whether or not these two PG’s are expressed. The ARMS PCR primer products lie 
outside the wiggle reads for the respective loci, meaning that the restriction digest experiment 
might not have detected a product regardless of the fidelity of primer design. The fact that the 
read counts vary with YBX1 treatment and the high similarity between the YBX1 RefSeq 
mRNA and these loci would seem to favour the reads at these loci having been mis-aligned 
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by the RNA-seq algorithm. This is a difficult conundrum to solve, for the reasons outlined 
above.  
Another possibility to consider, which hasn’t been addressed by the experimental work 
presented, is that some of the other pseudogenes listed in Table 3.1 may not form functional 
proteins but may be partially expressed as mRNA, and these products or fragments thereof 
could be acting as siRNA to the true YBX1 mRNA or to the six pseudogenes studied in this 
work. Teasing these effects out from background random variability would be very 
painstaking. The remaining 44 pseudogenes in the list in Table 3.1 were parsed through the 
Genome Browser for the same RNA-seq data and none showed any read counts at all. It is 
possible that small reads for RNAs under 100bp may be missed. To test this, the Genome 
Browser was inspected for micro-RNA200A, -B and –C which span between 68 to 95bp. All 
three of these micro-RNAs showed low level counts of between 3 and 7, which would 
indicate some low level expression. From this analysis then it would seem that the possibility 
of small undetected si-RNA type fragments from the remaining pseudogenes is a remote 
possibility for LNCaP cells at least. Further RNA-seq experiments could be performed with 
the remaining cell lines, at great costs, to evaluate this question completely.  
In conclusion, the candidate is confident that the techniques employed in this first 
section of work, and the results obtained, will allow for the confident interpretation of 
quantitative experimental data for the remaining experiments in this thesis. In particular, the 
results from QRT-PCR used throughout this research, and the  results of the Agilent 
microarray platform utilised for the work in Chapter 5, would have been open to question had 
the role of pseudogenes not been definitively addressed in this section. It can be confidently 
stated that of the 50 pseudogenes listed in Table 3.1, 48 do not seem to be expressed in 
LNCaP cells based on RNASeq data, and none in the common prostate cancer cell lines 
based on the restriction digest experiments. On combining the analysis of the restriction 
digests and the RNA-seq data in LNCaPs, it is possible, though probably unlikely, that some 
pseudogene product may be expressed from chromosome 14:65,548,876-65,550,399 and 
chromosome 9:35,960,925-35,962,454.  
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Chapter 4: The role of YBX-1 in EMT in 
prostate cancer 
 
4.1 INTRODUCTION 
The role of the epithelial-to-mesenchymal transition (EMT) in both normal 
embryological development, as well as in the development of cancer and abnormal fibrosis 
has been discussed in Chapter 1. The key features of cells undergoing EMT include loss of 
epithelial markers, gain of mesenchymal markers, increased cell motility and invasiveness, 
and reduced cell proliferation (Argast et al, 2011; Lim & Thiery, 2012; Peinado et al, 2007). 
It is apparent from the literature that EMT is a complex process which is difficult to study in-
vivo, and that the induction, regulation and abrogation of EMT is a multi-faceted process 
dependent on the interplay of a multitude of extracellular and intracellular signals, 
transcription factors, transcriptional repressors and  signalling pathways. The exact triggers 
that drive a particular cell to undergo EMT are not well understood, particularly in the setting 
of tumour biology. However, there is an abundance of evidence that establishes a role for 
EMT in the natural history of cancer pathogenesis, in particular in allowing tumour cells to 
escape a primary cancer mass, detach from adjacent cells,  intravasate into the blood stream 
and travel to distant locations in the body and establish metastatic deposits. Various 
researchers have also postulated the critical role of mesenchymal-to-epithelial transition 
(MET) in allowing tumour cells to revert to an epithelial phenotype in the metastatic locus 
and establish the intracellular and extracellular environment necessary for stable 
proliferation, angiogenesis and growth that recapitulates to a large degree the histologic 
appearance and biological behaviour of the parent tumour.  
The roles of key EMT transcription factors, including Snail1, Slug, Zeb1, and Twist1 
have been described (Bolos et al, 2003; Horikawa et al, 2007; Olmeda et al, 2007; Peinado et 
al, 2004a; Peinado et al, 2007; Peinado et al, 2003; Yang et al, 2004) . The possible role of 
YBX1 in inducing an EMT in prostate cancer cell lines would be an important process to 
confirm, given that YBX1 is a known regulator of both Snail1 and is regulated by 
Twist1(Shiota et al, 2008b). Some evidence that YBX1 does indeed induce an EMT through 
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its interaction with Snail1 has come from a group studying transformed breast cancer cell 
lines (Evdokimova et al, 2009). Evdokimova and colleagues established an invasive, 
malignant   breast cancer cell line (MCF10AT) by transformation with oncogenic H-Ras from 
parental benign immortalized MCF10A cells. In addition, they induced both cell lines to 
overexpress YBX1 (MCF10A-YB1 and MCF10AT-YB1). This paper showed that only the 
H-Ras transformed, YBX1 over-expressing cell line showed evidence of EMT induction, 
with loss of E-cadherin, and expression of N-Cadherin and vimentin demonstrated both with 
immunohistochemistry and western blot. In addition these cells showed reduced proliferation 
in concert with decreased expression of cyclins A2, B1, D1, D3, and E1. Furthermore, the 
MCF10AT-YB1 cells showed faster migration in a wound healing assay than MCF10A-
MSCV cells (untransformed by H-Ras). Further proof of a mesenchymal phenotype was 
achieved by injection of MCF10AT-YB1 cells into mouse mammary fat pads, with 
subsequent harvest and microscopy showing these cells invading and disseminating diffusely 
throughout the fat pads as single cells or small clusters, and failing to show any staining for 
E-cadherin but showing positive stains for N-cadherin and also epithelial cytokeratins. The 
investigators also went on to show that both YBX1 overexpression and hyper-activated Ras-
ERK signalling was necessary for induction of EMT in MCF10AT-YB1 cells. Finally the 
group showed that YBX1 overexpression correlated with translational induction of Snail1 
and that Snail1 was translated under YBX1 control in a cap-independent manner and was 
important in orchestrating the EMT changes seen. 
This is the only paper showing a direct role for YBX1 in inducing an EMT, albeit 
through its control and induction of Snail1 translation. However, it raises the important 
notion that YBX1 may have a key role to play in EMT induction in many cancer types, and 
this may partly explain the adverse prognosis associated with YBX1 nuclear overexpression 
in tumour cells documented in numerous studies. Investigating this possibility for prostate 
cancer cell lines in this thesis would provide an important insight into the mechanisms of 
YBX1 action in cancer biology. The precise reasons for why YBX1 overexpression in 
cancers may lead to an adverse prognosis are not known. If YBX1 has a direct role in EMT 
induction, then this would be an important insight and assist future efforts in understanding 
both YBX1 and prostate cancer biology.  
 
The hypotheses constructed for this section therefore included the following: 
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1. YBX1 overexpression in prostate cancer cell lines will lead to an increased 
expression of  the transcription factors Snail1 and Snail2, FOXC2 and Twist1 
2. YBX1 overexpression in prostate cancer cell lines will lead to recognisable changes 
in key EMT genes at both the mRNA and protein level, including down-regulation 
of E-cadherin and up-regulation of N-cadherin and vimentin. 
3. YBX1 overexpression in prostate cancer cell lines should demonstrate phenotypic 
traits of an EMT, including increased cell migration and invasion in in-vitro assays 
and decreased cell proliferation 
4. YBX1 knockdown in prostate cancer cell lines should show the opposite results to 
the above hypotheses.  
 
4.2 METHODS 
4.2.1 Cell culture 
Cell culture was performed as set out in Section 2.1. LNCaP, PC-3 and 22RV1 cells 
between passage 17 and 60 were grown in RPMI 1640 medium supplemented with 5% FBS 
without antibiotics, in a 5% CO2 incubator at 37°C. Cells were generally passaged at 80-90% 
confluence. All experimental treatments were carried out in 6 well plates, with cells seeded at 
9x10
4 
cells / well in 2ml medium per well.  
4.2.2 RNA purification and first strand cDNA synthesis 
RNA purification was carried out as per section 2.2. For most experiments, the TRI 
reagent protocol was used (section 2.2.1). When very high quality RNA was required, the 
RNeasy Mini Kit was used as per protocol (section 2.2.2). RNA quality was assessed using 
the Nanodrop™ Spectrophotometer as outlined in section 2.2.2. First strand cDNA synthesis 
was performed as per the protocol set out in section 2.3.  
4.2.3 YBX1 siRNA knockdown and plasmid overexpression 
YBX1 siRNA treatments were performed as described in section 2.6. For all 
experiments, knockdowns were performed in 6 well plates with each treatment consisting of 
3 wells YBX1 siRNA (Qiagen cat. #. SI03019191) and 3 wells of negative control siRNA 
(Qiagen cat. # 1027281) for each cell line. This was generally repeated on 3 separate days to 
give at least 9 biological replicates for most experimental treatments. In the same way YBX1 
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overexpression was performed as set out in section 2.7, with plasmid transfection also being 
performed in 6 well plates, with three wells containing YBX1 human cDNA ORF clone 
(Origene, cat. # RC209835) and 3 wells containing vehicle only treatment (Lipofectamine 
2000 + Opti-MEM®). Treatments were also repeated on 3 different days to generate 9 
biological replicates in most cases.  
4.2.4 Real-time Quantitative reverse transcriptase PCR (QRT-PCR) 
QRT-PCR was performed as described in section 2.5 using the Applied Biosystems 
7900HT Fast Real-Time PCR System for all experiments. Primers were designed manually 
for each gene of interest using Primer 3 (v. 0.4.0) (http://frodo.wi.mit.edu/). Where possible, 
all primers were designed to be exon-spanning , with a GC content between 40-60% and a 
Tm of  approximately 60°C and to encode products between 100-200bp for consistency. All 
primer pairs were checked for specificity using the UCSC In-Silico PCR tool 
(http://genome.ucsc.edu/cgi-bin/hgPcr) with the goal of achieving no matches for each primer 
pair upon computation. A list of all primers used in experiments can be found in Appendix  
A. For additional quality control, melt curves were generated for all primer pairs to rule out 
the presence of primer-dimers or unwanted products. Fold change for genes of interest were 
calculated using the CT method and using a reference gene, RPL32, as a control. Mean 
fold-change, standard deviation and standard error of the mean were calculated for each gene 
of interest using Microsoft® Excel 2007 statistical functions (Microsoft Office Excel 2007 
(12.0.6654.5003), © 2006 Microsoft Corporation) 
 
4.2.5 Incucyte proliferation assay 
Cell proliferation assays were carried out in LNCaP and PC-3 cells using the 
Incucyte™ ZOOM system (Essence Bioscience, Ann Arbor, Michigan, USA). The 
Incucyte™ system is a live cell imaging system consisting of a fully automated compact 
microscope system which fits inside a standard tissue culture incubator. Cell culture flasks 
and plates are placed within the housing of the device which itself is always in an incubator. 
The automated software allows live cell imaging and collection of data for cell proliferation 
and viability in both 2D and 3D culture. Figure 4.1 depicts an image of the system and cell 
culture containers compatible with the system. The software allows cell microscopy images 
to be photographed at predetermined intervals over a specified period, e.g. 24, 48, 72 or 96 
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hours. The system software ensures that the same location in each culture flask/plate is 
imaged each time, and cell proliferation is calculated using phase contrast imaging without 
cell-labelling to calculate an integrated confluence metric as a surrogate for cell number using 
a proprietary algorithm (Nelson T.). Multiple images are collected per well over time and 
averaged to provide a statistical measure of the well confluence, and these time 
measurements are sequenced to generate a plot of monolayer confluence vs time. 
 
 
Figure 4.1 The Incucyte™ ZOOM live cell culture microscopy system 
 
Cells were seeded in Essen ImageLock™ 96 well plates (cat# 4379) in 100µL of RPMI 
medium containing 5% FBS. LNCaP cells were seeded at 3000 cells per well and PC-3 cells 
at 2500 cells per well in order to achieve confluence by 72 hours. After overnight incubation 
cells were treated the following morning with scramble siRNA, YBX1 siRNA, YBX1 
overexpression plasmid or Opti-MEM® and Lipofectamine-2000 vehicle. Parental untreated 
cells were used for comparison of results. siRNA was prepared as outline in section 2.6 and 
treatment volumes scaled down for 3000 or 2500 cells instead of 90 000. Similarly YBX1 
overexpression plasmid was prepared as outlined in section 2.7 but scaled down for 3000 or 
2500 cells per well. Following treatment, plates were loaded into the Incucyte™ microscope 
and the Incucyte™ system software was used to adjust experimental conditions for single 
photos of each well every 12 hours for 72 hours. A single experiment was performed, 
consisting of 6 control parental wells for each cell line and 3 replicates for each treatment 
condition for both cell lines. 
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4.2.6 Transwell and Matrigel invasion assay 
Assessment of cell migration and invasion was performed using commercial kits as 
detailed in section 2.11. LNCaP cells (p22-38) and PC3 cells (p40-60) were utilized 
successfully. Cells were treated for YBX1 knockdown or overexpression as previously 
described and then re-seeded in the BD Biocoat™ Tumour Invasion System 24 well plate 
(BD Biosciences, Franklin Lakes, NJ, USA cat.# 354165) for Invasion assays or the BD 
Falcon™ Fluoroblok 24 Multiwell Insert System (cat.# 351158) for migration assays. 
Following incubation, cell invasion or transwell migration was assessed by photographing the 
24 well plates using an inverted fluorescence microscope (Nikon Eclipse Ti). The lower 
surface of the insert well was visualised to reveal the cells which had completely invaded the 
Matrigel or migrated through the PET membrane, and then representative photographs taken 
in 3 low power (4x) fields for each well insert. Figure 4.2 shows a schematic diagram of the 
BD Biocoat™ Tumour Invasion system to illustrate the principles of the experimental setup. 
Images were analysed using ImageJ 1.45s (Wayne Rasband, National Institutes of Health, 
USA; http:imagej.nih.gov/ij) and in-built functions used to calculate the number of cells 
which had completely invaded through the Matrigel or membrane in each image. Cells which 
had completely invaded or migrated through each well were visually identified and then the 
software settings adjusted to allow auto-detection of these cells using the Analyze Particles 
function with cut-offs for area based on a threshold which would detect only cells which had 
completed locomotion and resumed a typically flattened 2D-cell culture morphology on the 
underside of each well. For LNCaP cells, a Analyse Particles bracketing of “400-infinity” 
was used to detect cells and for PC-3 this parameter was set at “200-infinity”. Threshold 
Adjustment was set to 30 for LNCaP cells and 150 for PC-3 cells. Each image was then 
transformed in the following way to remove background noise and to allow identification of 
cells in each image Adjust>Threshold – Isodata; 2. Effects > Smooth; 3 Process> Make 
binary. Following this, features were counted using the Analyse Particles command. Results 
for each treatment well and replicates were averaged and the results analysed with Microsoft 
Excel 2010 T Test function for the Student’s t-Test, assuming a 2-tailed test, with 2 samples 
and unequal variance. Each treatment was replicated in 3 biological replicates in 2 separate 
experiments carried out on two different days.  
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Figure 4.2 Schematic diagram of the BD Biocoat™ Tumour Invasion System showing the cell culture 
insert in which cells are seeded and a bottom chamber containing chemoattractant. A porous PET 
membrane blocks transmission of fluorescent light to the cells in the upper chamber. This is covered 
by a layer of Matrigel matrix which blocks passage of all cells except those capable of invasion 
through a synthetic basement membrane. After 24 hour incubation, the chemoattractant in the lower 
wells is replaced with Calcein AM staining solution, which stains only cells that have migrated to the 
underside of the cell culture insert. An inverted fluorescence microscope is used to excite the Calcein 
AM dye and cause fluorescence of these migrated cells, allowing image capture through the 
microscope for cell quantification. 
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4.2.7 Fluoresence Activated Cell Sorting (FACS) 
LNCaP and PC-3 cells were seeded in 6 well plates at 10
5
 cells /well in 2mL medium  
and incubated overnight. The following morning cells were treated with YBX1 knockdown 
or scramble siRNA, or YBX1 overexpression by plasmid transfection or vehicle control. 
Cells were then incubated for 48 hours in a 37°C, 5% CO2
 
incubator. After 48 hours, cells 
were harvested for FACS analysis as follows : media was removed and retained for each 
well. 300µL of trypsin was added to each well and incubated for 3 minutes at 37°C. Wells 
were then flushed with 2mL of 5% FBS and the cell suspension added to the previously 
collected media for each well. This was centrifuged for 3 minutes at 15000rpm and the 
supernatant removed. 300µL of PBS was then added to resuspend the cell pellet and this was 
transferred into a 1.5mL Eppendorf tube containing 700µL 100% EtOH.  This was then 
centrifuged for 2 minutes at 13000rpm and the supernatant removed. The cell pellet was then 
washed in 500µL PBS and then respun at 13000rpm for 2 minutes.  Cells pellets were then 
resuspended in 500µL of a propidium iodide (30µg/mL)/ RNAse A(50µg/mL) solution in 
PBS. Samples were then stored overnight, protected from light. Cells were then ready for 
analysis the following morning. 500µL of cell suspension from each sample was transferred 
to a FACS tube by pipetting through the mesh cap and then spun down for 1 minute at 
1000rpm. The samples were processed on a FACS Canto I (BD Biosciences, Franklin Lakes, 
NJ, USA) with the following settings: FSC 60V, SSC 330V, PI 390V, PI-W vs PI-A gating 
of 2000. DNA histograms were analysed using ModFit LT V3.311 (Copyright 1994-2008 by 
Verity Software House).  
 
4.2.8 Western Blot 
Western Blot analysis was carried out according to the description set out in section 
2.8. Cells were treated in 6 well plates and harvested at appropriate time points using RIPA 
lysis buffer (50mM Tris-HCl pH7.4, 150mM NaCl, 2mM EDTA, 1% NP-40, 0.1% SDS) 
premixed with EDTA-free protease inhibitor cocktail (Roche, cat. # 04693159001). All samples 
were assayed for protein concentration using the BCA Protein Assay (Thermo-Scientific cat. 
#23225) according to the protocol in section 2.8.2. All proteins were run on 7% SDS 
resolving gels prepared as per the method in section 2.8.3, and membranes blotted using wet 
transfer as per section 2.8.4. Initially during early trials, semi-dry transfers were attempted 
but there were persistent problems with uneven blotting, bubble artefacts or in some cases 
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overheating or minor burns of the PVDF membrane despite standard protocols. For this 
reason wet transfers were adopted, with significant improvement in blot quality and 
consistency across experiments. Table 4.1 lists the antibodies used and their dilutions. 
 
 
 
Table 4.1 Primary and secondary antibodies utilised for western blot protocols 
 
Protein Antibody Manufacturer Dilution 
YBX1 Rabbit Polyclonal IgG Abcam cat. #12148 1:1000 
N-cadherin Rabbit polyclonal IgG Santa Cruz cat.#SC7939 1:500 
E-cadherin Mouse anti-E-cadherin BD Biosciences cat.# 610181 1:2000 
Vimentin Rabbit polyclonal IgG Cell Signalling #3932 1:1000 
Twist1 Rabbit polyclonal IgG Santa Cruz cat.# SC15393 1:500 
Actin Goat polyclonal IgG Santa Cruz cat.# SC1615 1:1000 
Secondary Donkey anti-goat IgG HRP Santa Cruz cat.# SC2020 1:5000 
Secondary Sheep anti-mouse ECL IgG HRP GE Healthcare cat.# NA931V 1:5000 
Secondary Donkey anti-rabbit ECL IgG HRP GE Healthcare cat.# NA934V 1:5000 
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4.3 RESULTS 
4.3.1 Validation of YBX1 siRNA knockdown and YBX1 overexpression 
YBX1 siRNA knockdown success was perfected over a period of two months using a 
commercial YBX1 siRNA, FlexiTube Human YBX1 siRNA (Qiagen, Cat. No. SI03019191). 
Through a process of siRNA dose titration as described in section 2.6, an optimum protocol 
was finalised which achieved reliable knockdown of YBX1. For all the experiments in this 
chapter, YBX1 siRNA knockdown was checked by QRT-PCR using the ∆∆Ct  method 
against a scramble siRNA control as outlined in section 2.6. If not explicitly documented in 
figures in this chapter, all knockdown and overexpression values for YBX1 in LNCaP cells 
were similar to levels depicted in Figure 4.3. 
 
 
Figure 4.3 Confirmation of YBX1 knockdown and overexpression in LNCaP cells.  
Cells were treated with siRNA as per protocol in section 2.6 and overexpression plasmid as per 
section 2.7. The effect on YBX1 mRNA levels was assessed using media containing 10nM 
dihydrotestosterone (DHT) (PYD, SYD) or ethanol (PYE, SYE). PY= Plasmid overexpression YBX1 
treatment; SY = siRNA YBX1 treatment. Results are shown as fold change compared to scramble 
siRNA or vehicle plasmid controls, for two separate biological replicates. YBX1-PL – primer for 
YBX1 plasmid mRNA. YBX1 = primer for genomic YBX1 mRNA. As apparent from the figure, 
YBX1 overexpresison was higher in media containing DHT than ethanol. For the case of YBX1 
knockdown, presence or absence of DHT did not seem to have a major effect. For LNCAP cells, 
YBX1 overexpression was 4-5 fold in the presence of DHT and knockdown was consistently 70-85%. 
Error bars show SEM for 2 biological replicates in each experiment.  
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For PC-3 cells, similar dose titration was carried out. YBX1 knockdown was similar in 
efficacy to that in LNCaP cells, with reliable YBX1 knockdown of 70-90% in repeated 
experiments. YBX1 overexpression was generally much higher, often 10-fold to 50-fold 
higher than plasmid vehicle treatments. If not explicitly documented within figures in this 
chapter, YBX1 knockdown and overexpression levels were in accordance with these figures 
throughout.  
4.3.2 Rationale for experimental investigations 
The following sections show the results of experiments carried out to ascertain whether 
YBX1 has a significant role to play in mediating an EMT in prostate cancer cell lines. For 
this work, two well-known cell lines were used – LNCaP and PC-3. The reason for selecting 
these cell lines include the fact that our custom Agilent 180K microarray was designed using 
probes based on LNCaP cells, so using these cells would allow meaningful correlation of 
results with the microarray work in Chapter 5. LNCaP cells possess a functional albeit 
mutated AR, and so a second cell line without an AR – PC-3 – was selected for comparison, 
given the fact that YBX1 has been shown to regulate the AR as described in Chapter 1. The 
important questions to answer was whether YBX1 affects certain key elements known to be 
affected in an EMT, specifically, cell proliferation (proliferation is suppressed or slowed 
during an EMT), cell invasion and migration, and finally to ascertain whether changes in 
YBX1 expression resulted in measureable changes in well-known EMT genes at the RNA 
and protein level. To this end, section 4.3.3 describes the results of proliferation assays 
performed in LNCaP and PC-3 cells using the verified YBX1 siRNA knockdown and 
plasmid overexpression vector. Sections 4.3.5 and 4.3.6 show the results of experiments 
using in-vitro models for cancer cell migration and invasion to assess the effects of changes 
in YBX1 expression on these phenomena. Section 4.3.7 and 4.3.9 assess the effect on EMT 
gene expression at the RNA and protein level respectively under different levels of YBX1 
knockdown and overexpression. Assessing these cell lines in this multi-pronged approach 
would provide a robust method for ascertaining whether changes in YBX1 expression 
actually cause any meaningful change in EMT gene expression or induce features of an EMT. 
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4.3.3 YBX1 knockdown or overexpression does not affect cell proliferation in LNCaP 
cells. YBX1 overexpression results in significantly reduced proliferation in PC-3 
cells and apoptosis 
Figures 4.3 and 4.4 show the results of proliferation assays carried out using the 
Incucyte™ Zoom system with LNCaP cells with knockdown of YBX1 compared to treatment 
with scramble siRNA, and also treatment with YBX1 overexpression plasmid and Opti-
MEM®/Lipofectamine vehicle only. Untreated parental cells are included as controls.  
In Figure 4.3 in LNCaP cells it can be seen that despite a 10% lower seeding density at 
0 hours for the YBX1 siRNA treated cells, there is no appreciable difference in the rate of 
change of cell confluence at each time point. Although the YBX1 plasmid treated cells were 
seeded at slightly higher density, the proliferation rate is no different to untreated cells or 
scramble siRNA, with the untreated cells, scramble siRNA and YBX1 overexpression 
plasmid wells all passing 95% confluence by 48 hours.  
In Figure 4.4 in PC-3 cells, initial seeding was near identical and the striking finding is a 
significantly reduced proliferation rate for cells treated with YBX1 overexpression plasmid. 
At 36 hours, confluence was 32% compared to 50% for vehicle controls (p=0.011, Student’s 
T-test, 2 tailed, equal variance assumed). At 72 hours the separation is more marked, with 
confluence static at 45.9% compared to 98% for vehicle controls (p=0.0033, Student’s T-test, 
2 tailed, equal variance assumed). In the case of cells treated with YBX1 siRNA, there is an 
apparent lag in proliferation and confluence at 36 hours when compared to scramble siRNA 
controls (confluence 49.4% for YBX1 siRNA compared to 63.6% for scramble siRNA 
controls), however this difference was not statistically significant (p=0.1593, Student’s T-
test, 2 tailed, equal variance assumed). The effect on cell proliferation seen for PC-3 cells 
overexpressing YBX1 was seen throughout experiments as part of a general effect of reduced 
cell survival, increased apoptosis and cell morphology in culture suggesting significant 
cellular stress – this is discussed in the next section , 4.3.2. 
Overall the results shown here do not support a significant role for YBX1 affecting 
proliferation in LNCaP or PC-3 cells. There appears to be a cell toxicity effect when YBX1 is 
overexpressed in PC-3 cells.  
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Figure 4.4 Incucyte™ proliferation assay following 72 hours treatment with YBX1 siRNA or 
scramble siRNA, YBX1 overexpression plasmid or carrier vehicle only in LNCaP cells. Cells were 
seeded in Essen ImageLock™ 96 well plates (cat# 4379) in 100µL of RPMI medium containing 5% 
FBS. LNCaP cells were seeded at 3000 cells per well in order to achieve confluence by 72 hours. 
After overnight incubation cells were treated the following morning with scramble siRNA, YBX1 
siRNA, YBX1 overexpression plasmid or Opti-MEM® and Lipofectamine-2000 vehicle. Parental 
untreated cells were used for comparison of results. siRNA was prepared as outline in section 2.6 and 
treatment volumes scaled down for 3000 cells instead of 90 000. Similarly YBX1 overexpression 
plasmid was prepared as outlined in section 2.7 but scaled down for 3000 or 2500 cells per well. 
Following treatment, plates were loaded into the Incucyte™ microscope and the Incucyte™ system 
software was used to adjust experimental conditions for single photos of each well every 12 hours for 
72 hours. A single experiment was performed, consisting of 6 control parental wells for each cell line 
and 3 replicates for each treatment condition for both cell lines. The system software ensures that the 
same location in each culture flask/plate is imaged each time, and cell proliferation is calculated using 
phase contrast imaging without cell-labelling to calculate an integrated confluence metric as a 
surrogate for cell number using a proprietary algorithm. As can be seen from the plots, in LNCaP cells 
there appears to be no significant difference in cell proliferation regardless of YBX1 treatment 
applied.  
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Figure 4.5  Incucyte™ proliferation assay following 72 hours treatment with YBX1 siRNA or 
scramble siRNA, YBX1 overexpression plasmid or carrier vehicle only in PC-3 cells. Cells were 
seeded in Essen ImageLock™ 96 well plates (cat# 4379) in 100µL of RPMI medium containing 5% 
FBS. PC-3 cells were seeded at 2500 cells per well in order to achieve confluence by 72 hours. After 
overnight incubation cells were treated the following morning with scramble siRNA, YBX1 siRNA, 
YBX1 overexpression plasmid or Opti-MEM® and Lipofectamine-2000 vehicle. Parental untreated 
cells were used for comparison of results. siRNA was prepared as outline in section 2.6 and treatment 
volumes scaled down for 2500 cells instead of 90 000. Similarly YBX1 overexpression plasmid was 
prepared as outlined in section 2.7 but scaled down for 2500 cells per well. Following treatment, 
plates were loaded into the Incucyte™ microscope and the Incucyte™ system software was used to 
adjust experimental conditions for single photos of each well every 12 hours for 72 hours. A single 
experiment was performed, consisting of 6 control parental wells for each cell line and 3 replicates for 
each treatment condition for both cell lines. The system software ensures that the same location in 
each culture flask/plate is imaged each time, and cell proliferation is calculated using phase contrast 
imaging without cell-labelling to calculate an integrated confluence metric as a surrogate for cell 
number using a proprietary algorithm. Again for this cell line it can be seen that YBX1 scramble 
siRNA treatment has no appreciable effect on cell proliferation compared to untreated cells or 
scramble siRNA or plasmid vehicle. YBX1 overexpression (light blue) resulted in significant cell 
toxicity as expected and cell proliferation was suppressed to 40% that of the other cell treatments at 
72 hours. 
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4.3.4 YBX1 overexpression causes apoptosis in PC-3 cells, hindering interpretation of 
results in this cell line 
It was noted during the experimental work investigating a possible EMT effect with 
YBX1 treatments that in PC-3 cells, while YBX1 siRNA knockdown did not seem to 
adversely affect the cells, treatment with YBX1 overexpression plasmid uniformly and 
consistently appeared to affect cells adversely, with decreased proliferation, cell lifting, and 
suspected apoptosis. This was evident in the proliferation assays shown in Figure 4.5 in the 
previous section. Figure 4.6 shows a low power (10x) micrograph of PC-3 cells following 
treatment with YBX-1 plasmid, and a comparison photo of PC-3 cells treated with YBX1 si-
RNA.  
 
Figure 4.6  40x micrographs showing PC-3 cells at 48 hours following A: YBX1 overexpression 
plasmid treatment, and B: YBX1 siRNA treatment.  Cells were plated at 90 000 cells per well in 6 
well plates in 1.5ml of 5% FBS media and allowed to settle overnight. The following morning cells 
were treated with YBX1 siRNA or overexpression plasmid as per protocol and allowed to proliferate 
for 48 hours. Media was not changed. Photomicrographs captured at 48 hours. It can be seen that 
YBX1 overexpression resulted in greatly reduced cell numbers, floating cells, altered morphology and 
increased cell death 
To confirm the findings, a FACS analysis was performed, which showed a large 
apoptotic fraction in PC-3 cells treated with YBX1 overexpression (Figure 4.7). The reasons 
for this dramatic effect were unclear, and despite titrating plasmid concentrations down to 
one tenth of the recommended protocol dose, the effect was maintained. Even at low plasmid 
doses, QRTPCR showed very large fold change of YBX1 mRNA in PC-3 cells, between 150- 
and 1000-fold in different experiments. Comparable fold change in LNCaP cells was usually 
between 3-6 fold up-regulation, with no adverse effects on cell morphology. For this reason, 
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meaningful interpretation of experimental results for PC-3 cells treated with YBX1 
overexpression in this chapter was not possible. However, the results for YBX1 siRNA 
knockdown in PC-3 cells were deemed interpretable owing to the lack of any obvious 
deleterious effect to cells in culture.  
 
 
Figure 4.7 FACS analysis of PC-3 cells treated with YBX1 overexpression plasmid (A) and YBX1 
siRNA (B).  Cells were plated at 90 000 cells per well in 6 well plates in 1.5ml of 5% FBS media and 
allowed to settle overnight. The following morning cells were treated with YBX1 siRNA or 
overexpression plasmid as per protocol and allowed to proliferate for 48 hours. Media was not 
changed. At 48 hours cells were collected by trypsinisation, washed in PBS and 100% EtOH and after 
which cells pellets were resuspended in 500µL of a propidium iodide (30µg/mL)/ RNAse 
A(50µg/mL) solution in PBS. Samples were incubated overnight and then processed on a FACS 
Canto I (BD Biosciences, Franklin Lakes, NJ, USA) with the following settings: FSC 60V, SSC 
330V, PI 390V, PI-W vs PI-A gating of 2000. DNA histograms were analysed using ModFit LT 
V3.311. As can be seen in the histograms, there is a large apoptotic population (16.5%) in cells treated 
with YBX1 overexpression plasmid compared to the YBX1 siRNA treated cells (3.7%).  
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4.3.5 YBX1 knockdown significantly impairs prostate cancer cell motility toward a 
chemo-attractant stimulus. YBX1 overexpression can also enhance migration in 
LNCaP cells.  
It was shown in section 4.3.3 that YBX1 expression levels do not have a significant 
effect on LNCaP and PC-3 proliferation levels. This is an important point to note as the next 
step was to investigate possible effects of YBX1 on migration and invasion in these cell lines. 
An important confounder of this could be altered proliferation, and the results in section 4.3.3 
reassured the candidate that this would not be an issue in proceeding with experiments in this 
section. 
In order to assess the role of YBX1 expression levels on LNCaP and PC-3 cells, two 
commercial in-vitro kits from BD Biosciences were used to separately assess migration and 
invasion through a synthetic basement membrane, as described below.  
To assess the effect of cell migration toward a chemo-attractant stimulus, LNCaP and 
PC-3 cells were treated with YBX1 knockdown or overexpression in 6 well plates and then 
re-seeded in BD Biosciences Falcon™ Fluoroblok 24 well plates in serum free medium in the 
cell inserts and RPMI containing 10% FBS in the lower wells as a chemo-attractant. Prior to 
re-seeding in the BD plates, cells from each treatment and cell line were aliquoted and held 
for later RNA analysis to prove the level of YBX1 knockdown and overexpression. These 
results are shown in Figure 4.8 which shows the results for both the migration experiment and 
the invasion experiments reported in the next section. Cells were incubated for 48 hours, 
stained with Calcein AM and then photographed using an inverted fluorescence microscope 
in 3 low power fields (lpf) per well. Results were calculated based on cells that had 
completely migrated through the trans-well membrane and resumed a complete flattened 
morphology on the underside of well inserts. 
Figure 4.9 shows the results for both cell lines in this trans-well migration assay. It can 
be seen that for PC-3 cells, YBX1 knockdown resulted in a dramatic decrease in the number 
of cells achieving complete migration through the PET membrane toward the FBS-rich media 
in the lower wells (mean 706 cells per lpf for scramble siRNA, compared to 52 cells per lpf 
for YBX1 siRNA; **P=0.0041, 2 tailed Student’s t-test). In LNCaP cells, YBX1 knockdown 
did not seem to make any difference to cell migration compared to negative control siRNA. 
However, YBX1 overexpression resulted in significantly larger numbers of cells achieving 
complete migration at 48 hours (mean 84 cells per lpf for YBX1 OE compared to 23 per lpf 
for vehicle control; **P=0.0018, 2-tailed Student’s t-test,2 samples, unequal variance 
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assumed). In the case of YBX1 overexpression in PC-3 cells, the opposite effect was seen, 
with significant repression of cell migration to levels below that of the vehicle only treatment. 
This is likely in large part be due to the toxic effects on cell viability of YBX1 
overexpression seen in PC-3 cells as elucidated in section 4.3.2 and makes these results 
uninterpretable. It is not clear why the levels of cell numbers between the PC-3 plasmid 
controls and siRNA controls differ to such a large extent (mean 706 for scramble siRNA 
compared to 75 for plasmid vehicle control). This disparity is seen again in the experiments 
using Matrigel invasion plates in the next section, and was seen across experiments on two 
different days, so is unlikely to be due to a cell seeding error. 
Figure 4.10 shows representative images from low power fluorescence microscopy 
views of representative wells from PC-3 YBX1 knockdown and LNCaP YBX1 
overexpression. The large difference in cell numbers completing migration is apparent in the 
PC-3 images. In the case of LNCaP cells, a moderate but significant increase in cell numbers 
is seen with YBX1 overexpression. 
 
 
Figure 4.8 Confirmation of YBX1 knockdown and overexpression 
QRTPCR Results for YBX1 knockdown and overexpression in LNCaP and PC-3 cells for cell 
migration and invasion experiments shown in Figures 4.9 - 4.12. Good knockdown of 82% and 85% 
was achieved for LNCaP and PC-3 cells respectively, with corresponding YBX1 over-expression 
being 4.16 and 152-fold.  
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Figure 4.9 - Average cell count per low power field of cells completing migration through PET 
membrane 
LNCaP and PC-3 Cells were seeded in 6 well plates for YBX1 treatment. After 24 hours cells were 
reseeded in a BD Fluoroblok™ 24 Multiwell Insert System at 3x104 cells/well and incubated for 48 
hours. Cells were then stained with Calcein AM and photographed under fluorescence microscopy. 
Images were analysed using ImageJ 1.45s and inbuilt functions used to generate cell counts per low 
power field. Values were averaged across three biological replicates. For LNCaP cells, YBX1 
overexpression (OE) results in significantly higher total cell numbers completing invasion 
(**P=0.0018, 2-tailed Student’s t-test,2 samples, unequal variance assumed). knockdown of YBX1 in 
PC-3 cells was also associated with decreased transwell migration compared to scramble siRNA 
treatment (**P=0.0041, 2 tailed Student’s t-test). (YBX1 OE = YBX1 overexpression) 
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Figure 4.10 – Low power (4x) microscopy views of transwell migration assays, LNCaP and PC-
3. Images taken at 48h using the experimental setup shown in Fig 4.2 
Cells were treated as described in figure 4.9. For PC-3 cells, treatment with scramble siRNA (inset A) 
did not affect migration. However, knockdown of YBX1 (B) resulted in a dramatic drop in both the 
number of cells achieving migration (P=0.0004, 2-tailed Student’s t-test, unequal variance assumed) 
and in the number of cells that achieved complete migration, as evidenced by the reconstitution of the 
typical flattened cell appearance (P=0.0178 for total cross sectional area of cells, 2-tailed Student’s t-
test, unequal variance assumed). For LNCaP cells, YBX1 overexpression with plasmid transfection 
(C) resulted in a moderate but appreciable increase in cell migration through the PET membrane 
compared to vehicle treatment only (D) (P=0.0227, 2-tailed Student’s t-test). 
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4.3.6 YBX1 overexpression in LNCaP cells results in increased invasion through a 
synthetic basement membrane. YBX1 knockdown in PC-3 cells greatly reduces 
the number of cells achieving complete invasion. 
Following the results from the previous section which established a role for YBX1 in 
directed cell motility toward a chemo-attractant stimulus, the ability of LNCaP and PC-3 cells 
to complete invasion through a synthetic basement membrane (Matrigel) was assessed. 
Basement membrane invasion is thought to be a key ability conferred to cells by an EMT 
based on the prior work by Evdokimova and colleagues (Evdokimova et al, 2009) suggesting 
YBX1 directly induces an EMT through its interaction with Snail1 in H-Ras transformed 
breast cancer cells. It was necessary therefore to test the effect of YBX1 treatment in prostate 
cancer cells in-vitro to confirm or exclude this mechanism in prostate cancer cell lines. 
Cells were seeded and treated as described in the previous section, and then re-seeded 
in a BD Biocoat Tumour Invasion System 24-well plate and incubated for 48 hours prior to 
Calcein AM staining and photography by fluorescence microscopy (see Figure 4.2). As can 
be seen in Figure 4.11, YBX1 overexpression in LNCaP cells resulted in an apparent increase 
in cell invasion through the Matrigel matrix toward the lower wells containing RPMI+10% 
FBS. The difference did not quite reach statistical significance however (mean 44 cells per 
lpf for YBX1 OE compared to 9 per lpf for plasmid vehicle only, P=0.0739, 2-tailed 
Student’s t-test,2 samples, unequal variance assumed). YBX1 knockdown in LNCaP cells did 
not seem to impede or improve cell invasion. In the case of PC-3 cells, there was a large 
difference in cells completing invasion for cells treated with scramble siRNA compared to 
YBX1 siRNA (mean 362 cells per lpf for scramble siRNA compared to 4 cells per lpf for 
YBX1 siRNA, p=0.04699, Student’s T-test, 2-tailed, unequal variance). This large difference 
in these two treatment arms mimics the same pattern in the trans-well assay reported in the 
previous section. Again YBX1 over-expression in PC-3 cells resulted in significant cell death 
and the results are not considered valid for interpretation. It can be seen from the data in 
Figure 4.4 that aside from YBX1 overexpression plasmid treatment in PC-3 cells, none of the 
other treatments appeared to affect cell proliferation. Figure 4.12 shows representative 
images taken from this experiment, showing the dramatic decrease in completed cell invasion 
for PC-3 cells treated with YBX1 siRNA, and the higher rate of completed invasion by 
LNCaP cells treated with YBX1 overexpression plasmid. 
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Figure 4.11 – Average cell count per low power field of cells completing invasion through 
Matrigel matrix  
LNCaP and PC-3 Cells were seeded in 6 well plates for YBX1 treatment. After 24 hours cells were 
reseeded in a BD Biocoat™ Tumour Invasion System 24 well plate at 3x104 cells/well and incubated 
for 48 hours. Cells were then stained with Calcein AM and photographed under fluorescence 
microscopy. Images were analysed using ImageJ 1.45s and inbuilt functions used to generate cell 
counts per low power field. Values were averaged across three biological replicates. For LNCaP cells, 
YBX1 overexpression results in higher cell numbers completing invasion compared to vehicle (44 vs  
9 cells/lpf, but this did not reach statistical  significance  P = 0.0739, 2-tailed Student’s t-test,2 sample  
unequal variance assumed). Knockdown of YBX1 in PC-3 cells resulted in significant inhibition of 
cell invasion compared to scramble siRNA treatment (4 vs 362 cells/lpf respectively, **p=0.04699, 2-
tailed Student’s t-test, 2 sample unequal variance assumed). 
 (YBX1 OE=YBX1 overexpression) 
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Figure 4.12 – Low power (4x) fluorescence microscopy views of Matrigel invasion assays, 
LNCaP and PC-3. Images taken at 48h using experimental setup shown in Fig 4.2 
Cells were treated as described in figure 4.9. For PC-3 cells, treatment with scramble siRNA (inset A) 
did not affect migration. However, knockdown of YBX1 (B) resulted in a dramatic drop in the 
number of cells achieving complete invasion (lack of a flat cell phenotype). For LNCaP cells, YBX1 
overexpression with plasmid transfection (C) resulted in a moderate but appreciable increase in cell 
migration through the PET membrane compared to vehicle treatment 
 only (D). This difference did not however reach statistical significance. 
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4.3.7 YBX1 overexpression in prostate cancer cell lines does not result in a change in 
the mRNA or protein levels of key EMT genes 
From the preceding experiments there was some mixed evidence to support the role of 
YBX1 in inducing an EMT in prostate cancer cell lines. YBX1 knockdown did not result in 
altered cell proliferation, thereby not supporting the tenet of slower proliferation of cells 
undergoing EMT (Argast et al, 2011). Scratch assays with PC-3 cells did not show any 
differences either, with rapid wound closure across all treatment arms (data not shown). The 
cell migration and invasion assays seem to provide some evidence for a role for YBX1 in cell 
migration and invasion, which would be in keeping with a role in EMT and support the work 
of Evdokimova in breast cancer cell lines (Evdokimova et al, 2009). However the results 
were mixed between the two cell lines and the very large differences in cell numbers showing 
invasion or migration in the  PC-3 scramble siRNA treated wells is difficult to explain. It was 
important to clarify whether YBX1 treatment in prostate cancer cells results in a change in 
key EMT proteins and transcription factors (Snail1, Snail2, Twist1, E-cadherin, N-cadherin, 
vimentin and FOXC2) that would support the hypothesis of YBX1 overexpression inducing 
EMT. For most other cancers studied, YBX1 nuclear localisation and overexpression confers 
an adverse prognosis for survival in patients. For this reason the results of YBX1 
overexpression treatments were particularly important in this section. A series of experiments 
were therefore designed to knockdown and overexpress YBX1 in LNCaP and PC-3 cells and 
assess the expression of key EMT genes, including Snail1 and Snail2, Cadherin-1 and 
Cadherin-2, vimentin and FOXC2. The working hypothesis was that overexpression of 
YBX1 would lead to an increased expression of EMT inducing or facilitating genes - Snail1 
and/or Snail2, increased N-cadherin (Cdh2) and decreased E-cadherin (Cdh1) expression, 
along with increased vimentin expression.YBX1 knockdown would be expected to show the 
opposite effects in gene  expression of these EMT genes. 
As can be seen in figure 4.12, YBX1 overexpression in PC-3 cells (black bars) does 
result in up-regulation of Snail1 and Snail2. It should be noted that the mRNA fold-change 
for YBX1 plasmid treatment (YBX1-PL in the figure) in PC-3 cells was very large – 183 fold 
(in other experiments levels of 1000-fold were achieved compared to mock treatment) and 
the treatment results in significant cell toxicity as shown in section 4.3.2. For this reason 
results are interpreted very cautiously, and the candidate was interested only in finding large 
effects in this cell line as possible proof of principle. Despite this high level of YBX1 mRNA 
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up-regulation, there is no appreciable change in N-cadherin (CDH2), which would be 
expected to be  
 
Figure 4.13 QRT-PCR results for EMT genes in PC-3 cells following YBX1 knockdown and 
overexpression  
PC-3 cells were treated in 6 well plates at 90 000  cells per well in 5% FBS and allowed to settle overnight. At 
16-24 hours cells were treated with YBX1 siRNA or  YBX1 plasmid over-expression vector. Media was not 
changed and cells were allowed to incubate for 48 hours. Cells were collected at 48 hours for RNA using Trizol 
reagent protocol. QRTPCR was performed in the standard fashion to assay levels of YBX1 and EMT genes. 
Results displayed as mean with error bars for SEM for three biological replicates (3 experiments on separate 
days with 3 treatment samples for each condition on each day), normalised to scramble siRNA or plasmid 
vehicle. As expected, YBX1 overexpression (black bars) results in up-regulation of Snail1 and Snail2. A 
characteristic of PC-3 cells noticed in multiple experiments is the extremely large fold change achieved for 
YBX1 at the mRNA level with plasmid transfection associated with significant cell toxicity. However, despite 
these high levels of overexpression, there is no appreciable change in the EMT genes E-cadherin (CDH1), N-
cadherin (CDH2), vimentin (VIM) and FOXC2. Similarly although good YBX1 knockdown was achieved 
(white bars), this did not translate to any significant change in the EMT genes. Error bars represent SEM (* p < 
0.05 compared to control) n ≥ 3. (YBX1 and YBX1-PL denote separate primer pairs for YBX1. YBX1 denotes 
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the ARMS-PCR primers described in chapter 3 which are located in the 3’ UTR. YBX1-PL denotes a separate 
primer pair to detect the plasmid YBX1 product as the mRNA for the plasmid ORF does not contain the 
3’UTR.) 
 
up-regulated with YBX1 overexpression. There is a fall in E-cadherin (CDH1) but this 
is not matched by an expected increase in vimentin. Both YBX1 knockdown and 
overexpression result in low-level up-regulation of FOXC2. The reasons for this are unclear. 
YBX1 knockdown (white bars) does not result in any change in E-cadherin, N-cadherin or 
vimentin. Snail1 shows some up-regulation even with YBX1 knockdown, which is an 
unexpected result.  
Figure 4.14 shows the corresponding experimental results for LNCaP cells. Very good 
YBX1 knockdown of over 85% was achieved, and good overexpression with mRNA levels 
showing almost 8-fold up-regulation (YBX1-PL, black bar). Again there is no significant 
change with YBX1 overexpression in the key EMT proteins E-cadherin, N-cadherin or 
vimentin. In addition, Snail1 shows down-regulation with YBX1 over-expression, again the 
opposite result to that seen in the paper by Evdokimova with breast cancer cell lines. FOXC2 
shows suppression with both YBX1 treatments, whereas in PC-3 cells it showed up-
regulation.  
As the results in the above cell lines were not uniform, it was important to compare 
what would happen in another cell line. The expreriments were repeated with 22RV1 cells 
using YBX1 overexpression plasmid (It was not possible to achieve significant knockdown in 
this cell line using standard siRNA doses – higher doses resulted in cell toxicity and death). 
Figure 4.15 shows the results of YBX1 overexpression in 22RV1 cells. It can be seen that 
despite good YBX1 overexpression there is no appreciable change in vimentin, E-cadherin or 
Twist1. Primers for P53 were added, an important cancer gene known to be upregulated by 
YBX1, for use as a positive control. P53 is induced by YBX1 overexpression, but with a 
wide standard error. However figure 4.16 confirms this induction with more confidence in 
LNCaP cells. This figure also shows the effect of increasing YBX1 over-expression plasmid 
on LNCaP cells. For most experiments in this thesis a dose of 1µg plasmid/well of a 6 well 
plate was used. This dose was doubled and tripled in this experiment and no significant 
change in EMT genes noted. With a 3µg plasmid dose, there was up-regulation of vimentin to 
approximately 1.7 fold compared to control, but no corresponding down-regulation of E-
cadherin (CDH1) and no appreciable induction of  Snail1. TP53 however shows up-
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regulation to about 2-fold compared to control in all three treatments. At the maximum dose 
of 3µg plasmid/well, significant cell toxicity and apoptosis was observed. It is not clear that 
high levels of YBX1 overexpression were directly responsible for apoptosis, as in other cell 
lines (breast cancer, melanoma) it has been shown that YBX1 antagonized apoptosis (Lee et 
al, 2008; Schittek et al, 2007). 
In summary, it can be seen that at the mRNA level in three different prostate cell lines, no 
appreciable change consistent with EMT is seen in relevant genes upon YBX1 knockdown or 
overexpression. In the next section, these same treatment effects are assayed at the protein 
level to confirm the findings and ensure that an effect at protein level was not missed owing 
to YBX1’s powerful role in transcription regulation which may lead to changes in target gene 
protein levels without significant changes in substrate mRNA levels.  
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Figure 4.14 QRT-PCR results for EMT genes in LNCaP cells following YBX1 knockdown and 
overexpression 
LNCaP cells were treated in 6 well plates at 90 000  cells per well in 5% FBS and allowed to settle 
overnight. At 16-24 hours cells were treated with YBX1 siRNA or YBX1 plasmid over-expression 
vector. Media was not changed and cells were allowed to incubate for 48 hours. Cells were collected 
at 48 hours for RNA using Trizol reagent protocol. QRTPCR was performed in the standard fashion 
to assay levels of YBX1 and EMT genes.  Results displayed as mean with error bars for SEM for 
three biological replicates, normalised to scramble siRNA or plasmid vehicle. In the case of LNCaP 
cells, the level of YBX1 over-expression (black bars) achieved is much more moderate than in PC-3 
cells – 7.8 fold in this experimental series. In contrast to PC-3 cells, there is no up-regulation of Snail1 
or Snail2 and again the remaining EMT genes show no appreciable up-regulation with YBX1 
overexpression. In contrast, YBX1 knockdown is associated with strong down-regulation of Snail2 
and vimentin and FOXC2 to some extent. There appears to be little evidence for YBX1 over-
expression inducing an EMT in LNCaP cells at the mRNA level. Error bars represent SEM (* p < 
0.05 compared to control) n ≥ 3. (YBX1 and YBX1-PL denote separate primer pairs for YBX1. 
YBX1 denotes the ARMS-PCR primers described in chapter 3 which are located in the 3’ UTR. 
(YBX1-PL denotes a separate primer pair to detect the plasmid YBX1 product as the mRNA for the 
plasmid ORF does not contain the 3’UTR.) 
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Figure 4.15 QRT-PCR results for EMT genes in 22RV1 cells following YBX1 overexpression by 
plasmid transfection 
QRT-PCR results for EMT genes in YBX1 overexpression in 22RV1 cells. Cells were treated in 6 
well plates at 90 000 cells per well in 5% FBS and allowed to settle overnight. At 16-24 hours cells 
were treated with YBX1 plasmid over-expression vector. Media was not changed and cells were 
allowed to incubate for 48 hours. Cells were collected at 48 hours for RNA using Trizol reagent 
protocol. QRTPCR was performed in the standard fashion to assay levels of YBX1 and EMT genes.  
Results displayed as mean with error bars for SEM for three biological replicates, normalised to 
plasmid vehicle. It was not possible to achieve significant YBX1 knockdown in 22RV1 cells despite 
multiple attempts using various siRNA doses. At higher siRNA doses only cell toxicity and apoptosis 
was observed. The results shown are only those for YBX1 overexpression. Despite 2.78 fold YBX1 
over-expression, it can be seen that the EMT genes vimentin (VIM) and e-cadherin (CDH1) do not 
appear to show any differential regulation. SNAI2 appears to be regulated with YBX1 overexpression, 
showing 38% knockdown. Twist1 , which is known to regulate and interact with YBX1, does not 
appear to show any differential regulation in 22RV1 cells. Error bars represent SEM (* p < 0.05 
compared to control) n ≥ 3. 
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Figure 4.16  QRT-PCR results for EMT genes in LNCaP cells following increasing YBX1 
overexpression plasmid dose titration 
LNCaP cells were treated in 6 well plates at 90 000 cells per well in 5% FBS and allowed to settle 
overnight. At 16-24 hours cells were treated with YBX1 plasmid over-expression vector. Media was 
not changed and cells were allowed to incubate for 48 hours. Cells were collected at 48 hours for 
RNA using Trizol reagent protocol. QRTPCR was performed in the standard fashion to assay levels 
of YBX1 and EMT genes.  Results displayed as mean with error bars for SEM for three biological 
replicates, normalised to plasmid vehicle. 1ug plasmid/well is the standard dose used for most 
experiments after initial titration. Increasing doses were tested to ascertain if higher levels of YBX1 
expression would drive an EMT. At 3µg/well significant cell toxicity and apoptosis was observed 
with no appreciable change in the EMT genes mRNA levels. In addition, YBX1 overexpression is 
associated with up-regulation of p53. Error bars represent SEM 
 (* p < 0.05 compared to control) n ≥ 3. 
.   
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4.3.8 EMT is inducible in LNCaP cells by treatment with DHT, insulin and TGFβ 
To confirm that an EMT is indeed inducible in LNCaP cells, this section reports data 
kindly provided by Dr. Jennifer Gunter and Dr. Brett Hollier (APCRC-Q), whose current 
research involves induction of EMT through insulin signalling pathways. The data shown in 
Figure 4.17 shows the effects on the expression of EMT genes of 48 hour treatments with 
insulin, DHT, DHT and insulin or TGFβ in LNCaP cells. In contrast to the minimal change 
seen in these genes with YBX1 treatment alone in the previous figures (4.11-4.14), the data 
here shows that robust changes in key EMT transcription factors and genes are reproducible 
with other stimuli that activate signalling pathways and EMT triggers that are probably not 
activated by changes in YBX1 expression levels alone. 
 
 
 
 
Figure 4.17 Induction of EMT genes in LNCaP cells through treatment with insulin, 
dihydrotestosterone (DHT) and transforming growth factor β (TGFβ 
 Cells were maintained in phenol red-free RPMI 1640
 
(Invitrogen, Mulgrave, VIC), 5% (v/v) foetal 
bovine serum (FBS) (Invitrogen). Cells were plated overnight in medium containing 5% FBS and 
changed after 24 hours to medium with 5% charcoal-stripped serum (CSS; Hyclone, Hudson, NH) for 
48hrs. Medium was changed one more time to serum-free RPMI containing 0.2% bovine serum 
albumin (SFM, 0.2%BSA, Sigma) and 10nM DHT was resupplied to cells as required for 24 hours. 
Cells were treated with 10nM insulin (Sigma), fresh DHT or 5ng/ml TGFβ (Cell Signalling) in SFM, 
0.2% BSA for 48hr. Each treatment was refreshed at 24 hours. RNA was extracted using Trizol 
reagent (Invitrogen) as directed by the manufacturer. cDNA synthesis and QRT-PCR was carried out 
as described previously 
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4.3.9 YBX1 knockdown or overexpression does not alter the protein levels of genes 
involved in EMT in prostate cancer cell lines 
Further to the QRT-PCR results reported in the previous sections, experiments were 
repeated with LNCaP and PC-3 cells to ascertain whether YBX1 overexpression might 
induce changes in proteins consistent with an EMT (increased N-cadherin and vimentin, 
decreased E-cadherin and increased Snail1 and Snail2 levels). Unfortunately it was not 
possible to achieve satisfactory blots of Snail1 and Snail2 with the antibodies available 
despite multiple experiments and antibody concentrations. This might have been due to low 
target levels of Snail or the fact that whole cell lysates were used and not nuclear lysates 
separately. Nonetheless, good quality blots were achieved for N-cadherin, E-cadherin and 
vimentin enabling interpretation of results with confidence. A similar experimental setup was 
used as in the last section, performing knockdown and overexpression of YBX1 in LNCaP 
and PC-3 cells according to the validated protocols and collecting protein for western blots at 
various timepoints. Twist1 was introduced as a negative control for these experiments – 
YBX1 is a downstream target of Twist1 and there is no data to suggest that YBX1 directly 
regulates Twist1. 
Figure 4.18 shows the results for western blot in LNCaP and PC-3 cells after YBX1 
knockdown in a 96 hour time-course experiment. It should first be noted that although there 
is ~50-60% knockdown of YBX1 protein in both cell lines at 48 hours, by 72 hours and 96 
hours levels of YBX1 have begun to recover to baseline levels in LNCaP cells and also in 
PC-3 cells. Similar issues were reported by Evdokimova and colleagues in achieving YBX1 
knockdown in MCF10AT breast cancer cells (Evdokimova et al, 2009). This may well be due 
to YBX1’s role as a stress response protein and also the fact that it is sequestered in stress 
granules. It may be that stored YBX1 is released from stress granules or newly synthesised at 
72 hours as cells enter a period of metabolic stress due to medium depletion. The second 
point to note is that LNCaP cells exhibit an epithelial phenotype with expression of E-
cadherin and absence of N-cadherin and vimentin. PC-3 cells however exhibit a more 
mesenchymal pattern, with absence of E-cadherin and expression of N-cadherin and 
vimentin. This may be due to the fact that at the time this cell line was originally harvested 
from a vertebral metastasis, it had not yet undergone a mesenchymal-to-epithelial transition 
(MET) and might still have been displaying the EMT phenotype which led to establishment 
of the metastasis in that patient in the first place. Therefore it appears that LNCaP cells are a 
suitable prostate cancer cell line to use for study of an EMT induction, while PC-3 cells 
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would represent a good candidate to assess suppression of the EMT phenotype and induction 
of MET. It should be noted however that other groups have reported that PC-3 cells also 
express an epithelial phenotype (Luo et al, 2006). Caution therefore needs to be exercised in 
interpreting results from the same cell line across different laboratories. (The candidate  
 
 
 
 
Figure 4.18 Western Blot showing time course treatment with YBX1 siRNA knockdown in 
LNCaP and PC-3 cells 
LNCaP and PC-3 cells were seeded in 6 well plates at 90 000 cells/well in 1.5ml 5% FBS and treated 
with YBX1 siRNA at 16-24 hours as described previously. Cells were harvested for protein at 0, 48, 
72 and 96 hours using RIPA buffer on ice and western blot performed to assess for any change in 
EMT proteins with time. At 48 hours there is appreciable knockdown of YBX1; however YBX1 
levels appear to recover to baseline levels by 72 hours and there is no change in N-cadherin or E-
cadherin levels, or vimentin in either cell line.  
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has also noted significant differences in behaviour of two different batches of LNCaP 
cells obtained from ATCC over the course of three years completing this research, with the 
latest clone (CRL-1740, LNCaP  clone FGC) showing slower proliferation and weaker 
attachment in monolayer than the previous clone used.) 
At 48 hours in figure 4.18 there is no change in E-cadherin in LNCaP cells and no 
indication that N-cadherin or vimentin are being induced and expressed. This is consistent 
with the hypothesis that YBX1 overexpression would induce an EMT and therefore 
knockdown should not affect E-cadherin levels or induce N-cadherin. In PC-3 cells, 
knockdown of YBX1 was not associated with loss of mesenchymal traits however; N-
cadherin and vimentin levels remained constant and there was no induction of E-cadherin 
expression. Twist1 levels did not fall with YBX1 knockdown in PC-3 cells. 
Figure 4.19 shows an identical experiment but in this case YBX1 was over-expressed 
with plasmid expression vector and a similar 96 hour time course conducted. The plasmid 
protein appears as a slightly higher molecular weight band above the wild-type YBX1 protein 
band, and is marked with asterisks (**) in the figure. Of note is that exogenous YBX1 seems 
to suppress endogenous YBX1 in both cell lines, but with a recovery of native YBX1 in 
LNCaPs.  
In LNCaP cells, if the hypothesis were true, it would be expected that YBX1 
overexpression resulted in expression of a mesenchymal phenotype, with loss of E-cadherin 
and new expression of vimentin and N-cadherin. This is not the case and E-cadherin levels 
remain steady. There is very faint expression of Twist1 in the 96h lane for LNCaP, but the 
loading control is not consistent with the previous lanes and leaves this open to interpretation. 
In the case of PC-3 cells, YBX1 overexpression was not expected to alter levels of N-
cadherin or vimentin and no expression of E-cadherin was expected. This is consistent with 
the blot findings. Once again Twist1 does not seem to be up-regulated in the time course, a 
finding consistent with other research showing that YBX1 is a downstream target of Twist1, 
with no clear evidence for any feedback regulation of Twist1 by YBX1 (Qin et al, 2011; 
Shiota et al, 2008b). 
In summary, from the results of the QRT-PCR and western blot experiments with 
YBX1 knockdown and overexpression, it does not appear that YBX1 overexpression directly 
drives expression of key EMT genes, including N-cadherin and vimentin. In addition there is 
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no up-regulation of the known EMT transcription factor Snail1 at the mRNA level. 
Conversely, YBX1 knockdown does not suppress the mesenchymal features of PC-3 cells.  
 
 
 
Figure 4.19 Western blot showing time course treatment with YBX1 overexpression by plasmid 
transfection in LNCaP and PC-3 cells 
LNCaP and PC-3 cells were seeded in 6 well plates at 90 000 cells/well and treated with YBX1 
overexpression plasmid at 16-24 hours as described previously. Cells were harvested for protein at 0, 
48, 72 and 96 hours in RIPA buffer on ice and western blot performed to assess for any change in 
EMT proteins with time. The plasmid encoded YBX1 protein is shown as a higher molecular weight 
band just above the native YBX1 band (** in figure). The blot shows no appreciable change in N-
cadherin or E-cadherin levels with YBX1 overexpression over 96 hours. In particular, E-cadherin 
levels do not diminish in LNCaP cells and N-cadherin expression is not induced. Vimentin expression 
is not evident in LNCaP cells treated with YBX1 overexpression. It is clear that PC-3 cells exhibit 
some mesenchymal signature by the presence of N-cadherin and vimentin. LNCaP cells exhibit a 
more typical epithelial signature with expression of E-cadherin and absence of N-cadherin and 
vimentin.  
  
** 
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4.4 DISCUSSION 
A central theme of this thesis is attempting to understand the role YBX1 plays in the 
aggressiveness of prostate cancer. Multiple studies in-vitro and in-vivo, as well as in tissue 
from human cancers, have shown that increased YBX1 levels and YBX1 nuclear localization 
are associated with an adverse prognosis in terms of cancer survival (Fujita et al, 2005; 
Gessner et al, 2004; Janz et al, 2002; Li et al, 2011; Schittek et al, 2007; Vaiman et al, 2007). 
To a large extent, the exact role that YBX1 plays in these different cancers has only been 
broadly sketched out. Several lines of research have shown that YBX1 has roles in DNA 
repair, radiation-resistance and resistance to chemotherapy and is involved in several 
important pathways that drive tumour growth.  
Tumours with biologic capability for invasion and distant metastasis are by definition 
more aggressive. It has been shown in a prostate cancer tissue micro-array that tumours 
showing high expression levels of vimentin and TGF-β had a higher risk for biochemical 
recurrence than tumours expressing lower levels (Zhang et al, 2009). Clearly the hallmarks of 
EMT in patient tumour samples bear clinical and prognostic significance.  It would be 
important to know whether YBX1 is contributing to a pro-invasive, pro-metastatic phenotype 
in prostate cancer cells, as this may have important implications for future therapeutic 
initiatives, given the pleiotropic roles described for YBX1 already. 
The work of Evdokimova and colleagues established an important precedent in the field 
of YBX1 research, showing that enforced YBX1 overexpression (at levels 2-fold higher than 
baseline) resulted in reduced E-cadherin expression, new expression of N-cadherin and 
vimentin. Furthermore, YBX1 in concert with Snail1 can drive an EMT in H-Ras 
transformed MCF10AT breast cancer cells (Evdokimova et al, 2009). The researchers also 
demonstrated a reversal of these protein patterns with YBX1 knockdown and also showed 
that YBX1 is responsible for inducing Snail1 translation in a cap-independent manner. To 
this candidate’s knowledge, work of this kind has not been published for YBX1 in other 
cancer cell lines. 
The experiments in this chapter have been designed to assess the role of YBX1 in 
modulating cell traits consistent with an EMT and thereby tumour aggressiveness.  This 
includes the typical EMT features of slower cell proliferation, increased cell motility, 
increased migration and invasion of basement membrane structures, and an “EMT signature” 
at the mRNA and protein level characterised by elevated levels of N-cadherin, vimentin, 
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Snail1 and Twist1 and decreased levels of E-cadherin. The results have shown conflicting 
data for the role of YBX1 
The cell proliferation experiments have not shown an obvious role for YBX1 in 
affecting cell proliferation in LNCaP and PC-3 cells, except for the dramatic differences 
noted in PC-3 cells with YBX1 overexpression leading to greatly reduced proliferation and 
cell toxicity including apoptosis. These results are at odds with some reports showing that 
YBX1 drives cell cycle progression by its regulation of CDC6 (Basaki et al, 2010). YBX1 is 
also known to interact with p53, an important regulator of the cellular response to DNA 
damage and induction of apoptosis (Okamoto et al, 2000).  
The assays for cell trans-well migration in response to a chemo-attractant, and tumour 
invasion in a synthetic basement membrane seemed to underpin a role for YBX1 in 
augmenting cell migration and invasion, particularly in LNCaP cells. The large differences in 
completed invasion seen in PC-3 cells treated with YBX1 siRNA would suggest that YBX1 
has an important role in the cell machinery involved in breaking down basement membrane 
and cell translocation through the extracellular matrix. These migration and invasion assays 
seemed to support an EMT phenotype being driven by YBX1 expression or overexpression. 
However, this hypothesis was not supported by the final experiments assessing key EMT 
genes at the mRNA and protein level. The QRT-PCR and western blot experiments show that 
despite high levels of YBX1 over-expression, no significant EMT related gene changes were 
seen in LNCaP cells and no reversion to a more epithelial phenotype was seen in PC-3 cells 
with YBX1 knockdown. In addition, at both the mRNA and protein level, there was no strong 
evidence for YBX1 overexpression inducing the EMT transcription factors Snail1 or Twist1. 
Taken together, the results reported in this section support a role for YBX1 driving tumour 
aggressiveness in prostate cancer cell lines by driving cell migration and invasion, but not 
through an EMT pathway.  
There are a number of possible reasons why the results in this section are not in 
agreement with the findings in the paper by Evdokimova and colleagues. Firstly, that paper 
examined the role of YBX1 in breast cancer cell lines, whereas this thesis examined prostate 
cancer cell lines, in particular LNCaP and PC-3. It can be seen that even within the same 
cancer sub-type, different cell lines exhibit very different phenotypes, and this is certainly the 
case here, with LNCaP showing an epithelial signature while PC-3 cells exhibit a more 
typically mesenchymal signature. It can be expected then that there would be even larger 
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differences when comparing these results to those from other cell lines such as breast 
carcinoma cell lines.  The second key point is that the researchers used untransformed 
MCF10A cells, which are benign human mammary epithelial cells, and an oncogenic H-Ras 
transformed clone, MCF10AT which was passaged through mouse xenografts and exhibits 
aggressive, invasive behaviour. It is known that oncogenic H-Ras transformation drives the 
Ras-ERK pathway and also activates the Snail1 promoter (Peinado et al, 2003). Twist1 may 
also require Ras-ERK signalling and PI3K-AKT signalling for expression (Evdokimova et al, 
2012). Although Ras-ERK and PI3K-AKT signalling was not assayed in LNCaP and PC-3 
cell lines, it is conceivable that no activation of Snail1 and Twist1 was seen in the results in 
this section due to an absence or dysfunctional signalling in these pathways in these cell lines. 
Up to 13% of prostate cancers in patients have been shown to harbour KRAS mutations 
(Blount & Cooke, 1996; Konishi et al, 1997; Konishi et al, 2002). 
The work by Evdokimova underlined the importance of both YBX1 and Ras-ERK 
signalling for expression of EMT features in MCF10AT cells. It is possible that the failure to 
see an induced EMT in prostate cancer cells reported here, despite YBX1 overexpression, 
may be due to a lack of other critical factors including an activated Ras-ERK pathway.  
Other more recent work has highlighted the fact that other molecules are also important 
in allowing YBX1 to facilitate the phenotypic features of an EMT. A recent paper showed 
that depletion of an isoform of p63 – ΔNp63α – is important for YBX1 mediated expression 
of EMT phenotype traits in squamous cell carcinoma (Di Costanzo et al, 2012).  In particular, 
ΔNp63α interacts with YBX1 and reduces the amount of YBX1 bound to Snail1 mRNA 
transcript. Knockdown of ΔNp63α released YBX1 resulting in EMT-type changes with 
decreased E-cadherin and increased N-cadherin.  
It appears however that in prostate cancer cell lines, the picture is more complicated, as 
induction of p53 by YBX1 overexpression would also potentially work against a role for 
YBX1 in EMT induction, as p53 is known to inhibit induction of EMT by repressing 
expression of ZEB1 and ZEB2 through up-regulation of micro-RNAs, in particular miR-200 
and miR-192 (Hur et al, 2012; Kong et al, 2009). 
It can be seen therefore that EMT induction is a complex process, with multiple 
transcriptional activators and repressors co-ordinating final gene expression. The results in 
this section show that YBX1 overexpression on its own is not enough to induce an EMT in 
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prostate cancer cell lines. However, there is clear evidence for YBX1 facilitating migration 
and invasion.  
Experiments in the following chapter will use microarray techniques and pathway 
analysis to broadly investigate the biological effects of YBX1 knockdown in LNCaP cells in 
order to shed light on which other pathways and molecules may be involved in explaining the 
enhanced motility and invasion reported here, in the absence of a demonstrated EMT, as well 
as uncovering other clues to the role of YBX1 in prostate cancer biology. 
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Chapter 5: Identification of novel genes 
regulated by YBX1 
 
5.1 INTRODUCTION 
The results in the last chapter do not lend support to the hypothesis that YBX1 
overexpression directly induces an epithelial to mesenchymal transition. However, the results 
do show that YBX1 knockdown or overexpression produces some marked effects in cell 
proliferation, motility and invasive behaviour. The possible gene pathways accounting for 
these experimental findings are uncertain. The literature is replete with numerous descriptions 
of proteins which are known to be regulated or interact with YBX1, as well as some 
established regulating pathways for YBX1, as described in Chapter 1. There are some 
intriguing clues that YBX1 affects the cytoskeleton, including an ability to promote 
microtubule assembly (Chernov et al, 2008b) and also to polymerize and form nanofibrils 
(Selivanova et al, 2010). In addition, YBX1 has been shown to perform the following 
functions:  activation of the collagen alpha 1(I) promoter (Sun et al, 2001); translational 
induction of the epithelial growth factor receptor (EGFR) (Stratford et al, 2007; Wu et al, 
2006); activation of extra-cellular Notch-3 receptors and triggering of the Notch-3 signalling 
pathway, potentially affecting the extracellular matrix environment (Rauen et al, 2009); 
assisting in strong induction of matrix-metalloproteinase 2 (gelatinase A) (Mertens et al, 
1998; Mertens et al, 2002). A number of lines of evidence therefore point to YBX1 
possessing the capability to interact with numerous cellular pathways and systems important 
for cell motility, interaction with the ECM and cellular response to the external environment.  
However, in order to obtain a detailed understanding of the specific roles YBX1 may 
play in tumour aggression, in prostate cancer in particular, it was deemed necessary to turn to 
a high throughput platform to assay numerous genes at once and obtain a global picture of 
YBX1 activity in prostate cancer cells. The Agilent Microarray platform presented a suitable 
option for high throughput analysis of the effect of YBX1 treatments on prostate cancer cells. 
Our laboratory is fortunate to have access to a 180K custom array, designed collaboratively 
by the candidate’s supervisor, Prof. Colleen Nelson, and Dr. Melanie Lehman, bio-
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informatician at the Vancouver Prostate Cancer Centre. At the time of writing the candidate 
is not aware of any published research using Microarray technology to study the effects of 
YBX1 knockdown or over-expression in a prostate cancer cell line, and this information, 
even if carried out on a single cell-line, would provide extremely useful clues in outlining 
which cellular processes were directly affected by YBX1 and provide insights into the role of 
YBX1 in tumour aggression. 
 
5.2 METHODS 
5.2.1 Cell culture and transfection 
LNCaP cells were seeded in 6-well plates at 9x10
5 
cells/well in RPMI, 5% FBS without 
antibiotics. After 24-48 hour incubation, cells were transfected with siRNA or plasmid vector 
once confluence was 60-70%. Cells were treated in triplicate with siRNA (YBX1 or 
scramble) or plasmid (YBX1 overexpression vector or empty plasmid vector) as described in 
chapter 2.6 and 2.7. Cells were incubated for 48 hours after transfection in a 5% CO2 
incubator at 37°C. Samples treated with YBX1 siRNA are denoted by SY, and samples 
treated with scramble siRNA are denoted by SC. Samples treated with YBX1 overexpression 
plasmid are denoted by PY, while samples treated with empty plasmid are denoted by PC.  
5.2.2 RNA isolation and QC 
RNA was isolated using the RNeasy Mini Kit (Qiagen) as described in section 2.2.2 
and then analysed on a Nanodrop Spectrophotometer and Agilent 2100 Bioanalyzer (Agilent 
G2939A). The sample RNA electrophoretograms are shown in Appendix D. 
5.2.3 Microarray  
Microarray  RNA retrieval from cell cultures was performed by the candidate. RNA 
amplification and labelling, reverse transcription to cDNA and creation of cRNA , as well as 
hybridization and array scanning was performed by Dr. Anja Rockstroh, PhD, a colleague at 
the APCRC-Q. Triplicates of each condition were prepared for microarray profiling which 
was performed on a custom 180k Agilent oligo-array (ID032034). This microarray 
incorporates human protein-coding probes as well as non-coding probes; with the probes 
targeting exonic regions, 3’UTRs, 5’UTRs, as well as intronic and intergenic regions. RNA 
was isolated using the RNeasy Mini Kit (Qiagen) and DNAse on-column treatment according 
to the manufacturer’s protocol. RNA samples were analysed on a NanoDrop and Bioanalyzer 
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(Agilent) to ensure the RNA was of high purity and quality. 150ng of RNA from each group 
was amplified and labelled according to the protocol for One-Color Microarray-Based Gene 
Expression Analysis (Low Input Quick Amp Labelling Kit, Agilent). The input RNA was 
reverse transcribed into cDNA, using an oligo-dT-promoter primer which introduces a T7 
promoter region. The subsequent in-vitro transcription uses a T7 RNA polymerase, which 
simultaneously amplifies target material and incorporates cyanine 3-labeled CTP. cDNA 
synthesis and in vitro transcription were performed at 40°C for 2 h, respectively. The labelled 
cRNA was purified with Qiagen’s RNeasy mini spin columns and quantified using a 
Nanodrop-1000. 1650ng cRNA from each sample was loaded onto the microarray and 
hybridized at 65°C for 17h. The arrays were scanned with the Agilent Microarray Scanner 
G2565CA. 
 
5.2.4 Microarray analysis 
Microarray data was processed and analysed by Dr. Melanie Lehman, bio-informatician at 
the Vancouver Prostate Cancer Centre. The microarray data was processed with Agilent 
Feature Extraction Software (v10.7). A quantile-between array normalization was applied and 
differential expression was determined using a Bayesian adjusted t-statistic from a Linear 
Models for Microarray Data (LIMMA) linear model. The p-values were corrected for a false 
discovery rate of 5%. Normalized gene expression data of the experiment are Minimum 
Information About a Microarray Experiment (MIAME) compliant and has been submitted to 
Gene Expression Omnibus (GEO, Accession number GPL16604). The gene expression levels 
are presented as log2 and were compared between two groups with a t-test. Genes that were 
significantly different between two groups were identified with a p value of <=0.05, and an 
average fold change of >=1.5. The filtered gene lists were examined by Ingenuity Pathway 
Analysis (IPA, Ingenuity Systems Inc.) for functional annotation and gene network analysis. 
 
5.3 RESULTS 
5.3.1 Transfection results and RNA quality 
Figures 5.1 and 5.2 show quality control information obtained prior to proceeding with 
the Microarray RNA labelling and incubation. Figure 5.1 shows the results of QRTPCR taken 
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from the LNCaP treatment samples demonstrating very good YBX1 knockdown (mean 87% 
knockdown), and overexpression (mean YBX1 fold change 5.7).  
Figure 5.2 shows the RNA electrophoretograms for the twelve samples and their 
respective RIN (RNA Integrity Number) values. As can be seen from the figure, all samples 
except sample PY2 (overexpression sample) showed very high RNA quality. After discussion 
with Dr. Anja Rockstroh (APCRC-Q Microarray specialist) and Dr. Melanie Lehman, it was 
agreed that this sample was still satisfactory to proceed to array analysis, despite the RIN 
number of 6.8. Full QC data for all samples can be found in Appendix D. 
Figure 5.3 shows a heat map charting the Pearson correlations for the Microarray 
samples. It is clear that the knockdown samples (SY) cluster together very well and the 
integrity of the knockdown data is strong. The overexpression samples (PY) do not cluster 
closely and possible reasons for this will be outlined in the Discussion. However, as will be 
shown in the next section, very few genes were differentially regulated in the overexpression 
samples compared to the plasmid vehicle control, and after analysis our group came to the 
conclusion that absence of YBX1 has more profound effects on cellular pathways than 
elevating levels of YBX1 even higher in LNCaP cells. This may of course not be the case for 
other prostate cancer cell lines, or cell lines of other tumour types. 
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Figure 5.1 Mean fold change for Microarray samples based on QRT-PCR analysis.  
LNCaP cells were treated with YBX1 siRNA and YBX1 overexpression plasmid as described 
previously (SY = YBX1 siRNA; PY = YBX1 plasmid overexpression vector) Prior to proceeding 
with RNA Bioanalyzer analysis and RNA labelling, RNA from samples was used to prepared cDNA 
for QRT-PCR analysis. Results show very satisfactory knockdown of YBX1 (mean 87%) and 
overexpression (mean 5.7, range 5.0-6.9 fold-change). Relative knockdown and overexpression were 
calculated by normalization to samples treated with scramble siRNA (SC1, SC2, and SC3) for the 
knockdown treatment, and by normalization to samples treated with empty plasmid vector (PC1, PC2  
and PC3) for the YBX1 overexpression treatment. 
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Figure 5.2 RNA samples summary electrophoretogram and RNA Integrity Number (RIN) 
scores 
All samples showed a satisfactory electrophoretogram and RIN score except for sample PY2 with a 
lower RIN score of 6.8. This sample was however deemed adequate for inclusion after discussion 
with Dr. Anja Rockstroh, PhD (Agilent Microarray specialist, APCRC-Q), and Dr. Melanie Lehman 
(Biostatistician, Vancouver Prostate Cancer Centre). 
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Figure 5.3 Heat map showing pairwise Pearson correlations for Microarray samples 
The YBX1 knockdown samples (SY1, SY2, SY3) cluster together with high correlation, providing 
reassurance for the integrity of the data in this group. By contrast, the YBX1 overexpression samples 
(PY1, PY2, PY3) do not show strong clustering, and most of the genes differentially expressed in this 
group were members of viral response families. 
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5.3.2 Microarray global results 
After analysis in the R statistical package the transformed raw data was uploaded to 
Ingenuity Pathway Analysis for further data interrogation. Figure 5.4 shows the global results 
for the Microarray. It is immediately apparent that the YBX1 knockdown samples showed a 
much larger number of differentially regulated genes, with 1650 genes showing a fold change 
greater than or equal to 1.5. 830 genes showed up-regulation and 820 genes down-regulation. 
This is in contrast to the YBX1 over-expression samples, in which only 30 genes showed 
differential regulation of which 27 showed up-regulation and three were down-regulated. 
Figures 5.5 and 5.6 list the global results for the YBX1 knockdown treatment, based on the 
Ingenuity analysis. 
 
 
 
Figure 5.4 Venn diagram overview of Microarray results 
YBX1 knockdown had a more marked effect than YBX1 overexpression, with 1650 genes showing 
differential regulation (fold change >= 1.5) compared to only 30 genes in the YBX1 overexpression 
samples. The number of genes showing up- or down-regulation was similar in the knockdown 
samples, while in the overexpression samples, most genes showing differential regulation were up-
regulated. Only seven genes showed differential regulation in both treatment arms.  
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Figure 5.5 Summary analysis of Top Networks and Bio Functions in YBX1 knockdown based on 
IPA analysis. The summary provided by Ingenuity software for the highest ranking pathways and 
networks provided reassurance that the cell treatment was successful, as many well reported systems 
influenced by YBX1 scored highly, including networks for DNA replication, recombination and 
repair and basic cellular processes. Cancer ranked as the top Disease or Disorder for genes affected by 
YBX1 knockdown, and the top four results for Molecular and Cellular functions are all important in 
general cell health but also in cancer survival and proliferation. 
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Figure 5.6 Top canonical pathways and molecules up-regulated and down-regulated by YBX1 knockdown in 
LNCaP cells. The DNA damage response features prominently in the canonical pathways, with regulation of 
BRCA1 a top-ranking score. 
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As is evident from the preceding figures, YBX1 knockdown affects cell functions involving 
cell movement and migration as well as invasion of tumour cells. Lipid synthesis is also 
strong increased. YBX1 knockdown also seems to affect cell cycle progression genes, in 
particular those responsible for checkpoint control and G2/M phase transition. The gene 
expression changes in the knockdown dataset suggest inactivation of pro-proliferative factors 
of the E2F family (z-score 2.787). This finding of YBX1 regulation of the E2F gene family  
has been recently published (Lasham et al, 2012).  However, the results for LNCaP and PC-3 
cells in Chapter 4 did not show any overt changes on cell proliferation as a result of YBX1 
knockdown. Figure 5.7 summarises the Cellular Functions gene analysis from the microarray 
dataset based on Ingenuity Pathway Analysis  
 
 
 
 
 
 
 
 
Figure 5.7 Ingenuity Cell Functions Annotation summary for top Functions upregulated or down-
regulated in YBX1 microarray knockdown dataset.  
Functions Annotation p-Value
Predicted 
Activation State
Activation 
z-score
cell movement 3.29E-06 Increased 2.720
apoptosis of kidney cell lines 1.04E-03 Increased 2.435
T-cell non-Hodgkin's disease 3.99E-03 Increased 2.376
T-cell non-Hodgkin's disease 3.99E-03 Increased 2.376
migration of cells 1.32E-05 Increased 2.335
differentiation of cells 1.10E-04 Increased 2.244
delay in cell cycle progression 1.30E-03 Increased 2.213
invasion of cells 3.35E-04 Increased 2.211
formation of cytoskeleton 4.77E-03 Increased 2.209
synthesis of lipid 3.90E-03 Increased 2.202
synthesis of lipid 3.90E-03 Increased 2.202
incidence of malignant tumor 4.28E-03 Increased 2.193
lymphatic node tumor 6.95E-03 Increased 2.188
cell movement of tumor cell lines 2.07E-03 Increased 2.139
endocytosis 2.20E-03 Increased 2.066
senescence of cells 7.04E-03 Increased 2.046
degradation of cartilage matrix 9.18E-04 Increased 2.000
Functions Annotation p-Value
Predicted 
Activation State
Activation 
z-score
checkpoint control 1.01E-07 Decreased -3.541
checkpoint control 1.01E-07 Decreased -3.541
organismal death 1.30E-06 Decreased -2.729
association of chromatin 1.05E-04 Decreased -2.613
G2/M phase 1.17E-05 Decreased -2.553
interphase 4.54E-08 Decreased -2.553
gliosis 1.64E-03 Decreased -2.545
gliosis 1.64E-03 Decreased -2.545
astrocytosis 2.72E-03 Decreased -2.545
astrocytosis 2.72E-03 Decreased -2.545
G2 phase 4.13E-04 Decreased -2.417
association of chromosome components 4.84E-05 Decreased -2.396
homologous recombination 1.40E-03 Decreased -2.234
homologous recombination 1.40E-03 Decreased -2.234
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 Figure 5.8 shows the results for the differentially expressed genes in the YBX1 over-
expression treatment. Only 30 genes show differential regulation, and nineteen of these are 
viral immune response genes based on Ingenuity Knowledge Base analysis (IFITM1, IFI6, 
IFI44L, IFI27, IFI44, IFIT1, IFIT2, IFIT3, RSAD2, BST2, CCL5, OASL, CXCL10, OAS1, 
DDX58, BIRC3, MDM2, CCL20 AND CXCL11.) It may be that the plasmid vector is 
inducing a host viral immune response which is augmented by YBX1 overexpression. 
However, IFITM1 and IFITM2 also show up-regulation in the YBX1 knockdown samples, 
although no plasmid was used in those treatments. However, it is possible that the YBX1 and 
scramble siRNA may be “recognized” as viral RNA by the cells and drive appropriate gene 
responses such as the Interferon-induced family of proteins. dsRNA and siRNA have been 
shown to induce a viral response in shrimp (Westenberg et al, 2005), and work in cultured 
human cell lines has demonstrated that siRNA treatment with 21-nucleotide siRNAs can 
induce up-regulation of interferon-stimulated genes(Sledz et al, 2003). This has also been 
shown to be the case with the use of shRNA treatment, which are processed to siRNAs within 
the cell (Bridge et al, 2003). 
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Figure 5.8 Genes differentially regulated by YBX1 overexpression 
Only 30 genes showed differential regulation between LNCaP cells treated with YBX1 overexpression plasmid and empty plasmid vector. A number of genes 
overexpressed are interferon induced proteins, suggesting the plasmid vector induces a cell viral response. The minimal differential regulation suggests that 
further YBX1 protein in LNCaP cells does not add any biological effect. 
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5.3.3 YBX1 knockdown regulates the expression of numerous important cancer-related 
genes 
Figures 5.9 and 5.10 show summary results for the top genes up-regulated and down-
regulated by YBX1 knockdown treatment. Only genes with a fold change of 2.0 or greater 
are listed.  
In total 580 genes known to play a role in human cancer were regulated by YBX1 
knockdown. Figures 5.9 and 5.10 show all genes with a 2.0 fold-change or greater. A large 
number of genes showed fold-change between 1.5 and 2.0 and are not discussed here. The 
entire dataset has been uploaded to NCBI GEO, accession number GPL16604. 
It is interesting to note the large number of well-known genes that show regulation by 
YBX1 knockdown in Figures 5.9 and 5.10, including MMP10 (matrix-metalloproteinase 10, 
IGF1(insulin-like growth factor 1), KLK2 (kallikrein-related peptidase 2), KLK3, SOX 9 
(SRY (sex determining region Y)-box 9) and SOX4, BCL2 (B-cell CLL/lymphoma 2), TNF 
(tumour necrosis factor)  and VIM (vimentin). For most of the listed genes, there is no 
description in the literature for their regulation by YBX1, making this list a very interesting 
resource for future experiments and validation work to tease out the role of YBX1 within the 
biochemical pathways and tumour networks affected by these genes. For the purposes of this 
thesis however, further attention was paid only to known prostate cancer genes showing 
regulation by YBX1 knockdown, which are listed in Figure 5.11. The intention was to 
specifically identify any possible role that YBX1 may have in affecting genes known to be 
important in prostate cancer. 
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Figure 5.9 Known cancer genes up-regulated by YBX1 knockdown   
Genes with known involvement in human cancers (based on IPA knowledge bank) with fold change above 2.0 shown in descending rank order
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Figure 5.10 Known cancer genes down-regulated by YBX1 knockdown 
 Genes with known involvement in human cancers (based on IPA knowledge bank) with fold change below -2.0 shown in descending rank order 
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5.3.4 YBX1 knockdown regulates numerous genes implicated in prostate cancer 
Figure 5.11 shows the subset of known cancer-related genes implicated in prostate 
cancer that are regulated by YBX1 knockdown. The top twenty up-regulated and down-
regulated genes only are shown. In total, 75 genes implicated in prostate cancer showed 
regulation by YBX1 knockdown, with fold change greater than 1.5 from baseline compared 
to the scramble siRNA treated cells. Of the 75 genes, only 6 are related to YBX1 by previous 
reports in the literature (Table 5.2). 
There are a number of important prostate cancer genes that appear in the list in Figure 
5.11, including IGF1, RELB, KLK2, KLK3, BRCA1, BRCA2, E2F1, AR, TNF and KLK15. 
This list of genes regulated by YBX1 may present an important starting point in elucidating 
the roles of YBX1 in promoting tumour aggression in both prostate cancer and other human 
cancers. 
 
174 
 
 
Figure 5.11 Known prostate cancer genes regulated by YBX1 knockdown 
 Genes with a known role in prostate cancer (based on IPA knowledge bank) with fold change above 2.0 or below -2.0 shown in descending rank order 
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Table 5.1 Known genes implicated in prostate cancer and regulated by YBX1 knockdown with reported interaction with YBX1 
6 of the 75 genes in the YBX1 knockdown Microarray dataset that are implicated in prostate cancer have previously been described to have an interaction 
(direct or indirect) with YBX1. Only the paper investigating YBX1 and the androgen receptor involved prostate cancer cell lines 
Gene Name Fold Change with 
YBX1 knockdown 
Relationship to YBX1 References 
IRF1 Interferon regulatory 
factor 1 
1.84 YBX1 binds to the Mf2 domain of IRF1 (Narayan et al, 
2011) 
CD24 CD24 molecule 1.62 YBX1 stimulates the production of CD44 in breast cancer cell 
lines, leading to CD44(high)/CD24(low) cells 
(To et al, 2010) 
MGMT O-6-methylguanine-DNA 
methyltransferase 
1.53 Knockdown of YBX1 in a glioblastoma multiforme cell line 
sensitizes the cells to temozolomide, bypassing the rescue to 
cells normally afforded by MGMT cleavage of methylated 
DNA adducts 
(Gao et al, 2009) 
NME1 NME/NM23 nucleoside 
diphosphate kinase 1 
-1.56 NM23 (NME1) competes for binding to the Gelatinase A 
promoter with YBX1, suppressing protein expression 
(Cheng et al, 2002) 
AR Androgen receptor -1.81 YBX1 induces AR expression at the transcriptional level (Shiota et al, 
2011a) 
TNF Tumour necrosis factor -2.2 TNF may induce suppression of the SMαA gene in human 
pulmonary fibroblasts by stimulating binding of YB-1 and Erg-
1 to the promoter where they act as transcriptional suppressors 
(Liu et al, 2009) 
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5.3.5 Important pathways regulated by YBX1 
This section outlines some important pathways found to be regulated by YBX1 
knockdown which are important in various cancers. The results here support prior knowledge 
for interaction for some of these pathways with YBX1 which has already been reported in the 
literature (eg. CDC6) and provide further confidence in the general results of the microarray. 
In depth pathway analysis using the Ingenuity suite provided confirmation that YBX1 
regulates pathways involved in DNA repair and cell cycle control, and an EMT network was 
constructed to evaluate from the microarray data whether there was any evidence for an effect 
on EMT genes by YBX1 knockdown. 
 
YBX1 regulates DNA repair pathways and cell cycle control 
 
Figure 5.12 shows the genes involved in DNA Double-strand break repair by 
homologous recombination. It can be seen that multiple genes in the pathway are down-
regulated by YBX1 knockdown, including BRCA1 and BRCA2, RPA (replication protein 
A1), RAD51 homolog (plays a role in homologous pairing and strand transfer of DNA), 
DNA polymerase 1 and DNA ligase. It is well known that YBX1 is a central player in the cell 
response to DNA damage, and the fact that this pathway is prominently ranked in the 
Microarray data lends support to the integrity of the data overall and for interpreting changes 
in other genes previously not known to be regulated by YBX1. It has been shown that YBX1 
directly trans-activates DNA polymerase alpha (En-Nia et al, 2005) and its role in DNA 
repair has been documented (de Souza-Pinto et al, 2009; Gaudreault et al, 2004; Ise et al, 
1999; Sorokin et al, 2005). 
 
 
Figure 5.12 (Overleaf) : Down-regulation of the DNA repair pathway with YBX1 knockdown 
The diagram shows the Ingenuity Pathway Analysis (IPA) pathway report for the DNA repair 
pathway. It can be seen that both BRCA1 and BRCA2 are down-regulated, as are DNA polymerase I 
and DNA Ligase. These changes are in keeping with YBX1’s known functions in DNA repair and 
response to DNA damage. However, the down-regulation of BRCA1 and BRCA2 are novel findings 
which have not been described previously in the literature. Down-regulated genes are shown in green. 
Up-regulated genes are shown in red. 
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Figure 5.13 shows an overview of cell cycle control of chromosomal replication. Multiple 
genes in this pathway are down-regulated, again illustrating the pivotal role YBX1 plays as a 
master transcriptional regulator. The interaction of YBX1 and CDC6 (cell division cycle 6 
homolog) has already been described (Basaki et al, 2010). CDC6 is involved in the initiation 
of DNA replication, and Basaki and colleagues showed that YBX1 knockdown leads to 
down-regulation of CDC6 levels, and also demonstrated by ChIP assay that YBX1 binds to a 
Y-box in the CDC6 promoter. CDT1 (chromatin licensing and DNA replication factor 1) is 
involved in formation of the pre-replication complex. CDC45 (cell division cycle homolog 
45) is a part of the multiprotein complex including CDC6/CDC18, also known as the 
minichromosome maintenance proteins (MCMs) and DNA polymerase. Studies in Xenopus 
suggest that the homolog is important in loading of DNA polymerase alpha onto chromatin. 
ORC1 (origin recognition complex, subunit 1) is a highly conserved protein complex 
consisting of 6 subunits which is essential for the initiation of DNA replication in eukaryote 
cells. ORC1 serves as a platform for the assembly of other initiation factors such as CDC6 
and MCM proteins. There is no report in the literature linking any of the proteins CDT1, 
MCMs, ORC1 or CDC45 to YBX1. 
 
 
 
 
Figure 5.13  (Overleaf) – IPA pathway report for Cell Cycle Control 
It is evident that YBX1 knockdown affects multiple genes integral to the cell cycle and control of cell 
cycle progression. This includes key genes including CDC6, the regulation of which is already 
described in the literature (Basaki et al, 2010). Numerous other genes including CDC45, CDT1, 
ORC1 and RPA are also suppressed by YBX1 knockdown.  Down-regulated genes are shown in 
green. Up-regulated genes are shown in red. 
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YBX1 knockdown does not affect genes involved in the EMT cascade 
In order to confirm further the findings in chapter 4 that YBX1 treatment does not 
appear to affect genes involved in EMT in LNCaP cells, the microarray dataset for YBX1 
knockdown treated samples was overlaid on a IPA pathway diagram for genes known to be 
involved in the EMT cascade (Figure 5.14). This pathway was constructed using the Grow 
and Connect features in Ingenuity Pathway Analysis, and biological relationship connections 
were automatically annotated by the software. It is evident from figure 5.13 that YBX1 
knockdown does not affect any of the key molecules involved in EMT induction. In 
particular, none of the transcription factors GSC, ZEB1, ZEB2, TWIST1, Snai1 and Snai2 
and Notch1 show any differential regulation. The only molecule showing differential 
regulation is vimentin, which may well be under direct regulation by YBX1 or another 
transcription factor regulated by YBX1. This figure confirms the findings of chapter 4 using a 
different approach, and adds more certainty to the findings.  
 
 
 
 
 
 
 
Figure 5.14 (overleaf) – Ingenuity Pathway Analysis for genes involved in EMT cascade 
Molecules known to be involved in EMT were assembled into a pathway diagram with known 
biological relationships annotated by the IPA software. Down-regulated genes are shown in green. 
Up-regulated genes are shown in red. Aside from vimentin, none of the other well described genes 
involved in EMT show differential regulation. It is possible that vimentin transcription is directly 
influenced by YBX1, owing to the lack of other pathway changes depicted here. 
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5.3.6 YBX1 knockdown induces reciprocal gene regulation to that induced by 
androgens 
In order to explore YBX1 regulation of the androgen receptor further (AR down-
regulated 1.81-fold in the YBX1 knockdown dataset) and to elucidate any associated effects 
on androgen-regulated networks, the IPA upstream regulator analysis tools were used to 
interrogate the expression data further. It was found that the dataset for YBX1 knockdown in 
LNCaP cells strongly resembles the gene expression changes observed after treatment with 
the anti-androgen Bicalutamide (z-score 2.184) and the diabetes drug Metformin (z-score 
2.356). Moreover, YBX1 knockdown induces a response that is opposite in gene expression 
levels to that seen in cells treated with DHT and the synthetic androgen metribolone (R1881). 
The latter two findings are based on sets of 85 and 31 genes listed as DHT and R1881 
responsive genes annotated in the Ingenuity Knowledge Base, respectively.  
To investigate this androgen response axis further, a more comprehensive list of DHT 
regulated genes was compiled, derived from several in-house microarray datasets on LNCaP 
cells. This list contains 1865 RefSeq genes (figure 5.15) that show differential expression 
after DHT treatment in three independent microarray studies and should therefore represent a 
very robust gene set reflecting the core response of LNCaP cells to androgens. 
 
 
  
Figure 5.15 Venn diagram showing common androgen regulated genes across three microarray 
datasets generated between the APCRC-Q and the Vancouver Prostate Centre 
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Overlaying this list with the set of genes differentially regulated by YBX1 knockdown 
produced a significant overlap consisting of 436 genes, with a p value < 2.2e-16 (Fisher’s 
Exact Test) as depicted in figure 5.16. 
 
Figure 5.16 Venn diagram showing overlapping gene set of 436 genes between YBX1 siRNA dataset 
and 1865 androgen regulated genes derived from the three APCRC-Q and VPC microarray datasets. 
 
Examining the directionality of differential expression within this group of 436 overlapping 
genes revealed a significant reciprocity between the two treatments. 377 of the 436 genes 
showed opposite or reciprocal directional regulation between the two treatments (ie. down-
regulated in one treatment but up-regulated in the other) with only 59 genes showing 
regulation in the same direction. Employing the algorithm utilised by the Ingenuity Upstream 
Analysis Tool to analyse this reciprocity yielded a Z-score of -15.36, which indicates a highly 
significant inactivation of the cellular androgen response in cells with reduced YBX1 levels. 
This finding indicates that YBX1 as a transcriptional and/or post-transcriptional regulator of 
gene expression controls many DHT regulated genes in an androgen-like fashion. 
The overlay in figure 5.16 shows that although 436 genes share regulation by both YBX1 
knockdown and DHT, a significant proportion of genes are affected only by one treatment or 
the other. In order to identify which genes, pathways and molecular functions are regulated 
by both treatments, an Ingenuity Core analysis was performed. The key shared biological 
functions and cell signalling pathways from this analysis are shown in figure 5.17.  
> fisher.test(overlap)
Fisher's Exact Test for Count Data
data:  overlap 
p-value < 2.2e-16
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Figure 5.17 Top Networks and Molecular and Cellular Functions for the 436 commonly regulated 
genes in the DHT/YBX1 siRNA overlay. Results produced by Ingenuity Core analysis. 
 
It can be seen from the above figure that the core networks that are regulated by both 
treatments in this shared gene set include Lipid Metabolism and Small Molecule 
Biochemistry and also Cell Cycle, DNA replication, Recombination and Repair. The lipid 
metabolism network appears prominently throughout the dataset in numerous analyses and 
this is borne out by other data from other groups in the candidate’s laboratory investigating 
lipid and steroid metabolism in prostate cancer and its relationship to androgen treatment or 
withdrawal, and the candidate’s own work with QRT-PCR showing changes in FASN and 
SREBP1 with YBX1 knockdown or overexpression (data not shown). 
The figures on the following pages show three key networks exported from Ingenuity with an 
overlay of the DHT treatment results and separately an overlay of the YBX1 siRNA 
treatment for each pathway. In each case it can be seen that there is significant reciprocity in 
the directionality of gene regulation for multiple genes in each pathway. The pathways 
depicted are Lipid Metabolism, Cell Cycle/Replication/Recombination and finally, Prostate 
Cancer Signalling. 
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Figure 5.18 Lipid Metabolism Pathway exported from Ingenuity Analysis. A. Pathway showing DHT 
treatment overlay. B. Pathway showing YBX1 siRNA treatment overlay. 
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Figure 5.19 Cell Cycle / Replication / Recombination Pathway exported from Ingenuity Analysis. A. 
Pathway showing DHT treatment overlay. B. Pathway showing YBX1 siRNA treatment overlay 
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Figure 5.20 Prostate Cancer Signalling Pathway exported from Ingenuity Analysis. A. Pathway 
showing DHT treatment overlay. B. Pathway showing YBX1 siRNA treatment overlay 
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5.4 DISCUSSION 
YBX1 has been implicated in the aggressive behaviour of multiple human cancers, with 
multiple studies showing that increased YBX1 expression and nuclear localization carries an 
adverse prognosis for patients whose tumour bears these features. However, the literature has 
not made clear the particular mechanisms or changes resulting from YBX1 overexpression 
that convey an aggressive phenotype to malignancies. There have been multiple reports about 
YBX1 interacting with various genes and proteins known to be implicated in tumour 
progression, but a global understanding has been lacking.  
The data presented in this chapter may contribute significantly to our understanding of 
the biological changes brought on by YBX1 overexpression. The microarray dataset has 
unveiled a large number of known cancer genes that appear to be regulated by YBX1, 
including the androgen receptor itself, confirming findings showing a regulatory role for 
YBX1 over the AR (Shiota et al, 2011a). The large number of cancer genes, and in particular 
prostate cancer genes, that show differential regulation by YBX1 knockdown is 
unprecedented, and will no doubt open the way for further validation studies in the future. 
The focus of this chapter was to present a global yet relevant summary of the dataset with 
particular relevance to prostate cancer. To our knowledge this is the first microarray dataset 
investigating the effects of YBX1 treatment in a prostate cancer cell line, using a custom 
180K array.  
Overall 1650 genes showed differential regulation in the knockdown samples and 30 in 
the overexpression samples. It is only possible to speculate as to why there is such a large 
discrepancy in the two treatment results. One plausible reason is that LNCaP cells may be 
saturated in terms of YBX1’s biological function and adding more protein to the cells does 
not influence molecular processes any further. This position can be supported by data 
showing that YBX1 inhibits mRNA transcription at high concentrations, and that 
transcription start sites are unmasked when YBX1 concentrations are lowered, allowing 
transcription initiation factors to bind to the mRNA (Nekrasov et al, 2003). 
In total, 580 known cancer related genes were differentially regulated in the knockdown 
dataset. Many of these genes have known roles in multiple cancers and in general cancer 
biology. For most of the genes with higher fold change, no relationship with YBX1 has 
previously been described.  
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Seventy five genes known to have a role in prostate cancer showed differential 
regulation by YBX1 knockdown. Importantly, certain key genes such as AR, KLK2 and 
KLK3, BRCA1, BRCA2, TNF and IGF1 were among the genes ranked in the dataset. Also of 
significance was that five of the eighteen prostate cancer genes listed in the OMIM database 
were amongst the differentially regulated genes. Again, no relationship with YBX1 has been 
described for most of these genes, except for the six genes listed in table 5.2 (IRF1, CD24, 
MGMT, NME1, AR, TNF). Only one of these, androgen receptor, was described in a prostate 
cancer cell line.  
Also of relevance to prostate cancer and cancer in general is confirmation that YBX1 
regulates cell cycle control and DNA repair pathways, with multiple proteins showing down 
regulation in the setting of YBX1 knockdown, as shown in figure 5.12 and figure 5.13. 
Several of the proteins in the cell cycle control pathway, including CDT1, ORC1, CDC45 
have not been reported to bear a relationship to YBX1 previously. 
The microarray dataset also allowed confirmation of the results from chapter 4, with an 
EMT cascade (figure 5.14) showing no significant change in key EMT genes aside from 
vimentin. In particular, there was no change seen in E-cadherin or N-cadherin, nor in any of 
the key transcription factors Twist1, Snail1 or Slug. This lends credence to the results in 
chapter 4 through yet another methodology, and reinforces that the findings in transformed 
breast cell lines described earlier (Evdokimova et al, 2009) do not necessarily hold true for 
other cancer cell lines.  
Further analysis showed that YBX1 knockdown appears to have a reciprocal regulatory 
effect to androgen treatment in LNCaP cells, with Ingenuity Core analysis of in-house 
microarray sets overlaid with the YBX1 knockdown expression data showing a large 
overlapping gene set showing inverse regulatory changes. Although YBX1 regulation of AR 
has been reported recently in the literature (Shiota et al, 2011a), there is little information on 
the nature of YBX1 regulation of the AR and any possible interaction of YBX1 with the 
androgen receptor protein directly. The findings presented in this chapter present a very 
interesting departure point for further investigation of the interaction between YBX1 and the 
AR, and an important question is to what extent does YBX1 regulate androgenic pathways on 
its own, and to what extent is this merely an indirect effect of regulation of AR. Of particular 
interest in Figure 5.20 is the fact that whereas androgen treatment with DHT results in 
upregulation of E2F1 which will drive cell cycle progression, YBX1 knockdown results in 
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the opposite effects with suppression of E2F1 and also of bcl2, which would result in reduced 
cell cycle progression and reduced cell survival respectively. The reciprocal effect of YBX1 
overexpression would presumably be to increase expression of these genes, allowing for 
increased cell cycle progression and cell survival. In this way higher YBX1 levels in prostate 
cancer cells could confer a survival advantage through these pathways. This question merits 
further investigation for validation. By extending the thought experiment further, YBX1 
overexpression in androgen depleted cells may therefore still allow prostate cancer 
proliferation in a castrate environment by allowing cells to bypass their dependence on 
androgen signalling in this setting.  
The large number of cancer genes regulated by YBX1 may seem unusual and somewhat 
spurious. However, it should be remembered that YBX1 binds to a fairly non-specific and 
short promoter recognition sequence, the reverse “CAAT” box. For this reason it is 
recognized that a large number of genes in the human genome will contain possible YBX1 
promoter recognition sites, but clearly not all of these sites will be true YBX1 promoter sites. 
This problem was addressed by a colleague at APCRC-Q, Dr. Shivashankar Hiriyur Nagaraj, 
who collated a reference list of possible YBX1 promoter binding sites in the human genome, 
using a Genomatix database (www.genomatix.de, Matrix name: V$YB1.01, October 2010). 
Owing to the large number of hits in the human genome, a “conserved” list was generated 
showing genes with promoter sites in both mice and humans. This is depicted in Table 5.3 
which shows the list of prostate cancer genes regulated in the YBX1 knockdown dataset. It is 
evident that most of the regulated genes have a YBX1 promoter when considering only 
human genes, but the conserved list of human and mice genes brings this number down. 
Nonetheless nineteen of the forty genes listed have a conserved YBX1 recognition site in 
their promoter region. The Genomatix matrix for YBX1 predicts matches in 24% of human 
promoters. The Genomatix Matrix Library annotation for YBX1 is shown in Appendix E. 
It appears evident therefore that YBX1 is a promiscuous transcription factor, which 
appears to regulate multiple human cancer genes including multiple important prostate cancer 
genes.  
In the next chapter an attempt will be made to translate the results of the microarray 
dataset reported here into a meaningful validation of selected genes important in prostate 
cancer. The microarray dataset has provided numerous possible leads for further work to 
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explore the role of YBX1 in prostate cancer, and several methods will be employed to 
validate a chosen set of genes and their proteins in both laboratory and clinical samples. 
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Table 5.2 Genomatix prediction of YBX1 promoter site in selected prostate cancer genes 
A bio-informatics approach was used to curate a list of gene with putative YBX1 binding sites in their promoter 
regions. Both human only and conserved sites in humans and mice were generated. Data kindly supplied by Dr. 
Shivashankar Hiriyur Nagaraj. 
UP-REGULATED YBX1 site in promoter DOWN-
REGULATED 
YBX1 site in promoter 
Gene Human Human & 
Mouse 
Gene Human Human & 
Mouse 
ARG2 Y Y MSMB Y  
TTR Y  KLK2 Y Y 
BAMBI Y Y KLK3   
PITX2 Y  TUBA3D Y  
TP53INP1   TRPM8 Y Y 
CD82 Y Y SGK1 Y Y 
UGT2B17   BCL2 Y  
IGF1 Y Y TNF   
RCAN2 Y Y BMPR1B Y Y 
PTGDS Y  EIF4EBP1   
RELB Y Y KLK15 Y  
TFF3   LPAR1 Y Y 
FGFR2 Y Y MAK   
IRF1 Y Y AR   
MXI1   FASN Y Y 
TUBB2A   MCM2 Y Y 
PIK3CB Y Y E2F1   
TUBB2B Y  BRCA1 Y Y 
NCOA7 Y  BRCA2   
EGFL7 Y Y MME Y Y 
193 
 
Chapter 6: Validation of novel genes regulated 
by YBX1 in prostate cancer 
 
6.1 INTRODUCTION 
The results in the previous chapter have uncovered a large dataset containing numerous 
clues to the possible roles of YBX1 in prostate cancer. As mentioned in Chapter 1, our 
understanding of the role of YBX1 in cancer aetiology and progression is limited, with most 
studies focussing on the role of YBX1 in conferring chemotherapy resistance and being a 
marker for recurrence when up-regulated. Despite a large number of papers in the scientific 
literature describing a host of interactions for YBX1 with various molecules and pathways, 
very little insight has been gained into how YBX1 mechanistically provides a survival 
advantage to cancer cells. The results in Chapter 5 have confirmed previously known 
information, including the role of YBX1 in cell cycle regulation and DNA damage repair and 
stability, but have also revealed that YBX1 potentially regulates a large number of genes 
implicated in cancer in general and prostate cancer, including the androgen receptor. Most of 
these have never been reported to interact with YBX1.  
The aim of the work in this chapter is to select a number of prostate cancer related 
genes that scored highly in the YBX1 knockdown dataset and to attempt to validate their 
regulation by YBX1 by a number of methods, including cell culture at the RNA and protein 
level, comparison with public microarray datasets, and finally creation of a small, proof-of-
principle tumour microarray from radical prostatectomy specimens. It is hoped that positive 
results in this regard will set the platform for a large body of further work to investigate novel 
roles for YBX1 in cancer biology. 
 
6.2 METHODS 
6.2.1 Cell culture and transfection 
LNCaP cells were seeded in 6-well plates at 9x10
5 
cells/well in RPMI, 5% FBS without 
antibiotics. After 24-48 hour incubation, cells were transfected with siRNA or plasmid vector 
once confluence was 60-70%. Cells were treated in triplicate with siRNA (YBX1 or 
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scramble) or plasmid (YBX1 overexpression vector or empty plasmid vector) as described in 
section 2.6 and 2.7. Cells were incubated for 48 hours after transfection in a 5% CO2 
incubator at 37°C. 
6.2.2 RNA isolation and QC 
RNA was isolated using the RNEasy Mini Kit (Qiagen) as described in section 2.2.2 
and then analysed on a Nanodrop Spectrophotometer and Agilent 2100 Bioanalyzer (Agilent 
G2939A). The sample RNA electrophoretograms are shown in Appendix D. 
6.2.3 First Strand synthesis and QRT-PCR 
First strand synthesis was performed as described in section 2.3. QRT-PCR was 
performed as described in section 2.5. Primers for each gene of interest are listed in Appendix 
A.  
6.2.4 Western Blot  
Western Blot was performed as described in Section 2.8. A list of antibodies used and 
dilutions is annotated in Appendix F. 
6.2.5 Preparation of prostate cancer tumour tissue microarray 
A small, proof-of-principle prostate cancer tissue microarray was prepared using 
banked radical prostatectomy specimens, and included samples of benign prostate, HGPIN, 
and Gleason patterns 3, 4 and 5 cancer. This tissue microarray was created by Michael 
Adamson (Laboratory Manager, Aquesta Uropathology, Brisbane), and the slides read, 
graded and annotated by Dr. Hemamali Samaratunga (Senior Pathologist, Aquesta 
Uropathology, Brisbane). Tissue blocks were selected from various patients to cover the 
range of pathologic findings necessary, and also to give a variety of YBX1 staining intensity 
from weak to strong across the benign and cancerous tissues, thereby allowing comparison 
with the staining levels of the selected proteins.  
 
6.2.6 Immunohistochemistry 
Immunohistochemical staining of the FFPE slides of the tumour microarray was 
performed by Michael Adamson and slides were read and annotated for staining intensity by 
Dr. Hemamali Samaratunga. 
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Immunostaining protocol for single antibodies 
Slides were deparaffinated followed by block peroxidation for 5 minutes. Heat retrieval 
was then used to uncover antigen sites using citrate (pH 6) and microwave heating for four to 
five minutes until solutions were boiled prior to addition of slides to the hot citrate buffer 
solution. Solutions were then microwaved further on low power (30%) for 20 minutes and 
then a further 10 minutes at 10% power. The primary antibody was incubated overnight at 
room temperature for 12-14 hours. This was followed by application of the secondary 
antibody,  Biocare Medical MACH 2 Dual Label, for 30-40 minutes at room temperature. In 
the case of rabbit primary antibodies, the Envsion+ System HRP (DAB) (polymer and 
chromogen) from Dako was used instead, with a 30-40 minute incubation. Following this 
step the HRP Chromogen (Betazoid, Biocare Medical) was applied for 5 minutes at room 
temperature. Counterstaining was performed with distilled water and haematoxylin (Lilly 
Myers) for 40 seconds followed by a water rinse and then the slides were blued in Scott’s 
Blueing solution. This was followed by another water rinse step followed by dehydration in 
alcohol, and finally mounting in permanent mounting medium and coverslipping.  
The YBX1 antibody used for staining in this TMA was kindly provided by Prof. 
Antony Braithwaite (University of Otago, New Zealand). The commercial Abcam YBX1 
antibody (ab12148) used in the western blot experiments was also used but staining was 
found to be inconsistent and low level for many blocks. The custom antibody designed by 
Prof. Braithwaite targets the N-terminal epitope and has been shown to be more reliable for 
many applications by colleagues at APCRC-Q. 
   
6.2.7 Selection of genes for validation from microarray dataset 
The large amount of data garnered from the microarray data presents some very 
interesting leads for validating the role of YBX1 in prostate cancer. Multiple genes 
implicated in cancer in general, and prostate cancer specifically, appear to be regulated by 
YBX1 knockdown. It was important to be able to validate some of these genes with further 
assays in order to validate the integrity of the microarray dataset and also to confirm a 
biological explanation for the findings in chapter 4 which might be accounted for by 
pathways outside of the well described EMT axis and effector genes. Within the available 
timeframe remaining during this research period, it was decided to focus on a small number 
of prostate cancer genes for validation from the microarray dataset and to attempt to validate 
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these both with cell line experiments in-vitro but also to perform validation through a custom 
tissue tumour microarray using immunohistochemistry. It was decided to select between 5 
and 10 genes/proteins for validation, based on available resources and time. Although there 
were 75 possible genes to choose from, it was decided to employ specific selection criteria to 
maximise the biological and clinical utility of validation studies. The selection criteria chosen 
were as follows: 
1. Select genes recognized as important in prostate cancer susceptibility, pathogenesis 
or progression, based on publicly accessible curated datasets, for example the 
OMIM Catalogue (Online Mendelian Inheritance in Man) 
2. Select genes whose function may explain the phenotypic features of invasion and 
cell migration seen in Chapter 4, but outside of an EMT canonical pathway 
3. Select genes for which there is no previous data describing a relationship with 
YBX1 
4. Select genes with large interacting networks or downstream gene targets, resulting 
in a large biological footprint if altered by YBX1 
5. Lastly, weighting was given to  the magnitude of fold change if other factors were 
equal 
Table 6.1 shows the OMIM database entries for prostate cancer (phenotype 176807, 
accessible at http://www.omim.org/entry/176807). It is interesting to note that of the 18 genes 
listed, 5 show regulation by YBX1, including the androgen receptor.  
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Table 6.1 OMIM Database listing for prostate cancer  
Genes with a well-established role in prostate cancer are listed, including the fold-change in the microarray data 
for YBX1 knockdown for relevant genes 
Location Phenotype Gene/Locus Fold change  MIM 
number 
1q42.2-q43 Prostate cancer, susceptibility to PCAP  602759 
3p26 Prostate cancer, hereditary HPC5  609299 
7p22.3 Prostate cancer, somatic MAD1L1  602686 
7p11-q21 Prostate cancer, susceptibility to HPC4  608658 
7q11.23 Prostate cancer, progression of HIP1  601767 
8p22 Prostate cancer, hereditary MSR1  153622 
10p15.1 Prostate cancer, somatic KLF6  602053 
10q23.31 Prostate cancer, somatic PTEN  601728 
10q25.2 Prostate cancer, susceptibility to MXI1 +1.79 600020 
11p11.2 Prostate cancer, susceptibility to CD82 +2.2 600623 
13q13.1 Prostate cancer BRCA2 -1.63 600185 
16q22.1 Prostate cancer, susceptibility to CDH1  192090 
16q22.2-q22.3 Prostate cancer, susceptibility to ZFHX3  104155 
19q Prostate cancer aggressiveness QTL HPCQTL19  607592 
20q13 Prostate cancer, susceptibility to, 3 HPC3  608656 
22q12.1 Prostate cancer, familial, 
susceptibility to 
CHEK2 -1.5 604373 
22q12.3 Prostate cancer, susceptibility to HPC6  609558 
Xq12 Prostate cancer, susceptibility to AR -1.8 313700 
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In order to select several genes for validation, the above selection criteria were 
employed, and weight was given to prostate cancer genes on the OMIM database. After an 
exhaustive manual process of reviewing each of the 75 prostate cancer genes regulated by 
YBX1 in the microarray dataset (including analysing gene pathways and networks using 
Ingenuity Pathway analysis and assessing the literature for each gene’s role in prostate 
cancer) a final list of 7 genes was selected for validation in further experimental work. This 
list is shown in Table 6.2. Each gene is shown with a brief description, as well as the 
magnitude of the fold change for that gene in the YBX1 knockdown microarray dataset and 
the expected change in the gene level in the setting of YBX1 overexpression as is commonly 
seen in aggressive human cancers clinically. 
Each gene will be reviewed below in terms of its known role in prostate cancer, and the 
relevant literature documenting this. Each gene was then validated using in-vitro cell 
treatments with LNCaP and PC-3 cells, as well as with the creation of a custom tissue 
microarray for immunohistochemistry from prostate cancer tumour samples. This process 
will be further outlined in the following sections. 
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Table 6.2 Final 7 genes selected from YBX1 knockdown microarray for validation 
The seven genes listed were selected based on weighting given to the OMIM Catalogue of known prostate cancer genes, Ingenuity pathway analysis and size of gene 
networks and number of downstream targets, known literature reports for the role of the gene in prostate cancer, and lastly fold change magnitude. References for the genes 
listed are annotated in the discussion in the following pages. 
Gene Locus Function Fold change  Expected change 
with YBX1 
overexpression 
CD82 11p11.2 
Metastasis suppressor - membrane glycoprotein.  Expression is down-
regulated in tumour progression 
of human cancers. Can be activated by TP53 by a consensus-binding 
sequence in the promoter. Loss of expression is correlated with poor 
survival in CaP patients 
 
2.2 Down-regulated 
CHEK2 22q12.1 Serine / threonine protein kinase CHK2 
Higher risk for CaP if truncating or mis-sense mutations 
 
-1.5 Up-regulated 
IGFBP5 2q33-q36 
Prolongs the half-life of the IGFs and either inhibits or 
stimulates the growth promoting effects of the IGFs on 
cell culture. They alter the interaction of IGFs with their 
cell surface receptors. Is induced in castration-induced regression and 
androgenindependent progression in mouse model 
 
3.43 Down-regulated 
ITGB1 10p11.2 
Integrin B1-membrane receptors involved in cell adhesion and recognition in 
a variety of processes including embryogenesis, tissue repair, immune 
response, and metastatic diffusion of tumour cells. 
It appears from most reports that ITGB1 is overexpressed 
in metastatic deposits in human cancers 
 
1.77 Down-regulated 
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MXI1 10q25.2 
MAX interactor 1 - transcriptional repressor. 
Binds with MAX to form a sequence specific DNA binding 
protein complex which recognizes the core sequence 5'-
CAC[GA]TG 
This antagonizes MYC transcriptional activity by 
competing for MAX. Suppresses proliferation in DU145 
cells. Region 10q24-q25 is involved translocations and 
deletions in prostate cancer 
 
1.79 Down-regulated 
RAC1 7p22 
ras-related C3 botulinum toxin substrate 1 
Plasma membrane associated small GTPase Promotes 
prostate cancer cell invasion via extracellular 
ATP. Activation of RAC1 is closely related to androgen 
independent cell proliferation of prostate cancer cells 
Rac3 isoform may be the most clinically significant 
Increased RAc1 suppresses p21 in prostate cancer cell 
lines which allows increased cell proliferation 
 
-2.64 Up-regulated 
TFF1 21q22.3 
Trefoil factor 1 / ps2 protein 
Breast cancer oestrogen inducible protein, stabilizer of 
the mucous gel overlying the gastrointestinal mucosa 
that provides a physical barrier against various 
noxious agents. Deficiency in breast cancer leads to 
increased tumourigenicity 
Seems to be overexpressed in prostate cancer tissues 
 
4.37 Down-regulated 
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6.2.8 Laboratory validation 
Table 6.2 sets out the relevant  and salient points regarding CD82, CHEK2, ITGB1, 
IGFBP5, MXI1, RAC1 and TFF1 in various aspects of prostate cancer pathogenesis and 
aggression. None of these proteins has been linked to YBX1 in the existing literature, and 
these proteins were selected for validation based on the factors listed in section 6.2.7. In the 
next section, these proteins were validated at the mRNA level using QRT-PCR in LNCaP and 
PC-3 cells treated with YBX1 knockdown or overexpression. Following that, five candidates 
were chosen for validation with western blotting based on the expression pattern and 
regulation seen at the mRNA level. A public prostate cancer microarray dataset was 
interrogated to establish whether these seven proteins and YBX1 can discriminate for various 
outcomes, including early relapse or death from prostate cancer. The final analysis was 
creation of a small scale tumour microarray using tissue samples from several prostate cancer 
patients as well as benign tissue to assess the expression of these proteins in radical 
prostatectomy specimens and to assess for any association between expression levels and 
Gleason grade or YBX1 expression level. This will serve as a baseline study in planning for a 
larger TMA using the APCRC-Q Bio-resource outside the scope of this PhD. For the sake of 
brevity, these seven genes of interest will be referred to hereon collectively by the first letter 
acronym, CRIMTIC. 
 
6.3 RESULTS 
 
6.3.1 The CRIMTIC genes show regulation by YBX1 at the mRNA level in LNCaP and 
PC-3 cells 
Banked RNA samples from prior experiments were used to conduct QRT-PCR analysis 
of the levels of the CRIMTIC genes in the setting of YBX1 knockdown or overexpression. 
Primers for the CRIMTIC genes were designed de novo, using Primer3 and using an exon-
spanning approach to ensure a unique primer pair with no unexpected products.  Figure 6.1 
shows the results of QRT-PCR using LNCaP cDNA from cells treated with YBX1 
knockdown or overexpression. It can be seen that all 7 genes show differential regulation, and 
most knockdown samples (shown as white bars) recapitulate the results of the knockdown 
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microarray dataset (shown as grey bars). CD82, IGFBP5, MXI1 and TFF1 all show up-
regulation by YBX1 knockdown in both the PCR and microarray results. The same genes 
also show down-regulation by YBX1 overexpression, except for TFF1, which shows up-
regulation. In the case of CHEK2, levels are repressed in the microarray data and also by 
YBX1 overexpression, while YBX1 knockdown leads to a slight up-regulation, out of 
keeping with the microarray. The results for ITGB1 and RAC1 are more difficult to interpret; 
RAC1 levels show suppression with all three treatments while ITGB1 shows up-regulation 
with both YBX1 knockdown and overexpression. In the case of TFF1, levels are increased 
compared to control treated samples in both YBX1 treatments and the microarray data.  
Figure 6.2 repeats the same experiment using PC-3 cells. It can be seen that the expression 
levels do not quite match the LNCaP data. Only IGFBP5, MXI1 and TFF1 show similar 
results to LNCaP cell treatments. In the case of CD82, expression levels are elevated for all 
treatments. In the case of CHEK2, the microarray data shows down-regulation of this gene 
but in the PC-3 cells levels are elevated regardless of YBX1 treatment. IGFBP5 shows strong 
suppression by YBX1 overexpression. It is difficult to read too much into these results, as 
they are comparing microarray data from LNCaP cells with QRT-PCR data from PC-3 cells. 
However, the experiment was deemed necessary to perform in order to attempt to choose 
proteins for validation at the protein level with as much information as possible.  
Based on the results from these two experiments, and giving weight to the LNCaP data, five 
proteins were chose for validation by western blot. These were selected on the basis, where 
possible, of showing differential and opposite regulation by YBX1 knockdown and 
overexpression, harmony of results between the LNCaP and PC-3 cells, and other 
information including the size of known networks for the protein based on Ingenuity Pathway 
analysis (this was especially the case for ITGB1). TFF1 was not considered for validation at 
the protein level as the mRNA data did not seem to show differential regulation. CHEK2 was 
also not included as it did not show strong differential change in the LNCaP data. For this 
reason, CD82, IGFBP5, ITGB1, MXI1 and RAC1 were selected for validation at the protein 
level. In addition, it was decided to include the androgen receptor (AR) for protein validation 
(down-regulated 1.8-fold in the YBX1 knockdown microarray), as this important protein is 
critical in prostate cancer and its progression. In addition it was shown in a recent paper that 
AR expression is regulated by YBX1 in LNCaP cells (Shiota et al, 2011a), and it was thought 
desirable to confirm this in LNCaP cells.  
203 
 
 
 
Figure 6.1 QRT-PCR results for 7 genes of interest in LNCaP cells, compared to YBX1 
knockdown results in micro-array 
LNCaP cells were seeded in 6 well plates at 9x10
5
 cells / well and incubated for 48 hours and then 
treated with YBX1 siRNA or control, or YBX1 overexpression plasmid or control. At 48 hours cells 
were harvested and QRT-PCR performed to assess the effect of YBX1 treatment on the 7 genes of 
interest. The experiment was repeated on three different days with three samples plated for each 
treatment on each day. The fold change for each gene in the YBX1 knockdown treatment in the 180K 
microarray are shown for comparison. It can be seen that the PCR results for YBX1 knockdown (KD) 
mimic the micro-array results for CD82, IGFBP5 and MXI1. These genes also show down-regulation 
with YBX1 overexpression, supporting the notion that YBX1 is an important regulator for these 
genes. CHEK2 appears suppressed by YBX1 overexpression however, as does RAC1. TFF1 appears 
up-regulated by YBX1 knockdown and overexpression, suggesting a bimodal regulatory mechanism. 
Error bars represent SEM ( * p < 0.05 compared to control) Results show for 2 biological replicates 
(YBX1P = primers for YBX1 plasmid protein) 
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Figure 6.2 QRT-PCR results for 7 genes of interest in PC-3 cells, compared to YBX1 
knockdown results in micro-array 
PC-3 cells were seeded in 6 well plates at 9x10
5
 cells / well and incubated for 48 hours and then 
treated with YBX1 siRNA or control, or YBX1 overexpression plasmid or control. At 48 hours cells 
were harvested and QRT-PCR performed to assess the effect of YBX1 treatment on the 7 genes of 
interest. The experiment was repeated on three different days with three samples plated for each 
treatment on each day. The fold change for each gene in the YBX1 knockdown treatment in the 180K 
microarray are shown for comparison. In this cell line only MXI1 and RAC1 recapitulate the results 
of the micro-array. The other genes show variable, unpredictable regulation, with CD82 and TFF1 up-
regulated by both treatments. CHEK2 shows overexpression with YBX1 plasmid transfection but no 
knockdown with YBX1 knockdown. IGFBP5 is down-regulated as expected with YBX1 
overexpression (the reverse of the micro-array result). ITGB1 however is also suppressed with YBX1 
overexpression, not in keeping with the micro-array result. (YBX1P = primers for YBX1 plasmid 
protein) Results show for 2 biological replicates. 
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6.3.2 YBX1 regulates selected CRIMTIC proteins and the androgen receptor at the 
protein level in LNCaP and PC-3 cells 
 
Given that most of the literature reports investigating the role of YBX1 in human 
cancers have emphasised that YBX1 overexpression and nuclear localization appear to be the 
important changes conferring an adverse prognosis to a particular cancer, it was considered 
important to assess protein level changes of the selected CRIMTIC genes for both YBX1 
knockdown and overexpression. This was especially important considering that only the 
YBX1 knockdown microarray data provided useful data for target selection. To this end, 
experiments were repeated to generate fresh protein for western blot in LNCaP and PC-3 
cells. Cells were treated in 6-well plates as previously described for YBX1 knockdown or 
overexpression, and various time points used for protein collection. It was found that a 48 
hour time point provided the most reliable window for showing YBX1 knockdown at the 
protein level, and the reasons for this were reviewed in section 4.3.9, highlighting the 
difficulties other researchers have encountered in sustaining YBX1 protein knockdown 
beyond 48 hours. For YBX1 overexpression, it was decided to perform a 96–hour time course 
experiment as it was not clear how long it would take for changes in the CRIMTIC genes to 
manifest at the protein level. However at 96 hours in PC-3 cells with YBX1 overexpression it 
was evident by observation that the cells were extremely stressed, with many detached cells 
and lower cell numbers generally than at 48 and 72 hours. For this reason, a 72-hour time 
point was used for Western Blot in PC-3 cells for the overexpression experiments. 
Figure 6.3 shows the results for western blotting of LNCaP protein lysates 48 hours 
after YBX1 knockdown. It can be seen that good knockdown of YBX1 is achieved, and AR 
shows corresponding down-regulation. It was not possible to detect CD82 in LNCaP or PC-3 
cells. It is known that the protein is not expressed in PC-3 cells (Park et al, 2012), as detailed 
earlier in section 5.3.7, but it was hoped that expression might be achieved through YBX1 
knockdown. However, from the results for the immunohistochemistry of the TMA later in 
this chapter (section 6.3.4) it can be seen that CD82 is expressed in prostate cancer and stains 
well using the same antibody as used in this western blot.  ITGB1 does not show any 
appreciable change with YBX1 knockdown, and IGFPB5 expression was also difficult to 
reveal, with faint staining becoming apparent with YBX1 overexpression in figure 6.4. MXI1 
also stained very faintly, with no appreciable change. RAC1 shows some down-regulation in 
this experiment with YBX1 knockdown.  
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At the protein level therefore in LNCaP cells, only RAC1 could be shown to 
recapitulate the results of the microarray findings, with suppression of the protein being 
evident.  
 
 
Figure 6.3 Western Blot showing correlation of YBX1 knockdown in LNCaP cells with proteins 
of interest at 48 hours 
LNCaP cells were seeded in 6 well plates in 5% FCS and RPMI at 90 x10
5 
cells/well and once 
confluence reached 60-80%, treated with YBX1 or scramble siRNA for 48 hours. Cells were 
harvested in RIPA-buffer with EDTA protease inhibitor cocktail and western blotting performed as 
described. The blots were normalised to actin as loading control to allow interpretation of protein 
expression levels. Both AR and RAC1 show down-regulation with YBX1 knockdown. CD82 is not 
present, and is also not induced in YBX1 knockdown. There appears to be no change in the very low 
levels of MXI1 and ITGB1 is also unchanged. IGFBP5 could not be detected in the setting of YBX1 
knockdown.  
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Figure 6.4 shows the results of a time course experiment for YBX1 overexpression in 
the same cell line, using antibodies to the same proteins. In this case it can be seen that AR 
expression increases with increasing YBX1 levels, as does the level of ITGB1 and RAC1. A 
faint band appears for IGFBP5 at 72 hours, but this may be due to unequal loading of wells  
as evident when comparing this band to the bands in the actin control. Again, CD82 and 
MXI1 showed no detectable expression. (However both are seen to be expressed in the IHC 
TMA, figure 6.9). For RAC1 the change is difficult to explain given the PCR results in figure 
6.1.  ITGB1 shows higher mRNA expression levels with YBX1 over-expression compared to 
knockdown in the microarray data, and this is reflected at the protein level. To confirm the 
changes in ITGB1 and RAC1, and to address the unequal protein loading in the lanes for each 
time point, ImageJ software was used to normalise the expression levels for ITGB1 and 
RAC1 at each timepoint by calculating the blot intensity for each band at each timepoint and 
normalising the expression levels back to the level at 0 hours and against each corresponding 
actin band at each time point. The results for this transformation are shown graphically in 
Figure 6.5, in which it can be seen that there is a sharp rise in RAC1 levels at 48 hours to 5.45 
times that of baseline, and smaller rise in ITGB1 levels to 1.6 times the baseline level. 
Despite numerous repeated experiments performed for the results in this section over several 
weeks, it was not possible to obtain perfect blots for each protein band and time point 
together in every experiment, making it impossible to assimilate three true biological 
replicates from different days. Inevitably in each experiment isolated treatments or bands 
would not stain or would be spoiled by artefact. The figures shown here (6.3, 6.4, 6.6) 
therefore represent the single complete experiments (from between 4 to 6 repeats of each 
experiment) in which usable western blots were obtained for each treatment and protein and 
timepoint across the whole experiment.  For this reason statistical analysis was not possible 
for the results shown in this section.  
Attempting to explain the changes seen at the mRNA and protein level in the setting of 
regulation by a transcription factor such as YBX1 can be a difficult proposition. YBX1 is a 
multi-functional protein with roles in transcription and translation and stress response. While 
it may up-regulate a gene at the transcriptional level, it may prevent translation of that same 
mRNA to protein at the ribosome, or vice-versa. This shows the importance of validating 
microarray findings at both the mRNA and protein level. 
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Figure 6.6 shows western blot results for PC-3 lysates at 72 hours after YBX1 
overexpression treatment. Unlike the LNCaP results, the obvious difference here is that  
 
 
Figure 6.4 Western Blot showing correlation of YBX1 overexpression in LNCaP cells with 
proteins of interest 
LNCaP cells were seeded in 6 well plates in 5% FCS and RPMI at 90 x10
5 
cells/well and once 
confluence reached 60-80% , treated with YBX1 over-expression plasmid for 96 hours. Cells were 
harvested in RIPA-buffer with EDTA protease inhibitor cocktail at the time points shown and western 
blotting performed as described.  Time point 0h represents untreated cells. The blot is normalised to 
actin as loading control to allow interpretation of protein expression levels (see Figure 6.5). The 
YBX1 plasmid generated protein appears as a separate band above the native YBX1 protein from 
48hrs. AR, ITGB1  and RAC1 all show up-regulation with YBX1 overexpression. CD82 and MXI1 
could not be detected. IGFBP5 is expressed at low levels but appears to increase over the time course. 
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Figure 6.5 Normalised expression levels of ITGB1 and RAC1 in Western blot from Figure 6.4 
In order to address the uneven loading of wells in the western blot shown in Figure 6.4, Image J 
software was used to calculate blot intensity for each band and derive normalised expression levels for 
both proteins based on levels at 0 hours and normalised to the actin staining at each time point. The 
results clearly show a large increase in RAC1 levels at 48 hours coinciding with high YBX1 
overexpression levels, and a smaller increase in ITGB1 at the same time point. 
 
ITGB1 appears to be suppressed by YBX1 overexpression. RAC1 shows perhaps 
fainter staining, but overall not a large change. MXI1, IGFBP5 and CD82 are not expressed, 
and neither is AR, as expected. It is clear that there are differences between the two cell lines, 
and this reflects the importance of validating data across as many cell lines as possible where 
time and resources permit. LNCaP and PC-3 cell lines, although extensively used by the 
research community, do in reality reflect the biology of prostate cancer in the two patients 
from which these cell lines were generated. Although we have learnt a great deal about 
prostate cancer from these cell lines, it is difficult to extrapolate findings from the use of 
these cell lines to a broader clinical context. For this reason, as mentioned earlier, further 
validation was performed with the assistance of a local pathology service to identify 
expression of the CRIMTIC proteins and YBX1 in human benign and malignant prostate 
cancer specimens in a TMA, presented below.  
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Figure 6.6 Western Blot showing correlation of overexpression in PC-3 cells with proteins of 
interest 
PC-3 cells were seeded in 6 well plates in 5% FCS and RPMI at 90 x10
5 
cells/well and once 
confluence reached 60-80%, treated with YBX1 overexpression plasmid for 72 hours. Cells were 
harvested at 72 hours in RIPA-buffer with EDTA protease inhibitor cocktail and western blotting 
performed. As expected AR is absent in PC-3 cell lysate as is CD82. ITGB1 appears to be down-
regulated with YBX1 overexpression, whereas RAC1 appears unchanged. IGFBP5 and MXI1 could 
not be detected.  
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6.3.3 Prostate cancer genes regulated by YBX1 discriminate for adverse outcomes in a 
public prostate cancer patient microarray dataset 
As another means of validation of the CRIMTIC genes in this section of work, data 
from a public microarray dataset was mined to assess the correlation of expression of YBX1 
and the CRIMTIC genes and to ascertain whether these genes could differentiate for 
outcomes of interest, including distinguishing metastatic samples, disease relapse or death 
from prostate cancer.  The Grasso microarray dataset (Grasso et al, 2012) has been uploaded 
to Oncomine (Oncomine ver. 4.4.3, accessed Oct-Nov 2012 at www.oncomine.com). The 
authors performed array comparative genome hybridization (aCGH) copy number and 
expression profiling (using a Agilent Whole Human 44K element array) on a matched cohort 
of benign prostate tissues, 59 localized prostate cancers and 35 lethal heavily pre-treated 
metastatic castrate resistant prostate cancers (CRPCs) from rapid autopsy specimens. The 
profiles were uploaded to Oncomine, where data could be analysed by a number of filters, 
including cancer site, survival, staged survival and analysis of various mutational events. 
Copy number and gene expression data is also available from GEO (GSE35988). 
This dataset was analysed and mined to assess whether the CRIMTIC genes and YBX1 
could discriminate for chosen outcomes. An important question to answer was whether the 
CRIMTIC genes were significantly altered in patients with adverse outcomes or in more 
aggressive disease sites. Although expression levels were available in the dataset for Alive vs 
Deceased patients, it was not clear from which sites the expression levels were calculated. 
The next best proxy was a comparison of expression levels in primary tumours compared to 
metastatic tumour sites in each patient. This is shown graphically in Figure 6.7, which shows 
an analysis of comparative expression levels of the CRIMTIC genes and YBX1 from three 
sites in study patients – benign prostate tissue, primary tumour and metastatic deposit. RAC1 
was the only gene not included in the Grasso array. It can be seen that the expression levels 
of CHEK2, ITGB1, TFF1 and YBX1 are all significantly different in metastatic tumour sites 
compared to primary tumour sites (comparing box 1 vs 2 for each gene in the figure). 
CHEK2 levels and YBX1 expression levels are higher in metastatic deposits whereas ITGB1 
and TFF1 show lower expression levels in metastatic sites compared to primary tumour. For 
CD82, MXI1 and IGFBP5 there was no significant difference in expression levels between 
primary and metastatic tumour sites. An increased level of YBX1 in metastatic tumour is in 
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keeping with a hypothesised role for YBX1 in promoting tumour metastasis, survival and 
aggression. According to the literature, CHEK2 is usually mutated or down-regulated in 
aggressive prostate cancer, so the findings here of an increased expression level in metastatic 
sites is not in keeping with prior reports (see Discussion below). Similarly for TFF1 previous 
reports have shown an increased level of this protein in aggressive prostate cancer, whereas 
the Grasso dataset show lower levels in metastatic tumour. For ITGB1 however, various 
authors have reported either an increase or decrease in expression levels of this protein in 
advanced prostate cancer. The Grasso dataset shows a lower expression level in metastatic 
deposits compared to primary tumour deposits. To investigate these disparities further, the 
Oncomine database was searched for other similar datasets of clinical prostate cancer 
specimens with available microarray expression data for these CRIMTIC genes. However, no 
other dataset was found which had significant patient numbers or contained all or most of 
these genes to allow for a meaningful analysis. At the time of writing, the Grasso dataset was 
the largest and most replete dataset, containing probes to an extensive gene set, and was the 
only dataset in which the CRIMTIC genes could be meaningfully analysed.  
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Figure 6.7 Analysis of CRIMTIC genes from Grasso dataset aligned on tumour site 
Data for relevant probes was exported from the Grasso prostate cancer dataset (Grasso et al, 2012) 
from the Oncomine online microarray data repository (www.oncomine.org ver. 4.4.3) and genes of 
interest analysed in a co-expression analysis with YBX1 and aligned on sample site – primary tumour 
or metastatic deposit. Relative expression levels of each gene shown as box plots.   It can be seen that 
CHEK2, ITGB1, TFF1 and YBX1 all show significantly different expression between the two groups. 
There was however no significant difference in the level of CD82, IGFBP5 or MXI1 expression 
between the two groups Data shown as box plots centred on log 2 median values; ** p≤0.05 for 
primary tumour compared to metastatic tumour only. 0 = benign prostate; 1= primary tumour (n=59); 
2 = metastatic tumour (n=35) 
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6.3.4 The CRIMTIC genes show differential expression in a tumour microarray panel 
 
The findings in the previous sections show varying results for expression levels of 
CRIMTIC genes which were not always in concert when comparing QRT-PCR results with 
western blots and also the results from the Grasso dataset analysis. It was an interesting co-
incidence to note that the proteins which were not stained in western blots in LNCaP and PC-
3 protein lysates – CD82, IGFBP5 and MXI1, were also the same proteins that showed no 
differential expression in the Grasso dataset in figure 6.7. However it was important to know 
whether these proteins are expressed well in benign and malignant prostate tissue at the 
protein level, in order to support future work with these proteins. Also important would be to 
check the expression levels of the other proteins which did show differential expression 
between primary and metastatic tumour in the Grasso dataset – CHEK2, ITGB1 and TFF1. 
Furthermore, RAC1 showed significant changes in the western blots but was not part of the 
Grasso array dataset, so it was relevant to validate whether this protein is well expressed in 
clinical prostate tissue samples. To achieve this, a custom-made small-scale prostate cancer 
TMA (Figure 6.8) using radical prostatectomy specimens was created with the assistance of 
Dr. Hema Samaratunga and Dr. Michael Adamson of Aquesta Pathology, Brisbane. The 
TMA was constructed to allow rapid proof-of-principle analysis of expression levels for the 
selected CRIMTIC genes (CD82, IGFBP5, MXI1, RAC1 and ITGB1) in benign and 
malignant prostate tissues from a number of patients. The TMA was not designed to allow a 
statistical comparison, but to serve as a baseline to proceed to a larger scale TMA experiment 
using the APCRC-Q Bio-resource in the future.  The same antibodies were used in the IHC as 
for the Western Blots performed in figures 6.3, 6.4 and 6.6 (see Appendix F for antibodies 
used), except for the YBX1 antibody which in this case was that supplied by Prof. A. 
Braithwaite. Each row in Figure 6.8 (A-F) represents sections from a different patient, 
allowing some biological inferences to be made for each protein with comparison to YBX1. 
No quantitative analysis was performed with these sections.  
ITGB1 staining was uniformly low across all tissues and blocks and it was not clear if 
this was a technical issue or reflected a biological fact. The images for this protein have 
therefore not been included here. However, ITGB1 protein was well stained in the western 
blots. In contrast, whereas CD82, IGFBP5 and MXI1 stained poorly or not at all in the 
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LNCaP and PC-3 western blots, staining in the TMA for all three proteins was evident and 
clearly varied across tissue type (benign vs. cancer) and to some extent with YBX1 staining.  
YBX1 stained moderately (2+) in benign tissue but was prominent in HGPIN (3+) and 
in one block containing Gleason 4 tumour (D) and Gleason 5 tumour (F). CD82 stained 
strongly in benign tissue and at low levels in HGPIN (B), and stained at a stronger level in 
Gleason 4 cancer when YBX1 stained weakly (C) compared to strongly (D). This is in 
keeping with the expectation that higher levels of YBX1 will lead to suppression of CD82. 
IGFBP5 stained at similar levels across all samples except for HGPIN where staining 
was only (1+). However, according to the literature and the results of the QRT-PCR 
experiments, IGFBP5 should be suppressed with higher levels of YBX1. This does not seem 
to be the case in the TMA sections here. MXI1 is absent in benign tissue but stains strongly 
in HGPIN, and stains strongly in prostate cancer when YBX1 expression is strong (D and F). 
This is out of keeping with the literature for the protein (see Discussion below), which 
suggests that it is a tumour suppressor and should decrease in expression in higher cancer 
grades and that it should also be suppressed by YBX1 based on the microarray and LNCaP 
QRT-PCR results.  
Finally, RAC1 expression appears prominent throughout all the tissues examined, 
including benign, HGPIN and Gleason pattern 4 and 5 tumours. Staining appears to be 
weaker when YBX1 is more strongly expressed (D vs C and F vs E), but a larger TMA would 
be needed to confirm this quantitatively. According to the literature, RAC1 should be more 
strongly expressed with increasing cancer grade and should be up-regulated by YBX1 
according to the microarray result. However this was not borne out in the QRT-PCR 
experiments but was seen at the protein level in LNCaP cells with YBX1 overexpression 
(Figure 6.4). 
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Figure 6.8 Tissue tumour microarray (TMA) constructed from radical prostatectomy 
specimens, stained with YBX1 and CRIMTIC antibodies 
 A TMA was created fom radical prostatectomy specimens from different patients , containing a 
spectrum of disease from benign tissue to Gleason pattern 5 prostate cancer.  Immunohistochemical 
staining was carried out for YBX1, CD82, IGFBP5, MXI1, RAC1 and ITGB1.  ITGB1 staining was 
uniformly poor and was not included in this analysis. Each row contains specimens from the same 
patient tumour block to allow biological comparison. Rows C and D represent two different patients 
with different levels of YBX1 staining. Rows E and F also represent two different patients, one with 
weak staining for YBX1 in the Gleason 5 cancer (E), while row F represents a patient with strong 
staining for YBX1 within the pattern 5 tumour. The purpose of this TMA was to establish a proof-of-
principle that these proteins are variably expressed in benign and malignant prostate tissue and to 
assess whether there is variability depending on YBX1 expression levels. The bracketed numbers 
indicate staining intensity for YBX1 as graded by a uropathologist.  
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6.4 DISCUSSION 
Prior to discussing the findings in this chapter it is important to review the relevant 
literature for the CRIMTIC genes and their known role in prostate cancer. 
6.4.1 CD82 
CD82, also known as KAI1 and ST6, is a metastasis suppressor gene product. It is a 
membrane glycoprotein and part of the transmembrane 4 superfamily. Expression of this 
gene has been shown to be down-regulated in tumour progression of human cancers. 
Expression of this gene is strongly correlated with TP53, and the loss of expression of TP53 
and CD82 is associated with adverse survival outcomes in prostate cancer patients. CD82 has 
been shown to increase homotypic aggregation of DU145 cells, and this aggregation is likely 
mediated through Src (Jee et al, 2003). This concept was subsequently developed further later 
by another group who showed that CD82 inhibits integrin-induced invasion by negatively 
regulating c-Met and Src kinases (Sridhar & Miranti, 2006). Another interesting  paper 
reported that CD82 mediates anti-metastasis activity by binding to vascular endothelial cell 
surface protein DARC (gp-Fγ) which results in inhibition of tumour cell proliferation and 
induces senescence by altering the expression of TBX2 and p21(Bandyopadhyay et al, 2006). 
More specific peri-cellular effects of CD82 were described in a recent paper, which showed 
that high CD82-expressing prostate cancer cells in-vitro appeared to inhibit the extracellular 
expression of fibronectin and interfered with the activation of beta(1)integrin at the cell 
surface, as well as showing greatly diminished motility in a scratch assay.  
The literature is replete with descriptions of the role of this gene in prostate cancer, 
with a PubMed search yielding 64 publications in this regard. One of the earliest reports for 
this gene’s role in prostate cancer came from 1995 (Dong et al, 1995), the researchers 
demonstrating that introduction of CD82 into rat AT6.1 prostate cancer cells was able to 
suppress metastasis. The same group soon after demonstrated down-regulation of 
CD82/KAI1 in clinical tumour samples from patients with lymph node metastases (Dong et 
al, 1996), and in patients who had failed androgen ablation, over 90% of the primary tumour 
sites showed down-regulation of CD82, with 60% having no protein expression at all. These 
findings were corroborated soon afterward with another group demonstrating staining of 
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CD82/KAI1 in BPH tissues but with increasingly less staining in prostate cancer samples 
from patients, inversely correlated with Gleason grade (Ueda et al, 1996). More recently , 
CD82 has been used to sub-classify prostate cancer patients with circulating tumour cells into 
groups at low and high risk for micro-metastases, with high expression of CD82 showing 
correlation with lower risk of metastasis (Murray et al, 2010). Loss of CD82 staining was 
also reported to be associated with metastasis in a number of other cancers, including 
pancreatic cancer (Guo et al, 1996), melanoma (Takaoka et al, 1998), colorectal (Lombardi et 
al, 1999) ovarian cancer (Liu et al, 2000), endometrial cancer (Liu et al, 2003) and breast 
cancer (Yang et al, 2000; Yang et al, 2001). Various groups have tried to understand the 
regulatory process surrounding this gene. Epigenetic modification and in particular promoter 
methylation has been ruled out (Sekita et al, 2001). Further to this, another group could not 
demonstrate that TP53 acts as a transcriptional regulator of CD82 expression in bladder 
cancer or prostate cancer cell lines (Jackson et al, 2002). It has been shown that low levels of 
KAI1 mRNA in LNCaP cells are caused by binding of beta-catenin/Reptin complexes to a 
specific motif in the proximal promoter, which prevents the binding of the Tip60/Pontin 
activator complexes, thereby inhibiting transcription of CD82 in this cell line. The PC-3 cell 
line has also been shown to lack CD82 expression, and restoration of CD82 in this cell line 
results in inhibition of HIF-1alpha and VEGF expression, while the level of the VHL-protein 
was significantly elevated (Park et al, 2012) Further work on regulation of CD82 has shown 
that its promoter contains a consensus binding motif for ATF3, and that KAI1 is a functional 
downsteam target of the NDRG1 pathway (Liu et al, 2011a) 
 
6.4.2 CHEK2 
Checkpoint kinase 2, (or CDS1/CHK2/RAD53) is a nuclear serine-threonine-protein 
kinase and cell cycle checkpoint regulator and probable tumour suppressor. It contains a 
forkhead–associated protein interaction domain which is necessary for activation in the 
setting of DNA damage. CHEK2 is phosphorylated in the setting of replication blocks and 
DNA damage and inhibits CDC25C phosphatase, which prevents entry to mitosis. CHEK2 
has also been shown to stabilize TP53, leading to G1 arrest. Furthermore, CHEK2 interacts 
with and phosphorylates BRCA1, which permits BRCA1 to restore survival after DNA 
damage. CHEK2 mutations have been linked with Li-Fraumeni syndrome, a high penetrance 
familial cancer phenotype usually associated with inherited TTP53 mutations.  
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CHEK2 mutation was first identified as a risk factor for prostate cancer in 2003, with 
4.8% of  US men showing germ line mutations and 3.3% of Finnish men in a second study 
(Holyoake et al, 2008) (Tripathi et al, 2009). Both protein truncations and an isoleucine for 
threonine substitution were shown to predispose to prostate cancer risk (Yamashita et al, 
2009). The LNCaP cell line, which carries wild-type TP53, harbours a CHEK2 mutation 
(c.1160C>T/p. Thr387Asn) and this was shown to impair CHEK2 autophosphorylation and 
activation (Wang et al, 2011). Mutations in CHEK2 have also been shown to predispose to 
breast cancer risk (Ahn et al, 2010; Jeter et al, 2011). 
 
6.4.3 IGFBP5 
Insulin-like growth factor binding protein 5 (also known as IGFBP5) is an insulin-like 
growth factor (IGF) binding protein which prolongs the half-life of IGFs and has been shown 
to either inhibit or stimulate the growth promoting effects of IGFs on cell culture. IGF 
binding proteins act to alter the interaction of IGFs with their cell surface receptors. In a 
mouse model of wild-type and mutant IGFBP5, both forms were found to inhibit the IGF axis 
and inhibit growth (Tripathi et al, 2009). 
IGFBP5 has been linked to various cancers, initially by detection of mRNA level 
changes in microarray datasets. IGFBP5 was found to be up-regulated in tamoxifen-resistant 
human breast cancer xenografts (Ahn et al, 2010; Becker et al, 2005) and also to be 
differentially expressed in breast cancer cell lines that were ER/PR positive compared to 
ER/PR negative cell lines (Akkiprik et al, 2006). Further work in breast cancer has found 
IGFBP5 to be overexpressed in lymph node metastases of breast tumours and overall 
expression correlated positively to receptor status, Her2 status and the likelihood of distant 
metastases or clinical relapse (Li et al, 2007). IGFBP5 has been found localised to either the 
cytoplasm or nucleus in breast cancer cell lines, with mutation of the nuclear localization 
sequence resulting in cytoplasmic accumulation of the protein and greater cell proliferation 
and migration than cells expressing wild-type IGFBP5 (Akkiprik et al, 2009). Finally, in 
MCF7 breast cancer cells, IGFBP5 has been found to increase cell survival and adhesion and 
decrease migration in-vitro (Sureshbabu et al, 2012). 
 IGFBP5 was found to be up-regulated in a prostate cancer cDNA microarray using PC-
3 cells in which P75 neurotrophin receptor expression had been reintroduced (P75NTR). 
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P75NTR is a tumour suppressor and restoration of this protein in PC-3 cells also restored 
levels of IGFBP5. (Nalbandian et al, 2005). Another interesting paper revealed that IGFBP5 
is regulated by ST7, a putative tumour suppressor gene on chromosome 7 which suppressed 
the growth of PC-3 cells, possibly through a role for IGFBP5 in modulating the extra-cellular 
matrix environment (Hooi et al, 2006). IGFBP5 was also found to be up-regulated in bone 
marrow stromal cells by androgen deprivation, and this increase was reversed with androgen 
treatment (Xu et al, 2007). IGFBP5 has been found to be up-regulated in LNCaP cells in 
which NANOG (Nanog homeobox- a transcription regulator involved in embryonic stem cell 
proliferation and self-renewal) expression has been artificially induced (Jeter et al, 2011). 
These cells were found to have developed a castration-resistant phenotype, and in DU-145 
cells the changes led to tumour regeneration.  
Work in a mouse gut adenoma model using a cDNA microarray approach identified 
IGFBP5 levels to be altered as a result of APC gene deletion or mutation, leading the authors 
to postulate that IGFBP5 might be a downstream target of the Wnt pathway (Reichling et al, 
2005). IGFPB5 has been found to be overexpressed in more aggressive, high grade ovarian 
cancers (Wang et al, 2006). 
IGFBP5 urine mRNA has also been identified as a useful biomarker to identify bladder 
cancer patients, along with CDC2, MDK and HOXA13 (Holyoake et al, 2008). 
It is evident from the literature that the role of IGFBP5 in cancers is complex. This 
molecule affects the IGF axis but has roles outside this pathway. It has disparate roles 
depending on tumour type and cancer cell line variety, making it difficult to make any 
assumptions about how levels of this protein will affect behaviour in a particular cancer cell 
line. In PC-3 cells it has been found to be involved in tumour suppressor pathways, whereas 
in LNCaP cells it has been seen to be co-expressed with NANOG to induce a more 
aggressive phenotype. 
 
6.4.4 ITGB1 
Integrin beta 1 (also known as FNRB, MDF2, MSK12 and CD29) is a beta-subunit of 
the integrin family, heterodimeric membrane receptors involved in cell adhesion and 
recognition in a variety of processes including embryogenesis, haemostasis, tissue repair, 
immune response and tumour metastases. The ITGB1 gene encodes a beta subunit for which 
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multiple splice variants are known to exist. There have been a number of reports on the role 
of ITGB1 in prostate cancer. ITGB1 is expressed in luminal prostate epithelial cells but not in 
basal cells and is growth inhibitory to prostate cancer cells in-vitro (Fornaro et al, 1998). Its 
anti-proliferative effect is likely partially mediated through upstream control of p27(kip1), 
with knockdown of p27 resulting in loss of ITGB1 anti-proliferative activity in prostate 
cancer (Fornaro et al, 1999). Immunohistochemical studies have revealed reduced expression 
of ITGB1 in prostate cancer at the mRNA level compared to normal prostate, however at the 
protein level, only the beta1C variant shows reduced expression in cancer, whereas the 
beta1A protein shows comparable expression in normal and neoplastic prostate (Perlino et al, 
2000). The beta1A variant of ITGB  has also been implicated in prostate cancer escape of 
apoptotic triggering by TNFα through an interaction with survivin (Fornaro et al, 2003).  
Irradiation of prostate cell lines in-vitro has been shown to inhibit integrin expression, in 
particular beta1 integrins, and reduced adhesion to fibronectin (Simon et al, 2005). The 
beta1C integrin variant is important in binding of prostate cells to basement membrane 
laminin-1, and loss of beta1C integrin and laminin-1 appears to predispose to a more 
aggressive prostate cancer phenotype (Goel et al, 2006). Conversely, another group has 
shown that beta1 integrins have an active role in the degradation of the extra-cellular matrix, 
in particular in degradation of type IV collagen in the basement-membrane, promoting 
prostate cancer cell invasion (Sameni et al, 2008). Beta1C levels were found to be increased 
in clinical prostate specimens of men undergoing radical prostatectomy who had undergone 
androgen deprivation therapy (ADT) prior to surgery, compared to men who had not had 
ADT prior to surgery or who had a cystoprostatectomy for bladder cancer (Fuzio et al, 2009). 
Clues to the regulation of ITGB1 in prostate cancer cells come from one study showing 
knockdown of forkhead box 2 (FOXF2) led to down-regulation of ITGB1(van der Heul-
Nieuwenhuijsen et al, 2009). Furthermore, high KAI/CD82 expression levels appear to 
inhibit integrin beta1 activation but do not affect overall integrin beta1 levels (Lee et al, 
2011a). An interesting mechanism for the PC-3 cell invasion assay results seen in chapter 4 in 
this thesis comes from work showing that heat shock protein 90 (HSP90) is localized at the 
leading edge of migrating PC-3 cells and that HSP90 is involved in prostate cancer cell 
invasion through the integrin beta1/FAK/c-Src signalling pathway (Liu et al, 2011b). It also 
appears that induction of Snail in prostate cancer cell lines leads to a decrease in integrins 
α5,α2 and    thereby predisposing to an invasive phenotype (Neal et al, 2011). 
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6.4.5 MXI1 
MAX interactor 1 ( synonyms: bHLHc11, MAD2 and MXD2) encodes a transcriptional 
repressor thought to be a negative regulator of MYC function, and is commonly accepted to 
be a tumour suppressor. This protein inhibits the transcriptional activity of MYC by 
competing for MAX, a basic helix-loop-helix protein that binds to MYC and is required for 
its function. Defects in this gene are common in prostate cancer patients. There are three 
alternatively spliced transcripts encoding different isoforms. Mutations of this protein in 
prostate cancer were first described in 1995 with allelic loss in region 10q23-25 being a fairly 
common finding (Eagle et al, 1995; Gray et al, 1995; Prochownik et al, 1998). Other reports 
have thrown into question the existence of MXI1 mutations as playing a role in prostate 
cancer, suggesting other candidates such as PTEN, at the same locus, as being more 
important in prostate cancer aetiopathogenesis (Edwards et al, 1997; Hermans et al, 2004; 
Kuczyk et al, 1998). Since 2007 there have been no further papers published regarding MXI1 
and prostate cancer; however, research in other cancers including melanoma, B-cell 
malignancies and renal cancer have resulted in sporadic publications on this protein. 
 
6.4.6 RAC1 
The ras-related C3 botulinum toxin substrate 1 (p21-Rac1/TC-25) is a GTPase which 
belongs to the RAS superfamily of small GTP-binding proteins. These proteins regulate a 
large number of cellular processes, including growth, differentiation, movement and lipid 
vesicle transport. They are the downstream effectors of most receptor tyrosine kinases and are 
coupled to intracellular signalling cascades such as the MAPK pathway, usually via 
interaction with Raf kinase. Activating mutations of small GTPases, usally Ras, can produce 
a cellular response in the absence of ligand and drive malignant progression. RAC1 has key 
roles in cell migration and adhesion assembly and disassembly, and helps regulate 
phagocytosis of apoptotic cells, epithelial cell polarization and growth factor induced 
formation of membrane ruffles.  
There is a significant body of literature describing a role for RAC1 in cancer and 
prostate cancer. RAC1 has been shown to inhibit p21 expression in prostate cell lines 
including PC-3 and LNCAP-104R1, and is shown to be higher in androgen independent cell 
lines, allowing increased proliferation through suppression of p21(Knight-Krajewski et al, 
2004). This line of investigation was confirmed later by a different group showing a vital role 
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for RAC1 in prostate cell line proliferation and resistance to apoptosis (Kobayashi et al, 
2010). 
 RAC1 has also been shown to be highly expressed in HGPIN and prostate cancer from 
human prostate samples, compared to adjacent normal epithelium, and increased RAC1 
expression discriminated for decreased disease-specific survival in multivariate analysis 
(Engers et al, 2007). Interestingly, small Rho GTPases, including reduced levels of RAC1, 
appear to impair the endocytic activity of dendritic cells in the tumour micro-environment 
(Tourkova et al, 2007). This may have important implications in the emerging treatment 
modality of dendritic cell vaccines for the treatment of prostate cancer, in which patient 
response is unpredictable. It may be possible in the future to create a panel of markers, 
including RAC1, which could be used to predict the likelihood of response to these expensive 
treatments in a particular patient.  
RAC1 has been implicated in the tropism of C4-2 prostate cancer cells to bone in an in-
vitro model, with evidence to show that PTEN expression (often lost in prostate cancer) can 
attenuate the activity of RAC1 and decrease migration toward bone conditioned medium (Wu 
et al, 2007). In a similar vein, RAC1 is important for tumour cell diapedesis in PC-3 cells 
(Sequeira et al, 2008). Other investigators looking at PC-3 interaction with an in-vitro bone 
model found that RAC1 mediates tight binding of prostate cancer cells to bone marrow 
endothelial cells and promotes retraction of endothelial cells required for tumour cell 
diapedesis (Chatterjee et al, 2011). This paper also showed that RAC1 leads to beta 1 integrin 
activation, facilitating tight binding to endothelial cells. This is interesting in light of the other 
roles for ITGB1 described above. Another group specifically showed that prostate cancer cell 
breaching and invasion of bone marrow through endothelial cells was specifically regulated 
by RAC1 and RAP1 GTPases (Barthel et al, 2012). 
 Another mechanism whereby RAC1 can contribute to prostate cancer progression is 
the finding that RAC1, influenced by the Rho guanosine triphosphatase Vav3, can lead to 
ligand-independent activation of the androgen receptor, resulting in androgen-independent 
growth of prostate cancer cells in culture, soft agar and mice (Lyons et al, 2008). 
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6.4.7 TFF1 
Trefoil factor 1 (BCEI – breast cancer oestrogen inducible sequence expressed in 
Trefoil factor/ D21S21/PS2) is a membrane of the trefoil family, proteins with at least one 
copy of the trefoil motif, which is a 40-amino acid domain that contains three conserved 
disulphides. These are stable secretory proteins expressed in gastrointestinal mucosa, the 
function of which has not been fully elucidated. Postulated functions include protecting the 
mucosa from insults, stabilizing the mucous layer and involvement in healing. The gene has 
been implicated in human cancer, including prostate cancer. Overexpression of TFF1 has 
been identified in a number of epithelial cancers, including pancreatic, large intestine, gastric, 
endometrial and ovarian cancers (Henry et al, 1991; Luqmani et al, 1992). Staining in 
prostate and bladder cancers was also seen, but not as frequently as the other tumour types. A 
more refined paper investigating the presence of TFF1/PS2 in prostate specimens showed that 
TFF1 staining is absent in benign tissue but present in normal and PIN glands adjacent to 
prostate cancer areas, as well as in areas of neuroendocrine differentiation. It was also seen to 
be present in the carcinomas of patients that had relapsed after hormonal therapy (Bonkhoff 
et al, 1995). TFF1 therefore may have a biphasic expression pattern, appearing in pre-
malignant glands and in advanced disease. Interestingly another study analysed the 
expression of the gene at the RNA level and found expression of TFF1 in 92% of the cancer 
specimens from a series of prostate biopsies of men with localised prostate cancer, whereas it 
was absent from 83% of the BPH specimens from the same series (Colombel et al, 1999). 
Another paper found PS2/TFF1 protein expression in 10% of prostate cancer tissues 
examined, and found a correlation with Gleason grade but not overall tumour stage (Ather et 
al, 2004). There seems to be evidence therefore that TFF1 may be expressed at the RNA level 
fairly commonly in prostate cancers but that other factors are necessary for expression at the 
protein level, possibly correlating with more aggressive or locally advanced disease.  Plasma 
levels of TFF1 and TFF3 are also elevated in men with advanced prostate cancer, though the 
levels did not correlate with the degree of immunohistochemical staining in the same patients 
(Vestergaard et al, 2006). Promoter methylation appears to be an important regulatory 
mechanism for TFF expression in prostate cancer, with several cell lines showing promoter 
hypomethylation for TFF1 and TFF3 with high expression levels, and concomitant 
hypermethylation of the TFF2 promoter and low or no expression seen for TFF2 
(Vestergaard et al, 2010). 
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6.4.8 Discussion of Findings 
An attempt was made in the work reported in this chapter to validate the role of YBX1 
in regulating several of the gene hits from the microarray dataset at the RNA and protein 
level, and also with publicly available array datasets, such as the Oncomine repository. To a 
large extent this has been successful, and a number of the seven selected targets have indeed 
been shown to be regulated by YBX1 in LNCaP and PC-3 cells, and in the Grasso tissue 
microarray data, with the custom TMA showing expression at the protein level in human 
prostate tissue for all the genes except for ITGB1, which stained poorly. The key question is 
whether the changes induced by YBX1 in these genes predispose to more aggressive prostate 
cancer. The general assumption for interpreting changes in the CRIMTIC genes in the light of 
YBX1 regulation is that the direction of gene change with YBX1 overexpression would be 
the change carrying an adverse or more aggressive phenotype. This is based on the pattern 
seen in other cancers, where YBX1 overexpression carries an adverse prognosis in many 
cancers, as set out in Chapter 1. In this context, interpreting the results from the QRT-PCR 
data from the LNCaP and PC-3 cell lines in figure 6.1 and 6.2 needs to be borne in mind 
when assessing figures 6.6.  
For example, it can be seen from figure 6.1 that CD82 is down-regulated in YBX1 
overexpression compared to knockdown, and in figure 6.6 it can be seen that a lower relative 
expression level of CD82 was seen in metastatic tumour samples compared to primary 
tumour. These two results are in concordance therefore and in keeping with the reports in the 
literature for this protein acting as a tumour suppressor in prostate cancer and being down-
regulated in concert with TP53 in aggressive prostate cancers (section 6.4.1). 
 In the case of ITGB1, lower levels of expression are seen in metastatic tumour in 
figure 6.6; this protein is suppressed at the mRNA level in PC-3 cells when YBX1 is 
overexpressed (figure 6.2) but appears to increase with YBX1 overexpression at the protein 
level in PC-3 cells (figure 6.4). The literature reports have been variable for this gene, 
reporting both up- and down-regulation in aggressive prostate cancer.  
 In the case of CHEK2, expression levels were higher in metastatic deposits in figure 
6.6, which also follows the PC-3 data in figure 6.2 but not that of LNCaP cells (figure 6.1) or 
the microarray data. CHEK2 has been reported to act as a tumour suppressor in prostate 
cancer (section 6.4.2) and therefore these experimental findings are at odds with published 
reports.  
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For IGFBP5, there was no appreciable difference in expression levels for this protein 
between primary and metastatic tumour in the Grasso dataset. This gene was strongly 
suppressed at the mRNA level in both LNCaP and PC-3 cells with YBX1 overexpression 
(figures 6.1 and 6.2) but unfortunately this could not be confirmed at the protein level in 
western blots from these cell line lysates. The literature reports for this protein in prostate 
cancer are varied depending on cell line – it can act as a tumour suppressor or be involved in 
inducing a more aggressive phenotype (section 6.4.3). 
MXI1 levels were higher in metastatic tumour deposits in the Grasso dataset, but lower 
in both LNCaP and PC-3 cells in the QRT-PCR data when YBX1 was over-expressed. This 
protein did not stain in the LNCaP or PC-3 western blots. MXI1 has been reported as a 
tumour suppressor in prostate cancer, with mutations impeding its ability to inhibit MYC. 
However, recently this hypothesis has been thrown into question and there have been no 
reports on this protein in prostate cancer since 2007. 
Finally TFF1 levels were relatively lower expressed in the Grasso dataset metastatic 
deposits (figure 6.6) which echoes the PC-3 data but not the situation in LNCaPs (comparing 
figure 6.1 and 6.2). According to the literature, TFF1 is not expressed in BPH tissue but is 
seen in a high proportion of primary prostate tumours. Its expression levels in advanced or 
metastatic disease are less clear (section 6.4.7).  
These multiple data points are summarised in table 6.3, in which the known changes in 
the CRIMTIC genes that are observed to occur in prostate cancer according to the literature 
are matched with the changes in the results reported here. In addition the change for each 
gene seen in the YBX1 knockdown microarray data are shown, as well as the expected 
change in the setting of YBX1 overexpression. Where the experimental results agree with the 
expected change for each gene if YBX1 were overexpressed, these are shown in green. It can 
be seen that all 7 genes have been shown to correlate with the literature in at least one 
methodology, but not all. This is not unexpected, given that two different cell lines, LNCaP 
and PC-3, were used, as well as data from a tissue microarray dataset of castrate resistant 
disease. At the mRNA level, in LNCaP cells with YBX1 overexpression, three genes show 
regulation in the way expected with YBX1 overexpression: CD82, IGFBP5 and MXI1 and 
TFF1.  PC-3 cells show the most consistent change in these genes at the mRNA level, with 
all genes moving in the expected direction with YBX1 overexpression except for CD82 and 
RAC1. In LNCaP cells at the protein level ITGB1 and RAC1 are also elevated, as described 
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in the literature, and for RAC1 this is in keeping with the expected change when YBX1 is 
overexpressed. In PC-3 cells at the protein level, only ITGB1 and RAC1 could be confirmed 
on western blot (figure 6.5). RAC1 levels decreased in keeping with expected change after 
YBX1 overexpression and in agreement with some reports in the literature.  RAC1 showed 
no change. In the Grasso dataset, CHEK2, ITGB1 and TFF1 behaved according to the 
expected change with YBX1 overexpression, though of these only ITGB1 recapitulates 
behaviour reported for it in the literature.  
Finally in the IHC results from the TMA, further confirmation was added that CD82, 
MXI1 and IGFBP5 are in fact well expressed in benign and malignant tissue, and of the four 
proteins evaluated in the TMA, only the expression levels of CD82 matched what was 
expected from the literature and regulation with respect to YBX1.  
In summary, using Figure 6.3 and the above discussion, the most promising CRIMTIC 
candidates for future investigation for a role in prostate cancer and regulation by YBX1 
appear to be CHEK2 and ITGB1, and possibly TFF1. 
The results in this chapter illustrate the complexity of validating gene targets from an 
array dataset, but the results are encouraging, especially at the protein or IHC level for CD82, 
IGFBP5, MXI1 and RAC1 and ITGB1. None of these seven genes have previously been 
reported to be associated with YBX1, so these findings may represent a significant departure 
point for further studies into the role of YBX1 in prostate cancer and its orchestration of 
molecular change in concert with multiple known cancer genes.  
In summary, the results presented here provide evidence from multiple methodologies 
that the CRIMTIC genes do appear to be regulated by YBX1 in different ways, and this may 
well have significance for the role of YBX1 in facilitating prostate cancer progression and 
aggressiveness. It remains to explore the significance of these proteins and YBX1 in a larger, 
curated TMA, which can hopefully occur as a new project leading off from this PhD thesis. 
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Table 6.3 Summary of results for CRIMTIC genes and correlation with literature reports for gene changes in prostate cancer 
The reported changes for each gene observed in prostate cancer, or advanced prostate cancer are summarised in column one  
(D=down-regulated, M= mutated, U = up-regulated, N=no change, ?U = possible up-regulation) 
For each gene the corresponding results for each methodology are annotated using the same symbols.  
Where the experimental outcomes agree with the expected change with YBX1 overexpression, these findings are shown in green 
(YBX1 OE = YBX1 over-expression) 
Gene 
Literature 
reported change 
associated with 
prostate cancer 
aggression 
Change in 
Microarray 
knockdown 
data 
Expected 
change with 
YBX1 
overexpression  
mRNA 
change in 
LNCAP YBX1 
OE 
mRNA 
change in 
PC-3 YBX1 
OE 
Protein 
change in 
LNCaP YBX1 
OE 
Protein 
change in 
PC-3 YBX1 
OE 
Expression 
level in 
metastases 
vs primary 
lesion, 
Grasso data 
         
CD82 D U D D U   N 
CHEK2 M/D D U D U   U 
IGFBP5 U U D D D ?U  N 
ITGB1 U /D U D N D U D D 
MXI1 M/D U D D D   U 
RAC1 U D U D N U N  
TFF1 U U D U U   D 
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Chapter 7: General Discussion 
7.1 OVERVIEW 
Prostate cancer is an important disease in the modern era, based on its 
prevalence, the controversies surrounding diagnosis and treatment selection, the long 
lead time prior to the development of aggressive disease and metastatic disease, and 
the paucity of effective treatment options for advanced and metastatic disease. YBX1 
has been shown to be an important prognostic indicator in numerous cancers, and its 
diverse roles suggest that it may play a role as a central regulator in tumour 
progression. Very little was known about YBX1 in prostate cancer, but recent work 
has outlined its association with clusterin, the progression to androgen independent 
disease and regulation of the androgen receptor. The work presented in this thesis has 
demonstrated the following important points regarding YBX1 in prostate cancer: 
1. YBX1 pseudogenes do not appear to be expressed at appreciable levels in 
6 different prostate cancer cell lines, and therefore assays and experiments 
using these cell lines are unlikely to be compromised by expression of 
pseudogene mRNA and protein. We have created a YBX1 RefSeq-specific 
primer pair that should reliably exclude pseudogene amplification in PCR 
assays and this can be verified in other cell lines. There may be low level 
expression of pseudogenes on chromosome 14:65548876-65550399 and 
chromosome 9: 35960925-35962454 based on RNA-seq data. 
2. YBX1 does not appear to induce an EMT in prostate cancer cell lines 
without the presence of other factors, for example an activated H-Ras 
pathway.  Although results in transformed breast cancer cell lines have not 
been reproduced here, we have demonstrated strong evidence for effects 
on migration and invasion in prostate cancer cell lines. 
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3. Microarray cDNA expression analysis has revealed a very diverse set of 
genes regulated by YBX1. Many of these are genes implicated in diverse 
cancers, including prostate cancer. Significant results included AR, 
BRCA1, BRCA2, bcl2 and a number of genes already implicated in 
prostate cancer including MXI1, CD82 and CHEK2. YBX1 knockdown 
was shown to have reciprocal effects in a gene subset to that caused by 
androgen treatment.  
4. Validation of  YBX1 regulation of  several genes implicated in prostate 
cancer has been completed and confirms that CD82, CHEK2, MXI1, 
ITGB1, IGBP5, RAC1 and TFF1 all show evidence of YBX1 regulation in 
different assays and cell lines but with some conflicting results. However, 
the overall results support further investigation of these proteins and their 
relationship with YBX1. 
In summary, the results here add significantly to the body of knowledge on 
YBX1 and in particular with respect to prostate cancer. The findings confirm the 
previously known roles for YBX1 in RNA and DNA regulation, DNA repair and 
stress response, but also unveil a number of new associations, in particular for 
regulation of cancer genes. YBX1 may indeed have a master regulatory role in the 
progression of prostate cancer and further work to clarify this might identify this 
protein as a plausible future therapeutic target in men with prostate cancer, allowing 
researchers and clinicians to add a true molecularly-targeted therapy to their 
armamentarium for this challenging cancer.  
 
7.2 YBX1 PSEUDOGOGENES 
 
The existence and potential confounding role of YBX1 pseudogenes has not really 
been addressed in the scientific literature. This is despite evidence for their existence 
(Makino et al, 1996) and expression, in particular YBX1P1 and YBX1P10 (Table 
1.2, Chapter 1). The candidate has noted that many papers investigating YBX1 do 
not use QRT-PCR for YBX1 assays, but assess the level of this protein in other 
ways, often through reporter gene assays or GFP or luciferase constructs that express 
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exogenous YBX1 protein in cell systems. However, these same papers do use QRT-
PCR to examine expression levels of other genes affected by YBX1. This may 
suggest that the creation of reliable primers for YBX1 has been a concern and that 
some researchers may have bypassed this difficulty through alternative methods and 
assays. It was known that the work in this thesis would rely heavily on QRT-PCR 
and western blots, and so the design and use of reliable, YBX1-RefSeq specific 
primers was important from the outset. The work reported in Chapter 3 has addressed 
this previously unexplored question and resolved some points. The first is creation of 
a YBX1-specific primer set using the ARMS methodology (Newton et al, 1989). The 
specificity of this primer pair was tested using RFLP-digestion of PCR products from 
various prostate cancer cell lines using this ARMS-primer pair and a non-ARMS 
primer pair for YBX1 which was designed without the terminal differentiating 3’ 
base. Across 6 different cell lines expression of YBX1 pseudogenes could not be 
demonstrated, based on the lack of digestion of the non-ARMS PCR products. As a 
further measure to validate the specificity of the ARMS primer pair, the PCR 
products from ARMS-based primer reactions were sent to the Brisbane node of the 
Australian Genome Research Facility (AGRF) for sequencing. However, we were 
warned from the outset by AGRF specialists that our short PCR product of only 98bp 
would not guarantee reliable sequencing, and in general most sequencing platforms 
require a template of at least 150bp. However we proceeded with sequencing the 
results of our PCR reactions. On analysis of the sequencing data it became evident 
that only the central 50bp portion of our 98b PCR product had been reliably 
sequenced, with poor quality data and missing base reads affecting the terminal 20-
30bp regions at the 5’ and 3’ ends. Thus it was impossible to check the identity of the 
final 3’ base at the end of each primer pair and verify that the primers were in fact 
specific and not causing amplification of pseudogene mRNA. Owing to the poor 
quality of the sequencing results this data was not included in Chapter 3. The 
candidate was fortunate to have access to a large in-house RNA-seq experiment 
being conducted at the same time as the work on pseudogenes, and so this platform 
was used to interrogate the LNCaP transcriptome in order to assess whether any of 
the PG loci were expressing RNA that was not being detected by the restriction 
digest methodology already performed. The RNA-seq results in Chapter 3 did 
provide clarity that of the 50 pseduogenes listed in Figure 3.1, 48 did not show any 
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RNA reads in LNCaP cells, and two pseudogenes from Table 3.1, chromosome 14 
and chromosome 9: 35960925-35962454 did show significant reads, although it was 
not possible to say definitively whether these represented true PG expression or 
misalignments from the RNa-seq algorithm. The fluctuation of the reads with YBX1 
treatments suggests it may be due to misalignment, unless it can be shown that 
YBX1 itself is regulating pseudogene expression at these loci. The read counts were 
not evenly distributed amongst the pseudogenes, a fact more in favour of genuine PG 
expression. The close homology of the RefSeq YBX1 mRNA and the PG mRNA 
sequences means even RNA-seq technology cannot provide a definitive answer in 
this case. For the pseudogene on chromosome 7, the ARMS PCR primer product did 
lie within the region showing wiggle RNA reads, which suggests that the lack of any 
digestion products for this PG in the restriction digest experiments represents a true 
negative. Overall, the combined RNA-seq and restriction digest results have helped 
to rule out PG expression in LNCaP cells for 48 out of fifty possible pseudogenes 
(there are however only 10 officially annotated YBX1 pseudogenes). Although 
YBX1 pseudogenes have been demonstrated to be expressed in human tissues, to this 
candidate’s knowledge this has not been shown for any particular cell line yet, and 
remains an unanswered question. The work in Chapter 3 can be taken further by 
harvesting RNA from both benign and malignant prostate cancer tissue and using the 
same PCR digestion technique, and also RNA-seq, to ascertain whether any 
pseudogene expression is occurring. Following on from this, an in-vivo model could 
be constructed to test the effect of both commercial YBX1 siRNA on YBX1 
expression and also on PG expression, as well as using pseudogene products as 
potential siRNA to test whether there is an endogenous suppression loop present.   
For the purposes of the work carried out in this thesis, the results in Chapter 3 have 
allowed a high degree of confidence that there is no significant pseudogene 
expression for the vast majority of possible PG candidates. This gives the candidate 
confidence that future work to examine the role of YBX1 in more detail will not be 
hampered by contamination from pseudogene products in assays. The restriction 
digest  techniques can be easily applied to other cell lines for clarification of the 
same question by other groups, providing discriminating primers can be designed 
and the sequences differ enough between pseudogene and the REfSeq gene to allow 
unique restriction enzyme selection.  
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7.3 YBX1 AND EMT IN PROSTATE CANCER 
 
The discussion in Chapter 1 has illustrated the importance of EMT as a process 
in both development and cancer pathogenesis. It is clear that EMT is an important 
area of study in cancer biology currently and that the induction and regulation of this 
process appears central to cancer cell invasion and metastasis. The paper by 
Evdokimova and colleagues (Evdokimova et al, 2009) appears to be the only paper 
in the peer-reviewed literature apparently demonstrating a central role for YBX1 in 
the induction of EMT in a cancer cell line. As outlined in Chapter 4, this paper 
showed that H-Ras transformed MCF10AT breast cancer cells displayed a more 
aggressive phenotype in the setting of ectopic YBX1 overexpression, with invasion 
and metastasis of breast cancer cells in a mouse model that were not reproduced by 
untreated cells. This is the only paper to describe a direct role for YBX1 in EMT 
induction, and this was therefore an important avenue to investigate in prostate 
cancer, as there are similarities between prostate and breast cancer in a number of 
ways, both being epithelial cancers driven by hormonal factors and with many genes 
implicated in the pathogenesis of both entities. The discovery that YBX1 drives EMT 
in prostate cancer would certainly be an important addition to our knowledge of this 
protein and open up new avenues for investigation and possibly therapeutics in the 
future.  The experiments in Chapter 4 aimed to address this question in a number of 
ways, firstly by testing for the presence of EMT-type phenotypical features in 
prostate cancer cell lines such as decreased cell proliferation, enhanced invasion and 
motility. The results in section 4.3 do not support a role for EMT related gene 
changes driving the invasive and migratory changes seen in the transwell and 
Matrigel assays. The Incucyte proliferation assay showed a trend toward decreased 
proliferation with YBX1 knockdown (Figures 4.4 and 4.5) but this was not 
statistically significant. This goes against the decreased proliferation expected if 
YBX1 is driving EMT in a setting of higher than usual YBX1 levels as in many 
cancers, and certainly not YBX1 suppression. YBX1 overexpression had a marked 
deleterious effect on PC-3 cell survival, inducing apoptosis and significantly 
reducing proliferation, as depicted in section 4.3.4. This hampered interpretation of 
234 
 
results using this experimental treatment in this cell line, and this was acknowledged 
in the discussion of the results. It would be interesting to expand the experiments 
performed to include other prostate cancer cell lines and a non-prostate control cell 
line and assess whether this was a common occurrence – it did not appear to 
adversely affect LNCaP cells.  YBX1 knockdown appeared to have a dramatic effect 
on the migration and invasion capabilities of LNCaP and PC-3 cells in an in-vitro 
tumour invasion model and transwell migration assay (Section 4.3.5-4.3.6). The 
results in this section strongly suggested an effect on motility and invasion, with 
knockdown of YBX1 strongly suppressing cell migration (Figure 4.8) and Matrigel 
invasion (Figure 4.10). Conversely YBX1 overexpression enhanced migration and 
invasion in the same model systems in LNCaP cells, whereas YBX1 knockdown did 
not really affect these behaviours in LNCaP cells. Phenotypically therefore there was 
evidence that YBX1 treatments did produce obvious changes in migration and 
invasion, however the mechanism for this effect was unknown. A role for EMT in 
this process was not borne out by the results in sections 4.3.7, in which QRT-PCR 
assays of YBX1 treated PC-3 and LNCaP cells did not show evidence of induction of 
the EMT transcription factors or the EMT signature genes vimentin or N-cadherin, 
and no appreciable change in E-cadherin that was consistent (The data in section 
4.3.8 make the important point that EMT gene signatures can be induced in LNCaP 
cells under other conditions, e.g. treatment with insulin and TGFβ). The results of 
western blotting showed similar results, with no real change in the EMT proteins 
demonstrated (Section 4.3.9). In summary, no strong evidence for an EMT with 
YBX1 overexpression could be demonstrated, and it must be assumed that the results 
of the invasion and migration assays reported in Chapter 4 are due to activation or 
suppression of different pathways affecting motility, cell-cell adhesion and invasion. 
One possible candidate gene which may be responsible for these findings in LNCaP 
and PC-3 cells is RAC1. RAC1 has been shown in the literature to have important 
effects in prostate cancer with roles in modulating proliferation (Kobayashi et al, 
2010), tropism to bone (Wu et al, 2007) and diapedesis of PC-3 cells in-vitro 
(Sequeira et al, 2008). The results reported in Chapter 6 provide evidence for the 
regulation of RAC1 by YBX1, and this relationship has not been reported in the 
literature before.  
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 The reasons for the differences seen between the results here and those of the 
Evdokimova paper have been discussed in Section 4.4, and include the fact that 
results in a breast cancer cell line might not be reproducible in a prostate cancer cell 
line. More importantly, the fact that Evdokimova and colleagues used H-Ras 
transformed cells is important, as it has been shown that viral infection and core viral 
proteins can induce EMT on their own or in conjunction with TGF-β signalling 
(Battaglia et al, 2009; Sides et al, 2011). Evdokimova tested for the effects of TGF-β 
signalling with pan-TGF-β neutralizing antibodies, and this did not affect the YBX1 
mediated phenotypic changes seen in the MCF10AT cells with Ras-ERK signalling. 
They established that hyperactivated Ras-ERK together with YBX1 overexpression 
was necessary for EMT induction. Our work here did not examine the level of 
activation of the Ras-ERK pathway in LNCaP or PC-3 cells, it is known that 13% of 
prostate cancers harbour KRAS mutations and therefore if this is the case in cell lines 
studied it may be impossible to see an EMT signature under untransformed 
conditions. It has been shown that AR binding to Src is necessary for Ras/ERK 
pathway activation (Migliaccio et al, 2011) and since PC-3 cells lack AR it may 
partially explain the lack of EMT type features in the experiments performed. 
However there is ample evidence from other papers that PC-3 cells do express an 
intact Ras-MAPK/Akt pathway (Skvortsova et al, 2008). The results obtained in the 
microarray analysis in Chapter 5 also do not support a direct role for EMT induction 
by YBX1, with none of the major EMT proteins or transcription factors showing 
regulation by YBX1 knockdown (Figure 5.14). 
The experimental results in this section could be expanded and illuminated 
further using more sophisticated experimental models, including 3-D cell culture 
models (possible in the Incucyte™ machine) to analyse proliferation and cell 
migration in a model that more closely mimics tumour biology and cell-cell 
interaction. Members of our group are currently using such a system to investigate 
other aspects of EMT induction in prostate cancer cell lines. In addition, it would be 
very interesting to proceed to in-vivo mouse models and perform tumour injection 
experiments with YBX1 suppressed and overexpressing cells and assess tumour cell 
migration and invasion, while at the same time modulating EMT triggers and 
suppressors.  
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7.4 MICROARRAY ANALYSIS AND DISCOVERY OF NOVEL YBX1 
REGULATED PROSTATE CANCER GENES AND PATHWAYS 
 
The results of Chapter 4 do not support a hypothesis of YBX1 alone being 
sufficient to induce an EMT when overexpressed in the prostate cancer cell lines 
LNCaP and PC-3. However, the interesting findings of the effects of YBX1 
treatments on cell invasion and migration prompted questions on what mechanisms 
underlie these changes in cell behaviour. It was decided to make use of our custom 
180K Agilent microarray platform to interrogate LNCaP cells in the setting of YBX1 
knockdown and overexpression to uncover new pathways or genes that are regulated 
by YBX1 that could help to explain the cell invasion and migration findings in 
Chapter 4. This would also add to the body of knowledge on YBX1 in general and its 
role in other cancer types.  
The results of the microarray analysis in Chapter 5 have provided some 
reassuring confirmation that the YBX1 treatments were successful and reproduced 
many findings already known from the scientific literature, particularly regarding the 
role of YBX1 in DNA replication, recombination and repair, cell cycle regulation 
and cellular assembly and organization (Figures 5. and 5.6) In addition to these 
canonical functions for YBX1, it was revealed that a large number of genes 
implicated in cancer and prostate cancer specifically were regulated by YBX1 
(Figures 5.9 to 5.11). Included amongst these were many important and well known 
genes, including MMP10, SOX9, IGF1, KLK2, KLK3, Bcl2, vimentin, TNF, E2F1, 
FASN and AR. The interaction with AR has already been documented (Shiota et al, 
2011a) and it was satisfying to see that connection confirmed in these results, and in 
addition the in-depth analysis of YBX1 knockdown and its effects causing reciprocal 
gene regulation to that of DHT treatments was a surprise finding. No doubt a 
significant proportion of the genes shown to be differentially regulated in the 
analysis will have been under androgen control primarily and not YBX1 – for 
example the kallikreins 2 and 3. However, the biological effects of these downstream 
changes are identical regardless of whether it is YBX1 or AR directly influencing a 
specific pathway.  Also of importance were the microarray findings confirming 
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YBX1 regulation of DNA double strand break repair (Figure 5.12) in which BRCA1 
and BRCA2 feature prominently. At the time of writing there are no published 
reports describing a relationship between YBX1 and BRCA1 or BRCA2 – this 
represents a potentially important future area of study. With respect to cell cycle 
control (Figure 5.13), the relationship of YBX1 with CDC6 is confirmed (Basaki et 
al, 2010). These results were not confirmed with functional assays during this 
research however. To our knowledge this microarray represents the first microarray 
analysis of the effects of YBX1 knockdown in a prostate cancer cell line, and 
illustrates the fact that YBX1 plays a central role in cancer biology, including effects 
on proliferation and influencing multiple cancer-related genes. Some recent papers 
have examined YBX1 knockdown in other cancer cell lines through a microarray 
platform. A team from the University of Auckland led by Prof. Antony Braithwaite 
(who supplied the YBX1 antibody for the IHC and TMA experiments in Chapter 6) 
examined the effects of YBX1 knockdown in three cancer cell lines : MCF-7 
(breast), A549 (lung) and HCT116 (colorectal) (Lasham et al, 2012). A summary of 
their results is presented in Figure 7.1. In light of the fact that these are not prostate 
cancer cell lines, it was not expected that there would be many intersections between 
our results sets and those reported in this paper. However it was interesting to see 
that IGFBP5 (selected for validation in Chapter 6) and MCM2 (down-regulated 1.69 
in our YBX1 knockdown (KD) data) and  TGFBR3 (up 1.65 in our YBX1 KD data) 
were common data points. The focus of this paper was the association between 
YBX1 expression and that of E2F1 regulated genes,  and the authors demonstrated a 
correlation for this in addition to showing that YBX1 regulated expression of an 
E2F1 reporter construct. 
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Figure 7.1 Results of YBX1 knockdown in three different cancer cell lines 
 Reproduced from Lasham, A., W. Samuel, H. Cao, R. Patel, R. Mehta, J. L. Stern, G. Reid, 
et al. 2012. "YB-1, the E2F pathway, and regulation of tumor cell growth." J Natl Cancer 
Inst 104 (2): 133-46.  
 
In our YBX1 KD dataset, E2F1 was down-regulated 1.67-fold, suggesting YBX1 
positively regulates E2F1. 
Another recent paper examined the effects of YBX1 siRNA treatment in an ovarian 
cancer cell line (SKOV-3) and performed microarray analysis (Basaki et al, 2007). 
The results are shown in Figure 7.2. It is interesting to note that there are a number of 
commonalities between this dataset and that of our own microarray. In particular, the 
MCM genes (minichromosome maintenance complex genes, a hexameric complex 
involved in the initiation of eukaryotic gene transcription) 2, 3, 4 and 10 are all 
down-regulated in our dataset between 1.5 and 1.69-fold. In this ovarian dataset 
MCM2, 3 and 4 do not meet our criteria for differential regulation (1.5-fold change) 
but MCM10 is up-regulated 1.7-fold. CDC6 appears again in this dataset, except here 
it is up-regulated 1.66 fold, whereas it is down-regulated in our YBX1 KD data. 
Although unchanged but listed in the ovarian data, EPHA2 is up-regulated 1.84-fold 
in our YBX1 KD data. In contrast, the ovarian dataset shows differential regulation 
of ESR1 and VEGF, which are unchanged in our data. Conversely, our data shows 
up-regulation of MMP3, MMP10, MMP11 and MMP13 between 1.5 and 2.4-fold, 
whereas in the ovarian data the only MMP reported is MMP7 which is down-
regulated 1.32-fold.  
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Figure 7.2 Differentially regulated genes in SKOV-3 cells transfected with YBX1-
siRNA  
Reproduced from Basaki, Y., F. Hosoi, Y. Oda, A. Fotovati, Y. Maruyama, S. Oie, M. Ono, 
et al. 2007. "Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of 
malignant characteristics by human ovarian cancer cells." Oncogene 26 (19): 2736-46  
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These data illustrate the difficulty in making comparisons between similar cell 
treatments (in this case YBX1 siRNA transfection) across different cancers, and 
underscores the importance of robust data for each cancer from both laboratory in-
vitro work and clinical specimens. The treatment of prostate cancer lags behind the 
treatment of a number of other cancers for which targeted therapies have been 
developed, for example the use of tyrosine-kinase inhibitors in renal cell carcinoma 
(RCC), particularly in the setting of metastatic disease. Various agents have been 
developed in this cancer which target receptor tyrosine kinases, and take advantage 
of a relatively ubiquitous and activated pathway in RCC. Different approaches have 
been developed, resulting in the availability of seven agents targeting the VEGF/ 
VEGF receptor or mTOR pathway and numerous trials have examined various 
combinations and sequences of these agents in order to maximize clinical benefit and 
minimise side-effects (Felici et al, 2012; Santoni et al, 2012; Turnbull et al, 2012). 
Although these agents are not a panacea, with only a proportion of patients achieving 
a durable response and rarely complete cure, they do represent a desirable goal for 
our management of prostate cancer – the identification of a common pathway that 
can be targeted across many different patients with one or more agents. At this stage, 
our knowledge and understanding of prostate cancer has not given us the insights to 
identify such a suitable target.  
It was however interesting to be able to identify a number of known prostate 
cancer genes from the microarray data that are regulated by YBX1 (Table 6.1 and 
6.2). These included CD82, CHEK2, IGFBP5, ITGB1, MXI1, RAC1 and TFF1. 
Their regulation by YBX1 was confirmed at the RNA and protein level in the 
experiments in Chapter 6. This was a technically intensive exercise owing to the 
multiple genes being assayed and it has to be noted that it was difficult to find a 
common thread for each gene in both the LNCaP and PC-3 cell lines at both the 
RNA and protein level. As can be seen from the results in section 6.3.1 and section 
6.3.2, a particular gene might be upregulated at the RNA level by YBX1 knockdown, 
but the opposite would be seen in the other cell line or at the protein level, or the 
results might differ to what was seen in the microarray. Nonetheless most of the 
selected genes did show evidence of regulation by YBX1 across different assays. The 
difficulties in obtaining complete western blots for each protein at every time point 
and for every treatment was frustrating, and meant it was not possible to quantify 
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apparent changes seen on the time course experiments statistically. This deserves 
further work for the best candidate genes, with dedicated experiments focussing on 
one protein at a time and more work finding the best antibody for each. Owing to 
time pressures and the long delays in receiving new antibodies from overseas 
suppliers, it was not possible to repeat the western blot experiments with new 
antibodies for the proteins which did not stain well (CD82, IGFBP5 and MXI1). 
Overall RAC1 and ITGB1 emerged as the most promising candidates for future 
study, based on the combined results from the experiments performed and what is 
known about the function of each protein from the literature. Finally, an attempt was 
made to assay the expression of these proteins in human benign and malignant 
prostate tissue using a pilot TMA (Figure 6.8) constructed from the tissue of several 
patients. This did show that in fact CD82 and  IGFBP5 and MXI1 area all expressed 
in human prostate and should not be disregarded as other possible candidates for 
study in relation to regulation by YBX1. 
 
7.5 FUTURE WORK 
The results reported in this thesis have raised as many questions as have been 
answered. The development of a technique to exclude pseudogene expression using 
PCR and RFLP has provided a useful tool for use in other cell lines, and has 
reassured the candidate that results in quantitative automated assays will not be 
corrupted by expression of YBX1 pseudogenes. 
Some important concepts have been established from the results in Chapters 4, 
5 and 6. In particular, although there is no strong evidence to support YBX1 inducing 
an EMT, the results from the invasion and transwell assays showed that YBX1 
knockdown or overexpression does have a significant effect on prostate cancer cell 
migration and invasion. The results in Chapter 5 have established a large dataset of 
genes regulated by YBX1, and for most no reports exist in the literature on these 
relationships. In addition, YBX1 has been shown to regulate the AR and to have a 
reciprocal effect on AR regulated pathways in the setting of YBX1 knockdown. 
Finally in Chapter 6, several candidate genes from the microarray data were selected 
to test their regulation by YBX1, and the expression of these proteins confirmed in a 
small prostate cancer TMA. Several of these genes, including RAC1, can directly 
242 
 
contribute to prostate cancer aggression and play a role in metastatic disease, as 
evidenced by existing literature.  
Therefore, some immediate options for future work exist from the results 
reported. These include: 
a) Further experiments to confirm the effect of YBX1 knockdown and 
overexpression on cell morphology and invasion and migratory potential. 
Initially these would include experiments using the Incucyte platform and 
utilise time-course experiments in both 2D and 3D media to test the effect 
of YBX1 treatments on cell proliferation, migration and invasion and 
morphology. It would be very interesting to see this work repeated in a 
collaboration with Prof. D. Hutmacher using the unique 3D bone scaffold 
developed at QUT. 
b) Following on from this, in-vivo mouse model work using LNCaP and PC3 
cells injected in a xenograft model would provide a very interesting 
examination of the effect of YBX1 treatment in assessing how much of an 
effect there is on cell invasion and metastatic capacity in the setting of 
YBX1 overexpression or knockdown 
c) Further work to investigate the relationship between YBX1 and the 
androgen receptor would be very important. The Ingenuity Core Analyses 
reported in Chapter 5 have provided an interesting foundation to explore 
reciprocal regulation of androgen regulated pathways by YBX1 and AR. 
Fundamental questions include the nature of YBX1 regulation of AR – 
some of these questions are being looked at by a colleague, Dr. Anja 
Rockstroh, using RIP-Chip techniques and trying to identify whether 
YBX1 binds to the AR promoter region. Further work in this direction 
would be important, as well as experiments using co-immunoprecipitation 
to identify any direct interaction between YBX1 and AR. Experiments to 
knock down either YBX1, AR or both would be important to ascertain 
whether the regulatory changes in the pathways outlined in section 5.3.7 
are due to an indirect effect by YBX1 through the AR, or whether YBX1 
can directly affect gene expression for some genes in the subset. Further 
microarray experiments using DHT treatment, androgen depletion, and 
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YBX1 overexpression and knockdown would be needed to uncover these 
interactions in detail. 
d) The work in Chapter 6 established that several key prostate cancer genes – 
CD82, RAC1, IGFBP5, MXI1, ITGB1 and CHEK2 – show regulation by 
YBX1 at the protein or RNA level, or both. It would be important to 
perform further studies to ascertain whether changes in these proteins in the 
setting of YBX1 regulation will produce changes in prostate cancer cells in 
keeping with aggressive behaviour. In this regard in-vivo work using mouse 
xenograft models and prostate cancer cells treated with knockdown or 
overexpression of these proteins would provide important validation of any 
biological effect including changes in invasive and metastatic potential. 
Secondly, validation of these proteins using the APCRC-Q Bio-resource in 
a large TMA with statistical power would provide confirmation from 
clinical samples whether or not any of these proteins show a definite 
association with tissue YBX1 staining and also Gleason Grade, both 
independently and in relation to YBX1 levels.  
 
Prostate cancer therapeutics lacks a pivotal molecule, aside from the androgen 
receptor, that can be targeted in multiple patients. YBX1 has been shown to be an 
adverse prognostic factor when overexpressed in multiple cancers. The results in this 
thesis have shown that it does affect prostate cancer cell invasion and migration in-
vitro, and that a large number of cancer and prostate cancer genes show regulation by 
YBX1 knockdown, including the AR and AR-regulated pathways. YBX1 
knockdown also affects the expression of several key prostate cancer related genes. 
Performing the work outlined above would be the next step in investigating the role 
of YBX1 in prostate cancer and may provide foundational evidence that YBX1 may 
be a suitable therapeutic target for a large cohort of prostate cancer patients, 
particularly those at risk of metastatic disease or with established systemic disease. 
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Appendix A 
 
Primers used in PCR and QRT-PCR 
All primers were purchased as 100µM liquid stocks and aliquoted to 5µM working stocks for PCR 
Gene Forward Primer Reverse Primer 
YBX1 – ARMS primer ACAAAAGATTGGAGCTGAAGACCTA AAAACCCCATGCTGCATAGATAAT 
YBX1 – non-ARMS 
primer 
AACAAAAGATTGGAGCTGAAGACCT TAAAAACCCCATGCTGCATAGATAA 
YBX1 plasmid primer AAGTGATGGAGGGTGCTGAC TGACCTTGGGTCTCATCTCC 
RPL32 CATCTCCTTCTCGGCATCAT ACCCTGTTGTCAATGCCTCT 
TWIST1 CCGGAGACCTAGATGTCATTG CAGAATGCAGAGGTGTGAGG 
P53 TGGATTGGCAGCCAGACT CATCTGGACCTGGGTCTTC 
P65 CACCATCAAGATCAATGGCTAC CTGATAGCCTGCTCCAGGTC 
CDH1 GAGAAGAGGACCAGGACTTTGAC AGATACCGGGGGACACTCAT 
CDH2 GGAGTCAGTGAAGGAGTCAGC CCTGACAAGCTCTTGAGGAAA 
VIMENTIN CAATCTTTCAGACAGGATGTTGAC GTGAGGTCAGGCTTGGAAAC 
FOXC2 GCCTAAGGACCTGGTGAAGC TTGACGAAGCACTCGTTGAG 
SNAIL1 TGCAGGACTCTAATCCAGAGTTTAC ACTGGACACACATACAGTGATTATTTC 
SNAIL2/SLUG ACTGGACACACATACAGTGATTATTTC AGAGAGGCCATTGGGTAGC 
CD82 TGTACCAGGAGGGCTGCAT CCCAGGAGCTCGATGATG 
CHK2 CTCTTGGAAGTGGTGCCTGT ACATTGAGAGCTGGGTCTGC 
IGFBP5 GAGCAAGTCAAGATCGAGAGAGA GGAGATGCGGGTGTGTTT 
ITGB1 TGCATACAATTCCCTTTCCTC TCAAATTGAACCTCATCTCCAA 
MXI1 GCCAACAGATCTACACACAATGA TGCAGTCTGGTCCTAGTGGA 
RAC1 CGTGCAAAGTGGTATCCTGA CAGCACCAATCTCCTTAGCC 
TFF1 CAGACAGAGACGTGTACAGTGG AATTCACACTCCTCTTCTGGAG 
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Appendix B 
 
FASTA sequences of hYBX1 and its pseudogenes taken from NCBI (NG Reference Seq): 
 
 
1 >gi|109134359|ref|NM_004559.3| Homo sapiens Y box binding protein 
1 (YBX1), mRNA: chr1:42,920,722-42,921,136 (+) 
GGGCTTATCCCGCCTGTCCCGCCATTCTCGCTAGTTCGATCGGTAGCGGGAGCGGAGAGCGGACCCCA
GAGAGCCCTGAGCAGCCCCACCGCCGCCGCCGGCCTAGTTACCATCACACCCCGGGAGGAGCCGCAGC
TGCCGCAGCCGGCCCCAGTCACCATCACCGCAACCATGAGCAGCGAGGCCGAGACCCAGCAGCCGCCC
GCCGCCCCCCCCGCCGCCCCCGCCCTCAGCGCCGCCGACACCAAGCCCGGCACTACGGGCAGCGGCGC
AGGGAGCGGTGGCCCGGGCGGCCTCACATCGGCGGCGCCTGCCGGCGGGGACAAGAAGGTCATCGCAA
CGAAGGTTTTGGGAACAGTAAAATGGTTCAATGTAAGGAACGGATATGGTTTCATCAACAGGAATGAC
ACCAAGGAAGATGTATTTGTACACCAGACTGCCATAAAGAAGAATAACCCCAGGAAGTACCTTCGCAG
TGTAGGAGATGGAGAGACTGTGGAGTTTGATGTTGTTGAAGGAGAAAAGGGTGCGGAGGCAGCAAATG
TTACAGGTCCTGGTGGTGTTCCAGTTCAAGGCAGTAAATATGCAGCAGACCGTAACCATTATAGACGC
TATCCACGTCGTAGGGGTCCTCCACGCAATTACCAGCAAAATTACCAGAATAGTGAGAGTGGGGAAAA
GAACGAGGGATCGGAGAGTGCTCCCGAAGGCCAGGCCCAACAACGCCGGCCCTACCGCAGGCGAAGGT
TCCCACCTTACTACATGCGGAGACCCTATGGGCGTCGACCACAGTATTCCAACCCTCCTGTGCAGGGA
GAAGTGATGGAGGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATGTA
TCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAGGACGGCAATG
AAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCTCAACGTCGGTACCGCCGC
AACTTCAATTACCGACGCAGACGCCCAGAAAACCCTAAACCACAAGATGGCAAAGAGACAAAAGCAGC
CGATCCACCAGCTGAGAATTCGTCCGCTCCCGAGGCTGAGCAGGGCGGGGCTGAGTAAATGCCGGCTT
ACCATCTCTACCATCATCCGGTTTAGTCATCCAACAAGAAGAAATATGAAATTCCAGCAATAAGAAAT
GAACAAAAGATTGGAGCTGAAGACCTAAAGTGCTTGCTTTTTGCCCGTTGACCAGATAAATAGAACTA
TCTGCATTATCTATGCAGCATGGGGTTTTTATTATTTTTACCTAAAGACGTCTCTTTTTGGTAATAAC
AAACGTGTTTTTTAAAAAAGCCTGGTTTTTCTCAATACGCCTTTAAAGGTTTTTAAATTGTTTCATAT
CTGGTCAAGTTGAGATTTTTAAGAACTTCATTTTTAATTTGTAATAAAAGTTTACAACTTGATTTTTT
CAAAAAAGTCAACAAACTGCAAGCACCTGTTAATAAAGGTCTTAAATAATAAAAAAAAAAAAAAA 
 
2 >gi|172088067:101-1596 Homo sapiens Y box binding protein 1 
pseudogene 1 (YBX1P1) on chromosome 14:chr14:65,548,902-65,550,397 
(-) 
TTCGATCGGTAGCGGGAGCGGAGAGCGGACCCCAGAGAGCCCTGAGCAGCCCCACCGCCGCCGCCGGC
CTAGTTACCGTCACACCCCGGGAGGAGCCGCAGCTGCCGCAGCCGGCCGCAGTCACCATCACCGCAAC
CATGAGCAGCGAGGCCGAGACCCAGCAGCCGCCCGCCGCCCCCGCCCTCAGCGCCGCCGACACCAAGC
CCGGCACTACCGGCAGCGGCGCAGGGAGCGGTGGCCCGGGCGGCCTCACATCGGCGGCGCCTGCCGGC
GGGCACAAAAAGGTCATCGCAACGAAGGTTTTGGGAACGGTAAAATGGTTCAATGTAAGGAACGGATA
TGGTTTCATCCACAGGAACGACACCAAGGAAGATGTATTTGTACACCACACTGCCATGAAGAAGAATA
ACCCCAGGAAGTACCTTCGCAGTGTAGGAGATGGAGAGACTGTGGAGTTTGATGTTGTTGAAGGAGAA
AAGGGTGCGAAGGCAGCAAATGTTACAGGTCCTGGTGGTGTTCCAGTTCAAGGCAGTAAATATGCAGC
AGACCGTAACCATTATAGACGCTATCCACGTCCTAGGGGTCCTCCACGCAATTACCAGCAAAATTACC
AGAATAGTGAGAGTGGGGAAAAGAACGAGGGATCGGAGAGTGCTCCCGAAGGCCAGGCCCAACAACGC
CGGCCCTACCGCAGGCGAAGGTTCCCACCTTACTACATGCGGAGACCCTATGGGCGTCGACCACAGTA
TTCCAACCCTCCTGTGCAGGGAGAAGTGATGGAGGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTA
GACCAGTGAGGCAGAATATGTATCGGGGATATAGACCACGATTCCGCAGAGGCCCTCCTCTCCAAAGA
CAGCCTAGAGAGGACGGCAATGAAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCC
ACCTCAACGTCGGTACCGCCGCAACTTCAATTACCGACGCCGACGCCCAGAAAACCCTAAACCACAAG
ATGGCAAAGAGACAAAAGCAGCCAATCCACCAGCTGAGAATTCGTCCGCTCCCGAGGCTGAGCAGGGC
GGGGCTTGAGTAAATGCCGGCTTACCATCTCTACCATCATCCGGTTTAGTCATCCAACAAGAAGAAAT
AATGAAATTCCAGCAATAAGAAATGAACAAAAGATTGGAGCTGAAGACCTTAAATGCTTGCATTTTGC
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CCGTTGACCAGATAAATAGATCTGCATTATCTATGCAGCATGGGGTTTTTATTATTTTTACCTAAAGA
CGTCTCTTTTTGGTAATAACAAACGTGTTTTTTAAAAAAGCCTGGTTTTTCTGAATACGCCTTTAAAG
GTTTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAAGAACTTCCTTTTTAATTTGTAATAAA
AGTTTACAACTTGATTTTTTCAAAAAAGTCAACAAACTGCAAGCACCTGTTAATAAAGGTCTTAAAAA 
 
4 >gi|255304925:101-1653 Homo sapiens Y box binding protein 1 
pseudogene 2 (YBX1P2) on chromosome 7: chr7:105,009,538-105,011,090 
(-) 
AGTTCGATCGGTAGCGGGAGCGGAGAGCGGACCCCGGAGAGCGGACCCCAGAGAACCCTGAGCAGCCC
CGCCGCTGCCGGCCTAGTTACCGTCATACCACGGGAGGAGCCGCAGCTGCCGCAGCCGGCCCCAGTCT
CCATCACCGCAACCAATGAGCAGCAAGGCCGAGACCCAGCAGCCACCCGCCGCCCCCGCCTTTCCCCC
CACCGCCCCCCTCCCGTCCCCCCGCCGCCCCCGCCCTCAGCGCCGCCGACACCAAGCCCGGCACTACG
GGCAGCTGCGCAGGGAGCGGTGGTCCGGGCGGCCTCACATCGGCGGCGCCTGCCAGCGTGGACAAGAA
GGTCATCGCAGTGAAGGTTTTGGGAACAGTAAAATGGTTCAATGTAAGGAACGGATATGGTTTCATCA
ACAGGAATGACACCAAGGAAGATGTATTTGTACACCAGACTGCCATAAAGAATAACCCCAGGAAGTAC
CTTCGCAGTGTAGGAGATGAAGAGACTGTGGAGTTTGATGTTGTTGAAGGAGAAGAGGGTGCGGAGGC
AGCAAATGTTACAGATCCTGGTGGTGTTCGAGTTCAAGGCGGTAAATATGCAGCAGATCGTAACCATT
ATAGACGCTATCCACGTCATAGGGGTCCTCCACGCAATTACCAGCAAAATTACCAGAACAGTGAGAGT
GGGGAAAAGACCGAGGGATCGGAGAATGCTCCCGAAGGCCAGGCCCAACAATGCCGGCCCTACCGCAG
GCAAAGGTTCCCACCTTACTACATGCGGAGACCCTATGGGTGTCGACCACAGTATTCCAGCCCTCCTG
TGCAGGGAGAAGTGATGGAGGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAG
AATATGTATCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCTTGCCAAAGACAGCCTAGAGAGTA
CGGCAATGAAGAAGATAAAATCAAGGAGATGAGACCCAGGGTCAGCAGCCACCTCAACGTCGGTACCG
CAGCAACTTCAATTACCAACGCAGATGCCCAGAAAACCCTAAATCACAAGATGGCAAAGAGACAAAAT
CAGCCAATCCACCAGCTGAGAATTCGTCTGCTCCCGAGGCTGAGCAGGGCGGGGCTGAGTAAATGCCG
GCTTACCATCTCTACCATCATCCGGTTTAGTCATCCAACAAGAAGAAATATGAAATTCCAGCAATAAG
AAATGAACAAAAGATTGGAGCTGAAGACCTTAAGTGCTTGCTTTTTGCCCGTTGACCAGATAAATAGA
ACTATCTGCATTATCTATGCAGCATGGGGTTTTTATTATTTTTACCTAAATATGTCTCTTTTTGGTAA
TAACAAACGTGTTTTTTTTAAAAAGCCTTGTTTTTCTCAATACGCCTTTAAAGGTTTTTAAATTGTTT
CATATCTGGTCAAGATGAGATTTTTAAGCACTTTATTTTTAATTTGTAATAAAAGTTTACAACTTGAT
TTTTTCAAAAAAGTCAACAAACTGCAAGCACCTGTTAATAAAGGTCTTAAATAATAA 
 
 
>gi|374671832:101-1009 Homo sapiens Y box binding protein 1 
pseudogene 3 (YBX1P3) on chromosome 3 
CAGCAACCACAACCCTGAGCAAAGACGCCAAGGCAGCCAACCCCAAGCCGGCACCACCTGCAGCGGCG
CAGGGAGCAGTGGCAAGGGCGACCTCACAGGCGGCGCCTGCTGATGGGGATAAGATCACCGCAAGGAA
GATTTTGGGAACAGTAAAATGGTTCAATGTAAGAAATAAATGGTTTCATCTATGCGAATGGCACCAAG
GAAGATGCAGTTGTACAGCAGAATACCATACAGAAGAGTAACCCCAGGAAGTACCTTAGCAGTGTAGG
ACACGGAGAGACTGTGGAGTTTGATGATGTTGCAGCAGAAAAGGGTGGGGAGGCAGTAAATGTTACAG
GCCCCTGTAGAGTCCAGTTGATAGCAGTAAGTATGCAGCTGACCTTAACCATCATTGACGCTATCCAT
GTGGTCCTCAGGCAATTACCAGTAGAATTACCAGAATAGTGAGAGTGGAGAAAAGAACGAAGGACGGG
AGAGTGCTCCCTTAGGCTCGGCCCAACAATGCCGGCCCTGCTGCAGGCGAAGGTTCCTGCCTTACTAC
AGGCAGAGACCCTACGGAAATTGACCACCATATTCTAACCCTCCTTGCAGGGAGCAGCGACGGAGGGT
GCTAACAACTGGGGTGCAGGAGCACAAGGTAGGCCAGTGAGGCAGGATATTTGTATGGTTTATAGACC
ACGATTCCTCAGGGAACCTCATCGCCAAAGCCAGCCTAGAGAGGACGGCAGTGAAGAGAGTAAAGAAA
ATCAAGATGAGACCCAATATCAGCAGCGACCTCAACATCGGTGCTGCTAAAACCCCAATTATCTATGT
AGACTCCCAGAAAACCCTAAACCACAACATGGCAAAGAGACAACAGCAGCCAGTCCACCAGTCAAGAA
TTCTGCACCCGAGGCAGAAGAAGGT 
 
 
 
 
 
 
 
 
 
11 >gi|225637465:101-920 Homo sapiens Y box binding protein 1 pseudogene 4 
(LOC100131012) on chromosome 7: chr7:151,456,855-151,457,674 (+) 
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AGTTCGATCGGGAGCGGGGAGCGGGGAGCGGGTCCCAGAGAGCCCTGGGCAGCCCCACCGCCGCTGTGGCCTAGTT
GCCACCACAGCCCGGGAGGAGCCCAGGCACCGTCACCCCCGCCGTTTGGGGAACAAATGGTTCAGGGTAAGCAACA
GATACGGTTTCATCAACAGGAACGTCACCAAGGAAGATGTGTGTTCATCAGACTGCCGTGAAGGAGAACCCCGGGG
AGGACCCTGGCGGCGGGGGAGCTGCGGAGGCCGCGGAGTCCGATGTTGAGGGAGAAAAGGGCGAGGCGGCGGCAAG
TGTTCCAGGGCCTGGTGGGGCCCAGGTCAAGGCAGTAAACCTGCGGCCACCGTAACCACTGCAGACGCGGGACCTC
CCCGCCGTCACCGGCAGAATCACCAGAATCCTCCGTGGGGAACGGAAGGAGGGATGAGACAGCGCTGCCGCGGGCC
AGGCCCACCACGCGGGCCCCACCGCAGAGTCCCACTTTCCTCCATGGAGGCCGCAGTTCTCCAGCCTCCGGGGCGG
CCGGGAGCAGCGATGCGGGGGTGACAGCGCGGGGAGCGGGGACACCAGCGGGGCAGCGAGTGTACCGGGGACGCAG
ACCACGATTCCGCAGGACCCACCTCACCCAAGACGGCCTGTAGAGGACAGCGAGGAAGAGGATAAAGACAATCCGG
GAGATGAGACCCAAGGTCACCAGCCACCTCAGCACCGGGGCCGCCGCAACTTCGATTACCGACGCGGTCGCACAGA
AAACCCTAAACCACAAGATGGCAAAGACACAGAAGCAGCTGATCCACCAGCTGAGAATTC 
 
>gi|374717348:101-875 Homo sapiens Y box binding protein 1 pseudogene 5 
(YBX1P5) on chromosome 5 
GACACCAAACCCAGCACCAGGGGCAGCGCACAGGGATCGGTGGCCAGGGTGCCTCACATCGGCTGCGCCTGCCCGC
GAGGACAAGAAGGATGGGGTTTCATCAGCGGGAATGACACCAAGGAAGATGTATTTTGTACAGCAGACTGCCATAA
AGCAGCAGCAGCTCAGGAATCACCTTCGCAGCGTGGTCGTGGAGAGCTGTGGAGTTTGGTGTTGAAGGAGCAAAGG
GTGCGGAGGCGGCAAATGCCACGGGCCCTGGTGGCGGTCCAGTACGAGGCAGTACATGCAGCGACCGCAACCCTTT
GAGACGCCATCCGCACTGCAGGCGCCTCGTGCACTTAGCAGTAGGATCAACAGAATAGTGGGCGTGGGTGAAAAAC
AAGGGATGGGAGCGCGCCCAAGGGCCAGGCCCAACCACGCGCCGGCTGCAGGCGCAGGGCCCCACCTACCACCTGC
GGAGACCCACGGGCACGGACTACCACTCCAGCCCTCCTGCAGGAGCAGGGATGGGGGTGCCCACAGTCAGGCGCAG
GAGAACAGGGTAGACCAGGGAGGCAGGATGTGCAGCCGGGACTCACACCCCAATTCTCCTCGCCAGAGACAGCCAG
CAGTGGACACCGACCAAGACGATAAAGAAAATCAAGGGGCTAAGACCCAAGGTGAGCAGCCGCCTCAACATCAACT
ACCGACACAGACACCCAGAAAACTCTAAACCACAAGATGGCAAAGAGACAAAAGCAATCCATCAGCTGAGAATCCG
GCTCCCAAGGCTGAG 
 
>gi|354725930:101-1899 Homo sapiens Y box binding protein 1 
pseudogene 6 (YBX1P6) on chromosome 9 
AGTTCGATCGGTAGCGGGAGCGGAGAGCGGACCCCAGAGAGCCCTGAGCAGCCCCACCACCACCGCTGGCCTAGCT
ACCATCACACCCCGGGAGGAGCCGCAGCTGCCGCAGCCGGCCCCAGTCACCATCACCACAACCTTGAGCAGCGAGG
CCGAGACCCAGCAGCCGCCCGCCGCTTGCCGCTCGCCGCCCCCCGCCCTCAGCGCCGGTGACACCACGCCCGGCAC
TACGGGCAGCGGCACAGGAAACGGTGGCCCGGGAGGCTTCACATCAGCAGCACCTGCCGGCGGGGACAAGAAGGTC
ATCGCAACGAAGGTTTTGGGAACAGTAAAATGGTTCAACTTAAGGAACGGATATGCTTTCATCAACAGGAATGACA
TCAAGGAAGATACATTTGTACCCCAGACTGCCAAAACGAAGAATAACCCCAGGAGGTACCTTCGCAGTGTAGAAAT
GGAGAGACTGTGGAGTTTGATGTGGTTGAAGGAGAAAAGGGTGCAGAGGCAGCACATGTTATAGGTCCTGGTGGTG
TTCCAGTTCAAGGCAGTAAACATGCAGCAGACCGTAACCCTTATAGATGCTATCCACGTCGTAGGGGTCCTCCACC
CAATTACCAGCAAAACTACCAGAATAGCGAGAGTGGGGGAAAGAACGAGGGATGGGAGCGTGCTCCCCAAGGCCAG
GCTCAACCACGCCGGCCCTACAGCAGGTGAAGGTTCCCACCTTCCTACATGCGGAGACCCTATGGGCGTGGACCAC
AGTATTCCAACCCTCCTGTGCAGGGAGAAGTGATGGAGGGTGCTGACAACCAGGGTGCAGGAAAACAAGGTAGATC
AGTGTGGCAGAGTATATATCAGGGATATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAG
GACGGCAATGAAGAGGATAAAGAAAATCAACGAGGTGAGACCCAAGGTCAGCAGCCACCTCAACGTCGGTACCGCC
GCAACTTACCGACGCAGACACACAGAAAACCCTAAACCGGCCAGGTGCGGTGGCTCATGCCTGTAATCCCAGCACT
TTGAGAGGCCGAGGCGGGCGGATCACCTGGGGTCAGGAATTCGAGACCATCCTGGCTAACAAGGTGAAACCCCGTC
TCTACTAAAAATACAAAAAATTAGCCGGGCGCGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCA
GGAGAATGGCGTGAACCCGGGAAGCGGAGCTTGCAGTGAGCCGAGATTGCGCCACTGCAGTCCGCAGTCCGGCCTG
GGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTAGCCAGGTATGGTGGTGGGCG
CCTGTATGTAGTTCCAGCTACTCAGAAGGCTGAGGCAGGAGAATTGCCTGAACCCGGGAAGCGGAGGTTGCAGTGA
GCCGAGATCGCGCCATTGCACTCCAGCCTGGGGGACAAGAGCGAGGCCCCGTCTCAAAAAAAAAAAAAAAAAAAAA
AAAAAAACCCAGAAAAGAAAACCCTAAACCACAAGGTGGCAAAGAGACAAAAGCAGCCGATCCACCAGCTGATAAT
TGAGAATTAGTCCGCTCCCGAGGCTAAGCAGGGCGGGGCTGAGTAAATTCCGACTTATCATCTCTATCATCAACCG
GTGTAGTCATCCAACAAGAAGAAATATGAAATTCCAGCAATAAGAAATGAACAAAAGATTGGAGCTGAAGACCTTA
AGTGCTTGCTTTTTGCCCATTGACCAGATAAATAGAACTATCTGTATTATC 
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>gi|371941020:101-941 Homo sapiens Y box binding protein 1 pseudogene 7 
(YBX1P7) on chromosome 2 
AGCAGCAAGTCCCCGGCCCAGGAGCCGCCAGCGGCCCCCACCGCCCTCGTCCCTGCCCTCGGTGCTGCCGGCACCA
AGCCCAGCACCACGGACAGCGCCGGCGCCTGCCAATGGGGAAAAGGTCATTGCAAGGAAGGTTTTGGAGACAATAA
AATATTTCAGCGTAAGAAACAGATATGGTTTCACCAAGAGGAATGATACCGAGGAAGATGCATTTGTGTACCAGAC
TGCTGTAAAGAAGAATAACCCCAGGAAGTACCTTCGCAGGGTAGGATATGGAATGACTGTGGAGTTCGATGTCATC
TAAGGAGAGGAGGACCCTGGCAGCAAGTGTCACAGGCCCTGGTGGAATTCCAGGTCAAAGAGGTAAACGTGGAGCA
GGCTGCAACCATGATAGACTCCGCGTCATAGGGGTCCTCAATAGTGAGAGAGAGAAAAAGAACAGGATGGGACAGT
GGTCCCACAGGGTGCACACCTCACTACACTCAGATAACCTGCGGGCAATCACAGTATTCCCACCCTCCCTTGCAGG
GAGAAGAAGTGGAGGTGCTGACAGCCAGGGCGCAGGGGCACAAGGTAAACCAGTGAGGCGGGATGTGGATGGGGCT
AGAGACCACGGTTCCACAGGAGCTCTCCTTGCCAAAGATGACCGAGAGAGGACAGCAATGACATGGGTAAGGAAAA
CCAAGGCAATGAACCCAGGGTCAGCAGACACTTCAGCCTCGGGGCAGCCACAACTTCAAGTACCAGCCCTGATGCT
CAGAACACCCCAAACGACAAGATGGTAGAGACAAAAGCTGAGAATTCATCCACTCCTGAGGCTGAGCAGAATGTGG
CTGAG 
 
>gi|374088014:101-811 Homo sapiens Y box binding protein 1 pseudogene 8 
(YBX1P8) on chromosome X 
TGCAAACAGGACAAGAAGGTTATCCCAGTGAAAGTTTGGGAACAGTAAGATGGTTCAGTGTAAGAAATATATATGG
TTTCGTCCACAGGAATGACACTGGGTGAGATGTATTTGTATGCCAGATTGTCATAAAGAAGAATAACCCCCAGGAA
ACACCCTGGCAGTACAGGGGATGGAGAAGCTGTGGAGTTCGATGTTGAAGGAGAAAACGGTACACAGGCAGCAAAG
ATTGCAGGCCCTGGTGGAGTTCCAGTGCCAGGCAGTACAGATGCAGTAGACTGAAGCCATTATAGATGTTATCTGC
ATCATGGGGGTCTTCCACACGGTCACCAGCACAATTACCAGAACAATGAGAGTGGGGAAAAGAAGGATTGGAGAGT
TCCCTTAAACGTCAGGCCTTACAGCACACAGAAGATGCCTCCTCCCTTGCAGAGACCCTATGATTCTTGACCAGAG
TGTTCTAACCCTCCTGTGCAGAGACAAGTGATGGAGGGTGGTGACAACCAGGGTGAAGGAGAAGAGGTAGGTCAGT
GAGACAGATTACGTATTGGGGTTACAGACCACGAATCTCCAGGGCCCCTCCTCACCTAGAACAGTAATGAACACCC
AAGGCCAGCAGCCATGTCATTGTAGGCACCCCCCAACTTCAGTTACCAGCACAGACACCCAGAAAACCCTGAACCA
CAAGATGGCAAAGAGACTGACAGCTAG 
 
>gi|373938469:101-790 Homo sapiens Y box binding protein 1 pseudogene 9 
(YBX1P9) on chromosome 1 
GCCTTGGCTGCCCAGGGAGTAGTGGCCTCGGCGGCCTCACATCCATGGTTCTGTGGGTAGGGACAAGAAGGTCATG
GCGAAGATTTTCGGGAAAAGGAAAATGATTCAATGTAAGAAACAGATCTGCCATTAAAAAAGAACCCCAGGAAGTA
CCTTGGCTGTGTAGGAACTGGAGAGACTGTGGAGTCTGACGCTGAAGGAGAAAAGGGTGTGGAAGCAGCAGATGTC
ACAGCCCTGGTGGAATTCCACTGCAAGGCAGTAAACGTGGAGCAGGCCGTAACCATTATGGAAGCAATCCACGTCC
TGGGGGTCCTCCACACAATTACCAGCGGAATTACCAGAATAGTGAGCGTGGGGAAAAGAAGGAAGGATAGGAGAGT
GCTCCCAAAGGCCAGGCCCAACAAGACTGGCCCTTCCTCAGGAGAAGGTTCCTGGAGAAGGTTCCTGCCCTACTAC
CTGAAGAGACCCTATGGGCGTGGACCACAGTGTTCCAGCCCTCCAGCGCAGGGAGCGGAGATGGAGGATGCTGACA
GCCAGGGTGCAGGAGCACCAGGTAGACCAGTGAGGCAAGATATGTATGTGGCTATAGGCCATGATTCCACTGGGGC
CCTCTTAGCCAAAGACAGCCTAGAGAGGATGGTGATGAAGAGGATAAAAAGAAATCAAGGAGATGAGACCCCAGGT
CAGCAG 
 
 
 >gi|169646967:101-1614 Homo sapiens nuclease sensitive element 
binding protein 1 pseudogene 10 (BA327L3.4) on chromosome 9: 
chr9:35,960,941-35,962,454 (-) 
AGTTCAATCGGTAGCGGGAGCGGAGAGCTGACCCCAGAGAGCCCTGGGCAGCCCCACCTCCGCCGCCGGCCTAGTT
ACCATCACACCCCGGGAGAAGCCGCAGCTGCCGCAGCCGGCCCCAGTCACCATCACCGCAACTATGAGCAGCGAGG
CCGAGACCCAGCAGCCGCCCGCCGCTCCCCCACGCCGCCCCCGCCCTCAGCGCCGCCGACACCCACCCCAGCACTG
CAGGCAGCGGCGCAGGAAGCGGTGGCCCGGGCGGCCTCACATCGGCGGCGCCTGCCGGCGGGGACAAGAAGGTCAT
CGCAACGAAGGTTTTGGGAACAGTAAAATGGTTCAGTGTAAGGAACGGATATGGTTTCATCAACAGGAATGACACC
AAGGAAGATGTATTTGTACACCAGACTGCCAGAAAGAAGAATAACCCCAGGAAGTACCTTCGCAGTGTAGGAGATG
GAGAGACTGTGGAGTTTGATGTTGTTGAAGGAGAAAAGGGTGCGGAGGCAGCAAATGTTACAGGGCCTGGTGGTGT
TCCAGTTCAAGGCAGTACATATGCAGCAGACCGTAACCATTATAGACGCTATCCACGTCGTAGGGTCCTCCACGCA
ATTACCAGCAAAATTACCAGAATAGTGAGAGTGGGGAAAAGAACGAGGGATCGGAGAGTGCTCCCGCAGGCCAAGC
CCAACAACGCCGGCCCTACCGCAGGCGAAGGTTCCCACCTTACTACATGCGGAGACCCTATGGGCGTCGACCACAG
TATTCCAACCCTCCTGTGCAGGGTGAAGTGATGGAGGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAG
TGAGGCAGAATACGTATCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCACGCCAAAGACAGCCTAGAGAGGA
CGGCAATGATGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCTCAACGTCGGTACCGCCGC
AACTTCAATTGCCGACGCAGACACCCAGAAAACCCTAAACCACAAGATGGCAAAGAGACAAAAGCAGCCGATCCAC
CAGCTGAGAATTCGTCCACTCCTGAGGCTGAGCGGGGCAGGACTGAGTAAATGCCAGCTTACCATCTCTACCATCA
TCCGGTTTAGTCATCCAACAGGAAGAAATATGAAATTCCAGCTATAAGAAATGAACAAAAGATTGGAGCTGAAGAC
CTTAAGTGCTTGCTTTTTGCCCGTTGACCAGATAAATAGAACTATCTGCATTATCTATGCAGCATGGGATTTTTAT
TATTTTTACCTAAAGACGTCTCTTTTTGGTAATAACAAACGTGTTTTTTAAAAAAGCCTGGTTTTTTTCAATACGC
CTTTAAAGGTTTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAAGAACTTCATTTTTAATTTGTAATAAA
AGTTTACAACTTGATTTTTTCAAAAAAGTCAACAAACTGCAAGCACCTGTTAATAAAGGTCTTAAATAAT 
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>Chromosome 15: 61032287-61033781 (+) 
catgcctataatcacagcactttgggaggctgaggtgggcagatcacttg 
gagtcaggagttcgagaccagcctggccaacatggtaaatccccatgtcg 
AGTTCGATCGGTAGCGaGAGtGGAGAGCaGACCAGAGAGCCCTaAGCAGC 
CCCACCGCCtCCGCCGGCCTAtTTACCATCACAaCCCaGGAGGAGCCGCA 
GCTGCCGCAGCCcGGCCCCAGTCACCATCACtGCAACCATGAGCAGCGAG 
GCgGAGACCCAGCAGCCGCCgcCCGCCCCCGCCCTCAGCtCCaCCtACAC 
CAAGCCCGGCACTACGGGCAGCGGCGCAGGGAaCGGTGtCCtGGGCGGCC 
TCACAcCGaCGGCGCCTGCCGGCGGGGACAAGAAaGTCATCGCAACGAAG 
GTTTTGGGAACAGTAAAATGGTTCAATGTAAGGAACaGATATGGTTTCAT 
CAACAGGAATGACACCAAGGAAGATGTATTTGTACcCCAGACTGCCAtag 
AGAATAACCCCAGGAAGTACCTTCccagggtagataggGAGACTaTGGAG 
TTTGATGTTGTTGAAGGAGAAAAGGGTGCGGAGGCAGCAcATGTTACAGG 
TCCTGGTGGTGTTCtAGTTCAAGGCAGTAAATATGCAGCAGACtaTAACC 
ATtaTATAGACGCTATCCAGTCGTgGGGGTCCTCCACGCAATTACCAGCA 
AAATTACCAGAAcAGTGAGAGTGGGGAAAAGAACGAGGGATCGGgGAGTG 
CTCCCGAAGGCCAGGCCCAACAACGCCGGCCCTACggcggcaAAGGTTCC 
CACCTgACTcCATGCGGAGACCCTATGGGtGTCGACCACAGcATTCCAAC 
CTGTGCAGGGAGAAGTGATGGAGGGTGCTGgCAACCAGGGTGCAGGAGAA 
CAAcGTAGACCAaTGAGGCAGAATATGTgTtGGGGATATAGACCACGgTT 
CCGCAGGGGCCCTCCTCGCCcAAaACAGCCTAGAGAGGACGGCAATGAAG 
AAGATAAAGAAAATCAAGGAGgTGAcACCCAAGGTCAGCAGCCACCTCAA 
CGTCGGTACCtCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCC 
TAAACCACAAGATGGCAAAGAGACAAAAGCAGCaGATCCACCAGtTGAGA 
ATTCGTCCaCTCCgGAGGCTGAGCAGGGCaGGCTGAGTAAATGCCGGCTT 
CATCTCTACCAacaTACAGTTTAGTCATCCAACAAGAAGAAATATGAAAT 
TCCAGCAATAAGAAATGAACAAAAGATTGGAGtgGAAGACCTAAAGTGCT 
TGCTTTTTGCCCGTTGACCAGAgAAgcAGAACTATCTGCcTTATCTATGC 
AGCATGaGGTTATTATTTTTACtaaaaaCgAAAGACGTCTCTTTTTGGTA 
ATAACAAACGTGTTTTTTtttttttAAAGCCTGGTTTTTCTCAATACGCC 
TTTcAAGGTTTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAAG 
AACTTCATTTTTAATTTGTAATAAAAGTTTACAACTTGATTTTTTCAAAA 
AAGTCAACAAACTGCAAGCACCTGTTAATAAAGGTCTTAAATAATttttt 
gtttgtttgtttttgagacggagtctcgctctgtcgcccaggctggagtg 
cagtggcgggatctcggctcactgcaagctccgcctcccgggttc  
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Appendix C 
 
Restriction sites for YBX1-ARMS PCR product (98bp) for YBX1 RefSeq sequence and 
YBX1 pseudogenes 
YBX1 : chr1:42,920,722-42,921,136 (+) 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
AcuI CTGAAGN14N2 1 36/34 36,62 
AluI AGCT 1 14 14,84 
AluBI AGCT 1 14 14,84 
ApeKI GCWGC 1 81/84 81,17 
BbsI GAAGACN2N4 1 24/28 24,74 
BbvI GCAGCN8N4 1 93/97 93,5 
BpiI GAAGACN2N4 1 24/28 24,74 
BpuAI GAAGACN2N4 1 24/28 24,74 
BseXI GCAGCN8N4 1 93/97 93,5 
BstC8I GCNNGC 1 32 32,66 
BstV1I GCAGCN8N4 1 93/97 93,5 
BstV2I GAAGACN2N4 1 24/28 24,74 
Cac8I GCNNGC 1 32 32,66 
CviAII CATG 1 85/87 85,13 
CviJI RGCY 1 14 14,84 
CviKI-1 RGCY 1 14 14,84 
Eco57I CTGAAGN14N2 1 36/34 36,62 
Eco57MI CTGRAGN14N2 1 36/34 36,62 
FaeI CATG 1 88/84 88,10 
FatI CATG 1 84/88 84,14 
Fnu4HI GCNGC 1 82/83 82,16 
Fsp4HI GCNGC 1 82/83 82,16 
Hin1II CATG 1 88/84 88,10 
HincII GTYRAC 1 47 47,51 
HindII GTYRAC 1 47 47,51 
Hpy8I GTNNAC 1 47 47,51 
Hpy166II GTNNAC 1 47 47,51 
Hsp92II CATG 1 88/84 88,10 
ItaI GCNGC 1 82/83 82,16 
Lsp1109I GCAGCN8N4 1 93/97 93,5 
MboII GAAGAN7N1 1 29/28 29,69 
NlaIII CATG 1 88/84 88,10 
SatI GCNGC 1 82/83 82,16 
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TseI GCWGC 1 81/84 81,17 
BisI GCNGC 1 82/83 82,16 
BlsI GCNGC 1 83/82 83,15 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
GluI GCNGC 1 82/84 82,16 
     
HpyCH4V TGCA 2 70,81 70,11,17 
SetI ASST 2 16/12,24/20 16,8,74 
 
Chromosome 15: 61032287-61033781 (+)  
(Cells highlighted in red show restriction enzymes which do not cleave the true YBX1 ARMS product) 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
ApeKI GCWGC 1 81/84 81,17 
BbsI GAAGACN2N4 1 24/28 24,74 
BbvI GCAGCN8N4 1 93/97 93,5 
BpiI GAAGACN2N4 1 24/28 24,74 
BpuAI GAAGACN2N4 1 24/28 24,74 
BseXI GCAGCN8N4 1 93/97 93,5 
BstC8I GCNNGC 1 32 32,66 
BstV1I GCAGCN8N4 1 93/97 93,5 
BstV2I GAAGACN2N4 1 24/28 24,74 
Cac8I GCNNGC 1 32 32,66 
CviAII CATG 1 85/87 85,13 
FaeI CATG 1 88/84 88,10 
FatI CATG 1 84/88 84,14 
Fnu4HI GCNGC 1 82/83 82,16 
Fsp4HI GCNGC 1 82/83 82,16 
Hin1II CATG 1 88/84 88,10 
HincII GTYRAC 1 47 47,51 
HindII GTYRAC 1 47 47,51 
Hpy8I GTNNAC 1 47 47,51 
Hpy166II GTNNAC 1 47 47,51 
HpyCH4V TGCA 1 81 81,17 
Hsp92II CATG 1 88/84 88,10 
ItaI GCNGC 1 82/83 82,16 
Lsp1109I GCAGCN8N4 1 93/97 93,5 
MboII GAAGAN7N1 1 29/28 29,69 
MnlI CCTCN6N1 1 81/80 81,17 
NlaIII CATG 1 88/84 88,10 
SatI GCNGC 1 82/83 82,16 
TseI GCWGC 1 81/84 81,17 
BisI GCNGC 1 82/83 82,16 
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BlsI GCNGC 1 83/82 83,15 
GluI GCNGC 1 82/84 82,16 
 
Homo sapiens Y box binding protein 1 pseudogene 1 (YBX1P1) on chromosome 
14:chr14:65,548,902-65,550,397 (-) 
 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
AcuI CTGAAGN14N2 1 36/34 36,58 
AluI AGCT 1 14 14,80 
AluBI AGCT 1 14 14,80 
ApeKI GCWGC 1 77/80 77,17 
BbsI GAAGACN2N4 1 24/28 24,70 
BbvI GCAGCN8N4 1 89/93 89,5 
BfuCI GATC 1 60/64 60,34 
BglII AGATCT 1 60/64 60,34 
BpiI GAAGACN2N4 1 24/28 24,70 
BpuAI GAAGACN2N4 1 24/28 24,70 
BseXI GCAGCN8N4 1 89/93 89,5 
Bsp143I GATC 1 60/64 60,34 
BssMI GATC 1 60/64 60,34 
BstC8I GCNNGC 1 32 32,62 
BstKTI GATC 1 63/61 63,31 
BstMBI GATC 1 60/64 60,34 
BstV1I GCAGCN8N4 1 89/93 89,5 
BstV2I GAAGACN2N4 1 24/28 24,70 
BstX2I RGATCY 1 60/64 60,34 
BstYI RGATCY 1 60/64 60,34 
Cac8I GCNNGC 1 32 32,62 
CviAII CATG 1 81/83 81,13 
CviJI RGCY 1 14 14,80 
CviKI-1 RGCY 1 14 14,80 
DpnII GATC 1 60/64 60,34 
Eco57I CTGAAGN14N2 1 36/34 36,58 
Eco57MI CTGRAGN14N2 1 36/34 36,58 
FaeI CATG 1 84/80 84,10 
FatI CATG 1 80/84 80,14 
Fnu4HI GCNGC 1 78/79 78,16 
Fsp4HI GCNGC 1 78/79 78,16 
Hin1II CATG 1 84/80 84,10 
HincII GTYRAC 1 47 47,47 
HindII GTYRAC 1 47 47,47 
Hpy8I GTNNAC 1 47 47,47 
Hpy166II GTNNAC 1 47 47,47 
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Hsp92II CATG 1 84/80 84,10 
ItaI GCNGC 1 78/79 78,16 
Kzo9I GATC 1 60/64 60,34 
Lsp1109I GCAGCN8N4 1 89/93 89,5 
MboI GATC 1 60/64 60,34 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
MboII GAAGAN7N1 1 29/28 29,65 
MflI RGATCY 1 60/64 60,34 
MseI TTAA 1 24/26 24,70 
NdeII GATC 1 60/64 60,34 
NlaIII CATG 1 84/80 84,10 
PsuI RGATCY 1 60/64 60,34 
SatI GCNGC 1 78/79 78,16 
Sau3AI GATC 1 60/64 60,34 
Tru1I TTAA 1 24/26 24,70 
Tru9I TTAA 1 24/26 24,70 
TseI GCWGC 1 77/80 77,17 
XhoII RGATCY 1 60/64 60,34 
BisI GCNGC 1 78/79 78,16 
BlsI GCNGC 1 79/78 79,15 
DpnI GATC 1 62 62,32 
GluI GCNGC 1 78/80 78,16 
MalI GATC 1 62 62,32 
 
Homo sapiens Y box binding protein 1 pseudogene 7 (YBX1P7) on chromosome 2 
 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
AcuI CTGAAGN14N2 1 36/34 36,61 
AfaI GTAC 1 29 29,68 
AflII CTTAAG 1 23/27 23,74 
AluI AGCT 1 14 14,83 
AluBI AGCT 1 14 14,83 
BbsI GAAGACN2N4 1 24/28 24,73 
BceAI ACGGCN12N2 1 96/1 96,1 
BfaI CTAG 1 57/59 57,40 
BfrI CTTAAG 1 23/27 23,74 
BmcAI AGTACT 1 29 29,68 
BpiI GAAGACN2N4 1 24/28 24,73 
BpuAI GAAGACN2N4 1 24/28 24,73 
BspTI CTTAAG 1 23/27 23,74 
Bst98I CTTAAG 1 23/27 23,74 
BstAFI CTTAAG 1 23/27 23,74 
BstV2I GAAGACN2N4 1 24/28 24,73 
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Csp6I GTAC 1 28/30 28,69 
CviJI RGCY 1 14 14,83 
CviKI-1 RGCY 1 14 14,83 
CviQI GTAC 1 28/30 28,69 
Eco57I CTGAAGN14N2 1 36/34 36,61 
Eco57MI CTGRAGN14N2 1 36/34 36,61 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
FspBI CTAG 1 57/59 57,40 
Hpy99I CGWCG 1 43/38 43,54 
Hpy188I TCNGA 1 51/50 51,46 
MaeI CTAG 1 57/59 57,40 
MboII GAAGAN7N1 1 29/28 29,68 
MnlI CCTCN6N1 1 80/79 80,17 
MseI TTAA 1 24/26 24,73 
MspCI CTTAAG 1 23/27 23,74 
RsaI GTAC 1 29 29,68 
RsaNI GTAC 1 28/30 28,69 
ScaI AGTACT 1 29 29,68 
SmlI CTYRAG 1 23/27 23,74 
SmoI CTYRAG 1 23/27 23,74 
SspI AATATT 1 7 7,90 
TaqI TCGA 1 41/43 41,56 
TatI WGTACW 1 27/31 27,70 
Tru1I TTAA 1 24/26 24,73 
Tru9I TTAA 1 24/26 24,73 
TspDTI ATGAAN9N2 1 58/56 58,39 
Vha464I CTTAAG 1 23/27 23,74 
XspI CTAG 1 57/59 57,40 
ZrmI AGTACT 1 29 29,68 
 
Homo sapiens Y box binding protein 1 pseudogene 2 (YBX1P2) on chromosome 7: 
chr7:105,009,538-105,011,090 (-) 
 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
AcuI CTGAAGN14N2 1 36/34 36,62 
AflII CTTAAG 1 23/27 23,75 
AluI AGCT 1 14 14,84 
AluBI AGCT 1 14 14,84 
ApeKI GCWGC 1 81/84 81,17 
BbsI GAAGACN2N4 1 24/28 24,74 
BbvI GCAGCN8N4 1 93/97 93,5 
BfrI CTTAAG 1 23/27 23,75 
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BpiI GAAGACN2N4 1 24/28 24,74 
BpuAI GAAGACN2N4 1 24/28 24,74 
BseXI GCAGCN8N4 1 93/97 93,5 
BspTI CTTAAG 1 23/27 23,75 
Bst98I CTTAAG 1 23/27 23,75 
BstAFI CTTAAG 1 23/27 23,75 
BstC8I GCNNGC 1 32 32,66 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
BstV1I GCAGCN8N4 1 93/97 93,5 
BstV2I GAAGACN2N4 1 24/28 24,74 
Cac8I GCNNGC 1 32 32,66 
CviAII CATG 1 85/87 85,13 
CviJI RGCY 1 14 14,84 
CviKI-1 RGCY 1 14 14,84 
Eco57I CTGAAGN14N2 1 36/34 36,62 
Eco57MI CTGRAGN14N2 1 36/34 36,62 
FaeI CATG 1 88/84 88,10 
FatI CATG 1 84/88 84,14 
Fnu4HI GCNGC 1 82/83 82,16 
Fsp4HI GCNGC 1 82/83 82,16 
Hin1II CATG 1 88/84 88,10 
HincII GTYRAC 1 47 47,51 
HindII GTYRAC 1 47 47,51 
Hpy8I GTNNAC 1 47 47,51 
Hpy166II GTNNAC 1 47 47,51 
Hsp92II CATG 1 88/84 88,10 
ItaI GCNGC 1 82/83 82,16 
Lsp1109I GCAGCN8N4 1 93/97 93,5 
MboII GAAGAN7N1 1 29/28 29,69 
MseI TTAA 1 24/26 24,74 
MspCI CTTAAG 1 23/27 23,75 
NlaIII CATG 1 88/84 88,10 
SatI GCNGC 1 82/83 82,16 
SmlI CTYRAG 1 23/27 23,75 
SmoI CTYRAG 1 23/27 23,75 
Tru1I TTAA 1 24/26 24,74 
Tru9I TTAA 1 24/26 24,74 
TseI GCWGC 1 81/84 81,17 
Vha464I CTTAAG 1 23/27 23,75 
BisI GCNGC 1 82/83 82,16 
BlsI GCNGC 1 83/82 83,15 
GluI GCNGC 1 82/84 82,16 
HpyCH4V TGCA 2 70,81 70,11,17 
SetI ASST 2 16/12,24/20 16,8,74 
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Homo sapiens Y box binding protein 1 pseudogene 6 (YBX1P6) on chromosome 9 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
AcuI CTGAAGN14N2 1 36/34 36,62 
AflII CTTAAG 1 23/27 23,75 
AluI AGCT 1 14 14,84 
AluBI AGCT 1 14 14,84 
ApeKI GCWGC 1 81/84 81,17 
BbsI GAAGACN2N4 1 24/28 24,74 
BbvI GCAGCN8N4 1 93/97 93,5 
BfrI CTTAAG 1 23/27 23,75 
BpiI GAAGACN2N4 1 24/28 24,74 
BpuAI GAAGACN2N4 1 24/28 24,74 
BseXI GCAGCN8N4 1 93/97 93,5 
BspTI CTTAAG 1 23/27 23,75 
Bst98I CTTAAG 1 23/27 23,75 
BstAFI CTTAAG 1 23/27 23,75 
BstC8I GCNNGC 1 32 32,66 
BstDEI CTNAG 1 77/80 77,21 
BstV1I GCAGCN8N4 1 93/97 93,5 
BstV2I GAAGACN2N4 1 24/28 24,74 
Cac8I GCNNGC 1 32 32,66 
CviAII CATG 1 85/87 85,13 
CviJI RGCY 1 14 14,84 
CviKI-1 RGCY 1 14 14,84 
DdeI CTNAG 1 77/80 77,21 
Eco57I CTGAAGN14N2 1 36/34 36,62 
Eco57MI CTGRAGN14N2 1 36/34 36,62 
FaeI CATG 1 88/84 88,10 
FatI CATG 1 84/88 84,14 
Fnu4HI GCNGC 1 82/83 82,16 
Fsp4HI GCNGC 1 82/83 82,16 
Hin1II CATG 1 88/84 88,10 
HpyF3I CTNAG 1 77/80 77,21 
Hsp92II CATG 1 88/84 88,10 
ItaI GCNGC 1 82/83 82,16 
Lsp1109I GCAGCN8N4 1 93/97 93,5 
MboII GAAGAN7N1 1 29/28 29,69 
MseI TTAA 1 24/26 24,74 
MspCI CTTAAG 1 23/27 23,75 
NlaIII CATG 1 88/84 88,10 
SatI GCNGC 1 82/83 82,16 
SmlI CTYRAG 1 23/27 23,75 
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SmoI CTYRAG 1 23/27 23,75 
Tru1I TTAA 1 24/26 24,74 
Tru9I TTAA 1 24/26 24,74 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
TseI GCWGC 1 81/84 81,17 
Vha464I CTTAAG 1 23/27 23,75 
BisI GCNGC 1 82/83 82,16 
BlsI GCNGC 1 83/82 83,15 
GluI GCNGC 1 82/84 82,16 
SetI ASST 2 16/12,24/20 16,8,74 
 
Homo sapiens nuclease sensitive element binding protein 1 pseudogene 10 (BA327L3.4) on 
chromosome 9: chr9:35,960,941-35,962,454 (-) 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
AcuI CTGAAGN14N2 1 36/34 36,62 
AflII CTTAAG 1 23/27 23,75 
AluI AGCT 1 14 14,84 
AluBI AGCT 1 14 14,84 
ApeKI GCWGC 1 81/84 81,17 
BbsI GAAGACN2N4 1 24/28 24,74 
BbvI GCAGCN8N4 1 93/97 93,5 
BfrI CTTAAG 1 23/27 23,75 
BpiI GAAGACN2N4 1 24/28 24,74 
BpuAI GAAGACN2N4 1 24/28 24,74 
BseXI GCAGCN8N4 1 93/97 93,5 
BspTI CTTAAG 1 23/27 23,75 
Bst98I CTTAAG 1 23/27 23,75 
BstAFI CTTAAG 1 23/27 23,75 
BstC8I GCNNGC 1 32 32,66 
BstV1I GCAGCN8N4 1 93/97 93,5 
BstV2I GAAGACN2N4 1 24/28 24,74 
Cac8I GCNNGC 1 32 32,66 
CviAII CATG 1 85/87 85,13 
CviJI RGCY 1 14 14,84 
CviKI-1 RGCY 1 14 14,84 
Eco57I CTGAAGN14N2 1 36/34 36,62 
Eco57MI CTGRAGN14N2 1 36/34 36,62 
FaeI CATG 1 88/84 88,10 
FatI CATG 1 84/88 84,14 
Fnu4HI GCNGC 1 82/83 82,16 
Fsp4HI GCNGC 1 82/83 82,16 
Hin1II CATG 1 88/84 88,10 
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HincII GTYRAC 1 47 47,51 
HindII GTYRAC 1 47 47,51 
Hpy8I GTNNAC 1 47 47,51 
Hpy166II GTNNAC 1 47 47,51 
Enzyme Pattern Cuts 
Cut 
positions 
Fragment 
length 
Hsp92II CATG 1 88/84 88,10 
ItaI GCNGC 1 82/83 82,16 
Lsp1109I GCAGCN8N4 1 93/97 93,5 
MboII GAAGAN7N1 1 29/28 29,69 
MseI TTAA 1 24/26 24,74 
MspCI CTTAAG 1 23/27 23,75 
NlaIII CATG 1 88/84 88,10 
SatI GCNGC 1 82/83 82,16 
SmlI CTYRAG 1 23/27 23,75 
SmoI CTYRAG 1 23/27 23,75 
Tru1I TTAA 1 24/26 24,74 
Tru9I TTAA 1 24/26 24,74 
TseI GCWGC 1 81/84 81,17 
Vha464I CTTAAG 1 23/27 23,75 
BisI GCNGC 1 82/83 82,16 
BlsI GCNGC 1 83/82 83,15 
GluI GCNGC 1 82/84 82,16 
HpyCH4V TGCA 2 70,81 70,11,17 
SetI ASST 2 16/12,24/20 16,8,74 
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Appendix D 
RNA electrophoretograms and QC analysis for Microarray experiment 
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Appendix E 
Genomatix Matrix Library Information for YBX1 
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Appendix F 
 
Primary Antibodies used in Western Blot Experiments 
Protein Supplier Type Catalogue no. Dilution 
YBX1 Abcam Rabbit PC ab12148 1:1000 
Actin Santa Cruz Goat PC SC1615 1:1000 
N-Cadherin Santa Cruz Rabbit PC SC7939 1:500 
E-Cadherin BD Biosciences Mouse MC 610181 1:2000 
Vimentin Cell Signalling Rabbit PC 3932 1:1000 
Twist1 Santa Cruz Rabbit PC SC15393 1:500 
CD82 Abcam Rabbit PC ab66400 1:1000 
AR Santa Cruz Rabbit PC SC816 1:500 
CHK2 Abcam Rabbit PC ab47433 1:500 
ITGB1 Abcam Rabbit MC ab52971 1:500 
IGFBP5 Abcam Rabbit PC ab4255 1:1000 
MXI1 Abcam Rabbit PC ab28740 1:1000 
TFF1 Abcam Rabbit MC ab92377 1:1000 
RAC1 Abcam Rabbit MC ab33186 1:500 
 
Secondary Antibodies used in Western Blot Experiments 
Type Supplier Catalogue no. Dilution 
Donkey anti-goat IgG HRP Santa Cruz SC2020 1:5000 
Sheep anti-mouse IgG HRP GE Healthcare NA931V 1:5000 
Donkey anti-rabbit IgG HRP GE Healthcare NA934V 1:5000 
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